IMMUNOLOGY

- 1 -

IMMUNOLOGY

Thesis Program of the PhD Curriculum N094

CONTENT

1. Coordinator 2

2. Introduction 2

2.1 Aim of the PhD Program Immunology 2

2.2 Recommended Literature 2

3. Courses 3

3.1 Medical Propedeutics 3

3.2 Basic Seminar (2 X 2 Semester hours) 3

3.3 Journal Club and Progress Reports 4

3.4 Program for Elective Courses 5

4. Participating Faculty (Lectures) 7

4.1 PhD Thesis Supervisors 7

4.2 Teachers 9

5. PhD Thesis Projects 10 5.1 Description of Research Interests of Supervisors and available Techniques

10

Barbara Bohle Wilfried Ellmeier Erika Jensen-Jarolim Syliva Knapp Herwig Kollaritsch Rudolf Öhler Winfried F. Pickl Marcus Saeman Wolfgang Schreiner Hannes Stockinger Herbert Strobl Julia Walochnik Thomas Wekerle Ursula Wiedermann-Schmidt Gerhard Zlabinger

10 11 12 13 14 15 16 18 19 21 22 23 24 25 26

6. Curriculum Vitae 28

6.1 PhD Thesis Supervisors (index, in alphabetical order) 28

6.2 Teachers (index, in alphabetical order) 132

- 2 -

1. COORDINATOR

Wilfried Ellmeier, PhD, Professor of Immunobiology, Division of Immunobiology, Institute of

Immunology, Center for Physiology, Pathophysiology and Immunology , Medical University of

Vienna , Lazarettgasse 19, 1090, Vienna, Austria. Phone: +43-1-40160-65003, Fax: +43-1-

40160-965006

E-mail: [email protected]

2. INTRODUCTION

2.1 Aim of the PhD Program Immunology

Molecular and cellular defense mechanisms of the innate and the adaptive immune system

protect organisms against harmful pathogens and against the development of malignant

cells. However, overreactions of the immune system are responsible for the establishment of

immune-mediated diseases such as allergy, rheumatoid arthritis, inflammatory bowel

disease, multiple sclerosis, diabetes, psoriasis and atherosclerosis. It is of enormous

importance for contemporary biomedical science to increase the knowledge about the mode

of action of the immune system in order to design better therapies for the cure of these life-

threatening diseases. The objective of the PhD Program in Immunology is to provide to

students excellent training opportunities in the field of immunology. This will be achieved by

offering students the opportunity to work with faculty members on cutting-edge research

projects in stimulating research environments. Furthermore, students will obtain an in-depth

education and training on various immunological topics to obtain a broad knowledge in the

field of immunology. This should help to prepare the students for a successful scientific

career within academia and/or industry.

2.2 Recommended Literature

• Janeway’s Immunobiology – The Immune system in health and disease. Seventh Edition,

Kenneth M Murphy, Paul Travers, Mark Walport, Garland Science Textbook 2008 (as

alternative: Immunobiology, Charles Janeway, Paul Travers, Mark Walport, Mark Shlomchik,

Garland Science Textbooks, 2004).

• Molecular and Cellular Immunology, 6th Edition, Abul Abbas, Andrew Lichtman, Shiv Pillai.

Saunders, 2007.

- 3 -

3. COURSES

There are four types of courses offered in the N094 PhD program:

1. Medical Propedeutics (6 Semester hours)

2. Basic Lecture (2 x 2 Semester hours)

3. Journal Clubs and Progress reports (6 x 2 Semester hours)

4. Elective Courses (4 x 2 Semester hours)

3.1 Medical Prodedeutics (6 Semester hours)

The propedeutics are an obligatory part of the PhD studies (irrespective of the chosen

program). They have to be completed by the end of the fourth semester and comprise a

choice of medical and basic courses, of which 6 semester hours are obligatory. The selection

has to be done under the supervision of the thesis committee and the program coordinator

and is dependent on the undergraduate education and the selected thematic program.

Further information about the propedeutics can be found on the PhD N094 homepage.

3.2 Basic Seminar (2 X 2 Semester hours)

The aim of the Basic Lecture is to give students an advanced but still broad overview about

various immunological topics, which is a prerequisite for a successful career in the field of

immunology. The Basic Lecture will be held in two parts, each 2 semester hours during the

winter and summer semester. The lectures will take place as two blocks during two weeks in

January (winter semester) and June (summer semester). The topics include mechanisms of

innate and adaptive immune responses, as well as the immunopathology of important

immunologically-mediated diseases.

BASIC SEMINAR 1 (Winter semester, 2 Semester hours)

Topic Lecturer I. Overview of the immune system (1h) 1. General principles, cell subsets and lymphoid architecture (1)

Wilfried Ellmeier

II. Lymphocyte development and subset generation (2h) 1. B and T cell development (2h)

Wilfried Ellmeier

III. Innate Immunity (7h) 1. Basic principles of innate immune responses (2h) 2. Pattern recognition receptors (2h) 3. Radicals as effectors of innate immune cells (2h) 4. Phagocytosis and endocytosis (1h)

Sylvia Knapp Marcus Saeman Rudolf Öhler Renate Fuchs

IV. Lymphocyte Activation (10h) 1. Antigen processing and presentation (2h) 2. The biology of antigen presenting cells (2h) 3. Structure, function and signaling of immune receptors (4h) 4. Costimulatory molecules (2h)

Winfried Pickl Herbert Strobl Hannes Stockinger Peter Steinberger

V. Effector Mechanisms (5h) 1. The role of cytokines in the immune response (3h) 2. Cell-mediated Immunity and peripheral T cell subsets (1h) 3. Humoral Immunity (1h)

Martin Wilheim Wilfried Ellmeier Erika Jensen-Jarolim

VI. Tolerance mechanisms (2h) 1. Central and peripheral Tolerance (2h)

Gerhard Zlabinger

- 4 -

VII. Special tissues of the adaptive immune system (3h) 1. Skin Immunity (1h) 2. Mucosal Immunity (2h)

Adelheid Elbe Buerger Erika Jensen-Jarolim

BASIC SEMINAR 2 (Summer semester, 2 Semester hours) Topic Lecturer I. Type I allergy (4h) 1. General principles (2h) 2. Therapeutic approaches (2h)

Rudolf Valenta Barbara Bohle

II. Autoimmunity and inflammatory diseases (6h) 1. General principles (2h) 2. Clinical aspects of autoimmune diseases (2h) 3. Molecular and cellular mechanism of inflammatory diseases (2)

Günther Steiner Clemens Scheinecker Peter Pietschmann

III. Transplantation immunology (5h) 1. General principles (2h) 2. Experimental protocols for transplantation tolerance (2h) 3. Immunogenetic selection criteria (1h)

Gerhard Zlabinger Thomas Wekerle Gottfried Fischer

IV. Immunodeficiencies (3h) 1. Primary immunodeficiencies (2h) 2. HIV (1h)

Winfried Pickl Johannes Stöckl

V. Lymphoproliferative diseases and tumor immunology (4h) 1. Experimental systems for studying lymphomas and leukemia (1h) 2. Clinical insight into leukemia (1h) 3. Immune responses to tumors (1h) 4. Mouse models in cancer research (1h)

Veronika Sexl Ulrich Jäger Erika Jensen-Jarolim Maria Sibilia

VI. Immunotherapy (5h) 1. General principles (3h) 2. Clinical strategies for immunotherapy (2h)

Elisabeth Förster-Waldl Thomas Felzman

VII. Infection immunology (Immunity to Microbes) (3h) 1. Viruses and the Immune system (1h) 2. Strategies for vaccinations (2h)

Johannes Stöckl Ursula Wiedermann-Schmidt

3.3 Journal Clubs & Progress Reports (6 x 2 semester hours)

During the 6 semesters of their PhD studies, students have to participate in Immunology

Journal Clubs that will be held regularly at the institutions of the participating faculty

members. The topics of the Journal Club should be in accordance (or related) with the thesis

subjects of the student, however each Journal Club should be open for all students of the

immunology program. The primary aim of the Journal Clubs is to learn critical reading and

discussion of scientific papers. Therefore, students will have to read scientific publications, to

present them to the other participants and to discuss the presented results, methods and

interpretations under the guidance of the university teacher. The objective of the Journal

Clubs is to get familiar with the design of experimental studies and the interpretation of

results. In addition, Journal Clubs should train students in writing scientific papers. The

selection of the papers to be discussed can be made by the faculty member as well as by the

students.

Another important educational aspect of the PhD program immunology are Progress

Reports that should be given at least once a year by the PhD students. The Progress

Reports should serve as a basis for the evaluation of the PhD thesis. In addition to the

- 5 -

members of the PhD thesis committee, other faculty members and students from the host

institutions should listen to the seminar given by the PhD student. As a critical audience they

should stimulate the successful development of the PhD thesis, help to critically discuss the

data and provide suggestions for new experiments. Ideally, there should be a regular

Progress Report Series at each host institution of the participating faculty members. This

would allow a regular discussion of ongoing projects and studies of the host institution in

front of a rather broad audience and this will prepare the PhD students for future

presentations of their own scientific results to a larger and critical audience.

Journal Club/Progress Report (Winter and summer semester, 2 Semester hours each)

Title Lecturer Current topics in parasitology Aspöck, Auer, Hassl,

Walochnik (WS, SS) Immune responses to allergens Bohle (WS, SS) Current topics in immune cell development and function Ellmeier (WS, SS) Structural requirements of antigens and allergens for disease mechanisms and therapy.

Jensen-Jarolim (WS, SS)

Journal Club of the Surgical Research Laboratories Oehler (WS, SS) Integration of genome- and clinical data for immunology Renauld, Regele,

Schreiner (WS, SS) Journal Club & Progress Report Roth, Spittler, Oehler,

Wekerle, Weigel, Brostjan (WS, SS)

901840 Journal Club und Progress Report Stockinger (WS, SS) Clinical and basic aspects of human hematopoietic stem cells and dendritic cells

Strobl (WS, SS)

Journal Club and Progress Report Zlabinger, Pickl, Stöckl (WS, SS)

3.4 Program for Elective Courses /Thesis Seminars (4 x 2 semester hours)

The purpose of these seminars is to improve and deepen the knowledge in a particular field

of immunology. Topics covered in the seminars go beyond textbook knowledge and will

cover recent developments in a particular field. The topics of the seminars are grouped into

several subject categories (see below). Ideally, the majority of seminars chosen by the PhD

student should be in the subject of the individual thesis, however it is recommended to

choose at least one seminar in a subject that is not related to the topic of the student’s PhD

thesis.

THESIS SEMINARS (each 2 Semester hours)

Subject Categories Lecturer Allergy (Immediate Hypersensitivity) Title of Seminar: Therapeutic concepts for Type I allergies

Bohle (WS)

Immunological Methods Title of Seminar: Immunological methods in allergy research

Bohle (SS)

Lymphocyte Development Title of Seminar: Transcriptional control of immune cell development

Ellmeier (WS)

Activation and Regulation of Lymphocytes Title of Seminar: Molecular mechanisms of immune cell function

Ellmeier (SS)

- 6 -

Tumorimmunology Title of Seminar: TBA

Jensen-Jarolim (WS)

Allergy (Immediate Hypersensitivity) Title of Seminar: TBA

Jensen-Jarolim (WS)

Innate Immunity Title of Seminar: TBA

Knapp (WS)

Immunity to Microbes Title of Seminar: TBA

Knapp (SS)

Dendritic cells/ Tumorimmunology Title of Seminar: antigen-presenting cells as adjuvants for tumortherapy

Pickl (WS & SS)

Signal Transduction in Immune Cells Title of Seminar: DissertantInnenenseminar: Molecular basis of interaction- and communication mechanisms of immune cells (topic of seminar varies from semester to semester) Title of Seminar: Recognition mechanisms in immunity (topic of seminar varies from semester to semester)

Stockinger (WS) Stockinger (SS)

Neutrophils, Monocytes/Macrophages and Dendritic Cells Title of seminar: Differentiation and function of myelomonocytic cells

Strobl (WS)

Hematopoiesis Title of Seminar: Hematopoietic stem cell pathophysiology and lineage decisions in the hematopoietic system

Strobl (SS)

Tolerance and Autoimmunity Title of Seminar: Preclinical protocols for tolerance induction upon organ transplantation

Wekerle (WS)

Immunity to Microbes/ Immunological Methods Title of Seminar: Medical Parasitology Practical

Walochnik, together with Auer (WS, SS)

Immunity to Microbes Basics in Molecular Parasitology

Walochnik (SS)

Tolerance and Autoimmunity Title of Seminar: Immune Tolerance

Zlabinger (WS, SS)

Transplantation Title of Seminar: Immunosuppression

Zlabinger (SS)

- 7 -

4. PARTICIPATING FACULTY MEMBERS (LECTURES)

Faculty members participating in the PhD program Immunology can be grouped into either

PhD thesis supervisors or teachers. PhD thesis supervisors are offering internationally

peer-reviewed PhD projects to students and are actively supervising the research of the

students. Furthermore, PhD thesis supervisors are teaching in the various courses and

lectures. In contrast, Teachers do not offer a PhD project to the Immunology program

students, however they provide expertise in a particular field of immunology and therefore

help to cover a large variety of immunology topics.

4.1 PhD Thesis Supervisors Surename, first name, academic title

Research Institution Research Interests

Bohle Barbara, PhD Univ. Doz. DI. Dr.

Division of Immunopathology, Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology

Allergen-specific immune responses, Immunomodulation, Vaccine development

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/ipp/allergyresearch Ellmeier Wilfried, PhD Univ.Prof.Mag.Dr.

Division of Immunobiology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology

Lymphocyte Development, Signal transduction in immune cells

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/immunologie/ellmeier/index.html Jensen-Jarolim Erika, MD Univ.Prof.

Division of experimental Immunology and Oncology, Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology

Allergy, Food allergy AllergoOncology, Oncology

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/ipp; www.allergology.at Knapp Sylvia, MD, PhD a.o. Univ.Prof.Dr. PhD

Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine 1 and Center for Molecular Medicine

Innate Immunity; Immunity to Microbes; Neutrophils, Monocytes/Macrophages and DC

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/med1/infektiologie ; http://www.cemm.at Kollaritsch, Herwig Univ-Prof. Dr.

Division of Specific Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology

Travel Medicine, Vaccinology, Epidemiology

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/tropenmedizin/

- 8 -

Oehler Rudolf PhD Ao.Univ-Prof.Mag.Dr.

Department of Surgery, Research Laboratories

Transplantation Immunology, Tumorimmunology, Neutrophils, Monocytes/Macrophages and Dendritic Cells

E-mail: [email protected] Pickl Winfried F, MD Ao.Univ.Prof.Dr.

Division of Cellular Immunlogy and Immunehematology, Center for Physiology, Pathophysiology and Immunology

Activation and Regulation of Lymphocytes, Tumor Immunology, Immunity to Mocrobes

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/immunologie/ Säemann Marcus, MD Doz. Dr.

Internal III/Clinical Division of Nephrology & Dialysis

Transplantation Biology, Innate Immunity, Immunosuppression

E-mail: [email protected] Schreiner Wolfgang, PhD o.Univ.Prof.Dr.

Division of Biomedical Computersimulation and Bioinformatics

Informatics and Modeling in Medicine, Models, Immunological Computational Biology

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/msi/biosim/ Stockinger Hannes, PhD Univ.Prof. Dipl.-Ing. Dr.

Department of Molecular Immunology, Center for Physiology, Pathophysiology and Immunology

Activation and Regulation of Lymphocytes, Signal Transduction in Immune Cells, Immunological Methods

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/immunology Strobl Herbert, MD Ao.Univ.Prof

Institute of Immunology, Center for Physiology, Pathophysiology and Immunology

Human hematopoietic stem cells, dendritic cells, transcription control of differentiation, gene therapy, leukemia, autoimmune diseases, inflammation

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/immunologie Walochnik Julia, PhD Univ.Doz.Mag.Dr.

Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology

Tolerance induction in transplantation and allergy

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/hygiene/?s=parasitologie Wekerle, Thomas, MD Ao.Univ.Prof.Dr.med.univ.

Div. of Transplantation, Dept. of Surgery

Tolerance and Autoimmunity, Transplantation Immunology,

E-mail: [email protected] Homepage: http://www.muw.ac.at/transplant-lab

- 9 -

Wiedermann-Schmidt Ursula, MD, PhD, Univ.Prof. Dr.

Department of Specific Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology

Mucosa Immunity Immunity to Microbes Allergy

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/tropenmedizin Gerhard J. Zlabinger, MD Univ. Prof. Dr.

Division of Clinical and experimental Immunology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology

Allergy, Food allergy AllergoOncology, Oncology

E-mail: [email protected] Homepage: http://www.meduniwien.ac.at/immunologie/content/research/zlabinger.htm 4.2 Teachers

Ao.Univ.Prof.Dr. Herbert Auer Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology Ao.Univ.Prof. Dr. Adelheid Elbe-Buerger Department of Immundermatology, University Clinic of Dermatology Univ.Doz. Dr. Thomas Felzmann Children Cancer Research Institute Ao.Univ.Prof. Dr. Gottfried Fischer University Clinic for Blood Group Serology and Transfusion Medicine Ao.Univ.Prof. Dr. Elisabeth Förster-Waldl Department of Pediatrics and Adolescent Medicine Ao.Univ.Prof. DI. Dr. Renate Fuchs Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology Univ.Prof. Dr. Ulrich Jäger Clinical department of Hematology und Hämostaseology, University Clinic for Internal Medicine I Ao.Univ.Prof. Dr. Peter Pietschmann Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology Ao.Univ.Prof. Dr. Clemens Scheinecker Department of Rheumatology, University Clinic for Internal Medicine III Univ.Prof. Dr. Veronika Sexl Institute of Pharmacology, Center for Biomolecular Medicine and Pharmacology Univ.Prof.Dr. Maria Sibilia Institute of Cancer Research, University Clinic for Internal Medicine I Ao.Univ.Prof. Dr. Günter Steiner Department of Rheumatology, University Clinic for Internal Medicine III Univ.Doz. Dr. Peter Steinberger Immune Receptors and T-cell Activation, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Ao.Univ.Prof.Dr. Johannes Stöckl Division of Immune Regulation, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Ao.Univ.Prof. Dr. Martin Willheim Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology

- 10 -

5. PhD THESIS PROJECTS

5.1 Description of Research Interests of Supervisors Barbara Bohle, Division of Immunopathology, Department of Pathophysiology, Center for Physiology, Pathophysiology and Immunology Characterization of allergen-specific immune responses Abstract The long-term research interest of the Allergy Research group is to elucidate the immunological mechanisms underlying the induction, maintenance and immunotherapy of Type I allergy and to develop novel concepts for an efficient and safe specific immunotherapy of Type I allergy. (1) Cellular and molecular basis of Type I allergies We have a long lasting expertise in the isolation and characterization of allergen-specific T cells. Allergen-specific T cell cultures are applied to gain insights into the cellular response to allergens. We have shown that the immune response in allergic individuals is dominated by allergen-specific Th2 cells and lacks counter-regulating allergen-specific Th1 and regulatory T cells. On the other hand, we employ allergen-specific T cell cultures to characterize allergens with regard to their T cell epitopes and cellular cross-reactivity. These data lay the foundation for the development of novel vaccines for allergen-specific immunotherapy, such as hypoallergenic variants with reduced IgE-binding and retained T cell stimulatory capacity. (2) Novel vaccines for allergen-specific immunotherapy Allergen-specific immunotherapy (SIT) is the only treatment of Type I allergy that induces a modulation of the disease-eliciting immune response. Conventional SIT consists of multiple subcutaneous injections of crude allergen extracts into allergic individuals in order to induce a state of clinical tolerance to natural allergen exposure. However, the administration of allergens bears the risk to induce local and systemic side effects. Furthermore, SIT is not always effective. Therefore, a major goal of my group is to develop more efficient and safer vaccines for specific immunotherapy. For this purpose we link allergens with agents targeting the innate immune system in order to modulate the disease-eliciting immune response towards a more physiological response. Techniques “State of the art” immunological, biochemical and molecular biology techniques, such as the production and purification of recombinant allergens, RT-PCR, real-time PCR, ELISA, ELISPOT, SDS-PAGE, Western blotting, different applications of flow cytometry including cell surface staining, intracellular cytokine detection and determination of cell proliferation by CFSE staining; basic tissue culture techniques, isolation and characterization of allergen-specific T cells; allergen-induced mediator-release experiments with rat basophil leukemia cells (RBL) transfected with the human Fc epsilon receptor I and human basophils, basic allergological methods, i.e. skin prick tests, prick to prick tests and rhinomanometric measurements.

- 11 -

Wilfried Ellmeier, Division of Immunobiology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Molecular mechanisms of immune cell development and function Abstract Our long-term research interest is to understand molecular mechanisms that regulate the development and function of immune cells. The research in our laboratory focuses on studies to understand epigenetic and transcriptional control mechanisms that regulate CD8 coreceptor gene expression, on the identification of genes that control developmental processes such as CD4/CD8 cell fate decisions during T cell differentiation, and on studies to reveal the various roles of Tec family kinases in different cell lineages of the immune system. (1) Epigenetic gene regulation during T cell development Our laboratory is studying the regulation of CD8 coreceptor expression, a key molecule in the immune system for the development of the cytotoxic T cell lineage. CD8 coreceptor expression is tightly regulated during thymocyte development by the activity of at least five different cis-regulatory elements. We recently linked Cd8 enhancer function with chromatin remodelling of the adjacent genes Cd8a and Cd8b1 (Cd8) and demonstrated epigenetic control of the Cd8 gene complex. We have further identified that the zinc finger protein MAZR is an important regulator of CD8 expression. Ongoing studies in the laboratory aim to further characterize Cd8 cis-regulatory elements and to study MAZR function in more detail. (2) The role of Tec family kinases for immune cell function Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) form the second largest class of non-receptor protein tyrosine kinases. The analysis of mice lacking Tec family kinases has uncovered important functions for Tec kinases in cells of lymphoid origin. In addition, numerous reports exist that describe the expression and activation of Tec kinases in every cell type of the myeloid compartment. Tec family kinases can get activated by a broad range of signalling pathways including also non-immune-globulin like receptors such as: receptor tyrosine kinases, interleukin and toll-like receptors, integrins, G-protein coupled receptors and so-called "death" receptors. In order to shed further light into the function of Tec kinases in myeloid cells, we are analysing the function of a variety of primary myeloid cell types (e.g. mast cells and monocytes/macrophages) lacking single and/or multiple Tec kinase family members. Since some of the Tec family kinases are also involved in processes that when deregulated (such as Th1/Th2 differentiation, mast cell activation) can lead to diseases such as autoimmunity or allergy in man. Thus, the molecular analysis of the various Tec family kinase-deficient mice may not only contribute to our basic understanding of the role of Tec kinases in cells of the immune system, but may also help to indicate ways for potential therapeutic intervention. Techniques „State of the art“ basic molecular and cellular biology techniques, biochemical analysis of signal transduction pathways, yeast one-hybrid screens, chromatin immunoprecipitations, RNAi approaches, FACS, in vitro and in vivo immunological assays, retroviral-mediated gene transduction of bone marrow stem cells followed by the generating of bone marrow chimeras, (conditional) ES cell technology, and mouse molecular genetics tools (knockout and transgenics).

- 12 -

Erika Jensen-Jarolim, Division of Experimental Immunology and Oncology, IPP - Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology Allergology, oncology, allergooncology Abstract The group analyses the molecular features of allergens and antigens leading to sensitization and immunity. Both, mechanistic and therapeutic principles are being investigated. Techniques Molecular and cellular biology techniques, in vitro and in vivo immunological assays, and mouse models of allergy and tumor disease.

- 13 -

Sylvia Knapp, Division of Infectious Diseases and Tropical Medicine, Department of Internal medicine 1, Medical University Vienna; and Center for Molecular Medicine of the Austrian Academy of Sciences Innate Immune Response to Bacterial Infections Abstract Our research projects are addressing important clinical problems and focusing on innate immune mechanisms with relevant bacterial infections simulated under laboratory conditions. While our general objectives are in furthering our understanding of clinically relevant pathogens and host-pathogen interactions; our primary objectives are to positively impact and substantially enhance the current diagnostic procedures and ultimately influence therapies and survival. (1) Host recognition receptors and signaling pathways Our laboratory is investigating the role of pattern recognition receptors during clinically relevant bacterial infections, such as pneumonia induced by Streptococcus pneumoniae and Pseudomonas aeruginosa or septic infections like peritonitis. In doing so we were able to identify and characterize the distinct roles of e.g. TLRs, CD14, or LBP in vivo. Ongoing studies are aimed at a better understanding of the biological role of co-receptors such as TREM-1 or CD36. In a second line we are interested in understanding the impact of pre-existing tissue alterations on the course of infection. This question specifically addresses clinically important situations observed in hospitalized patients that are at increased risk for infections. Our studies are based on the concept that tissue damage (e.g. trauma, mechanical ventilation or non-infectious inflammation) results in the release and/or modification of endogenous molecules that in turn impact the function of immune effector cells. In accordance with this idea we recently demonstrated that oxidized phospholipids seriously impact host defense against E. coli in vivo. It is the aim of current projects to explore the generation of these lipid products in humans and to better characterize elicited effects in vitro and in vivo. (2) The role of bacterial virulence factors (toxins) during pneumonia. Pathogenic bacteria developed mechanisms to counteract host defense pathways. Among those, the secretion of pore-forming toxins is known to be a potent mechanism and associated with aggravated disease, tissue damage and potentially lethal outcome. We aim at understanding the molecular mechanism by which selected bacterial toxins attack host cells in order to identify novel targets for therapeutic interventions. Techniques In vitro and in vivo bacterial infection models (pneumonia, and peritonitis), basic cellular and molecular biology techniques, biochemical analysis of signal transduction pathways, RNAi approaches, FACS, in vitro immunological assays, basics in confocal microscopy.

- 14 -

Herwig Kollaritsch, Division of Travel Medicine and Infectious Disease Epidemiology, Institute for Specific Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology Epidemiology and Travel Medicine Abstract Our group is working in 2 major research fields: (1) Clinical Studies with new vaccines and proof of concept of recommended vaccination schedules: Clinical phase II-IV studies as well as post marketing surveillance and observational studies are performed. Currently, the focus is on immunogenicity and tolerability of different vaccinations such as a new genereation of bird flu vaccines or new vaccinations against Japanese Encephalitis. Ongoing projects are long term surveillance of antibody decline after TBE vaccination and seroprevalence of vaccine derived antibodies in 5-7 year old children. (2) Epidemiological Studies: In a nationwide surveillance system the epidemiology of vaccine-preventable diseases (Pertussis, Rotavirus, invasive pneumococcal disease, Hepatitis A, B, C, Measles, Mumps Rubella, Haemophilus influezae B) has been monitored for more than ten years by now. Data from this surveillance are used to i) evaluate current vaccination concepts, ii) establish and monitor new vaccination recommendations, iii) observe replacement phenomena under vaccination pressure, iv) give cost-benefit analyses for established vaccination programs and v) use the data from this project to induce new research projects in basic research and applied science.

- 15 -

Rudolf Oehler, Department of Surgery, Research laboratories Response of the immune system to therapy in surgical patients Abstract Our long-term research interest is to utilise the understanding of the response of the immune system to therapy in order to improve the clinical outcome. (1) Effect of chemotherapy on the immune response Our aim is to avoid undesired immunosuppression by chemotherapy and boost the immune response to cancer. Chemotherapeutic treatment of cancer patients supposedly mediates its effect via direct elimination of tumor cells. However, there is growing evidence that activation of immune cells in tumour's micro environment is essential for tumour regression. Our focus is the effect of chemotherapeutics on the immune response in cancer patients. Therefore we investigate circulating as well as tumour-infiltrating immune cells in patients during chemotherapy. Special emphasis is given to monocytes/macrophages and their responsiveness to stimuli. In addition we perform in vitro models with primary cells to investigate the hypotheses raised on the basis of the analysis of the clinical samples. (2) Non-HLA donor-specific antigens in transplantation immunology Our interest is to improve the donor-recipient matching in renal transplantation to prolong graft survival. About the half the renal graft recipients encounter late loss of organ transplants in renal transplantation. Although it is well established that major histo-compatibility complexes (HLA) are the main targets of humoral immunity there is evidence that non-HLA specific antibodies contribute substantially to late loss of organ transplants. Using proteomics technologies we identify antigens of pre-existing as well as transplantation-induced non-HLA donor-specific antibodies and develop analytical application platforms for their analysis. These platforms are then used to investigate the association of the specific antibodies with graft survival. Techniques „State of the art“ quantitative electrophoretic proteomics techniques, in vitro and in vivo immunological assays, FACS, biochemical analysis.

- 16 -

Winfried F. Pickl, Division of Cellular Immunology and Immunhematology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology The immunological synapse Abstract T cell activation is the result of a sustained antigen-specific interaction of a T lymphocyte with a professional antigen-presenting cell (pAPC) in a secondary lymphatic tissue. The detailed description of the molecular and functional events within the immunological synapse formed by T cells and pAPC is one of the keys to the better understanding of adaptive immune responses and their modulation. Model systems in which the immunological synapse can be rebuilt with receptors relevant for human diseases shall enable us to study the pathophysiology of allergies, autoimmune and infectious diseases as well as cancer in greater detail and may thus lead to novel strategies for their cure. (1) Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with TCR/CD3 ligands plus costimulatory molecules Inducible virus-like particles (VLP), decorated with T cell ligands of choice can be directly immunogenic for purified T lymphocytes. We found that lipid rafts are the keys to inducible VLP production and the selective enrichment on VLP of immunologically relevant molecules. VLP expressing combinations of T cell ligands plus antigen were produced and their impact on T cell activation was evaluated. Functional analyses showed, that they mediate strong, accessory cell-independent, antigen-specific T lymphocyte activation. Our data move virus biology, lipid rafts and aspects of lymphocyte activation into a novel biological context. We expect that both basic and applied research will profit from our reductionist system for antigen presentation and T lymphocyte activation. (2) A general strategy for decoration of virus (like) particles with functionally active lipid-modified cytokines Augmentation of immune responses against antigens by co-administration of appropriate adjuvants became general practice following the demonstration by Ramon more than 80 years ago that increased antitoxin responses in the presence of “helper substances” can be achieved. In proof of principle studies we have evaluated the ability of membrane anchored human and murine cytokines to “pseudotype” Moloney murine leukemia virus (MoMLV) particles. Based on this mechanism we have developed a system for the predictable decoration of enveloped viruses (or VLP) with functionally active cytokines that circumvents the need to modify viral proteins themselves. Virus (like) particles decorated with lipid-modified cytokines might help to improve viral strains for vaccination purposes, improve artificial antigen presenting platforms, facilitate the propagation of factor-dependent cell types, as well as gene transfer by viral systems in the future.

(3) Molecular and functional analysis of antigen receptors of allergen-specific helper T lymphocytes T lymphocytes play a central role in the pathogenesis of allergic diseases. During the sensitization phase, priming of allergen-specific (CD4+) T helper 2 (TH2) cells results in the production of TH2 cytokines, which are responsible for class switching to the epsilon Ig heavy chain, allowing IgE production by B-cells. Although TCR gene usage by allergen-specific T lymphocytes has been studied to a considerable degree in the past, no molecular or functional analyses of cloned and ectopically expressed human allergen-specific TCR have been reported so far. Consequently, biological model systems based on human allergen-specific TCR were still missing. Hence, one of our research-interests is devoted to test the feasibility of engineering allergen-specific T lymphocytes by genetic TCR transfer. Expressible allergen-specific TCRs may contribute to a better definition of the ‘allergen-specific synapse’ and thus the processes leading to allergic diseases and their cure in the

- 17 -

future. In a next step, w e plan to clone TCRs specific for other relevant allergens within the Christian Doppler Laboratory “Immunomodulation”. (4) Novel biomarkers to identify active chronic graft-versus-host disease patients with severe immunodeficiency Chronic graft-versus-host-disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT) and a leading cause of nonrelapse mortality resulting from profound immunodeficiency. Currently, biology-based markers both for diagnosis and monitoring activity of cGVHD as well as its functional consequences on the immune system are lacking. In close cooperation with the research group of Prof. Hildegard Greinix, Department of Internal Medicine I, Medical University of Vienna, we have identified memory B cell subsets a novel biomarkers to identify patients with severe immunodeficiency. A prospective study is currently being initiated in order to confirm and extend our earlier findings. Techniques Cellular and molecular biological techniques for the expression and functional evaluation of immune receptor molecules including retroviral gene transfer and transgenesis and flow cytometry. Immunological characterization of patients with leukemia and primary and acquired immunodeficiencies.

- 18 -

Marcus Säemann , Internal Medicine III, Clin. Division of Nephrology & Dialyis Experimental Immunsuppression and regulation of innate immunity Abstract: Our research is primarily devoted to understand immunological effector arms that can be manipulated in order benefit the host, e.g. to down-regulate immune responsiveness against alloantigens in organ transplantation. Furthermore, molecular mechanisms and targets of currently employed immunosuppressants are analyzed to gain more insights into the molecular drug action and also the basic regulation of the immune response. Another part of our research is focused on the potential link between arteriosclerosis and inflammation. In particular we study the potent immunomodulatory capacity of high-density lipoprotein hypothesizing that its atheroprotective and thereby life-enhancing potency is due to its anti-inflammatory action rather than being a simple cholesterol transport molecule. Finally, we have a prime interest in the diverse immunological mechanisms operative during host cell evasion also to take advantage from evolutionary driven strategies that can be mimicked for therapeutic purposes. (1) Regulation of innate immunity by mTOR Our laboratory is studying the regulation innate immune responses evoked by monocytes and peripheral dendritic cells by the mammalian target of rapamycin, a key molecule traditionally associated with translational control of eukaryotic cells, cell-cycle regulation and cell survival and currently therapeutically targeted by its naturally occurring inhibitor rapamycin or its dereivatives as immunosuppressant and anticancer drug. We recently identified mTOR as negative regulator of proinflammatory cytolkines as IL-12 and IL-23 but suppressor of the prototypical anti-inflammatory cytokine IL-10 in murine and human monocytes and peripheral myeloid dendritic cells. We have further identified that its regulatory role is exerted by the specific control of NF-kB activity, a pivotal proinflammatory transcription factor. Finally, in a relevant murine disease model employing Listeria monocytogenes we demonstrated that genetically-susceptible mice display an increased survival after mTOR inhibition by differentially regulating protective cytokine production. Ongoing studies in the laboratory aim to further elucidate the relative contribution of the mTOR subunits mTORC1 or Raptor versus mTORC2 or Rictor in dictating the final outcome of innate and adaptive immune responses including studies on optimized vaccination protocols or preventing virally-mediated immune escape. (2) The role of HDL as immunomodulatory molecule Several pivotal studies indicate that the quality rather than the quantity of HDL is decisive for its atheroprotective potency. Our studies could demonstrate that HDL exerts very potent effects on innate immune cells like monocytes/macrophages and dendritic cells by suppressing e.g. the production of various inflammatory cytokines. Interestingly, this potent immunomodulatory role is lost in high-risk populations such as end-stage renal disease patients exhibiting both a state of chronic inflammation and an excessively increased mortality rate. This study project aims to define the molecular pathways underlying this peculiar property of HDL envisioning a translational approach in patients with qualitatively inferior HDL and also identifying such high-risk patients with immunological methods. Techniques Current basic molecular and cellular biology techniques, biochemical analysis of signal transduction pathways (western blooting, immunoprecipitation, EMSA), RNAi approaches, FACS, in vitro and in vivo immunological assays and cell culture and finally mouse molecular genetics tools (knockout mouse models).

- 19 -

Wolfgang Schreiner, Division of Biomedical Computer Simulation and Bioinformatics, Core facility of Medical Statistics and Informatics Informatics and Modeling in Medicine Abstract My overall goal is the application of IT (information-techniques) within biomedical settings. It is achieved by combining and applying relevant IT to specific biomedical fields, in an interdisciplinary approach. Projects may relate to biomedical research as well as to clinical settings close to patient treatment. Research & Research Support: In the more simple cases, novel IT-tools are adapted and made available to support particular biomedical research projects within interdisciplinary cooperations. Within these projects, the IT then becomes an indispensable part of the final, overall achievement. In more advanced cases, those IT-tools already available are found insufficient, and new tools (algorithms) have to be developed so as to meet the needs of a given biomedical research endeavour. Then, IT-research and development in its own right is carried out. Finally, the most intriguing scenario is modeling of biomedical systems, with the intention to acquire further clues about a biomedical system’s internal functionality. For example, biomolecules can be modeled, the mutual forces and movements computed so as to understand and predict binding affinities and even enzyme functions in silico before being tested in a wet lab-setting. Or else, vascular models may be generated via optimization rules and then be checked to which extent resulting models match reality. We then make implications if the optimization rules applied may be similar to those criteria relevant in evolutionary shaping of physiological structures. Clinical Settings and Patient Treatment: Modern IT, if designed properly, lends itself as a very efficient support of patient treatment. The IT-people’s task is then to listen, pick up the clinician’s need and re-formulate it in a way that can be cast into an IT-application. Examples are applications for patient documentation and signal acquisition in clinical research. Integration of heterogeneous data sources, such as gene-sequence, gene-expression, proteomics, bio-signals and images is an ongoing an ever changing challenge. Another important aspect is consulting clinicians in IT-projects, such as AKIM, that are carried out by third parties. AKIM aims at renewing and fully integrating the IT-infrastructure of the 2000-bed Vienna General Hospital, including the research facilities of Medical University of Vienna. (1) Computational immunomics, also known as in-silico immunomics Our main interest is on the molecular interaction between T-cell-receptor (TCR), T-cell-epitope, and major-histocompatibility-complex (MHC). For that purpose we apply software engineering, mathematical and statistical methods on experimental x-ray data (see techniques). Investigations regard side chain placement of the peptide inside the MHC-binding-groove and prediction of the binding affinity of a TCRpMHC molecule for high throughput screening without pre-assigned calibration. We also perform stochastic simulation to investigate TCR activation. In particular, we evaluate how cooperative mechanisms between TCRs amay be essential in providing a high discrimination power between different peptides, despite binding affinities are rather similar. (2) Blood vessel modelling and visualization Vessel trees are generated by the algorithm of "Constrained Constructive Optimization" (CCO), which has been developed by our group. For a suitable choice of boundary conditions and constraints, each model tree is generated by stepwise adding new segments and optimizing the tree according to a given target (cost) function. The resulting trees are highly realistic structures, resembling corrosion casts of real arterial trees. Visualizations are

- 20 -

made in high-quality 3-D-representation, with optional shading and lighting. Recently, an interactive tool to manipulate and slice the model structures has been developed. (3) Medical Informatics consultancy and project management. I take part as a consultant to MUW in several IT-projects, among others AKIM (Allgemeines Krankenhaus Informations Management). The main challenge is to integrate different sources of data and enable the clinician to handle them in a seamless fashion. Techniques Modeling of peptides (side chain placement, backbone adjustment), scoring conformations (structure- and sequence-based), molecular dynamics simulations blood vessel modelling, stochastic simulations of particle- and molecule interactions, hemodynamic modeling, statistics, graphical display, data-integration of genome and patient-related data within the AKIM-framework at MUW-AKH, IT-consultancy for biomedical projects. Programming languages: FROTRAN, Java, SAS, Matlab.

- 21 -

Hannes Stockinger, Department of Molecular Immunology, Center for Physiology, Pathophysiology and Immunology Analysis of T cell antigen receptor and accessory receptor signaling to understand T cell regulation Abstract Hannes Stockinger is the chairman of the Department of Molecular Immunology of the Medica l Univers ity of V ienna that has outstanding expertise in the field of leukocyte biology with special emphasis on the function and signal transduction of plasma membrane receptors of T cells. For an immune response to occur, T cells must be exposed to two types of stimuli. The first signal, an antigen, ensures the specificity of activation and is transduced via the T cell antigen receptor. Second signals for T cells are transmitted via costimulatory receptors and cytokines that promote clonal expansion of the specific T cells and their differentiation into effector and memory cells. In addition, the immune system provides for control mechanisms, which maintain homeostasis after active immune responses to foreign antigens, and prevent or abort responses to self-antigens. The Department is particularly interested to uncover latter pathways aiming to identify targets to correct pathological and unwanted immune reactions, which occur during autoimmunity, allergy or transplantation. As tools for the experiments, a team of 16 young enthusiastic scientists generated a large panel of monoclonal antibodies towards immune cells receptors and established a number of “gain of function” and “loss of function” assays by using recombinant and tagged forms as well as siRNA sequences of membrane receptors and submembrane signaling molecules. In the course of these studies we contributed also substantially to the identification and characterization of lipid rafts, special membrane microdomains that control signal transduction across the plasma membrane. Currently, together with the Institute for Biophysics from the Johannes Kepler University in Linz, we are developing methods for detecting and tracking single molecules in living cells. We are now able to trace individual fluorescently labeled molecules in living cells in real time as well up to 1000-fold time lapse. The ability to follow molecules on the microsecond time scale and locate them with a resolution of a few dozen nanometers proves extremely useful when studying reorganization processes of membrane components or compartments within the membrane. The use of these high-resolution microscopy techniques are thought to open completely new vistas for studying signaling processes in living cells and develop novel diagnostic assays. The results of our studies were published in approximately 130 scientific papers, a variety of them in the very top journals such as Cell, Science and The Journal of Experimental Medicine that were cited nearly 5000 times. Four patents are currently active. Thesis Subjects Molecular interactions and transmembrane signaling of surface receptors of T cells. Techniques and infrastructure Cell culture, flow cytometry, molecular cloning, transfection and infection techniques, siRNA technology, immunological techniques (isolation, cultivation and stimulation of immune cells, ELISA, immunofluorescence, Western blotting, immunoprecipitation, etc), chromatography, advanced imaging (single molecule analysis, confocal microscopy).

- 22 -

Herbert Strobl, Division: “Molecular Biology of Hematopoietic Stem Cells and Dendritic Cells”, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Human hematopoietic stem cells and dendritic cell biology Abstract We focus on questions in cell biology applied to human immunology and molecular hematopoiesis. We aim to elucidate the transcriptional mechanismsunderlying the lineage differentiation of granulocytes, monocyte and dendritic cells from common myeloid progenitor/ stem cells. Furthermore, we study how certain dendritic cell subsets such as environmental exposed epithelial Langerhans cells get activated, and how they might be involved in tolerance induction. As a main model cytokine dependent unilineage differentiation cultures of human CD34 pos.cord blood progenitor/stem cells are combined with inducible retroviral vector systems. Furthermore, we performed functional genetic screens to identify novel regulatory proteins involved in myeloid progenitor/stem cell differentiation and leukemia.

Techniques Differentiation cultures of primary human CD34 pos. hematopoietic progenitor cells, multiparamter FACS, molecular/biochemical analyses, DNA cloning, construction of retroviral gene transfer vectors, functional genetic cDNA libarary screens. In all our projects we use retroviral/lentiviral gene transfer experiments. Specific ongoing projects:

Role of transcription factors in lineage decidisons of hematopoietic stem- and progenitor cells: We are currently studying several transcription factors: the role of Aryl hydrogen carbon receptor in myelopoiesis and dendritic cell differentiation; Interplay between nuclear hormone receptors VDR/RXRα with the master transcription factors GATA-1 and PU.1 in the lineage decisions of normal and leukemic stem cells; how are lineage decisions between monopoiesis versus granulopoiesis regulated?

Dendritic cells We study transcriptional regulators of DC subset differentiation and maturation. Among several questions: How do common monocytic precursors develop into Langerhans cells in the steady state versus into monocyte-derived DCs in inflammatory lesions? What is the role of microRNAs in DC subset differentiation and activation? What is the role of RelB during Langerhans cell activation? Identify novel transcriptional regulators in Langerhans cell differentiation. How are epithelial adhesion molecules induced during Langerhans cell differentiation. Apply organotypic epidermal cultures for studying Langerhans cell function. Clinical leukemia immunophenotyping Identify novel markers for identifying monocytic leukemias and Langerhans cell histiocytosis. Identify novel approaches for monitoring residual leukemic blasts after therapy, by using flow cytometry. Multicenter standardization efforts within the European group of Immunologic Leukemia lassification (EGIL).

- 23 -

Julia Walochnik, Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology Molecular parasitology Abstract The broader field of our working group is medical protozoology, with a general focus on molecular biological questions. Our main research topics are pathomechanisms, immunobiology, phylogeny and biocide susceptibility mainly in Leishmania spp., Toxoplasma gondii, Trichomonas vaginalis, and, particularly also in Acanthamoeba spp. Moreover, considerable research work has been done on vector-borne pathogens. During the past years we have established an extensive protozoal strain collection of well-defined clinical and environmental isolates. (1) Pathomechanisms and immunobiology of Acanthamoeba infections Our long-term research goal is to understand what makes certain Acanthamoeba strains virulent and what makes certain individuals susceptible to infection. Acanthamoebae are the causative agents of two very different disease entities. On one hand they evoke the so-called Acanthamoeba keratitis, a very often seriously progressing inflammation of the cornea occurring predominantly in contact lens wearers. On the other hand acanthamoebae are responsible for several highly destructive disseminating infections in the immunocompromised host, including dermatitis, pneumonitis and the usually fatal granulomatous amoebic encephalitis. We are currently the only department in Austria with an Acanthamoeba research group. The focus of our hitherto work has been the characterisation and classification of pathogenic and nonpathogenic Acanthamoeba strains employing morphological, physiological, molecular biological and immunological methods and the correlation of various characters with respect to pathogenicity. We also want to understand the regulation of cyst formation, because the cysts are the major problem in therapy. Moreover, we have been working on the immunoreactivities of Acanthamoeba spp. and on the serological reactivities of patients. (2) Anti-protozoal biocides Another major aim of our working group is to find substances active against Acanthamoeba and other parasitic protozoa as there currently is no specific treatment available for any of the different Acanthamoeba infections and also in other protozoal diseases treatment is highly problematic. We have been involved in several projects on biocides, including contact lens disinfectants, antibiotics and bioactive substances, and their activities on various parasitic protozoa. (3) Phylogeny of the amoebozoa The classification of the amoebae is especially controversial and has been revised many times. In the recent years molecular biological investigations, particularly rDNA sequencing, have brought some astonishing changes concerning the diversity and also the evolutionary and systematic positions of numerous amoebic lineages. But the vast majority of amoebae has not been thoroughly investigated or is even known to date. Our aim is to contribute to the elucidation of amoebozoan phylogeny. Techniques Cell culture, microscopy, „state of the art“ basic molecular techniques, PCR, DNA sequencing, 2D-electrophoresis, ÄKTA purification, in vitro immunological assays.

- 24 -

Thomas Wekerle, Division of Transplantation, Deptartment of Surgery Abstract The research efforts of my group focus on translational research in the area of two common immunological conditions: organ transplantation and allergy. We are interested in the development of experimental tolerance regimens with relevance for these two indications and the in-depth mechanistic analysis of such models. In particular, we pursue the concept of chimerism induction through the transplantation of hematopoietic stem cells which leads to robust, lasting tolerance towards antigens expressed on the transplanted cells. Protocols of allogeneic mixed (cellular) chimerism generated through the transplantation of donor bone marrow for the induction of donor-specific tolerance in transplantation, and protocols of molecular chimerism generated through the transplantation of syngeneic hematopoietic stem cells that have been retrovirally transduced ex vivo with a disease-causing antigen are being investigated.

- 25 -

Ursula Wiedermann-Schmidt Tropical Medicine, Center for Physiology, Pathophysiology and Immunology The research unit focuses on immunoprophylaxis and vaccination against infectious diseases, allergies and cancers, the development and validation of novel vaccine candidates and antigen delivery systems and the assessment of immediate and memory immune responses as well as vaccination failure after immunization. Vaccine development from bench to bedside in cooperation with clinical departments is performed with support of international vaccine companies. The following topics are being focused on:

• New antigen-delivery systems for vaccination: Lactic acid bacteria as edible vaccines; expression of recombinant allergens, tumor antigens (her-2/neu) and protozoal antigens (e.g. Toxoplasma gondii) Virosomes as adjuvants for systemic and mucosal vaccination with tumor antigens/peptides, allergen peptides etc.

• Use of mucosal adjuvants for enhanced immunogenicity, e.g. cholera B subunit, LTB from E. coli

• Development of a polyvalent allergy vaccine: development of novel allergen-chimers for nasal or oral vaccination against multisensitivities

• Development of a cancer vaccine against breast cancer and melanoma • Immunological assessment of phase I clinical trial with cancer vaccines • Characterization of cellular and humoral immune responses in responder versus

non/low-responder vaccinees • Immunological tolerance as vaccination strategy against immunological

hyperresponsiveness (incl. allergy, autoimmunity)

- 26 -

Gerhard J. Zlabinger, Division of Clinical and experimental Immunology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Bacterial and experimental Immunomodulation Abstract A longstanding interest of my research group concentrates on the issue of naturally occurring ways of immunomodulation as particularly operating in local immunity and on clinical conditions in consequence of inappropriate immune reactivity as observed after transplantation or in autoimmune diseases. Identification of immunological deregulation as early as possibly and the understanding of the ongoing processes are pivotal for early diagnosis and the development as well as implementation of purposeful interference strategies. (1) Mediators of Local Immunity Tamm Horsfall Protein (THP) is a heavily glycosylated protein, which is exclusively expressed in the thick ascending limb of the Henle’s loop in the kidney in amounts of 30 – 50 mg/day and therefore comprises the most abundant protein in the urine. THP is normally expressed only at the luminal surface of renal tubular epithelial cells and excreted to the urine. Considering the properties of THP, this protein is thought to be an essential defense molecule against UTI for at least two reasons: 1) Recent data unequivocally demonstrated that THP is pivotal to combat bacterial infection in vivo. THP-/- mice were shown to be profoundly hampered to combat colonization of the bladder tissue when infected with uropathogenic type-1 fimbriated E. coli. In addition, it has been demonstrated that the absence of THP predisposes the host to severe urinary tract infection. 2) Additionally to this physical - competitive action, which takes place in the lumen of the urinary tract, we have recently identified THP as an endogenous molecule that potently mediates immunomodulation. Because of its restricted expression the activity of THP can be expected to exclusively take place in the genitourinary tract. We found that THP is a strong activator of human DCs and initiates the upregulation of costimulatory molecule and MHC expression, inducing de novo cytokine production and optimal T cell stimulation. Interestingly, THP was shown to induce DC maturation via activating a TLR4 dependent cell signaling machinery. (2) Hallmarks of Antibody-mediated rejection In clinical transplantation, up to now, diagnostic and therapeutic efforts have mainly focused on T-cell-mediated immunity. However, over the last fifteen years there has been an increase in evidence for a critical role of B cell immunity and antibody-mediated effector mechanisms on graft loss. Although in the early days of transplantation humoral immunity was recognised to be causal for hyperacute graft rejection due to preformed anti-donor antibodies, only recently the important contribution of alloantibodies to more “common” rejection types could be established, e.g. acute or chronic rejection. Pivotal for the progress in the field have been the definition of acute Antibody-Mediated Rejection (AMR) as a novel clinical entity, the description of capillary deposition of C4 complement split product C4d as marker of AMR, and the establishment of efficient “anti-humoral” treatment, most importantly apheresis. Since it would be of great benefit if the reactivity of donor specific B cells (i.e. alloantibody production) could be accurately assessed prior to transplantation as well as for monitoring purposes in the post transplant phase we have started to implement a test procedure for ex vivo testing of alloantibody production. Appropriate stimulation of B-cells reveals the release of particular alloantibody specificities both in healthy individuals and in sensitized transplant patients. Follow-up studies in transplant patients will demonstrate the clinical relevance of such testing. Techniques

- 27 -

„State of the art“ basic molecular and cellular biology techniques, biochemical analysis of signal transduction pathways, FACS, in vitro immunological assays.

- 28 -

6. CURRICULUM VITAE

6.1 PhD Thesis Supervisor

Barbara Bohle 29

Wilfried Ellmeier 38

Erika Jensen-Jarolim 44

Sylvia Knapp 51

Herwig Kollaritsch 57

Rudolf Öhler 70

Winfried F. Pickl 73

Marcus Saeman 78

Wolfgang Schreiner 86

Hannes Stockinger 89

Herbert Strobl 96

Julia Walochnik 101

Thomas Wekerle 107

Ursula Wiedermann-Schmidt 115

Gerhard Zlabinger 126

- 29 -

Curriculum Vitae

Barbara Bohle

Division of Immunopathology, Dept. of Pathophysiology, Center for Physiology,

Pathophysiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20,

1090 Vienna, Austria;

Phone: +43-1-40400-5114, Fax: +43-1-40400-5130;

Email: [email protected];

Homepage: www.meduniwien.ac.at/ipp/allergyresearch Personal Data

Date of Birth: 15.09.1967

Place of Birth: Bregenz

Nationality Austria

Education

1997 - 2000 PhD thesis at the Institute of General and Experimental

Pathology, University of Vienna, with distinction

1992 – 1997 Undergraduate study "Food- and Biotechnology" at the

University of Natural Resources and Applied Life

Sciences, Vienna, awarded Master of Food and

Biotechnology with distinction

1985 - 1987 Academy for Medical and Technical Assistants, Vienna,

with distinction

1985 Highschool degree at the Bundesgymnasium Dornbirn with

distinction

Career History

Since 01/2008 Head of the Christian Doppler Laboratory for

Immunomodulation

Since 2002 Associate Professor

since 2002 Head of the research group “Allergy Research” in the

Dept. of Pathophysiology, Medical University of Vienna,

Vienna

2002 Venia docendi in Immunology

2000 University Assistant at the Dept. of Pathophysiology

- 30 -

(formerly: Inst. of General and Experimental Pathology)

1985 – 1990 Medical Technical Assistant at the Institute of General and

Experimental Pathology, University of Vienna, Vienna

Career-related Activities

Since 2007 Managing Editor for “International Archives of Allergy and

Immunology”

Since 2006 Treasurer of the Austrian Society of Allergology and

Immunology

Since 2006 Scientific Advisory Board member of the Paul Ehrlich

Institute, Langen, BRD

Since 2005 Secretary of the Immunology Section of the European

Academy of Allergology and Clinical Immunology (EAACI)

Awards

2007 WAO Henning Loewenstein Award 2007

2007 “Förderungspreis für Wissenschaft”, City of Vienna

2006 Clemens von Pirquet Award by the Austrian Society of

Immunology and Allergology (ÖGAI)

2006 International Award of the Pharmacia Allergy Research

Foundation (PhARF)

2005 Novartis Prize in Biology, Austria

2005 Allergopharma Award for allergy research

2004 Special Award “Food allergy. New insight in cross-

reactivity” by the Foundation for Allergy Research in

Europe (FARE)

2002 Dr. Karl Schleinzer Award of the University of Agricultural

Sciences, Vienna

2001 Allergopharma Award for allergy research

2000 Thesis prize of the Austrian Society of Immunology and

Allergology (ÖGAI)

Memberships

Austrian Society for Allergology and Immunology

European Academy of Allergology and Clinical Immunology (EAACI)

Sources of funding in last 6 years (2002-2008)

- 31 -

Period Organization Short Title K€/year

2008 - 2015 CDG + Biomay Christian Doppler Laboratory for

Immunomodulation

370

2008 - 2011 FWF SFB F01807-B13 "The role of cell-mediated

immunity in Type I food allergies"

446

2007 - 2010 FWF + MUW DK W1212: Inflammation and Immunity 44

2007 Federal Bank of

Austria

ÖNB 12158 “Immunological characteristics

of monomeric and self-assembled allergen-S

layer fusion proteins”

67

2005 - 2007 FWF SFB F01807-B04 "The role of cell-mediated

immunity in Type I food allergies"

48

2005 - 2007 Biomay Entwicklung von Impfstoffen und

Toleranzstrategien für Typ I Allergien

108

2001 - 2004 FWF FWF-SFB F01807 "The role of cell-mediated

immunity in Type I food allergies"

42

2004 - 2005 FWF SS 8808-MED 186

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

Since 2008 Marija Geroldinger-Simic In vivo immune responses to pollen-related food

allergens

Since 2007 Veroniqué Schulten Characterization of in vivo absorbed food

allergens

Since 2004 Marianne Gerstmayr Novel adjuvants for specific immunotherapy of

Type I allergies

2006 - 2008 Sonja Mutschlechner Characterization of naturally processed peptides of

Bet v 1 and hypoallergenic Bet v 1 isoforms isolated

from MHC class II molecules

2004 - 2006 Eva Maria Schimek Effects of cooking on the immunological

properties of food allergens

Publications

65 peer reviewed publications in scientific journals, 9 reviews and book chapters, > 40 invited

lectures, 3 patents

Peer reviewed manuscripts 2002-2008 (original research and reviews)

- 32 -

First, last or corresponding author manuscripts:

Gerstmayr, M., N. Ilk,I. Schabussova, B. Jahn-Schmid, E.M. Egelseer, U.B. Sleytr, C. Ebner

and B. Bohle. A Novel Approach to Specific Allergy Treatment: The Recombinant Allergen-S-

Layer Fusion Protein rSbsC-Bet v 1 Matures Dendritic Cells that Prime Th0/Th1 and IL-10-

Producing Regulatory T Cells. J Immunol, 179:7270, 2007

Bohle, B., Kinaciyan, T., M. Gerstmayr, A. Radakovics, B. Jahn-Schmid, and C. Ebner.

Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T cell

tolerance and immune deviation. J Allergy Clin Immunol, 120:707, 2007

Kinaciyan, T., B. Jahn-Schmid, A. Radakovics, B. Zwölfer, C. Schreiber, J.N. Francis, C.

Ebner and B. Bohle. Successful sublingual immunotherapy with birch pollen has limited

effects on concomitant food allergy to apple and the immune response to the Bet v 1-

homolog Mal d 1. J Allergy Clin Immunol, 119:937, 2007

Bohle, B., B. Zwölfer, A. Heratizadeh, B. Jahn-Schmid, Y. Dall Antonia, M. Alter, W. Keller, L.

Zuidmeer, R. van Ree, T. Werfel and C. Ebner. Cooking birch pollen-related food: divergent

consequences for IgE- and T cell-mediated reactivity in vitro and in vivo. J Allergy Clin

Immunol 118:242, 2006

Schimek, E.M., B. Zwölfer, P. Briza, B. Jahn-Schmid, L. Vogel, S. Vieths, C. Ebner and B.

Bohle. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their

mediator-releasing but not T cell-activating capacity. J Allergy Clin Immunol 116:1327, 2005

Jahn-Schmid, B., A. Radakovics, D. Lüttkopf, S. Scheurer, S. Vieths, C. Ebner and B. Bohle.

Bet v 1142-156 is the dominant T cell epitope of the major birch pollen allergen and important

for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 116:213, 2005

Bohle, B., A. Radakovics, D. Lüttkopf, S. Vieths and C. Ebner. Characterisation of the T cell

response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope

not cross-reactive with homologous pollen allergens. Clin Exp Allergy 35:1392, 2005

Bohle, B., B. Zwölfer, G.F. Fischer, U. Seppälä, T. Kinaciyan, C. Bolwig, M.D. Spangfort and

C. Ebner. Characterisation of the human T cell response to Antigen 5 from Vespula Vulgaris

(Ves v 5). Clin Exp Allergy 35:367, 2005

- 33 -

Konakci, K.Z., B. Bohle+, R. Blumer, W. Hoetzenecker, G. Roth, B. Moser, G. Boltz-

Nitulescu, M. Gorlitzer, W. Klepetko, E. Wolner and H.J. Ankersmit. Alpha-Gal on

Bioprostheses: Xenograft Immune Response In Cardiac Surgery. J Eur Clin Invest 35:17,

2005. +both authors contributed equally

Bohle, B., A. Breitwieser, B. Zwölfer, B. Jahn-Schmid, M. Sára, U. B. Sleytr and C. Ebner. A

Novel Approach to Specific Allergy Treatment: The recombinant fusion protein of a bacterial

cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v1)

combines reduced allergenicity with immunomodulating capacity. J Immunol 172:6642, 2004

Bohle, B., A. Radakovics, B. Jahn-Schmid, K. Hoffmann-Sommergruber, G. F. Fischer, and

C. Ebner. Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major

allergen in celery: evidence at the T cell level. Eur J Immunol 33:3303, 2003

Bohle, B., W. Hirt, P. Nachbargauer, H. Ebner, and C. Ebner. Allergy to millet: another risk

for atopic bird keepers. Allergy 58:325, 2003

Co-author manuscripts:

Mittermann, I., R. Reininger, M. Zimmermann, K. Gangl, J. Reisinger, K.J. AichbergerJ, E.K.

Greisenegger, V. Niederberger, J. Seipelt, B. Bohle, T. Kopp, C.A. Akdis, S. Spitzauer, P.

Valent, and R. Valenta. The IgE-Reactive Autoantigen Hom s 2 Induces Damage of

Respiratory Epithelial Cells and Keratinocytes via Induction of IFN-gamma. J Invest

Dermatol, in press

Leb, V.M., B. Jahn-Schmid, K.G. Schmetterer, H. J. Kueng, D. Haiderer, A. Neunkirchner,

G. F. Fischer, K. Nissler, A. Hartl, J. Thalhamer, B. Bohle, B. Seed, W. F. Pickl. Molecular

and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J

Allergy Clin Immunol. In press

Admyre, Ch., B. Bohle, S.M. Johansson, M. Focke-Tejkl, R. Valenta, A. Scheynius, and S.

Gabrielsson. B-cell-derived exosomes can present allergen peptides and activate allergen-

specific T-cells to proliferate and produce Th2-like cytokines. J Allergy Clin Immunol,

120:1418, 2007

Wallner, M., A. Stöckliner, T. Thalhamer, B. Bohle, L. Vogel, P. Briza, H. Breiteneder, S.

Vieths, A. Hartl, A. Mari, C. Ebner, P. Lackner, P. Hammerl, J. Thalhamer, and F. Ferreira.

Allergy multi-vaccines created by DNA shuffling of tree pollen allergens. J Allergy Clin

- 34 -

Immunol, 120:374, 2007

Fuchs, H.C, B. Bohle, Y Dall'Antonia, C. Radauer, K. Hoffmann-Sommergruber, A. Mari, O.

Scheiner, W. Keller and H. Breiteneder. Natural and recombinant molecules of the cherry

allergen Pru av 2 show diverse structural and B cell characteristics but similar T cell

reactivity. Clin Exp Allergy 36:359, 2006

Ma,Y., L. Zuidmeer, L., B. Bohle, S.T. Bolhaar, G. Gadermaier, E. Gonzalez-Mancebo, M.

Ferdandez-Rivas, A.C. Knulst, M. Himly, R. Asero, C. Ebner, R. van Ree, F. Ferreira, H.

Breiteneder and K. Hoffmann-Sommergruber. Characterization of recombinant Mal d 4 and

its application for component-resolved diagnosis of apple allergy. Clin Exp Allergy 36:1087,

2006

Ma,Y., G. Gadermaier, B. Bohle, S. Bolhaar, A. Knulst, Z. Markovic-Housley, H. Breiteneder,

P. Briza, K. Hoffmann-Sommergruber and F. Ferreira. Mutational analysis of amino acid

positions crucial for IgE-binding epitopes of the major apple (Malus domestica) allergen, Mal

d 1. Int Arch Allergy Immunol 139:53, 2006

Fernandez-Rivas, M., S. Bolhaar, E. Gonzlez-Mancebo, R. Asero, A. van

Leeuwen, B. Bohle, Y. Ma, C. Ebner, N. Rigby, A.I. Sancho, S. Miles, L. Zuidmeer, A. Knulst,

H. Breiteneder, C. Mills, K. Hoffmann-Sommergruber and R. van Ree. Apple allergy across

Europe: How allergen sensitization profiles determine the clinical expression of allergies to

plant foods. J Allergy Clin Immunol 118:481, 2006

Dehlink, E., T. Eiwegger, M. Gerstmayr, E. Kampl, B. Bohle, K.W. Chen, S. Vrtala, R.

Urbanek, and Z. Szépfalusi. Absence of systemic immunologic changes during dose-build-up

phase and early maintenance period in effective specific sublingual immunotherapy in

children. Clin Exp Allergy, 36:32, 2006

Roth-Walter, F., B. Bohle, I. Schoell, E. Untersmayr, O. Scheiner, G. Boltz-Nitzlescu, F.

Gabor, D. Brayden, and E. Jensen-Jarolim. Targeting antigens to murine and human M-cells

with Aleuria aurantia lectin-functionalized microparticles. Immunol Lett 100:182, 2005

Jahn-Schmid, B., GF. Fischer, B. Bohle, I. Faé, G. Gadermaier, A. Dedic, F. Ferreira and C.

Ebner. Antigen-presentation of the immunodominant T cell epitope of the major mugwort

pollen allergen, Art v 1, is associated with the expression of HLA-DRB1*01. J Allergy Clin

Immunol 115:399, 2005

- 35 -

Ballmer-Weber, B.K., A. Wangorsch, B. Bohle, S. Kaul, T. Kündig, K. Fötisch, R. van Ree,

and S. Vieths. Component-resolved in vitro diagnosis in carrot allergy: Does the use of

recombinant carrot allergens improve the reliability of the diagnostic procedure? Clin Exp

Allergy, 35:970, 2005

Reisinger J., A. Triendl, Kuchler E, B. Bohle, MT. Krauth, I. Rauter, P. Valent, F. Koenig, R.

Valenta, and V. Niederberger. IFN-gamma-enhanced allergen penetration across respiratory

epithelium augments allergic inflammation. J Allergy Clin Immunol, 115:937, 2005

Aichberger, K.J., I. Mittermann, I., R. Reininger, R., S. Seiberler, I. Swoboda, S. Spitzauer, T.

Kopp, G. Stingl, W. R. Sperr, P. Valent, A. Repa, B. Bohle, D. Kraft and R. Valenta. Hom s 4,

an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins can

induce T helper cell type 1-mediated autoractivity. J Immunol, 175:1286, 2005

Batard, T., A. Didierlaurent, H. Chabre, N. Mothes, L. Bussieres, B. Bohle, M.N. Couret, T.

Ball, P. Lemoine, M. Focke-Teijkl, A. Chenal, G. Clement, F. Dupont, P. Valent, M.T. Krauth,

C. Andre, R. Valenta and Moingeon, P. Characterization of Wild-Type Recombinant Bet v 1a

as a Candidate Vaccine against Birch Pollen Allergy. Int Arch Allergy Immunol, 136:239,

2005

Novak, N., R. Valenta, B. Bohle, S. Laffer, J. Haberstok, S. Kraft, and T. Bieber. FcepsilonRI

engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-

like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J

Allergy Clin Immunol 113:949, 2004

Repa, A., C. Wild, K. Hufnagl, B. Winkler, B. Bohle, A. Pollak and U. Wiedermann. Influence

of the route of sensitization on local and systemic immune responses in a murine model of

type I allergy. Clin Exp Immunol 137:12, 2004

Wagner, M., H. Poeck, B. Jahrsdoerfer, S. Rothenfusser, D. Prell, B. Bohle, E. Tuma, T.

Giese, J. W. Ellwart, S. Endres, and G. Hartmann. IL-12p70-Dependent Th1 Induction by

Human B Cells Requires Combined Activation with CD40 Ligand and CpG DNA. J Immunol

172:954, 2004

Reininger, R., I. Swoboda, B. Bohle, A. Hauswirth, P. Valent, H. Rumpold, R. Valenta, and S.

Spitzauer. Characterization of recombinant cat albumin. Clin Exp Allergy 33:1695, 2003

- 36 -

Jahn-Schmid, B., C. Harwanegg, R. Hiller, B. Bohle, C. Ebner, O. Scheiner, and M. Mueller.

Allergen microarray: comparison of microarray using recombinant allergens with

conventional diagnostic methods to detect allergen-specific serum immunoglobulin E. Clin

Exp Allergy 33:1443, 2003

Himly, M., B. Jahn-Schmid, K. Pittertschatscher, B. Bohle, K. Grubmayr, F. Ferreira, H.

Ebner, and C. Ebner. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug

propyphenazone. J Allergy Clin Immunol 111:882, 2003

Sengoelge, G., J. Kletzmayr, M. Papagiannopoulos, B. Bohle, W. H. Horl, M. Fodinger, and

G. Sunder-Plassmann. TGF-beta1 impairs homocysteine metabolism in human renal cells:

possible implications for transplantation. Transpl Int 16:843, 2002

Loibichler, C., J. Pichler, M. Gerstmayr, B. Bohle, H. Kisst, R. Urbanek, and Z. Szepfalusi.

Materno-fetal passage of nutritive and inhalant allergens across placentas of term and pre-

term deliveries perfused in vitro. Clin Exp Allergy 32:1546, 2002

Jahn-Schmid, B., P. Kelemen, M. Himly, B. Bohle, G. Fischer, F. Ferreira, and C. Ebner. The

T cell response to Art v 1, the major mugwort pollen allergen, is dominated by one epitope. J

Immunol 169:6005, 2002

Fritsch, R., D. Eselbock, K. Skriner, B. Jahn-Schmid, C. Scheinecker, B. Bohle, M. Tohidast-

Akrad, S. Hayer, J. Neumuller, S. Pinol-Roma, J. S. Smolen, and G. Steiner.

Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear

ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol

169:1068, 2002

Breitwieser, A., E. M. Egelseer, D. Moll, N. Ilk, C. Hotzy, B. Bohle, C. Ebner, U. B. Sleytr, and

M. Sara. A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion

protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured

monomolecular lattices and the functionality of the allergen. Protein Eng 15:243, 2002

Rausch-Fan, X., F. Leutmezer, M. Willheim, A. Spittler, B. Bohle, C. Ebner, E. Jensen-

Jarolim, and G. Boltz-Nitulescu. Regulation of cytokine production in human peripheral blood

mononuclear cells and allergen-specific Th cell clones by 1alpha,25-dihydroxyvitamin D3. Int

Arch Allergy Immunol 128:33, 2002

- 37 -

Invited Talks 2002-2008

2006 • XXV EAACI 2006, Vienna • Hautklinik Johannes Gutenberg-Universität Mainz, Germany • University of Salzburg, Austria • Paul Ehrlich Institut, Langen, Germany • 1st International Symposium on Molecular Allergology, Rome, Italy • IV European Asthma Congress, Teneriffe, Canary Islands 2007 • Interdisziplinäres Freiburger Allergiesymposium, Freiburg, Germany • 2.Gemeinsamer Allergiekongress Lübeck , Germany • Pirquet-Club, Kinderklinik, Medical University of Vienna • XXVI EAACI 2007 Göteborg, Sweden • Gesellschaft der Ärzte Wien • 5th EAACI GA2LEN Davos Meeting in Davos, Switzerland • AAAAI, San Diego, USA • 2nd International Symposium on Molecular Allergology, Rome, Italy 2008 • 12th International Paul Ehrlich Seminar, Bad Homburg, Germany • World Immune Regulation Meeting WIRM II, Davos, Switzerland, 17.3.-20.3.2008 • AAAAI, Philadelphia, USA • Paul Ehrlich Seminar, Bad Homburg, Germany • 3rd International Symposium on Molecular Allergology, Salzburg, Austria • XXVII EAACI 2008 Barcelona, Spain • Symposium on Specific Allergy (SOSA) , Copenhagen, Denmark

- 38 -

Curriculum Vitae

Wilfried Ellmeier Division of Immunobiology, Institute of Immunology, Center for Physiology, Pathophysiology and

Immunology, Medical University of Vienna, Lazarettgasse 19, 1090 Wien, Austria; Phone: +43-1-

40160-65003, Fax: +43-1-40160-965006;

Email: [email protected];

Homepage: www.meduniwien.ac.at/immunologie/ellmeier Personal Data

Date of Birth: 09.09.1966

Place of Birth: Mödling

Nationality Austria

Education

1990 – 1994 PhD studies (Biochemistry, Molecular Biology), University of

Vienna, with distinction

1989 – 1990 Diploma thesis at the Institute for Molecular Pathology (IMP) in

Vienna

1985 – 1990 Studies in Biochemistry, University of Vienna

1985 University entrance qualification, HTL-Mödling

Career History

Since 07/2007 Full Professor of Immunobiology

2005 - 2007 Associate Professor (a.o.Univ.Prof)

12/2002 Habilitation in Immunology, University of Vienna Medical

School

2000 Group Leader, Institute of Immunology, University of Vienna

1995 - 1999 Postdoctoral Fellow at the Skirball Institute, Howard Hughes

Medical Institute, New York University Medical Center, New

York, NY, USA

1999 - 1994 PhD Thesis performed at the Institute for Molecular Pathology

(IMP) in Vienna

Career-related Activities

2006 – present Member of the APART and DOC committee of the Austrian

Academy of Sciences

2005 - present Speaker and Coordiantor of the FWF Special Research

Program (Spezialforschungsbreich) SFB F23 „Immunological

- 39 -

Tolerance“

Awards

2005 “Förderungspreis für Wissenschaft”, City of Vienna

2005 Novartis prize 2004 in Biology

2003 Habilitation prize “Verein zur Förderung von Wissenschaft und

Forschung in den Neuen Universitätskliniken am AKH der

Stadt Wien” (VFWF).

2001 START Prize, BMBWK und FWF

2000 - 2002 APART Habilitation Fellowship, Austrian Academy of Sciences

1997 - 1999 Postdoctoral Fellowship of the Howard Hughes Medical

Institute

1995 - 1997 Erwin-Schrödinger Postdoctoral Fellowship, FWF

1993 EMBO "short-term" Fellowship, EMBO

Memberships

Austrian Society for Allergology and Immunology

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2007 - 2010 FWF Molecular characterization of the transcriptional

regulator MAZR

130

2007 - 2010 FWF + MUW DK W1212: Inflammation and Immunity,

subproject 3

44

2005 - 2009 FWF SFB F23 Immunological Tolerance:

SFB Coordination

100

2005 - 2009 FWF SFB F23 Immunological Tolerance: Subproject 5 110

2006 - 2009 EU EU Marie Curie Research & Training Network

(MRTN-CT-2006-035733)

100

2004 - 2006 Federal Bank of

Austria

Molecular Anaylsis of the function of a C2H2

zinc finger containing DNA binding molecules

during T cell development

30

2003 –

2007

FWF Epigenetic and transcriptional regulation of

CD8a and CD8b gene expression

100

2002 Federal Bank of

Austria

The regulation of T cell development:

Identification and characterization of candidate

genes

80

2001 - 2008 FWF and BM:WF

START

Molecular mechanisms of Lymphocyte

Development and Activation

150

- 40 -

2000 - 2004 K-Plus BMT Molecular Analysis of Dendritic Cell Function 100

2000 - 2003 FWF Molecular characterization of CD8 coreceptor

Gene Expression and Lineage Decisions During

T cell Development

110

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2000 - 2004 Colin Feik Molecular and functional characterization of the CD8

enhancer E8III

2001 - 2005 Christina Kösters Gain and Loss of Function Approaches to Study

Immune Cell Development and Function: B-4C- a Key

Player in Dendritic Cell Biology?

2001 - 2005 Bernd Unger Molecular Analysis of dendritic cells and

macrophages

2000 - 2005 Ivan Bilic Epigenetic mechanisms in the transcriptional

regulation of CD8 coreceptor expression during T cell

development

2001 -2006 Martin Melcher The role of Tec family kinases in macrophages

2004 –

present

Shinya Sakaguchi Molecular Analysis of CD8 gene expression

2005 –

present

Julia Raberger Tec family kinases and T cell function

2007 –

present

Wolf Gebhardt Identification of MAZR interacting factors

2007 –

present

Derya Köprölü The role of Tec family kinases in myeloid cells

2007 –

present

Anastasia Abramova Transcriptional regulation of CD8 gene expression

Publications 33 peer reviewed publications in scientific journals, 2 book chapters, > 30 invited lectures, 4

patents

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Ellmeier, W., Sunshine, M.J., Maschek, R. and Littman, D.R. (2002). Combined deletion of CD8 locus cis-regulatory elements affects initiation but not maintenance of CD8 expression. Immunity, 5, 623-34. Kioussis D. and Ellmeier, W. (2002) Chromatin and CD4, CD8A and CD8B gene expression

- 41 -

during thymic differentiation. Nat Rev Immunology, 12, 909-19. Taniguchi, I., Ellmeier, W., and Littman, D.R. (2004). The CD4/CD8 Lineage Choice: New Insights into Epigenetic Regulation During T Cell Development. Adv Immunol, 83, 55-89. Feik, N., Bilic, I., Tinhofer, J., Unger, B., Littman, D.R. and Ellmeier, W. (2005). Functional and Molecular Analysis of the Double-Positive Stage-specific CD8 Enhancer E8III During Thymocyte Development. The Journal of Immunology, 174, 1513-2. Bilic, I., Kösters, K., Unger, B., Hertweck, A., Maschek, R., Wilson, C.B. and Ellmeier, W. (2006) Negative regulation of CD8 expression via CD8 enhancer-mediated recruitment of the zinc finger protein MAZR. Nature Immunology, 7, 392-400. Christina Koesters, C. Bernd Unger, B. Bilic, I., Bluml, S., Lichtenberger, B., Schreiber, M., Stockl, J. and Ellmeier, W. (2007). Regulation of dendritic cell differentiation, maturation and subset distribution by the zinc finger protein CTCF. Immunology Letters, 109, 165-74. Bilic, I, and Ellmeier, W. (2007). The role of BTB domain-containing zinc finger proteins in T cell development and function. Immunology Letters, 108, 1-9. Melcher M, Unger B, Schmidt U, Rajantie IA, Alitalo K, Ellmeier W. 2008. Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival. Journal of Immunology, 180: 8048-56 Co-author manuscripts: Keppler, O.T., Welte, F.J., Ngo, T.A., Kathryn S. Patton, K.S., Tsou, C.L., Abbey, N.W., Sharkey, M.E., Yun You, Y., Scarborough, J.D., Ellmeier, W., Littman, D.R., Stevenson, M., Charo, I.F., Herndier, B.G., Speck, R.F., and Goldsmith, M.A. (2002). Progress Toward a Human CD4/CCR5-Transgenic Rat Model for de Novo Infection by Human Immunodeficiency Virus Type 1. The Journal of Experimental Medicine, 195, 719-36. Atkinson, B., Ellmeier, W., Watson, S.P. (2003). Tec regulates platelet activation by GPVI in the absence of Btk , Blood, 3592-9. Madakamutil, L.T., Gangadharan, D., Chrtisten, U., Lena, C.J., Wang-Zhu, Y., Attinger, A., Ellmeier, W., von Herrath, M.G., Jensen, P., Littman, D.R. and Cheroutre, H. CD8aa+ primary effector cell selectively differentiate into memory CD8 T cells. (2004). Science, 304, 590-93. Schmidt, U., van den Akker, E., Parren-van Amelsvoor, M., , Litos, G., de Bruijn, M., Hendriks, R.W., Ellmeier, W., Beug, H. and von Lindern, M. Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. Journal of Experimental Medicine,199, 785-95. Wu, P.Y., Tabuchi, R.S., Kato, R.M., Astrakan, A., Humblet-Baron, S., Kipp, K., Chae, K., Ellmeier, W., Witte, O.N., and Rawlings, D.J. (2004) Sustained correction of B cell development and function in a murine model of X-linked agamaglobulinemia (XLA) using retroviral.mediated gene transfer. Blood, 104, 1281-90. Sarafova, S.D., Erman, B., Yu, O., Van Laethem, F., Guinter, T., Sharrow, S.O., Feigenbaum, L., Wildt, F.L., Ellmeier, W. and Singer, A. (2005). Transcriptional Modulation of Coreceptor Expression during Positive Selection Dictates Lineage Fate Independently of TCR Specificity and Coreceptor Protein Identity, Immunity, 23:75-87. Marquez, M.E., Ellmeier, W., Sanchez-Guajardo, V., Freitas, A.A:, Acuto, O. and Di Bartolo, V.

- 42 -

(2005). CD8 T cell sensory adaptation dependent on TCR avidity for self-antigens. The Journal of Immunology, 175, 7388-97. Taschner, S., Koesters, C., Platzer, B., Jörgl, A., Ellmeier, W., Benesch, T. and Strobl, H. (2007). Downregulation of RXR expression is essential for neutrophil development from granulocyte/monocyte progenitors. Blood, 109, 971-9. Park JH, Adoro S, Lucas PJ, Sarafova SD, Alag AS, Doan LL, Erman B, Liu X, Ellmeier W, Bosselut R, Feigenbaum L, Singer A. (2007). 'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol. 10:1049-59. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. (2007). The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. PNAS, 104:13283-8. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, Takai T, Kodama T, Morio T, Geha RS, Kitamura D, Kurosaki T, Ellmeier W, Takayanagi H. 2008. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell, 132, 794-806. Invited Talks 2002-2008 2002 • St. Anna Kinderspital, Wien • Institut für Molekulare Pathologie, Wien • Universität Würzburg, Deutschland 2003 • Institute for Medical Biology and Human Genetics, University of Innsbruck • Institute for Pathophysiology, AKH Wien • Institut für Entwicklungsbiologie, Marseille, Frankreich • Talk at the “ThymOz” Conference on Heron Island, Australia 2004 • Technical University of Munich • Selected talk at the Cold Spring Harbor Conference "Gene Expression and Signaling in the Immune System", Cold Spring Harbor, New York, USA • Invitation to Chair and to talk at the minisymposium „Chromatin remodeling during lymphocyte differentiation“ at the 12th International Congress of Immunology, Montreal, 2005 • University of Erlangen, Germany • RIKEN Institute of Allergy and Immunology • Tokyo Medical and Dental University • University of Salzburg • Invited talk at the T cell workshop: “The immunological synapse – kinases in T cell signaling as potential drug targets”. Grossziethen, Germany 2006 • University of Munich, Germany • Karolinska Institute, Sweden • Selected to talk at the Cold Spring Harbor Conference "Gene Expression and Signaling in the Immune System", Cold Spring Harbor, New York, USA • Invited talk at the 3rd Aegean conference on “gene regulation in lymphocyte development. • Invited talk at the 7th EFIS Tatra Immunology Conference. • Invited talk at the EU MC RTN Minisymposium on Immunological mouse models

- 43 -

2007 • University of Oxford, England • Invited talk at the RIKEN workshop on “T cell development and transcription factors”, RIKEN, Yokohama, Japan.

- 44 -

Curriculum Vitae

Erika Jensen-Jarolim Division of Experimental Immunology and Oncology, IPP - Dept. of Pathophysiology, Center for

Physiology, Pathophysiology and Immunology, Medical University of Vienna, Währinger Gürtel

18-20, 1090 Wien, Austria;

Phone: +43-1-40400 - 5110, Fax: +43-1-40400-5130;

Email: [email protected];

Homepage: www.meduniwien.ac.at/ipp; www.allergology.at Personal Data

Date of Birth: 10.04.1960

Place of Birth: Vienna

Nationality Austria

Education

1978 – 1985 MD studies, University of Vienna

Career History

02/2008 Council member of the Veterinary University Vienna

Since 02/2007 Full Professor of Pathophysiology

07/2006 Head of IPP – Dept. Of Pathophysiology

1999 - 2006 Associate Professor (a.o.Univ.Prof)

05/1999 Habilitation in General and Experimental Pathology, Vienna

Medical School

1999 Leader of AllergoOncology Group, IPP

1990-1991 Postdoctoral Fellow at the Inselspital, University of Berne,

Switzerland

1989-1990 Postdoctoral Fellow at Rigshospitalet, Allergy laboratory,

University of Copenhagen, Denmark

Awards

05/2006 Teacher of the Month, Medical University Vienna

12/2005 Great Central-European Prize for Innovative Interdisciplinary

Cancer Research of the Funds of the City of Vienna

05/2005 Researcher of the Month, Medical University of Vienna

03/2005 Award of the ECARF (European Centre for Allergy Research

Foundation), Clinical Allergology.

2004 Bronze Medal of the Slovac Academy of Sciences.

- 45 -

2002 Research Prize of the Austrian Association for Crohn´s

disease and Colitis ulcerosa (ÖMCCV).

“Förderungspreis für Wissenschaft”, City of Vienna

2000 Pirquet Prize of the Austrian Society of Allergology and

Immunology.

1999 Habilitation Prize of the VFWF (Association for the Promotion

of Science and Research at the New University Departments

of the Vienna General Hospital).

1998 Research Prize of the ÖMCCV (Austrian Association for

Crohn´s disease and Colitis ulcerosa).

1990 Research Prize of the Hoechst AG, Frankfurt/Main, Germany

(later continued by Aventis Foundation).

1989 Research Prize of the Danish Allergy Foundation (founded in

1981), University Hospital, Copenhagen, Denmark.

Memberships

Austrian Society for Allergology and Immunology

Collegium Internationale Allergologicum

Verein zur Förderung von Wissenschaft und Forschung in den Neuen Universitätskliniken am

AKH der Stadt Wien (VFWF).

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2000-2003 Biomay “Neue Impfstrategien bei Typ I Allergie” 293

2002-2004 FWF “The role of allergen-specific antibodies and

anti-antibodies in molecular models of type I

allergy“

75

2001-2007 BioLifeSciences “Mimotope zur Therapie maligner Tumore” 101

2002 FWF FWF P14339-B08 „Mimotopes for

Immuntherapy of Allergic Disease II“

56

2003-2005 Fördergesellschaft

Kinderkrebs

“GD2 Mimotope DANN-vaccines for active

immunotherapy of neuroblastoma”

25

2003-2005 Jubiläumsfonds der

ÖNB

ÖNB 10326 “Generation of mimotopes of the

major fish allergen parvalbumin for the

treatment of food allergy – application of

phage display peptide libraries”

53

2004 Jubiläumsfonds der

ÖNB

ÖNB 10965 “Development of an active

immunotherapy for childhood neuroblastoma

55

- 46 -

with mimotope technology”

2004-2005 Hans und Blanca

Moser-Stiftung

“Translation of disialoganglioside epitope in

an immunogenic mimotope for

immunotherapy of neuroblastoma”

9

2005-2008 FWF “Allergen mimotopes for epitope studies and

vaccination”

105

2005-2007 Wiener Wirtschafts-

förderungsfonds

FA648A0201 “Biokompatible Partikel für

Schluckimpfung gegen Allergien”

36

2005-2006 Institut Danone “Das Sensibilisierungspotential von Bet v 1-

Homologen in älteren Patienten und Mäusen

beeinflusst durch antiazide Therapie“

14

2005-2008 FWF FWF P18238-B13 “Development of an oral

mimotope vaccine against tumors“

85

2005-2006 Medizinisch

Wissenschaftlicher

Fonds des

Bürgermeisters der

Stadt Wien

2484 “Development of an active

immuntherapy against carcinoembryonic-

antigen (CEA-) overexpressing tumors

24

2005-2007 Jubiläumsfonds der

ÖNB

ÖNB 11375 “The effect of total gastrectomy

on the development of food allergy in

humans”

49

2005 DAAD A/04/42152 “Magensäure-supprimierende

Medikamente während der Schwangerschaft

führen zur Sensibilisierung gegen

Nahrungsmitteln bei neugeborenen Mäusen”

4

2005 Alexander-von-

Humboldt-Stiftung

OST/11119407S “Magensäure-hemmende

Medikamente während der Schwangerschaft

führen zu Nahrungsmittelallergie im

Mausmodell“

13

2005-2006 Hans und Blanca

Moser-Stiftung

“Orale Mimotop-Immunisierungen zur IgE

Induktion gegen Tumorantigene“

7

2005-2006 Hans und Blanca

Moser-Stiftung

“Testung der anti-Tumor-Wirkung von

Pertuzumab-Epitop-spezifischen anti-HER-2-

Impfstoffen“

5

2006 FWF FWF H220-B13 “Mechanisms in the

sensitization and effector phase of food

allergy“

38

- 47 -

2006-2009 FWF, CCHD FWF W1205-B09 “Cellular interactions

decisive for the type of immune response to

orally applied antigens”

31

2006-2007 Funds of the City of

Vienna for Innovative

Interdisciplinary

Cancer Research

AP00181OFF “Immunogenicity and

therapeutic potency of mimotopes for the

carcinoembryonic antigen (CEA) in

transgenic mouse tumor models”

10

2006-2009 FWF FWF T283-B13 “Antazida induzieren

Nahrungsmittelallergie in Neugeborenen”

58

2006-2007 Hochschuljubiläums-

stiftung der Stadt

Wien

H-2182/2006 “IgE induzierte Ausschüttung

von TNF alpha bei Mastzellen und

basophilen Granulozyten und die Wirkung

auf Tumorzellen“

5

2006-2007 Funds of the City of

Vienna for Innivative

Interdisciplinary

Cancer Research

“Testung der anti-Tumor-wirkung von epitop-

spezifischen HER-2 Impfstoffen in human-

HER-2 transgenen Mäusen”

20

2007-2008 Hans und Blanca

Moser-Stiftung

AP00253OFF “Charakterisierung der

molekularen Mechanismen von Antikörpern

nach aktiver Impfung gegen das

Carcinomembryonale Antigen“

9

2007-2008 Hochschuljubiläums-

stiftung der Stadt

Wien

H-02325/2007 “Effektorzellen der IgE-

vermittelten Überwachung des

Tumorwachstums“

5

2007-2010 FWF, CCHD FWF FA102A004 “Cellular interactions

decisive for the type of immune response to

orally applied antigens“

44

2008-2009 Hans und Blanca

Moser-Stiftung

AP00326OFF “Investigating the tumoricidic

properties of an anti HER-2 antibody of the

IgE subclass

5

2008-2012 FWF “Allergen mimotopes for epitope studies and

vaccination”

154

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2001-2004 Schöll, Isabela PhD: Mechanism of type I allergy and novel

- 48 -

vaccination strategies for treatment.

2003-2006 Schöll, Isabella MDSci: Characterization of conformational epitopes

of allergenic molecules and generation of mimotopes

for active immunotherapy of type I allergies.

2002-2004 Riemer, Angelika B. PhD: Generation of epitope mimics of tumor-

inhibitory monoclonal antibodies: Targeting HER-1

and HER-2.

2003-2006 Untersmayr-Elsenhuber,

Eva

MDSci: Mechanisms of food allergy.

2001-2005 Hantusch, Brigitte PhD: Epitope mimics of grass pollen allergen Phl p 5

from phage display libraries: tools for anti-allergen

immunizations.

2002-2004 Walter, Franziska PhD: Design of an oral vaccine against birch pollen.

2003-2005 Walter, Franziska MDSci: Oral immunisation of allergen-loaded

microsphere with bioadhesive properties and their

impact on the immune system.

2003- in

progress

Szalai, Krisztina MDSci: Mapping and characterization of epitopes of

prevalent inhalative allergens with the mimotope

technology.

2004- in

progress

Szalai, Krisztina PhD: Generation of peptide-mimotopes to allergen-

specific IgE treatment of food allergy. Application of

phage display libraries.

2005 – in

progress

Kntittelfelder, Regina PhD: Molecular and immunological aspects of the

tumor antigen HER-2: a target for immunotherapy.

2006- in

progress

Brämswig, Kira PhD: Therapeutic potency of mimotopes in a

transgenic tumor mouse model.

2006- in

progress

Wallmann, Julia PhD: Immunotherapeutical approaches with different

constructs of grass pollen mimotopes in allergic

asthma.

2008- in

progress

Lukschal, Anna PhD: Epitop specific IgE detection.

2007- in

progress

Starkl, Philipp PhD: Cellular and molecular mechanisms of the

intestinal uptake of food allergens.

2007- in

progress

Krishnamurthy, Durga PhD: The role of the liver in the induction and control

of food allergy.

2008- in

progress

Weichselbaumer, Marlene Dr. med. Vet.: Immunization with carcinoembryonic

antigen (CEA) mimotope vaccine inhibits growth of

- 49 -

CEA positive mammary carcinomas in canine

patients.

Publications >100 peer reviewed publications in scientific journals, 57 invited lectures, patents see depatisnet Peer reviewed manuscripts 2002-2008 (original research and reviews)

First, last or corresponding author manuscripts:

Jensen-Jarolim E, Untersmayr E. Gender Medicine Aspects in Allergology. Allergy, in press. Hantusch B, Jensen-Jarolim E. Von der Allergenerkennung durch Antikörper zu neuen therapeutischen Konzepten. Wiener Med. WSchr, in press.

Untersmayr E, Diesner S, Brämswig KH, Bakos N, Wallmann J, Knittelfelder R, Szalai K, Schöll I, Scheiner O, Duschl A, Jensen-Jarolim E. Characterization of intrinsic and extrinsic risk factors for celery allergy in immuno-senescence. Mechanisms of Ageing and Development, in press.

Untersmayr E, Lukschal A, Hemmer W, Jarisch R, Jensen-Jarolim E. Exercise with latex sport bands represents a risk for latex allergic patients. Immunol. Letters, in press

Szalai, K., Fuhrmann J, Pavkov T, Keller W, Wallmann J, Vrtala S, Scheiner O, Saint-Remy J-M, Neumann D, Pali-Schöll I, Jensen-Jarolim E*. Mimotopes identify conformational B-cell epitopes on the two major house dust mite allergens Der p 1 and Der p 2. Mol Immunol, 2007 Oct 25; (Epub ahead of print).

Brämswig KH, Knittelfelder R, Riemer AB, Gruber S, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E. Mimotope immunization prevents growth of CEA-positive tumors in BALB/c mice. Clin Cancer Res, 2007 Nov 1; 13(21): 6501-6508.

Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Research 2007, Cancer Res. Apr.1; 67 (7): 3406-11. 2007.

Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, Jensen-Jarolim E, Pali-Schöll I. The impact of aluminum in acid-suppressing drugs on the immune response of BALB/c mice. Clin. Exp. Allergy, 2007 Oct;37(10):1566-73. Epub 2007 Sep 10.

Schöll I, Ackermann U, Blümer N, Özdemir C, Dicke T, Sel Se, Sel Sa, Wegmann M, Szalai K, Knittelfelder R, Untersmayr E, Scheiner O, Garn H, Jensen-Jarolim E, Renz H. Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2 bias in their offspring. FASEB, Apr;21(4):1264-70, 2007.

Riemer AB and Jensen-Jarolim E. Mimotope vaccines: Epitope mimics induce anti-cancer antibodies. Immunology Letters. 113(1): 1-5. 2007. Roth-Walter F, Jensen-Jarolim E. Oral immunotherapy against type I allergy. Allergy & Clinical Immunology International., J World Allergy Org, vol. 19, no. 1, pp. 21-26. 2007

- 50 -

Jensen-Jarolim E and Riemer AB. Small mimotopes are big in identifying B-cell epitopes. Blood, 15 Sept 2006, 108 (6): 1794-1795. 2006.

Bakos N, Schöll I, Szalai K, Kundi M, Untersmayr E, Jensen-Jarolim E. Risk assessment for elderly to develop respiratory and food allergy. Immunol. Letters 107 (1): 15-21. 2006.

Untersmayr E and Jensen-Jarolim E. Mechanisms of Type I food allergy. Pharmacol. Ther. 2006, Jul 26 (Epub ahead of print).

Untersmayr E and Jensen-Jarolim E. The effect of gastric digestion on food allergy. Curr. Opinion in Allergy & Clin Immunol. 6 (3): 214-9. 2006.

Schöll I, Kopp T, Bohle B, Jensen-Jarolim E. Biodegradable PLGA particles for improved systemic and mucosal treatment of type I allergy. Immunol Allergy Clin North Am, 26 (2): 349-64. 2006.

Riemer AB, Förster-Waldl E, Brämswig K, Pollak A, Zielinski CC, Pehamberger H, Lode HN, Scheiner O, Jensen-Jarolim E. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur. J. Immunol 36 (5): 1267-74. 2006.

Hantusch B, Knittelfelder R, Wallmann J, Krieger S, Szalai K, Untersmayr E, Volgel M, Stadler BM, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Internal images: Human anti-idiotypic Fab antibodies mimic the IgE epitopes of grass pollen allergen Phl p 5a. Mol. Immunol. 43 (14): 2180-7. 2006.

Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with Cetuximab mimotopes induces anti-EGFR antibodies with similar biological properties as the original antibody. J Nat.Cancer Inst 97 (22): 1663-70. 2005.

Schöll I, Kalkura N, Sheziankova Y, Bergmann A, Verdino P, Knittelfelder R, Kopp T, Betzel C, Dierks K, Hantusch B, Scheiner O, Boltz-Nitulescu G, Keller W, Jensen-Jarolim E. Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE crosslinking potential in mice. J. Immunol 175 (10): 6645-50. 2005.

Untersmayr E, Szalai K, Riemer AB, Hemmer W, Swoboda I, Hantusch B, Schöll I, Spitzauer S, Scheiner O, Jarisch R, Boltz-Nitulescu G, Jensen-Jarolim E. Mimotopes identify conformational epitopes on parvalbumin, the major fish allergen. Mol Immunol. 2006, 43 (9): 1454-61. Epub Sept. 5 2005..

Jensen-Jarolim E, Untersmayr E. Food safety: In vitro digestion assays are non predictive for allergenic potential of food in stomach insufficiency. View letter. Immunol. Letters 102 (1): 118-119. 2005, Epub 2005 Aug 18.

Szalai K, Schöll I, Förster-Waldl E, Polito L, Bolognesi A, Untersmayr E, Riemer AB, Boltz-Nitulescu G, Stirpe F, Jensen-Jarolim E. Occupational sensitization to ribosomal-inactivating proteins (RIPs) in researchers. Clin. Exp. Allergy, 35 (10): 1354-60.

Untersmayr E, Jensen-Jarolim E. In vitro tests zur Bestimmung der allergenen Potenz von "novel foods" und GVOs (genetisch modifizierten Organismen): Relevanz in vivo? Wiener Klin. Wochenschrift (117. Jg), 13-14: 437-439. 2005.

Roth-Walter F, Bohle B, Schöll I, Untersmayr E, Scheiner O, Boltz-Nitulescu G, Gabor F, Brayden D, Jensen-Jarolim E. Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. Immunol. Letters 2005, May 20 [Epub ahead of

- 51 -

print]

Untersmayr E, Jensen-Jarolim E. Anti-azide Therapie und verdauungslabile Allergene. Allergologie Jg. 28/4: 134-142. 2005.

Schöll I, Boltz-Nitulescu G, Jensen-Jarolim E. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Contr. Release 2005; 104 (1): 1-27.

Rausch-Fan X, Ulm C, Jensen-Jarolim E, Schedle A, Boltz-Nitulescu G, Matejka M. IL-1b-induced PGE2 production by human gingival fibroblasts is up-regulated by glycine. J. Periodontology 76(7): 1182-1188. 2005.

Roth-Walter F, Schöll I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 23(21): 2703-10. 2005.

Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of the trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu: a new method for epitope definition. Mol. Immunol. 42 (9): 1121-24. 2005. Epub 2005 Jan 8.

Untersmayr E, Poulsen LK, Platzer MH, Pedersen MH, Boltz-Nitulescu G, Skov PS, Jensen-Jarolim E. The effects of gastric digestion on codfish allergenicity. J Allergy Clin Immun 115 (2): 377-382. 2005.

Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J. 19 (6): 656-8. 2005 Jan 25; [Epub ahead of print]

Schöll I, Untersmayr E, Bakos N, Roth-Walter F, Gleiss A, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Antiulcer drugs promote oral sensitization and hypersensitivity to hazelnut allergens in BALB/c mice and humans. Am J Clin Nutr. 2005 Jan;81(1):154-60.

Hantusch B, Schöll I, Harwanegg C, Krieger S, Becker WM, Spitzauer S, Boltz-Nitulescu G, Jensen-Jarolim E. Affinity determinations of purified IgE and IgG antibodies against the major pollen allergens Phl p 5a and Bet v 1a: discrepancy between IgE and IgG binding strength. Immunol Lett. 2005 Feb 15;97(1):81-9.

Förster-Waldl E, Riemer AB, Dehof AK, Neumann D, Bramswig K, Boltz-Nitulescu G, Pehamberger H, Zielinski CC, Scheiner O, Pollak A, Lode H, Jensen-Jarolim E. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol. 2005 Feb;42(3):319-25.

Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, Scheiner O, Pehamberger H, Jensen-Jarolim E. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother. 54 (7): 677-684. 2005. [Epub] 2004 Nov 24;

Schöll I, Jensen-Jarolim E. Allergenic potency of spices: hot, medium hot, or very hot. Int Arch Allergy Immunol. 2004 Nov;135(3):247-61. Epub 2004 Nov 03. Review.

Roth-Walter F, Schöll I, Untersmayr E, Fuchs R, Boltz-Nitulescu G, Weissenbock A, Scheiner O, Gabor F, Jensen-Jarolim E. M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J Allergy Clin Immunol. 2004 Dec;114(6):1362-8.

- 52 -

Hantusch B, Krieger S, Untersmayr E, Schöll I, Knittelfelder R, Flicker S, Spitzauer S, Valenta R, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Mapping of conformational IgE epitopes on Phl p 5a by using mimotopes from a phage display library. J Allergy Clin Immunol. 2004 Dec;114(6):1294-300.

Untersmayr E, Ellinger A, Beil WJ, Jensen-Jarolim E. Eosinophils accumulate in the gastric mucosa of food-allergic mice. Int Arch Allergy Immunol. 2004 Sep;135(1):1-2. Epub 2004 Jul 29. No abstract available.

Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol. 2004 Jul 1;173(1):394-401.

Brunner M, Krenn C, Roth G, Moser B, Hetz H, Dworschak M, Jensen-Jarolim E, Wolner E, Spittler A, Sautner T, Bonaros N, Boltz-Nitulescu G, Ankersmith HJ. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med., 30 (7): 1468-73. 2004. Epub 2004 Feb 28.

Riemer A, Scheiner O, Jensen-Jarolim E. Allergen mimotopes. Methods. 2004 Mar;32(3):321-7. Review.

Walter F, Schöll I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E. Functionalization of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes. Biochem Biophys Res Commun, 315/2, 281-287. 2004.

Schoell I, Weissenböck A, Foerster-Waldl E, Untersmayr E, Walter F, Willheim M, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E. Allergen-loaded biodegradable PLGA nanoparticles down-regulate an ongoing Th2-response in the BALB/c mouse model. Clin Exp Allergy, 34(2):315-21. 2004.

Foerster E, Marchetti C, Focke M, Schoell I, Boltz-Nitulescu G, Scheiner O, Schmid E.R, Jensen-Jarolim E. Type I allergy to elderberry is elicited by a 33.2 kDa allergen with significant homology to ribosomal inactivating proteins (RIPs). Clin Exp Allergy, 33(12): 1703-1710. 2003.

Untersmayr E, Schöll I, Swoboda I, Beil WJ, Förster-Waldl E, Walter F, Riemer A, Kraml G, Spitzauer S, Kinaciyan T, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Antacid medication inhibits digestion of dietary proteins and causes food allergy: An fish allergy model in Balb/c mice. J Allergy Clin Immun, 112: 616-623. 2003.

Schöll I, Boltz-Nitulescu G, Jensen-Jarolim E. Mimotope und ihre Bedeutung für die Allergologie. Allergo Journal 6: 339-404. 2003.

Jensen-Jarolim E, Gscheidlinger R, Oberhuber G, Neuchrist C, Lucas T, Bises G, Radauer C, Willheim M, Scheiner O, Liu FT, Boltz-Nitulescu G. The constitutive expression of galectin-3 is downregulated in intestinal epithelia of Crohn's disease patients, and tumour necrosis factor alpha decreases the level of galectin-3-specific mRNA in HCT-8 cells. Eur J Gastroenterol Hepatol 14: 145-152. 2002.

Jensen-Jarolim E, Schmid B, Bernier F, Berna A, Kinaciyan T, Focke M, Scheiner O, Boltz-Nitulescu G. Allergologic exploration of germins and germin-like proteins, a new class of plant allergens. Allergy 57: 805-810. 2002.

Untersmayr E, Focke M, Kinaciyan T, Poulsen LK, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Anaphylaxis to Russian Beluga caviar. J Allergy Clin Immunol 109: 1034-5. 2002.

- 53 -

Schöll I, Ganglberger E, Förster-Waldl E, Vermes M, Baier K, Boltz-Nitulescu G, Scheiner O, Ebner C, Wiedermann U, Jensen-Jarolim E. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B-cell responses to the natural allergen using bystander help of T-cells. Clin Exp Allergy, 32: 1583-1588. 2002.

Co-author manuscripts:

Roth-Walter F, Berin CM, Arnaboldi P, Escalante C, Dahan S, Jensen-Jarolim E, Mayer L. Pasteurization of milk proteins promotes allergic sensitization in mice by enhancing uptake through Peyer’s patches. J Allergy Clin Immun., in press.

Untersmayr E, Vestergaard H, Malling H-J, Bjerremann Jensen L, Platzer MH, Boltz-Nitulescu G, Scheiner O, Skov PS, Jensen-Jarolim E, Poulsen LK. Indigestion of codfish represents a risk factor for anaphylaxis in allergic patients. JACI 119(3): 711-7. 2007.

Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, Jensen-Jarolim E, Pali-Schöll I. The impact of aluminum in acid-suppressing drugs on the immune response of BALB/c mice. Clin. Exp. Allergy, 2007 Oct;37(10):1566-73. Epub 2007 Sep 10.

Jin C, Bencurova M, Borth N, Ferko B, Jensen-Jarolim E, Altmann F, Hantusch B. Immunoglobulin E specifically bind plant N-glycans with high affinity could be generated in rabbits but not in mice. Glycobiology 16 (4): 349-57. 2006. [Epub 2005 Dec 21].

Fest S, Huebner N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C, Gaedicke G, Riemer AB, Michalsky E, Jaeger IS, Preissner R, Förster-Waldl E, Jensen-Jarolim E, Lode HN. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 66 (21): 1-9. 2006.

Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Heighthened levels of circulating S20 proteasome in critically ill patients. J. Clin. Invest. 35: 399-403. 2005.

Wagner S, Radauer C, Hafner C, Fuchs H, Jensen-Jarolim E, Wuthrich B, Scheiner O, Breiteneder H. Characterization of cross-reactive bell pepper allergens involved in the latex-fruit syndrome. Clin Exp Allergy. 2004 Nov;34(11):1739-46. PMID: 15544599

Beil W, McEuen AR, Schulz M, Wefelmeyer U, Kraml G, Walls AF, Jensen-Jarolim E, Pabst R, Pammer J. Selective alterations in mast cell subsets and eosinophil infiltration in two types of intestinal inflammation: Ascariasis and Crohn´s disease. Pathobiology. 2002-2003;70(6):303-13.

Mota G, Manciulea M, Cosma E, Popescu I, Hirt M, Jensen-Jarolim E, Calugaru A, Galatiuc C, Regalia T, Tamandl D, Spittler A, Boltz-Nitulescu G. Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol, 33: 2197-2205. 2003.

Ankersmith HJ, Moser B, Roth G, Bruinner M, Buchta C, Wolner E, Jensen-Jarolim E, Boltz-Nitulescu G, Volf I. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. Am J Transplant. 3: 754-759. 2003.

Hafner C, Samwald U, Wagner S, Felici F, Heere-Ress E, Jensen-Jarolim E, Wolff K, Scheiner O, Pehamberger H, Breiteneder H. Selection of mimotopes of the cell surface adhesion molecule Mel-CAM from a random pVIII-28aa phage peptide library. J Invest Dermatol 119:865-869. 2002.

Rausch-Fan X, Leutmezer F, Spittler A, Bohle B, Jensen-Jarolim E, Ebner C, Boltz-Nitulescu G. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-

- 54 -

specific Th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 128:33-41. 2002.

- 55 -

Curriculum Vitae

Sylvia Knapp, MD, PhD Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences and

Department of Medicine 1, Division of Infectious Diseases & Tropical Medicine, Medical

University Vienna; Währinger Gürtel 18-20, 1090 Vienna

Phone: +43-1-40400-5139 or 5140, Fax: +43-1-40400-5167

E-mail: [email protected]

Personal Data

Date of Birth: 15.09.1968

Place of Birth: Innsbruck

Nationality Austria

Education

24.11.2006

2001-2005

Ph.D. degree conferred by the University of Amsterdam, the

Netherlands

Ph.D. studies at the Academic Medical Center, University of

Amsterdam, the Netherlands

29.3.2004 Habilitation in Internal Medicine

1.5.2000 Licence in Internal Medicine

1994-2000 Residency in Internal Medicine, MUW

12.7.1993

1986 – 1993

M.D. degree conferred by the University of Vienna

Study of Medicine, University Vienna, Austria

03/91 – 10/91 Study of Medicine, Free University Berlin, Germany

Career History

10/2006 –

04/2006 –

Appointment as Head of Laboratory of the Division of Infectious

Diseases, Medical University Vienna

Principle Investigator at the Research Center for Molecular Medicine

(CeMM) of the Austrian Academy of Sciences

2005 – 9/2006 Staff member Intensive Care Unit, Dept. of Internal Med. I, Medical

Univ. Vienna: clinical duties and set-up of research lab

2001 – 2005 PhD study at the University of Amsterdam, Lab. of Experimental

Internal Medicine: research topic: Role of Toll-like receptors during

bacterial infections, supervisor: Prof. Dr. T. van der Poll

1994 – 2001 Residency in Internal Medicine, Medical University Vienna

1992 – 1994 Research fellow at Dept. of Internal Med. I, supervisor: Prof. Dr. U.

Jäger; topic: t14;18 breakpoint region binding proteins in follicular

lymphomas

- 56 -

08/1991 Summer Training Course in Laboratory Virology, National Institute of

Health, Department of Pathology, Tokyo, Japan, Prof. Dr. T. Kurata

05-07/1989 Undergraduate Research Training in the field of Kinins, Institute of

Physiology, University of Vienna, Prof. Dr. B. Binder

Career-related Activities

2003 – Reviewer for: J. Immunol, J. of Leukocyte Biology, Am. J. Physiol,

Clin. Immunol., J. of Endotoxin Res., Microbes and Infection, Expert

Review of Clinical Immunology, FEBS Letters, Scand. J. of Infectious

Diseases

2007 – Editorial Board Member: Clinical Immunology

2006 Member of Local Organizing Committee: International Cytokine

Conference, held in Vienna, 08/06

2004 – Reviewer for Hongkong Grant Council Review Board, Austrian

Academy of Sciences

2005 – Lecturer Tertial: Emergency and Intensive Care Medicine, MUW

2006 –

1998 –

PhD Supervisor (2)

(Co-)Supervision of MD-thesis students (6)

1994 – Attendance of various clinical courses, such as bronchoscopy,

gastroscopy, pacemaker, respirator,..

1996 – Various lectures for students and postgraduate lectures for clinicians

Awards

2007 Forschungspreis der Erste Bank

2006

2005

Förderpreis of the Austrian Society of Antimircobrial Chemotherapy

Förderpreis of the Austrian Society of Antimicrobial Chemotherapy

2005 Erwin Deutsch Award by the Austrian Society of Intensive Care

Medicine

1999 Award for Emergency Medicine

1994 Türck-Award by the Austrian Society of Hematology

1993 Hans and Blanca Moser Student’s fellowship

1990 Scholarship (Leistungsstipendium) of the University of Vienna

Memberships

Austrian Society of Internal Medicine

Austrian Society of Hematology

Austrian Society for antimicrobial Chemotherapy

Society of Critical Care Medicine

- 57 -

Austrian Society of Intensive Care Medicine Sources of funding in last 5 years (2002-2007)

Period Organization Short Title K€/year 2000-

2003

Bürgermeister Stadt

Wien

Intracellular Cytokines in Sepsis 8

2001-

2002

FWF (Schrödinger) The role of TLRs in infection 24

2002-

2003

FWF (Schrödinger) The role of TLRs in infection 24

2006-

2009

FWF (P18232-B11) Immunmodulatory role of oxidized

phospholipids (together with V.

Bochkov, * = 45% share)

90 *

2006-

2009

CeMM Innate immune response to bacterial

infections

230

2006-

2007

Jubiläumsstiftung Stadt

Wien, via Österr. Akad.

Wissenschaften

Leukozyte-migration during pneumonia 45

PhD supervision in last 5 years (2003-2008)

Period Name of student Topic

2003 – Ulrich Matt Endogenous modulators of inflammation

– impact on infectious diseases

2003 – Ana Zivcovic Role of PVL in S. aureus pneumonia

Publications 58 peer reviewed publications in scientific journals, 2 book chapters, 22 invited lectures Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Knapp, S., von Aulock, S., Leendertse, M., Haslinger, I., Draing, C., Golenbock, D., van der Poll, T. (2008) Lipoteichoic Acid-induced Lung Inflammation depends on TLR2 and the concerted action of TLR4 and Platelet-activating Factor Receptor. J Immunol 180, in press Knapp, S., Matt, U., Leitinger, N., van der Poll, T. (2007) Oxidized phospholipids inhibit phagocytosis and impair outcome in gram-negative sepsis in vivo. J Immunol 178, 993-1001 Knapp, S., Florquin, S., Golenbock, D. T., and van der Poll, T. (2006) Pulmonary LPS-binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol 176, 3189-3195 Knapp, S., Wieland, C. W., Florquin, S., Pantophlet, R., Dijkshoorn, L., Tshimbalanga, N., Akira, S., and van der Poll, T. (2006) Differential role of CD14 and Toll-like receptors 2 and 4 during Acinetobacter pneumonia. Am J Respir Crit Care Med 173, 122-129

- 58 -

Knapp, S., Schultz, M. J., and Poll, T. V. (2005) Host defense mechanisms in murine pneumoniae models. Shock 24 Suppl 1, 12-18 Knapp, S., van der Poll, T. (2004) Update on CD14, LBP and Toll-like receptors in acute infections. Yearbook of Intensive Care and Emergency Medicine (Vincent, J. L., ed), pp. 3-14, Springer Verlag, Brussels Knapp, S., Wieland, C. W., van 't Veer, C., Takeuchi, O., Akira, S., Florquin, S., and van der Poll, T. (2004) Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 172, 3132-3138 Knapp, S., Gibot, S., de Vos, A., Versteeg, H. H., Colonna, M., and van der Poll, T. (2004) Cutting Edge: Expression Patterns of surface and soluble TREM-1 in Human Endotoxemia. J Immunol 173, 7131-7134 Knapp, S., Hareng, L., Rijneveld, A. W., Bresser, P., van der Zee, J. S., Florquin, S., Hartung, T., and van der Poll, T. (2004) Activation of Neutrophils and Inhibition of the

Proinflammatory Cytokine Response by Endogenous Granulocyte Colony-Stimulating Factor in

Murine Pneumococcal Pneumonia. J Infect Dis 189, 1506-1515 Knapp, S., De Vos, A. F., Florquin, S., Golenbock, D. T., and Van Der Poll, T. (2003) Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice. Infect Immun 71, 6747-6753 Knapp, S., Leemans, J. C., Florquin, S., Branger, J., Maris, N. A., Pater, J., van Rooijen, N., and van der Poll, T. (2003) Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167, 171-179. Knapp, S., Branger, J., and van der Poll, T. (2002) Advances in research of the inflammatory response: The importance of Toll-like receptors. Wien Med Wochenschr 152, 552-554 Co-author manuscripts: Dessing, M., Knapp, S., Florquin, S., de Vos, A.F., van der Poll, T. (2007) CD14 facilitates invasive respiratory tract infections by Streptococcus pneumoniae. Am J Respir Crit Care 175, 604-611 Renckens, R., Roelofs, J. J., Knapp, S., de Vos, A. F., Florquin, S., and van der Poll, T. (2006) The acute phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter. J Infect Dis 193, 187-195 van Westerloo, D. J., Knapp, S., van't Veer, C., Buurman, W. A., de Vos, A. F., Florquin, S., and van der Poll, T. (2005) Aspiration pneumonitis primes the host for an exaggerated inflammatory response during Klebsiella pneumonia: the role of tumor necrosis factor-α. Crit Care Med 33, 1770-1778 Branger, J., Knapp, S., Weijer, S., Leemans, J. C., Pater, J. M., Speelman, P., Florquin, S., and van der Poll, T. (2004) The role of Toll-like Receptor 4 in Gram-positive and Gram-negative pneumonia in mice. Infect Immun 72, 788-794 Branger, J., Florquin, S., Knapp, S., Leemans, J. C., Pater, J. M., Speelman, P., Golenbock, D. T., and van der Poll, T. (2004) LPS-Binding Protein-deficient mice have an impaired Host Defense against Gram-negative but not Gram-postive pneumonia. Int. Immunol. 16, 1605-1611

- 59 -

Wieland, C. W., Knapp, S., Florquin, S., De Vos, A. F., Takeda, K., Akira, S., Golenbock, D. T., Verbon, A., and Van Der Poll, T. (2004) Toll-like Receptor (TLR) 2, but not LBP, CD14 or TLR4, mediates lung inflammation by non-capped lipoarabinomannan: relevance for atypical mycobacterial infections. Am J Respir Crit Care Med 170: 1367-1374 von Aulock, S., Morath, S., Hareng, L., Knapp, S., van Kessel, K. P., van Strijp, J. A., and Hartung, T. (2003) Liopteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology 208, 413-422 Schultz, M. J., Knapp, S., Florquin, S., Pater, J., Takeda, K., Akira, S., and Van Der Poll, T. (2003) nterleukin 18 impairs the pulmonary host response against Pseudomonas aeruginosa. Infect Immun 71, 1630-1634. Delle Karth, G., Koreny, M., Binder, T., Knapp, S., Zauner, C., Valentin, A., Honninger, R., Heinz, G., and Siostrzonek, P. (2002) Complicated infective endocarditis necessitating ICU admission: clinical course and prognosis. Crit Care 6, 149-154 Invited Talks 2002-2008 2003 • Toll-like receptors: Week of Allergy, EAACI, Ghent, Belgium, 18. Nov 2003 • The role of LBP in the innate immune response to bacteria, Seminar of the Dept. of Infectious Diseases, Academic Medical Center, Univ. Amsterdam, 13. Feb 2003 • Role of alveolar macrophages during pneumococcal pneumonia: Van Loghem Research Meeting, Amsterdam, The Netherlands, Jan 2003 2004 • The role of Toll-like Receptors during pulmonary inflammation: International Symposium on Thrombocyte and Leukocyte Immunobiology, Rust, Austria, May 2004 • The role of TLR2 during pneumococcal pneumonia: Van Loghem Research Meeting, Amsterdam, the Netherlands, 9. Feb. 2004 2005 • Treatment of Sepsis: Euroconference: Interactions between innate and adaptive immunity in mammalian defense against bacterial infections, Joachimstal (Berlin), Germany, June 2005 2006 • Innate Immune response to bacterial infections, Vet. Med. Seminars of the Institute of genetics and animal breeding, Vienna, 4.12.2006, Host: Prof. Dr. M. Mueller • Host defense mechanisms during bacterial pneumonia: Innate Immunity, Receptors, Response, Regulation: Joint Meeting of the Society of Leukocyte Biology and Int. Endotoxin and Innate Immunity Society, San Antonio, Texas, 11. Nov. 2006 • Pneumonie auf der Intensivstation: Expertpanel on Pneumonia, Linz, 26. June 2006 • Pathophysiologie der Sepsis: Wiener Intensivmedizinische Tage, Vienna, Feb. 2006 • Deutsch-österr. Kongress für Intensivmedizin, Saarbrücken, Germany, June 2006 2007 • Novel treatment options in sepsis, Annual Meeting of the Austrian Society of Lung diseases, Salzburg, 5.10.2007 • Toll and Toll-free Receptors in Sepsis: Sepsis workshop, Austrian Sepsis Society, Vienna, 5.5.2007, Host: Prof. Dr. H. Burgman • Innate Immune Response Mechanisms during bacterial infections: Infection and Immunology Seminars, University of Innsbruck, 7.2.2007, Host: Prof. Dr. G. Weiss • Role of Toll-like Receptors during bacterial Pneumonia: Seminar of the Max Perutz

- 60 -

Laboratory, Inst. of Microbiology and Immunology, 26.1.2007, Host: Prof. Dr. T. Decker • Abwehrmechanismen bei Pneumonie: Fortbildung der CeMIC, Vienna, 16.1.2007 2008 • Innate Immunity, KIT (Meeting of Infectios Diseases and Tropical Medicine), Innsbruck 28.2.2008 • TLR and NLR in Sepsis, Wilheminenspital Vienna, 14.1.2008

- 61 -

Curriculum Vitae Herwig Kollaritsch Division of Travel Medicine and Infectious Disease Epidemiology, Institute for Specific

Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology,

Medical University of Vienna, Kinderspitalgasse 15, 1090 Wien, Austria;

Phone: +43-1-40490 64850, Fax: +43-1-403 83 43 90;

Email: [email protected]

Personal Data

Date of Birth: 11.02.1956

Place of Birth: Vienna

Nationality Austria

Education

1993 Tropical Medicine update, London School of Hygiene and

Tropical Medicine

1991 Intensive Course on Tropical Medicine, Liverpool, UK

1990 Speciality in Hygiene, Microbiology and Preventive

Medicine

1989 Speciality in Specific Prophylaxis and Tropical Medicine

1985-1987 Field education Tropical Medicine, Nigeria

1982 DTM at Bernhard Nocht Institute for Tropical Medicine,

Hamburg, Germany

1981- Assistant Institute of Specific Prophylaxis and Tropical

Medicine, Univ.Vienna

1980/1981 Assistant, Infectious Disease Unit, Kaiser Franz Josef

Spital, Vienna

1974-1980 Medical doctor, University of Vienna

1974 University entrance qualification, Theresianum Wien

Career History

2004- Group Leader, Travel Medicine and Infectious Disease

Epidemiology

1997-2004 Head, Institute of Specific Prophylaxis and Tropical

Medicine

1996- Associate Professor (a.o.Univ.Prof)

1989 Habilitation in Specific Prophylaxis and Tropical Medicine,

University of Vienna Medical School

- 62 -

Career-related Activities 2007- Member of the Scientific Board of the Ministry of Defense

Republic of Austria 2007-

Member of the Scientific Board of the Ministry of Defense,

Republic of Austria

2003- Board Member of the Comission for International

Development at the Austrian Academy of Sciences

1999- Co-chair of the Advisory Board for Immunization Practices

of the Republic of Austria

1999- Member of the “Arzneimittelsicherheitsausschuss”

(supreme board for supervision of adverse drug reactions)

of Austria

1996- Member of TROPMEDEUROP (association of the Tropical

Institutes in Europe)

2000 - Board Member and Founding Member Austrian Society for

Travel- and Touristic Medicine

1984 - Local Secretary, The Royal Society of Hygiene & Tropical

Medicine, UK

1983 - Board Member, Austrian Society of Tropical Medicine and

Parasitology

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2000-2003 FWF Field validation of a HRP2-assay 30

1999-2003 Federal Bank of

Austria

Surveillance of vaccine preventable diseases

in Austria (Project 6165)

15

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2003-2005 Ulrich Gerstner Interactions between bloodchizontocidal arylaminoalkohols and other substance classes against Plasmodium falciparum in Thailand

2003-2005 Kamala Thriemer Interaction of Retinal and other antimalarials in Plasmodium falciparum

2003-2005 Leila Kyavar In vitro investigations of sensititvity of fresh isolates of Plasmodium vivax against chloroquin and other bloos schizonotocidals

2005-2006 Peter Starzengruber In vitro sensitivity of Plasmodium falciparum against Artemisinin, Chloroquine, Quinine and Mefloquine. Pharmacodynamic interactions between Lumefantrine and Monodesbutyl-Benflumetol

- 63 -

2005-2006 Maria Parizek In vitro sensitivity of Plasmodium falciparum against Lumefantrine and Desbutyl-Benflumetol. Pharmacodynamic interactions between Desbutyl-Benflumetol and Retinol

Publications Currently ~320 publications overall, 112 in peer-reviewed and Medline indexed scientific journals, 10 books, more than 20 book articles Peer reviewed manuscripts 2002-2008 (original research and reviews) Publications total: 53 (2002-2007) a) first, corresponding or last author total: 24 Top journals: 12 Bröker M, Kollaritsch H. After a tick bite in a tick-borne encephalitis virus endemic area: Current positions about post-exposure treatment. Vaccine. 2008 Feb 13;26(7):863-8. Epub 2007 Dec 4. Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, Klade CS. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007 Dec 1;370(9602):1847-53. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J. 2007 Sep;26(9):806-10. Rendi-Wagner P, Korinek M, Mikolasek A, Vécsei A, Kollaritsch H. Epidemiology of travel-associated and autochthonous hepatitis A in Austrian children, 1998 to 2005. J Travel Med. 2007 Jul-Aug;14(4):248-53. Rendi-Wagner P, Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B, Kollaritsch H. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine. 2007 Jun 28;25(27):5097-101. Epub 2007 Feb 20. Kollaritsch H, Wiedermann U. [Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea] Wien Med Wochenschr. 2007;157(5-6):102-6. Review. German. Wiedermann U, Kollaritsch H. Vaccines against traveler's diarrhoea and rotavirus disease - a review. Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):2-8. Review. Kollaritsch H, Maurer W. [Rabies: epidemiology, pre- and postexposure immunization] Wien Klin Wochenschr. 2006 Jun;118(11-12):312-20. Review. German. Rendi-Wagner P, Kundi M, Mikolasek A, Mutz I, Zwiauer K, Wiedermann U, Vécsei A,

- 64 -

Kollaritsch H. Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wien Klin Wochenschr. 2006 May;118(9-10):280-5. Rendi-Wagner P, Kundi M, Mikolasek A, Vécsei A, Frühwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine. 2006 Aug 14;24(33-34):5960-5. Epub 2006 May 23. Rendi-Wagner P, Zent O, Jilg W, Plentz A, Beran J, Kollaritsch H. Persistence of antibodies after vaccination against tick-borne encephalitis. Int J Med Microbiol. 2006 May;296 Suppl 40:202-7. Epub 2006 Mar 9. Review. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, Cerny A, Heim M, Bach D, Schroeder M, Kollaritsch H. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine. 2006 Apr 5;24(15):2781-9. Epub 2006 Jan 19. Rendi-Wagner P, Jeschko E, Kollaritsch H; österreichische Expertengruppe für Reisemedizin. [Travel vaccination recommendations for Central and Eastern European countries based on country-specific risk profiles] Wien Klin Wochenschr. 2005;117 Suppl 4:11-9. Review. German. Rendi-Wagner P, Hoeller K, Kollaritsch H; Osterreichische Expertengruppe für Reisemedizin. [Immunization recommendations for travel in the Mediterranean area] Wien Klin Wochenschr. 2004 Oct 30;116(19-20):652-60. German. Rendi-Wagner P, Kundi M, Zent O, Banzhoff A, Jaehnig P, Stemberger R, Dvorak G, Grumbeck E, Laaber B, Kollaritsch H. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine. 2004 Dec 9;23(4):427-34. Loebermann M, Kollaritsch H, Ziegler T, Rendi-Wagner P, Chambonneau L, Dumas R, Lafrenz M. A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther. 2004 Jul;26(7):1084-91. Rendi-Wagner P, Kundi M, Zent O, Dvorak G, Jaehnig P, Holzmann H, Mikolasek A, Kollaritsch H. Persistence of protective immunity following vaccination against tick-borne encephalitis--longer than expected? Vaccine. 2004 Jul 29;22(21-22):2743-9. Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection. 2004 Jun;32(3):149-52. Erratum in: Infection. 2004 Aug;32(4):249. Rendi-Wagner P, Georgopoulos A, Kundi M, Mutz I, Mattauch M, Nowak J, Mikolasek A, Vecsei A, Kollaritsch H. Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria.

- 65 -

J Antimicrob Chemother. 2004 May;53(5):826-31. Epub 2004 Apr 8. Eder G, Kollaritsch H. Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children. Vaccine. 2003 Sep 8;21(25-26):3575-83. Rendi-Wagner P, Wiedermann G, Stemberger H, Kollaritsch H. New vaccination strategies for low- and non-responders to hepatitis B vaccine. Wien Klin Wochenschr. 2002 Mar 28;114(5-6):175-80. Review. Wiedermann G, Kollaritsch H, Kundi M, Wernsdorfer WH. Relationships between mefloquine blood levels, gender, and adverse reactions. Am J Trop Med Hyg. 2002 May;66(5):445-6; author reply 446-7. No abstract available. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis. 2002 Mar 1;34(5):628-33. Epub 2002 Jan 16. Rendi-Wagner P, Noedl H, Wernsdorfer WH, Wiedermann G, Mikolasek A, Kollaritsch H. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop. 2002 Feb;81(2):167-73. b) co-author total: 29 Topjournals: 9 Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, Rendi-Wagner P, Steffen R, Van Damme P; ad hoc Travel Medicine Expert Panel for ESENEM. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: review and consensus statement on hepatitis A and B vaccination. J Travel Med. 2007 May-Jun;14(3):181-7. No abstract available. Lütgendorf C, Rojanawatsirivet C, Wernsdorfer G, Sirichaisinthop J, Kollaritsch H, Wernsdorfer WH. Pharmacodynamic interaction between atovaquone and other antimalarial compounds against Plasmodium falciparum in vitro. Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):70-6. Kyavar L, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer G, Sirichaisinthop J, Wernsdorfer WH. In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in Plasmodium vivax. Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):62-9. Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine. 2007 Jan 15;25(5):927-31. Epub 2006 Sep 18. Weinke T, Liebold I, Burchard GD, Frühwein N, Grobusch MP, Hatz C, Kollaritsch H, Nothdurft HD, Reisinger E, Rieke B, Schönfeld Ch, Steffen R, Stich A.

- 66 -

[Prophylactic immunization against enterotoxin-forming Escherichia coli travellers' diarrhea and cholera: does it make sense and for whom?] Dtsch Med Wochenschr. 2006 Jul 28;131(30):1660-4. Review. German. No abstract available. Thriemer K, Wernsdorfer G, Rojanawatsirivet C, Kollaritsch H, Sirichainsinthop J, Wernsdorfer WH. In vitro activity of artemisinin alone and in combination with retinol against Plasmodium falciparum. Wien Klin Wochenschr. 2005;117 Suppl 4:45-8. Samal D, Rojanawatsirivet C, Wernsdorfer G, Kollaritsch H, Sirichaisinthop J, Wernsdorfer WH. Synergism of desbutyl-benflumetol and retinol against Plasmodium falciparum in vitro. Wien Klin Wochenschr. 2005;117 Suppl 4:39-44. Attlmayr B, Kollaritsch H, Wernsdorfer WH, Miller RS, Sirichaisinthop J, Noedl H. Drug sensitivity of Plasmodium falciparum along the Thai-Myanmar border using the new field-deployable HRP2 in vitro assay. Wien Klin Wochenschr. 2005;117 Suppl 4:35-8. Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M. Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother. 2005 Aug;49(8):3575-7. Nothdurft HD, Bialek R, Burchard GD, Hatz C, Jelinek T, Kollaritsch H, Schönfeld C, Volkmer KJ; Ausschuss "Reisemedizin" der Deutschen Gesellschaft für Tropenmedizin und Internationale Gesundheit. [Consensus recommendations for malaria prophylaxis] Dtsch Med Wochenschr. 2005 Jun 3;130(22):1392-6. Review. German. No abstract available. Pirker-Krassnig DK, Wernsdorfer G, Sirichaisinthop J, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer WH. Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand. Wien Klin Wochenschr. 2004;116 Suppl 4:47-52. Woitsch B, Wernsdorfer G, Prajakwong S, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer WH. Comparative study of the in vitro sensitivity of Plasmodium falciparum to artemisinin in two border areas of Thailand. Wien Klin Wochenschr. 2004;116 Suppl 4:35-40. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am J Trop Med Hyg. 2004 Dec;71(6):711-4. Noedl H, Wernsdorfer WH, Kollaritsch H, Looareesuwan S, Miller RS, Wongsrichanalai C. Malaria drug-susceptibility testing. HRP2-based assays: current data, future perspectives. Wien Klin Wochenschr. 2003;115 Suppl 3:23-7. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G,

- 67 -

Richter J; European Network on Surveillance of Imported Infectious Diseases. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis. 2004 Nov 1;190(9):1541-6. Epub 2004 Sep 28. Mühlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjørup I, Behrens RH, Clerinx J, Björkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C, Kollaritsch H, Kapaun A, Knobloch J, Iversen J, Kotlowski A, Malvy DJ, Kern P, Fry G, Siikamaki H, Schulze MH, Soula G, Paul M, Gómez i Prat J, Lehmann V, Bouchaud O, da Cunha S, Atouguia J, Boecken G. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J. 2004 Mar 8;3:5. Reinthaler FF, Feierl G, Beubler E, Kollaritsch H, Ruckenbauer G, Klem G, Wendelin I, Marth E. Treatment of travelers' diarrhea among Austrian tourists. J Travel Med. 2004 Jan-Feb;11(1):66-8. No abstract available. Wichmann O, Jelinek T, Peyerl-Hoffmann G, Mühlberger N, Grobusch MP, Gascon J, Matteelli A, Hatz C, Laferl H, Schulze M, Burchard G, da Cunha S, Beran J, McWhinney P, Kollaritsch H, Kern P, Cuadros J, Alifrangis M, Gjørup I; European Network on Surveillance of Imported Infectious Diseases (TropNetEurop). Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malar J. 2003 Jun 25;2:17. Epub 2003 Jun 25. Lux D, Prajakwong S, Kollaritsch H, Wernsdorfer G, Wernsdorfer WH. In-vitro sensitivity testing of Plasmodium vivax: response to lumefantrine and chloroquine in northwestern Thailand. Wien Klin Wochenschr. 2003;115 Suppl 3:50-4. Ogwang S, Engl M, Vigl M, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Clinical and parasitological response of Plasmodium falciparum to chloroquine and sulfadoxine/pyrimethamine in rural Uganda. Wien Klin Wochenschr. 2003;115 Suppl 3:45-9. Noedl H, Wongsrichanalai C, Miller RS, Myint KS, Looareesuwan S, Sukthana Y, Wongchotigul V, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Plasmodium falciparum: effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II. Exp Parasitol. 2002 Nov-Dec;102(3-4):157-63. Melzer H, Baier K, Felici F, von Specht BU, Wiedermann G, Kollaritsch H, Wiedermann U, Duchêne M. Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):179-83. Steffen R, Kollaritsch H, Fleischer K. Travelers' diarrhea in the new millennium: consensus among experts from German-speaking countries. J Travel Med. 2003 Jan-Feb;10(1):38-45. Review. No abstract available. Erratum in: J Travel Med. 2003 May-Jun;10(3):199.

- 68 -

Mühlberger N, Jelinek T, Behrens RH, Gjørup I, Coulaud JP, Clerinx J, Puente S, Burchard G, Gascon J, Grobusch MP, Weitzel T, Zoller T, Kollaritsch H, Beran J, Iversen J, Hatz C, Schmid ML, Björkman A, Fleischer K, Bisoffi Z, Guggemos W, Knobloch J, Matteelli A, Schulze MH, Laferl H, Kapaun A, McWhinney P, Lopez-Velez R, Fätkenheuer G, Kern P, Zieger BW, Kotlowski A, Fry G, Cuadros J, Myrvang B; TropNetEurop; Surveillance importierter Infektionen in Deutschland Surveillance Networks. Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis. 2003 Apr 15;36(8):990-5. Epub 2003 Apr 2. Jelinek T, Peyerl-Hoffmann G, Mühlberger N, Wichmann O, Wilhelm M, Schmider N, Grobusch MP, von Sonnenburg F, Gascon J, Laferl H, Hatz C, Alifrangis M, Burchard G, McWhinney P, Schulze M, Kollaritsch H, da Cunha S, Beran J, Kern P, Gjørup I, Cuadros J. Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in Europe. Malar J. 2002 Oct 11;1:11. Epub 2002 Oct 11. Jelinek T, Schulte C, Behrens R, Grobusch MP, Coulaud JP, Bisoffi Z, Matteelli A, Clerinx J, Corachán M, Puente S, Gjørup I, Harms G, Kollaritsch H, Kotlowski A, Björkmann A, Delmont JP, Knobloch J, Nielsen LN, Cuadros J, Hatz C, Beran J, Schmid ML, Schulze M, Lopez-Velez R, Fleischer K, Kapaun A, McWhinney P, Kern P, Atougia J, Fry G, da Cunha S, Boecken G. Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin Infect Dis. 2002 Mar 1;34(5):572-6. Epub 2002 Jan 21. Melzer H, Fortugno P, Mansouri E, Felici F, Marinets A, Wiedermann G, Kollaritsch H, Von Specht BU, Duchêne M. Antigenicity and immunogenicity of phage library-selected peptide mimics of the major surface proteophosphoglycan antigens of Entamoeba histolytica. Parasite Immunol. 2002 Jun;24(6):321-8. Noedl H, Wernsdorfer WH, Krudsood S, Wilairatana P, Wiedermann G, Kollaritsch H, Looareesuwan S. Predictive role of laboratory and clinical treatment response parameters and glucose-6-phosphate dehydrogenase status in the therapy of falciparum malaria. Wien Klin Wochenschr. 2002 Feb 28;114(4):158-63. Invited Talks 2002-2008 2002: 22.1.2002, Wien, Ana Grand Hotel, Chiron-Behring Encepur-Pressekonferenz 30.1.-1.2.2002, Deutschland, Bayern, Spitzingsee Malaria Expertenworkshop2002 26.2.-2.3.2002, Saalfelden Österr. Apothekertagung, Reisemedizin update 2001 9.3.2002, Wien, Ärztekammer f.NÖ Fortbildung Reisemedizin 16.3.2002, Linz, Reisemedizinischer Tag Impfplan 2002 20.3.2002, Wien, Betriebsärzte-Fortbildung Hepatitiden 4.4.2002, Wien, Aventis Pasteur Bezirksärztefortbildung Reisemedizin aktuell

- 69 -

9.4.2002, Glaxo Academy, Hotel Bristol Infektionen rund ums Mittelmeer 12.4.2002, Salzburg, Öst.Bundesheer Impfprävention beim Bundesheer 13.4.2002, Salzburg, 11.Öst.Impftag Pertussisepidemiologie in Österreich 18.4.2002, Pflegeheim Baumgarten, Wien Hepatitiden 29.5.-31.5.2002, Grado, Fortbildung der öst.Arztakademie Reisemedizin 29.6.2002, Bregenz, Ärztekammer Reisemedizin update 3.7.2002, Univ.Kinderklinik Wien Mittagsfortbildung Malaria 17.9.2002, Burgenland, Bezirksärztefortbildung Reisemedizin update 26.9.2002, Apotheke Traismauer, Aventis Pasteur Der österreichische Impfplan 3.10.u.4.10.2002, Gmunden, Impfsymposium Pertussisepidemiologie Pneumokokkenepidemiologie 12.10-13.10.2002, Reisemedizinische Konsenstagung Österreich Malariakonsens 15.10.2002, Linz, Glaxo Academy Hepatitis und Pertussis 26.10/27.10 2002, Taufers/Südtirol, Herbstgespräche f.Pharmazeuten Reisen mit Kindern 5.11.2002, Wien, Pflegeheim Liesing Hepatitiden 2003: 25.1.2003, Wiener Geriartrietage Spezifische Prophylaxe für Senioren 30.1.2003, Fortbildungszyklus der ÖGTP Die neuen Malariaempfehlungen 27.2.2003, Saalfelden/Apothekertage Reisemedizin update 7.3.2003, Bundesministerium f.Inneres Der Pockenalarmplan 15.3.2003, Linzer Reisemedizinische Tagung Der österreichische Malariakonsens 20.3.2003, Firma ABB Impfungen bei Auslandseinsätzen 25.3.2003, MA 15 Gesundheitsamt Der Pockenalarmplan/Schulung für Amtsärzte 1.4.2003, 2.Bundesheerimpftag Pockenschutzimpfung 4.4.2003, Österr.Impftag Die Pockenimpfung 23.4.2003, Sozialmedizinisches Zentrum Ost Impffortbildungsstunde 5.5.-9.5.2003 8th Int.Conf.for Travel Medicine New York Traveler’s Vaccines 29.5.-31.5.2003, Grado, Fortbildung der öst.Arztakademie Reisemedizin

- 70 -

26.6.2003, Wiener Rettung Pockenalarmplan 1.7.-3.7.2003, Hamburg, Bernhard Nocht Institut Malariaworkshop 2003-12-16 9.10.2003, Impfsymposium Gmunden FSME-Ergebnisse einer Immunitätsstudie 13.10.2003, Wiener Ärztekammer Impffortbildung für Schulärzte 4.11.2003, Laa an der Thaya Reiseimpfungen/Fortbildung Bezirksärzte 10.11.2003, Salzburg/Renaissance Hotel Epidemiologie von reiseassoziierten Infektionen 2004: 20.3.2004, Fortbildungszyklus der ÖGTP Reisemedizinisches Update 2.3.2004, Saalfelden Apothekertage Impfplan 2004 und Reisemedizinisches update 20.3.2004, Linzer Reisemedizinische Tagung Präsentation des Konsensus für Mittelmeerimpfungen 26.3.2004, Österreichsicher Bundesheerimpftag Flaviviren in der Reisemedizin 27.3.2004, Österreichischer Impftag FSME 24.5.-29.5.2004, Öst.Akademie der Ärzte/Grado Seminar Reisemedizin Seminar Impfplan 3.6.-6.6.2004, 6th Nordic-Baltic Congress on Infectious Diseases Oral Presentation: Travelers Diarrhea 17.9.-18.9.2004, 4. Reisemedizinische Konsensustagung (Leogang/Salzburg) Kongressorganissation Malarialeitlinien 15.10.2004, Impfsymposium Gmunden Oral Presentation: TBE vaccination 2005: 19.1.-22.1.2005, Pädiatrisches Symposium Obergurgl Hepatitis und Typhus 26.1.2005, Ärztekammer Salzburg Fortbildung Reisemedizin 3.3.2005, Saalfelden Apothekertage Impfplan 2005 und Reisemedizinisches update 12.3.2005, Linzer Reisemedizinische Tagung Präsentation des reisemed.Konsensus Osteuropa 17.3.2005, Glaxo Academy Reisemedizinische Fortbildung 31.3.2005, Apothekerkammer Österreich Hepatitis als Reiseimpfung 9.4.2005, Österr.Impftag Salzburg Rotavirusimpfstoffe Tollwutreferenzstelle für Österreich 22.4.2005, ESIDOG (Europ.Soc.for Infections in Obstetrics and Gynecology) Impffortbildung für Gynäkologen

- 71 -

28.4.2005, Fortbildungszyklus der ÖGTP Reisemedizinisches Update 14.5.2005, 9th Intl.Conference of Int.Soc.Travel Med Vaccine Boosters-Evidence for Current Recommendations Grazer Impftag (14.5.2005) Rotavirusepidemiologie in Österreich 24.5.-28.5.2005, Öst.Akademie der Ärzte/Grado Seminar Reisemedizin Seminar Impfplan 25.6.2005, Arbeitskreis Vorsorgemedizin Vorarlberg Reisemedizinisches update 2005 5.10.2005, Bezirksärztefortbildung Zams/Tirol Impfplan 2005 7.10.-8.10.2005, Impfsymposium Gmunden Rotavirusepidemiologie in Österreich Rotavirusimpfstoffe 14.10.2005, ESIDOG (Europ.Soc.for Infections in Obstetrics and Gynecology) Impffortbildung für Gynäkologen, Teil 2 20.10.2005, Apothekerkammer Kärnten Impffortbildung für Apotheker 26.10.2005, Pharmazeutische Herbsttagung Triest Avian Influenza 5.11.2005, Pädiatrische Impffortbildung Linz Rotavirusvakzinen 17.11.-19.11.2005, ÖGTP-Jahrestagung 2005 Fortbildung Reisemedizin 21.11.2005, Karl Landsteiner Gesellschaft Symposium Vogelgrippe 15.12.2005, Fortbildungszyklus der ÖGTP Vogelgrippe-facts and fiction 2006: 21.2.2006 and 28.2.2006, European Insurance Company, Vienna Travel risks 23.2.2006, Seminar für Journalisten, Wien Die wirklichen Infektionsgefahren in den Tropen 9.3.2006, Saalfelden Apothekertage Impfplan 2006 und Reisemedizinisches update 16.3.2006, Glaxo Academy Reisemedizinische Fortbildung 6.4.2006, Wiener Arbeiterkammer Influenzapandemie Apothekenfortbildung im Pharmaziezentrum Wien (27.4.2006) 28.4.2006, Impfplan 2006, Rotaviren, Hepatitis ESIDOG Impfseminar Wien (28.4.2006) Grundlagen des Impfwesens 5.5.2006, Auswärtiges Amt Berlin, Reise- und Tropenmedizin Tagung 2 Vorträge: Zeckenübertragene Infektionen; Impfungen und Boosterung 11.5.2006, Glaxo Academy Wien Rotavirusepidemiologie und Rotavirusimpfung 13.5.2006, Pannonischer Impftag Burgenland Auffrischungen von Impfungen 23.5.-26.5.2006, Fortbildung der Wiener Arztakademie Grado 3 Vorträge: Impfseminar Kinderimpfungen; Impfseminar Reiseimpfungen; Symposium

- 72 -

Rotavirusvakzinen 9.6.2006, Bundeskongress der medizinisch technischen Berufe Wien Infektionsgefahren im Ausland 15.6.2006, ESIDOG Impfseminar Linz Grundlagen des Impfwesens 23.6.2006, Österreichisches Bundesheer Innsbruck Tropen- und Reisemedizin 24.6.2006, Bregenzer Impftag Kampf den Durchfallserkrankungen: Rotaviren, Reisediarrhoe 22.8.-23.8.2006, Österreichische Arztakademie, Velden 2 Vorträge: Reiseimpfupdate, neue Impfstoffe 26.8.2006, Österreichische Parkinsongesellschaft, Jahrestagung, Karlstein Impfnebenwirkungen beim neurologischen Patienten 21.9.2006, Novartis Fortbildung, Baden Influenza 5.10.2006, Landessanitätsdirektion Tirol, Innsbruck Fortbildung über neue Impfstoffe 12.10.2006, Novartis Fortbildung Krems Influenza 19.10.2006, Bundesverband der medizinisch technischen Berufe, Wien Influenza und Pandemie 3.11.2006, Impfsymposium Gmunden 10 Jahre Infektionssurveillance – was hats gebracht? 4.11.2006, Jahrestagung der ÖGTP, Linz Update Reisemedizin 16.11.2006, GlaxoSmithKline Fortbildung, Linz Reisemedizin update 17.11.2006, ESIDOG Vorarlberg Grundlagen des Impfwesens 18.11.2006, ESIDOG Innsbruck, Seefeld Grundlagen des Impfwesens 11.12.2006, GlaxoSmithKline Fortbildung Wien Rotavirusepidemiologie und Impfung 2007: 18.1.2007, Fortbildung Novartis Wien Tollwut Zecken und Co 12.2.2007, Sauerhof, Baden Apothekerkammerfortbildung: Impfupdate 15.2.2007, Naturhistorisches Museum Wien Pharmazeuten: Neue Impfungen 21.2.2007, Krems, Kloster UND Apothekerkammer NÖ, Fortbildung Tollwut 1.3.2007, Saalfelden Öst.Apothekertage. Reisemedizin update 9.3.2007, ESIDOG: Impfseminar f. Gynäkologen Oberösterreich 10.3.2007, Linzer Reisemedizinische Tagung Entsendungseignungsuntersuchung 13.3.2007, GlaxoSmithKline interne Schulung Hepatitis 17.3.2007, Öst.Kongress für Infektionskrankheiten Reiseimpfungen 23.3.2007, Öst.Bundesheerimpftag Japan Encephalitis 24.3.2007, Öst.Impftag

- 73 -

Infektionssurveillance 29.3.2007, Öst.Gesellschaft f.Infektionskrankheiten Faszination Vakzination 5.5.2007, Bezirksärztefortbildung NÖ Reisemed.update und Hepatitis 8.5.2007, Ärztekammer Salzburg Reisemedizin.update 9.5.2007, Mini-Med-Studium Donauuniversität Impfungen 1.6.2007, ESIDOG Impfseminar für Gynäkologen Salzburg 7.5.2007, Ärzteakademie Grado Lunchsymposium Reisemedizin 8.5.2007, Ärzteakademie Grado Impfupdate öst.Impfplan 23.6.2007, Apothekertage Pörtschach Kinder und Senioren auf Fernreisen 26.9.2007, Fortbildungsakademie Innsbruck Impfupdate 27.9.2007, Impfsymposium Gmunden Pneumokokkensurveillance 2.10.2007, Ärztekammer Wien Giftiger Dienstag. Der öst.Impfplan 11.10.2007, Gesellschaft der Ärzte, Novartis Influenza 19.10.2007, Apotheke Trausmauer Fortbildung Influenza 23.10.2007, Arbeiterkammer Wien Fortbildung Impfwesen 6.11.2007, Europ.Reiseversicherung Mitarbeiterschulung Reisemedizin 7.11.2007, AGES Zukunftskonferenz, Messe Wien: Klimaveränderungen und Tropenkrankheiten

- 74 -

Curriculum Vitae

Rudolf Oehler Dept. of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria;

E-mail: [email protected]

Personal Data

Date of Birth: 21.12.1963

Place of Birth: Brixen/Bressanone, Italy

Nationality Italian

Education

1990 – 1994 Ph.D. work at the Institute of Biochemistry, University of

Vienna (Prof. A. Barta)

1988 – 1989 Diploma work at the Institute of medical Microbiology,

University of Innsbruck (Prof. G. Stöffler)

1982 – 1989 Studies in Microbiology, University of Innsbruck

1982 High school degree for electric engineering in Bolzano,

Italy

Career History

Since 2001 Associate Professor (a.o.Univ.Prof), Department of

Surgery, University of Vienna

2001 Habilitation in Medical Chemistry, University of Vienna

Medical School

1994-2001 University Assistant, Department of Surgery, University of

Vienna

1989 - 1990 Technical assistant at the Diagnostic Laboratory "Dr.

Rohrer", Innsbruck, Austria

Awards

2000 Forschungsförderungspreis der Arbeitsgemeinschaft für

Klinische Ernährung

Memberships

2006 Founding member of the Austrian Proteomic Association

(AuPA)

1995 Founding member of the Cell Stress Society International

(CSSI)

- 75 -

Sources of funding in last 6 years (2002-2008)

Period Organization

20078 European Society of Organ Transplantation

2006 Commission of the European Communities (MTKI-CT-2005-029946;

coordination)

2003 Oestrreichische Nationalbank (#9917), Vienna, Austria

2002 Lorenz Böhler Gesellschaft, Vienna, Austria

2001 ESPEN, Geneva, Switzerland

2000 Oestrreichische Nationalbank (#8311), Vienna, Austria

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student

2004-2007 Wolfgang Winkler

2000-2004 Maria Zellner

2007 - present Anna Michlmayr

2007-present Suzann Baumann

2006-present Senada Skeledzic

Publications 27 peer reviewed publications in scientific journals, 1 invited review, 2 book chapters, > 6

invited lectures, 1 patent Peer reviewed manuscripts 2002-2008 (original research and reviews) Exner, R., Weingartmann, G., Spittler, A., Brabec, M., Roth, E., and Oehler, R. (2002) Glutamine deficiency renders human monocytic cells more susceptible to specific apptosis triggers. Surgery 131, 75-80 Oehler, R., Pusch, E., Dungel, P., Zellner, M., Munk-Eliasen, M., and Roth, E. (2002) Reduced expression of the major inducible 70 kDa heat shock protein in glutamine starved leukocytes. Brit.J.Nutr. 87, S17-S21 Roth, E., Oehler, R., Manhart, N., Exner, R., Wessner, B., Strasser, E., and Spittler, A. (2002) Regulative potential of glutamine--relation to glutathione metabolism. Nutrition 18, 217-221 Zellner, M., Hergovich, N., Roth, E., Jilma, B., Spittler, A., and Oehler, R. (2002) Human monocyte stimulation by experimental whole body hyperthermia. Wien. Klin. Wochenschr. 114, 102-107 Oehler, R., and Roth, E. (2003) Regulative capacity of glutamine. Curr Opin Clin Nutr Metab Care 6, 277-282. Oehler, R., and Roth, E. (2003) Glutamine Metabolism. In: Cynober, L., ed. Amino acid metabolism and therapy in health and nutritional disease, 2nd. Ed., pp. 169-185, CRC Press, Boca Raton, FL.

- 76 -

Roth, E., Zellner, M., Wessner, B., Strasser, E., Manhart, N., Oehler, R., and Spittler, A. (2003) Glycine-an inert amino acid comes alive. Nutrition 19, 817-818. Zellner, M., Gerner, C., Eliasen, M., Wurm, S., Pollheimer, J., Spittler, A., Brostjan, C., Roth, E., and Oehler, R. (2003) Glutamine starvation of monocytes inhibits the ubiquitin-proteasome proteolytic pathway. BBA - Molecular Basis of Disease 1638, 138-148 Zellner, M., Gerner, C., Munk Eliasen, M., Wurm, S., Pollheimer, J., Spittler, A., Brostjan, C., Roth, E., and Oehler, R. (2003) Glutamine starvation of monocytes inhibits the ubiquitin-proteasome proteolytic pathway. Biochim Biophys Acta 1638, 138-148 Pollheimer, J., Zellner, M., Eliasen, M., Roth, E., and Oehler, R. (2005) Increased susceptibility of Glutamine-depleted monocytes to fever-range hyperthermia: The role of 70 kDa Heat shock protein. Annals of Surgery 241, 349-355 Zellner, M., Winkler, W., Hayden, H., Diestinger, M., Eliasen, M., Gesslbauer, B., Miller, I., Chang, M., Kungl, A., Roth, E., and Oehler, R. (2005) Quantitative Validation of different Protein Precipitation Methods in Proteome Analysis of Blood Platelets. Electrophoresis 26, 2481-2489 Eliasen, M. M., Brabec, M., Gerner, C., Pollheimer, J., Auer, H., Zellner, M., Weingartmann, G., Garo, F., Roth, E., and Oehler, R. (2006) Reduced stress tolerance of glutamine-deprived human monocytic cells is associated with selective down-regulation of Hsp70 by decreased mRNA stability. J Mol Med 84, 147-158 Eliasen, M. M., Winkler, W., Jordan, V., Pokar, M., Marchetti, M., Roth, E., Allmaier, G., and Oehler, R. (2006) Adaptive cellular mechanisms in response to glutamine-starvation. Front Biosci 11, 3199-3211 Skeledzic, S., Ahrer, K., Bohmig, G. A., Muehlbacher, F., and Oehler, R. (2007) Identification of non-HLA antigens in renal transplantation by proteomics. Transplant-Internat. 20, 40 Winkler, W., Zellner, M., Diestinger, M., Babeluk, R., Marchetti, M., Goll, A., Zehetmayer, S., Bauer, P., Rappold, E., Miller, I., Roth, E., Allmaier, G., and Oehler, R. (2008) Biological variation of the platelet proteome in the elderly population and its implication for biomarker research. Mol Cell Proteomics 7, 193-203 Invited Talks 2002-2008 2002 • 24th Int. Congress of the Eur. Soc. of Enteral and Parenteral Nutrition, Glasgow, UK 2004 • 2nd Austrian Proteome Research Symposium, Vienna, Austria 2006 • 2nd Int. Workshop on Platelet disorders, oxidative stress and ageing, Rome, Italy 2007 • 1st Central and Eastern European Proteomic Conference, Prague

- 77 -

Curriculum Vitae

Ao. Univ. Prof. Dr. Winfried F. PICKL Division of Cellular Immunology and Immunehematology, Institute of Immunology, Center for

Physiology, Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse

8A, 1090 Vienna, Austria;

Phone: +43-1-4277-64945, Fax: +43-1-4277-9649;

Email: [email protected];

Homepage: www.meduniwien.ac.at/immunologie/ Personal Data

Date of Birth: 20.07.1964

Place of Birth: Klagenfurt

Nationality Austria

Education

1991, July 5th Medical Degree, University of Vienna, Medical School

1989–1991 Doctoral Thesis, Institute for Blood Group Serology and

Tissue Typing, University of Vienna, Medical School

1985 – 1990 Studies in Biochemistry, University of Vienna

1983–1989 Medical Student, University of Vienna, Medical School

1983, June 1st A-Level with distinction: High School for Business

Administration, Klagenfurt

Career History

09/2004–present Head of Research Unit ‘Cellular Immunology and

Immunohematology’, Institute of Immunology, Medical

University of Vienna

09/2002–present Principal Investigator, Institute of Immunology, University

of Vienna, Medical School, and Medical University of

Vienna

2002, Nov. 25th Board Certification in Immunology, Austrian Medical

Association 02/2002–08/2002 Training in Hematology and Internal Medicine, Department

of Internal Medicine I, Division of Hematology and

Hemostaseology, University of Vienna, Medical School

06/2000–01/2002 Principal Investigator, Institute of Immunology, University

of Vienna, Medical School

1999, March 25th Habilitation and Associate Professorship in Immunology,

Institute of Immunology, University of Vienna, Medical

- 78 -

School

01/1998–05/2000 Research Fellow in Molecular Biology and Genetics,

Department of Molecular Biology, Harvard Medical School,

Boston (Prof. Brian Seed)

1996, Sept. 1st Assistant Professor in Immunology, Institute of

Immunology, University of Vienna, Medical School

06/1995–12/1997 Research Fellow, Institute of Immunology, University of

Vienna, Medical School

01/1995–05/1995 Training in Surgery and Dermatology, Austrian Armed

Forces Military Hospital, Vienna

10/1994–12/1994 Training as Military Assistant Doctor, Vienna and

Innsbruck Medical Corps, Austrian Armed Forces

11/1991–09/1994 Research Fellow, Institute of Immunology, University of

Vienna, Medical School

07/1991-10/1991 Research Fellow, Institute for Blood Group Serology and

Tissue Typing, University of Vienna

Awards

2007 Karl Landsteiner Award of the Austrian Society for

Allergology and Immunology

1999 APART research fellowship, Austrian Academy of

Sciences

1998 Erwin Schroedinger research fellowship, Austrian Science

Foundation

1993 National Award in Rheumatology, Ministry of Health,

Science and Education, Austria

1991 Best Thesis, Austrian Society of Immunology and

Allergology (ÖGAI)

Memberships

Austrian Society for Allergology and Immunology

Austrian Society for Rheumatology

European Group for the Immunological Characterization of Leukemias (EGIL)

European Leukemia Network (ELN)

American Association of Immunologist (AAI)

American Society for Hematologist (ASH)

Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year

- 79 -

2002-2005 Academy of Sciences Better definition of the immunological

synapse

150

2002-2005 FWF Influencing the allergen-specific immune

response

80

2005-2008 FWF Allergy-SFB:Further development of

Anergosomes

80

2008 - 2011 FWF Allergy-SFB: Rebuilding the allergen-specific

synapse

90

2006 -2009 FFG Membrane anchored cytokines and integral

membrane proteins: Novel adjuvants for

virus vaccines

80

2008-2014 Christian Doppler

Society

CDG Laboratory for Immunomodulation-

Subproject #4

90

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic

2001-2005 Sophia Derdak Immunosomes: VLP driving primary T cell responses

2003-

present

Victoria Leb Anergosomes and TCR transgenic allergen-specific T

cells

2004-

present

Hans Küng Decoration of enveloped viruses with cytokines

2005-

present

Klaus Schmetterer Functional genetic screening for immunomodulatory

molecules

2006-

present

Alina Neunkirchner Antigen-presenting platforms induced by viral core

proteins

2006-

present

Daniela Haiderer Development of novel adjuvants for viral vaccines

Publications

60 peer reviewed publications in scientific journals, 9 book chapters, 1 patent application Peer reviewed manuscripts 2002-2008 (original research) Greinix, H. T., Pohlreich, D., Kouba, M., Kormoczi, U., Lohmann, I., Feldmann, K., Zielinski, C., and Pickl, W. F. (2008). Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 14, 208-219. Leb, V. M., Jahn-Schmid, B., Schmetterer, K. G., Kueng, H. J., Haiderer, D., Neunkirchner, A., Fischer, G. F., Nissler, K., Hartl, A., Thalhamer, J., et al. (2008). Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol 121, 64-71.

- 80 -

Sillaber, C., Mayerhofer, M., Bohm, A., Vales, A., Gruze, A., Aichberger, K. J., Esterbauer, H., Pfeilstocker, M., Sperr, W. R., Pickl, W. F., et al. (2008). Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 38, 43-52. Aichberger, K. J., Mayerhofer, M., Gleixner, K. V., Krauth, M. T., Gruze, A., Pickl, W. F., Wacheck, V., Selzer, E., Mullauer, L., Agis, H., et al. (2007). Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109, 3031-3041. Attarbaschi, A., Mann, G., Schumich, A., Konig, M., Pickl, W. F., Haas, O. A., Gadner, H., and Dworzak, M. N. (2007). CD44 deficiency is a consistent finding in childhood Burkitt's lymphoma and leukemia. Leukemia 21, 1110-1113. Gleixner, K. V., Mayerhofer, M., Sonneck, K., Gruze, A., Samorapoompichit, P., Baumgartner, C., Lee, F. Y., Aichberger, K. J., Manley, P. W., Fabbro, D., et al. (2007a). Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92, 1451-1459. Gleixner, K. V., Rebuzzi, L., Mayerhofer, M., Gruze, A., Hadzijusufovic, E., Sonneck, K., Vales, A., Kneidinger, M., Samorapoompichit, P., Thaiwong, T., et al. (2007b). Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 35, 1510-1521. Kondo, R., Gleixner, K. V., Mayerhofer, M., Vales, A., Gruze, A., Samorapoompichit, P., Greish, K., Krauth, M. T., Aichberger, K. J., Pickl, W. F., et al. (2007). Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood 110, 661-669. Kueng, H. J., Leb, V. M., Haiderer, D., Raposo, G., Thery, C., Derdak, S. V., Schmetterer, K. G., Neunkirchner, A., Sillaber, C., Seed, B., and Pickl, W. F. (2007). General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol 81, 8666-8676. Mayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J., Ott, R. G., Greish, K., Nakamura, H., Derdak, S., et al. (2007). Targeting of heat shock protein 32 (Hsp32) / heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood. Rebuzzi, L., Willmann, M., Sonneck, K., Gleixner, K. V., Florian, S., Kondo, R., Mayerhofer, M., Vales, A., Gruze, A., Pickl, W. F., et al. (2007). Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 115, 320-333. Aichberger, K. J., Mayerhofer, M., Vales, A., Krauth, M. T., Gleixner, K. V., Bilban, M., Esterbauer, H., Sonneck, K., Florian, S., Derdak, S., et al. (2006). The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood 108, 3538-3547. Attarbaschi, A., Mann, G., Konig, M., Steiner, M., Strehl, S., Schreiberhuber, A., Schneider, B., Meyer, C., Marschalek, R., Borkhardt, A., et al. (2006). Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res 12, 2988-2994. Bilban, M., Heintel, D., Scharl, T., Woelfel, T., Auer, M. M., Porpaczy, E., Kainz, B., Krober,

- 81 -

A., Carey, V. J., Shehata, M., et al. (2006). Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 20, 1080-1088. Derdak, S. V., Kueng, H. J., Leb, V. M., Neunkirchner, A., Schmetterer, K. G., Bielek, E., Majdic, O., Knapp, W., Seed, B., and Pickl, W. F. (2006). Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proc Natl Acad Sci U S A 103, 13144-13149. Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Bohm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., et al. (2006). PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107, 752-759. Pfistershammer, K., Klauser, C., Pickl, W. F., Stockl, J., Leitner, J., Zlabinger, G., Majdic, O., and Steinberger, P. (2006). No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 36, 1104-1113. Sonneck, K., Florian, S., Bohm, A., Krauth, M. T., Kondo, R., Hauswirth, A. W., Gleixner, K. V., Aichberger, K. J., Derdak, S., Pickl, W. F., et al. (2006). Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma 47, 897-906. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., et al. (2005a). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105, 3303-3311. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Vales, A., Kondo, R., Derdak, S., Pickl, W. F., Selzer, E., Deininger, M., Druker, B. J., et al. (2005b). Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 65, 9436-9444. Mayerhofer, M., Aichberger, K. J., Florian, S., Krauth, M. T., Hauswirth, A. W., Derdak, S., Sperr, W. R., Esterbauer, H., Wagner, O., Marosi, C., et al. (2005). Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. Faseb J 19, 960-962. Wohrl, S., Loewe, R., Pickl, W. F., Stingl, G., and Wagner, S. N. (2005). EMPACT syndrome. J Dtsch Dermatol Ges 3, 39-43. Steinberger, P., Majdic, O., Derdak, S. V., Pfistershammer, K., Kirchberger, S., Klauser, C., Zlabinger, G., Pickl, W. F., Stockl, J., and Knapp, W. (2004). Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172, 2352-2359. Selenko-Gebauer, N., Majdic, O., Szekeres, A., Hofler, G., Guthann, E., Korthauer, U., Zlabinger, G., Steinberger, P., Pickl, W. F., Stockinger, H., et al. (2003). B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170, 3637-3644. Javaherian, K., Park, S. Y., Pickl, W. F., LaMontagne, K. R., Sjin, R. T., Gillies, S., and Lo, K. M. (2002). Laminin modulates morphogenic properties of the collagen XVIII endostatin domain. J Biol Chem 277, 45211-45218.

- 82 -

Curriculum Vitae

Marcus Säemann Internal Medicine III, Clin. Division of Nephrology & Dialyis, Medical University of Vienna,

Währinger Gürtel 18-20, 1090 Wien, Austria; Phone: +43-1-404005593, Fax: +43-1-

404004392; e-mail: [email protected];

Personal Data

Date of Birth: 3.2.1971

Place of Birth: Vienna

Nationality Austria

Education

2002-2008 Fellowship Internal Medicine, Spec. Nephrology, Vienna

1998-2002 Postdoctoral fellow at the Inst. of Immunology, Vienna

1995-1998 Diploma thesis at the Institute of Immunology, Vienna

1989-1998 Studies in Human Medicine, University of Vienna

1989 University entrance qualification, G3 Vienna

Career History

2007 Associate Professor (Privat Dozent)

2006 Establishment of the Pancreas-Transplant Program at the

MUV, Minneapolis, Mn, Dep. of Surgery (Prof. DER

Sutherland)

04/2006 Habilitation in Internal Medicine, University of Vienna

Medical School

2002 Group Leader, Exp. Nephrology & Immunosuppression

MUV

1998-2002 Postdoctoral fellow at the Inst. of Immunology, Vienna

Memberships Member of the Austrian Society of Allergology und Immunology, 1998 General Secretary of the Austrian Society of Allergology und Immunology, 2006-2008 Member of the Austrian Society of Transplantation, Transfusion und Genetics, 2001 Member of the Transplantation Society, 2000 Member of the European Society of Transplantation (ESOT), 2004 Member of the Austrian Society of Nephrology, 2005 Member of the German Society of Nephrology, 2005 Member of the American Association of Immunology, 2000 Associate Editor of the European Journal of Clinical Investigation, 2002 Editorial Board of Transplant International, 2003 Society of Innate Immunity (Founding member), 2006 Member of the Scientific Comittee for ECI 2009 ("Immune Interventions")

- 83 -

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2007-2009 Else-Köner Fund HDL as immunomodulator 75000

2007-2008 Else-Köner Fund THP and the myeoloma kidney 80000

2003-2005 Austrian National

Bank Fund

JAK3 as immunosuppressive target 25000

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2004 - 2006 Marko Poglitsch Insights into the molecular mode of

malonotrilamides on T-cell activation

2006 - 2008 Barbara Vodenik Inhibition of mTOR prevents the anti-inflammatory

action of glucocorticoids

2007 - 2008 Philipp Steininger GSK3 as immunosuppressive target

Publications Peer reviewed manuscripts 2002-2008 (original research and reviews) Säemann M.D., Parolini O., Böhmig G.A., Kelemen P., Krieger P.-M., Knarr K., Kammlander W., Neumüller F., Hörl W.H., Diakos C., Stuhlmeier K., Zlabinger G.J. Bacterial metabolite interference with maturation of human monocyte-derived dendritic cells. J Leuk Biol 2002, 71:238-246 Böhmig G., Regele H., Exner M., Derhartunian V., Kletzmayr J., Säemann M.D., Hörl W.H., Druml W., Watschinger B. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002, 13(4):1091-1099 Diakos C., Prieschl E., Säemann M.D., Böhmig G.A., Baumruker T., Zlabinger G.J. Increased nuclear export of NF-AT by the short-chain fatty acid n-butyrate. J Biol Chem 2002, 277:24243-24251 Krieger P.-M., Säemann M.D., Böhmig G.A., Mühlbacher F., Zlabinger G.J. Targeting the ERK1/2-signalling pathway results in alloantigen-specific anergy in human T-cells. Transplant Proc 2002, 34:1403-1404 Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J. CD40-triggered human monocyte-derived DC convert to tolerogenic DC when JAK3 activity is prevented. Transplant Proc 2002, 34:1407-1408 Sanzone S, Zeyda M., Säemann M.D., Soncini M, Holter W, Fritsch G., Knapp W., Candotti F., Stulnig T.M., Parolini O. SLAM-associated protein deficiency causes imbalanced early signal transduction and blocks downstream activation in T cells from X-linked lymphoproliferative disease patients. J Biol Chem 2003, 278(32): 29593-29599 Zeyda M., Szekeres A.B., Säemann M.D., Geyeregger R., Stockinger H., Zlabinger G.J., Waldhausl W., Stulnig T.M. Suppression of T cell signaling by polyunsaturated fatty acids: selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J Immunol 2003, 170(12):6033-6039 Säemann M.D., Zeyda M., Diakos C., Szekeres A.B., Bohmig G.A., Kelemen P., Parolini O.,

- 84 -

Stockinger H., Prieschl E.E., Stulnig T.M., Baumruker T., Zlabinger G.J. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 2003, 75(11):1864-1872 Staffler G., Prager E., Zeyda M., Säemann M.D., Stulnig T., Hilgert I., Zlabinger G.J., Horejsi V., Stockinger H. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J Immunol 2003, 171(4):1707-1714 Säemann M.D., Diakos C., Kelemen P., Kriehuber E., Zeyda M., Böhmig G.A., Hörl W.H., Baumruker T., Zlabinger G.J. Prevention of CD40-Triggered Dendritic Cell Maturation and Induction of T-Cell Hyporeactivity by Targeting of Janus Kinase 3. Am J Transplant 2003, 3(11):1341-1349 Fabrizii V., Winkelmayer W.C., Klauser R., Kletzmayr J., Säemann M.D., Steininger R., Kramar R., Hörl W.H., Kovarik J. Patient and graft survival in older kidney transplant recipients: does age matter? J Am Soc Nephrol 2004, 15(4):1052-1060 Wimmer T., Cohen G., Säemann M.D., Hörl W.H.. Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. Nephrol Dial Transplant 2004, 19(9):2192-2197 Säemann M.D., Kelemen P., Böhmig G.A., Hörl W.H., Zlabinger G.J. Hyporesponsiveness in alloreactive T-cells by NF-kappaB inhibitor-treated dendritic cells: resistance to calcineurin inhibition. Am J Transplant 2004, 4(11):1341-1349 Säemann M.D., Weichhart T., Zeyda M., Staffler G., Schunn M., Stuhlmeier K.M., Sobanov Y., Stulnig T.M., Akira S., von Gabain A., von Ahsen U., Hörl W.H., Zlabinger G.J. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest. 2005, 115(2):468-475 Zeyda M., SäemannM.D., Stuhlmeier K.M., Mascher D.G., Nowotny P.N., Zlabinger G.J., Waldhausl W., Stulnig T.M.. Polyunsaturated fatty acids inhibit dendritic cells function without impairment of NF-kB. J Biol Chem 2005, 280(14):14293-14301 Kirsch B., Zeyda M., Grisar J., Smolen J.S., Watschinger B., Stulnig T.M., Hörl W.H., Zlabinger G.J. Säemann M.D. The active metabolite of leflunomide A77 1726 interferes with dendritic cell function. Arthritis research and therapy 2005, 2005;7(3):R694-703 Zeyda M., Stuhlmeier K.M., Kirsch B., Watschinger B., Hörl W.H., Stulnig T.M., and Säemann M.D. The malononitrilamide FK778 inhibits Activation of NF-kB in Human Dendritic Cells. Transplant Proc 2005, 37(4):1970-1971 Zeyda M., Geyerreger R., Poglitsch M., Watschinger B., Hörl W.H., Stulnig T.M., and Säemann M.D. The novel immunosuppresant FK778 inhibits Formation of the Immunological Synapse. Transplant Proc 2005, 37(4):1968-1969 Zeyda M., Poglitsch M., Geyeregger R., Smolen J.S., Zlabinger G.J., Hörl W.H., Waldhäusl W., Stulnig T.M., and Säemann M.D. The Active Leflunomide Metabolite Teriflunomide Disrupts the Interaction of T Cells with Antigen-Presenting Cells: Involvement of Impaired Integrin Activation and Immunological Synapse Formation. Arthritis and Rheumatism 2005, 52(9):2730-2739 Zeyda M., Kirsch B., Geyeregger R., Stuhlmeier K., Zlabinger G.J., Hörl, W. H., Säemann M.D., Stulnig T. M. Inhibition of human dendritic cell maturation and function by the novel immunosuppressant FK778., Transplantation. 2005 27;80(8):1105-1151 Diakos C., Prieschl E.E., Bohmig G.A., Csonga B,, Sobanov Y., Baumruker T., Säemann

- 85 -

M.D. Zlabinger G.J. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine transcription in mast cells. Biochem Biophys Res Commun. 2006;349(2):863-868 Körmöczi G.F., Säemann M.D., Buchta C., Peck-Radosavljevic M., Mayr W.R., Schwartz D.W., Dunkler D., Spitzauer S., Panzer S. Influence of clinical factors on the haemolysis marker haptoglobin. Eur J Clin Invest. 2006;36(3):202-209 Kirsch B.M., Geyeregger R., Stuhlmeier K., Säemann M.D. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol. 2006;16(3-4):254-257 Zeyda M., Geyeregger R., Poglitsch M, Säemann M.D. Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-kappaB in immunological synapse formation. J Leukoc Biol. 2007;81(1):319-327 Geyeregger R., Zeyda M., Bauer W., Kriehuber E., Säemann M.D., Zlabinger G.J., Maurer D., Stulnig T.M. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin bundling protein fascin. Blood. 2007; 109(10):4288-95 Grisar J.C., Aletaha D., Steiner C.W., Kapral T., Säemann M.D., Steiner S., Schwarzinger I., Buranyi I., Steinere G., Smolen J. Endothelial progenitor cells in active rheumatoid arthritis: Effects of TNF and of glucocorticoid therapy. Ann Rheum Dis. 2007; 66(10):1284-8 Bobacz K., Sunk IG., Hofstaetter JG., Amoyo L., Toma CD., Akira S., T. Weichhart, Säemann M.D., J. S. Smolen. Toll-like receptors and chondrocytes: The lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum. 2007;56(6):1880-93 Haidinger M., Gyeregger R., Poglitsch M., Weichhart T., Zeyda M., Vodenik B., Stulnig T.M., Böhmig G.A,, Hörl W.H., Säemann M.D. Anti-thymocyte globulin impairs T-cell/antigen-presentingcell interaction: disruption of immunological synapse and conjugate formation. Transplantation 2007;84(1):117-21

Manfred Hecking, Kainz A, Schillinger M., Posch C., Birsan T., Rasoul-Rockenschaub S., Böhmig GA, Schmaldienst S., Watschinger B., Hörl W.H., Mühllbacher F., Säemann M.D. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine. Transpl Int. 2008;21(3):223-33.

Pfistershammer K, Klauser C., Leitner J., Stöckl J., Majdic O., Weichhart T., Sobanov Y., Bochkov V., Säemann M.D., Zlabinger GJ., teinberger P. Identification of the scavenger receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein. J Leukoc Biol. 2008;83(1):131-8. M.D. Säemann, G.A. Böhmig, Zlabinger G.J. Short-chain fatty acids: physiological mediators of a balanced host-microbial relationship. Wi Kli Wo 2002;8-9: 289-300 M.D. Säemann, Zlabinger G.J. How to make clinical use of bacterial evasion strategies. Eur J Clin Invest 2003;33(3):189-190 M.D. Säemann. Prevention of allograft rejection by selective JAK3 inhibition. European Surgery 2004 M.D. Säemann, Zeyda M, Stulnig T.M., Bohmig G.A., Wekerle T, Hörl W.H., Zlabinger GJ. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic

- 86 -

transplantation. Transpl Int. 2004;17(9); 481-489 M.D. Säemann, T. Weichhart, W.H. Hörl, Zlabinger G.J. Tamm-Horsfall Glycoprotein: Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. Eur J Clin Invest. 2005;35(4):227-235 T. Weichhart, Zlabinger G.J, Säemann M.D. The multiple functions of Tamm-Horsfall Protein in health and disease: a mystery clears up. Wi Kli Wo 2005;117(9-10):316-322 M.D. Säemann, T. Weichhart. Causes of recurrent urinary tract infections: new insights. Dtsch Med Wochenschr. 2005;130(36):2031-2034 M.D. Säemann, W.H. Hörl, T. Weichhart. Uncovering host defences in the urinary tract: cathelicidin and beyond. Nephrol Dial Transplant. 2007;22(2):347-349 T. Weichhart, W.H. Hörl, M.D. Säemann, Biological action of rapamycin in renal transplantation. Am J Kidney Dis. 2008; 51(3):531 Weichhart, M. Haidinger, W.H. Hörl, M.D. Säemann, The current concept of molecular defense mechanisms operative during urinary tract infection. Eur J Clin Invest 2008; in press Invited Talks 2002-2008 2002 Suppression of early T cell activation by selectivev JAK3 targeting. Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J.. Nieren und Hochdruckkrankheiten (ERA/EGTA, Denmark) CD40-triggered human monovyte-derived DC convert to tolerogenic DC when JAK3 activity is prevented. Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J.. Nieren und Hochdruckkrankheiten (Kongress der Gesellschaft f. Nephrologie, Düsseldorf and ERA/EGTA, Denmark) Induction of allogeneic regulatory cells by differentiated myeloid dendritic cells. Säemann M.D., Kelemen P., Böhmig G.A., Hörl W.H., Zlabinger, Nieren und Hochdruckkrankheiten (Kongress der Gesellschaft f. Nephrologie, Düsseldorf sowie ERA/EGTA, Denmark) Suppression of early T cell activation by selective JAK3 targeting. Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J.. Acta Chirurgica Austriaca 2003 (Austrotransplant) 2003 Selective inhibition of Jun N-terminale kinase in alloreactive human T cells is primarily immunosuppressive, but enhances activation-induced cell death in conjunction with mTOR targeting. Säemann M.D., M. Soncini, Zeyda M., Zlabinger G.J., Knapp W., Hörl W.H., Parolini O. Nephrol Dial Transplant Vol 18 Suppl 4 2003 (World Congress of Nephrology 2003) Immunosuppressives in the Pipeline (Seminar at the Dep. of Internal Medicine III 2004) 2004 Säemann M.D. Immunostimulatory effects of Tamm-Horsfall Glycoprotein. (Seminar at the Institute for Immunology 2004)

- 87 -

Säemann M.D., Human monocyte-derived dendritic cells express high levels of angiotensin converting enzyme (ACE): modulation by vitamin-D and implications for renal disease (28. Wiss. Kongress Hypertonie, Hannover) Säemann M.D. Seminar at the Dep. of Internal Medicine III 2004 (“Tamm-Horsfall Glycoprotein: A multilayered defense molecule against urinary tract infection”) Säemann M.D., Geyerreger R., Zeyda M., Weichhart T., Zlabinger G.J., Stulnig T.. NF-� B regulates TCR/CD3 complex recruitment into the immunological synapse (3rd Int Congress of Immunosuppression, San Diego) Zeyda M., Poglitsch M., Geyeregger R., Zlabinger G.J., Watschinger B., Hörl W.H., Stulnig T.M., and Säemann M.D.. Profound disruption of the Immunological Synapse Formation by the novel immunosuppressant FK778. (3rd Int Congress of Immunosuppression, San Diego) Zeyda M., Kirsch B., Watschinger B., Stulnig T.M., Hörl W.H., Zlabinger G.J.. Säemann M.D.. The novel immunosuppressant FK778 prevents activation of NF-kB in human myeloid dendritic cells. 2005, (3rd Int Congress of Immunosuppression, San Diego) Säemann M.D., Seminar at the Medical University of Innsbruck 2004 (“Janus kinase-3 inhibition as a novel immunosuppressive option for allogeneic transplantation”) 2005 Säemann M.D., Transplantkonferenz 2005 ("C2-Spiegelmonitoring aus der Sicht des Nephrologen") Kirsch B., Zeyda M., Grisar J., Smolen J.S., Watschinger B., Stulnig T.M., Hörl W.H., Zlabinger G.J.. Säemann M.D. The active metabolite of leflunomide A77 1726 interferes with dendritic cell function. (Keystone Symposium on DCs) Säemann M.D. State of the Art: Kidney and pancreas transplantation. (Seminar at the Dep. of Internal Medicine III 2005) Säemann M.D. Zeyda M., Poglitsch M., Geyeregger R., Zlabinger G.J., Watschinger B., Hörl W. Initiating allograft immunity: effect of immunosuppression on evolution of the Immunological Synapse. (5th Basic Science Congress on Transplantation, Nantes, France) Säemann M.D. Tamm-Horsfall Protein: ein antimikrobielles Protein des Urogenitaltrakt. (DgfN Saarbrücken) Säemann M.D. Effect of Immunsuppression the very early manifestations of alloimmuneresponsiveness. (Austrotransplant) Kirsch B., Watschinger B., Hörl W.H.,. Säemann M.D., Alemtzumab induction therapy differentially affects dendritric cell subset distribution in renal transplant patients. (Austrotransplant) Säemann M.D. Bedeutung des Tamm-Horsfall Protein als protektives Molekül bei Harnwegsinfektionen. (KfH Würzburg) 2006 Säemann M.D. Insights into the molecular mechanisms of urinary tract infection (Nephro School, Freising, Germany)

- 88 -

Säemann M.D. Impact of innate immunity on the process of allogeneic transplantation. (DfGN, Essen, Germany) Säemann M.D. Innate immunity: the neglected arm of transplant effector systems (Astellas TX360 Symposium, Vienna, Austria) Säemann M.D. Innate immunity and allogeneic transplantation. (ÖGN, Semmering, Austria) Säemann M.D. Novel insights into immunosuppressive proteocols (NephroMeeting, Fuschl, Austria) Säemann M.D. Options for Renal Transplant Immunosuppression .(Seminar at the Dep. of Internal Medicine III 2005) Weichhart T, Costantino G., Zeyda M., Poglitsch M., Soleiman A., Watschinger B., Zlabinger G.A., Hörl W.H., Müller M., and Säemann M.D., The immunosuppressive drug rapamycin promotes proinflammatory responses in antigen-presenting cells", presented at the Annual meeting of the Society of Nephrology, Essen, Austria, September 2006, (Oral) Weichhart T, Hörl W.H., Säemann M.D., Antiinflammatory effects on HDL on innate immune cells: implications for dialysis HDL and ist lost function, presented at the Annual meeting of the Austrian Society of Nephrology, Semmering, Austria, October 2006, (invited Oral) Weichhart T, Costantino G., Zeyda M., Poglitsch M., Soleiman A., Watschinger B., Zlabinger G.A., Hörl W.H., Müller M., and Säemann M.D., Thomas Weichhart, "The immunosuppressant rapamycin promotes Toll-like receptor-mediated inflammatory responses", presented at the Annual meeting of the Austrotransplant Society, Fuschl, October 2006, (Oral) Vodenik B., Weichhart T, Watschinger B., Hörl W.H., Säemann M.D. Inhibitors of mTOR prevent the anti-inflammatory effecs of corticosteroids: implications for transplant patients, presented at the Annual meeting of the Austrotransplant Society, Fuschl, October 2006, (Oral) 2007 Säemann M.D. MPA and mTOR-Inhibitors: a comprehensive overview (REN, Vienna, Austria) Säemann M.D. Individual immunosuppression for the individual renal transplant patient (Nephro School, Freising, Germany) Weichhart T., Constantini G., Poglitsch M., Mueller M., Zeyda M., Hörl W.H., Hengstschläger M., Säemann M.D. The mammalian target of rapamycin is a negative regulator of NF-kB in professional antigen-presenting cells: impact on innate immunity. (ATC, San Francisco, USA) Säemann M.D. Dual effects of proliferation signal inhibitors: impact for renal transplantation. (PSI Academy, Vienna, Austria) Haidinger M., Gyeregger R., Poglitsch M., Weichhart T., Zeyda M., Vodenik B., Stulnig T.M., Böhmig G.A,, Hörl W.H., Säemann M.D. Anti-thymocyte globulin impairs T-cell/antigen-presentingcell interaction: disruption of immunological synapse and conjugate formation. ERA-EGTA, June 2007 (Travel Award)

- 89 -

Weichhart T, Costantino G., Zeyda M., Poglitsch M., Soleiman A., Watschinger B., Zlabinger G.A., Hörl W.H., Müller M., and Säemann M.D., Thomas Weichhart, Inhibition of mTORC1 promotes Toll-like receptor-mediated inflammation, European Society of Organ Transplantation, September 2007, (Young Investigator Award) Säemann M.D. Molecular Mechanisms Operative Durino Urinary Tract Infection (Univ. Klinik f. Nephrologie, Zürich, CH) Säemann M.D. Immunsosuppression: now and tomorrow: an overview. (Austrotransplant, Fuschl, Salzburg) 2008 Säemann M.D. Post-Transplant Diabetes mellitus (Nephroschool, Vienna) Saemann M.D. Immunosuppression in living-donor Renal Transplantation. (R.E.N. Meeting Transplant08) Säemann M.D. Innate Immunity during urinaty tract Infection (Nephrology Meeting, Berlin) Säemann M.D. Post-Transplant Diabetes mellitus (Int. Med.III/Dep. of Nephrology, Vienna, MUV)

- 90 -

Curriculum Vitae

Wolfgang Schreiner Division of Biomedical Computer Simulation and Bioinformatics,Core facility of Medical

Statistics and Informatics, Medical University of Vienna, Spitalgasse 19, 1090 Wien, Austria;

Phone: +43-1-40400-6679, Fax: +43-1-40400-6677;

Email: [email protected];

Homepage: http://www.meduniwien.ac.at/msi/biosim/

Personal Data

Date of Birth: 24.06.1954

Place of Birth: Wien

Nationality Austria

Education

1979 Post Doc Research Fellow (Computer Simulation), Royal

Holloway College, London

1978 – 1979 PhD Studies (Computer Simulation), Department of

Experimental of Physics, University of Vienna, Austria

1973 – 1978 Studies in Physics and Mathematics, University of Vienna,

Austria

1972 - 1973 Military service at army hospital, Vienna

1972 University entrance qualification, AHS-Matura with

distinction, Vienna

Career History

Since 05/1995 Full Professor of Medical Computer Sciences

Head of Section for Biomedical Computer Simulation and

Bioinformatics, Core Unit for medical Statistics and

Informatics, Medical University of Vienna.

1991 – 1995 Group leader for Biomedical Computer Simulation,

Department of Medical Computer Sciences, University of

Vienna Medical School

1991 Apointed “Unversitätsdozent” for Medical Informatics,

University of Vienna Medical School

01/1991 Habilitation in Medical Informatics, University of Vienna

Medical School

1985 – 1991 University Assistant at the 2nd Department of Surgery,

University of Vienna Medical school. Working field:

- 91 -

Statistics and Informatics in support of patient treatment

and medical research. Numerous projects on IT-

applications within a clinical and research setting.

1984 – 1985 Assistent at the Assistant at the 2nd Department of

Surgery, University of Vienna Medical school. Working

field: Statistics and Informatics in support of patient

treatment and medical research.

1983 Scientific Writer, Authorship of the TextBook “Radioation

Dose Estimation after Incorporatin of Open

Radionuclides”.

1979 – 1983 Assistant at the Department for Experimental Physics,

University of Vienna, Austria. Research work on computer

simulation of thermodynamic model systems.

Career-related Activities

1985- 1987 Software Coordinator for the International Working Group

of Coronary Sinus Interventions

1985- 1995 Consultant for IT – support for Ludwig Boltzmann Institute

for Research in Cardiac Surgery, University of Vienna.

1991 - 1995 IT – planning delegate for migration of the 2nd Department

of Surgery –to the new AKH-building. Initiator of the

“Chirurgie-EDV-Paket” (Surgery-IT-software-package),

later to become the research support-facility “ArchiMed”.

Establishment of close cooperation between Department

of Surgery and Department of Medical Computer

Sciences.

1995 - 1997 Member of the Executive Board for Clinical Affairs of the

Medical Faculty. (“Klinikenkonferenz”). This position made

it possible to initiate the AKIM – Projekt together with

heads of several clinical departments, the dean of the

medical faculty, the medical director of AKH, the technical

director of the AKH, administrative director, nursing

directrice of the AKH, the Vienna “Gesundheitsstadtrat”

and head of the “Wiener Krankenanstaltenverbund”. AKIM

was initiated 1997 and ist still ongoing (as of 2008).

1995 - 1999 Member of the Faculty Committee (Fakultätskollegium)

and its executive board (Leitungsausschuß), Faculty of

Medicine.

1995 - 2002 Member of the “Institutskonferenz” of the Department for

- 92 -

Medical Computer Sciences

1995 - 1998 Member of the “Strukturkommission” of the Medical

Faculty.

1995 - 2002 Member of evaluating commissions for appointments of full

professorsof several disciplines

1998 - present Member of the AKIM – Arbeitsgremium

2002 - 2007 Head of the IT-coordination board if the Department of

Medical ‘Statisitcs and Informatics

2002- 2002 Founder of bioinformatics -coordination board at the MUW

2005 - present Project leader for AKIM-Bioinformatics - Platform

2006 - present Member of the executive board for the curriculum in

Medical Informatics at MUW and coordinator for teaching

at MSI.

2006 - present Coordinator for teaching affairs at the MSI.

Awards

1992 Best presentation award „Gesellschaft für Biomedizinische

Technik“

1993 Staatspreis für Ersatzmethoden zum Tierversuch:

Computersimulation des Coronarkreislaufes

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2005-2006 BMWF Austrian Grid: Immunosimulation 41

2008 –2009 BMWF Austrian Grid: Immunosimulation 36

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2006-2008 Bernhard Knapp Genetic algorithms for pMHC modelling

Publications

Peer reviewed manuscripts 2003-2008 (original research and reviews) First, last or corresponding author manuscripts: Knapp B, Omasits U, Schreiner W: Side chain substitution benchmark for peptide/MHC interaction. Protein Sci. 17(6):977-82, 2008 Schreiner W, Karch R, Neumann M, Neumann F, Szalowski P, Roedler S: Optimized arterial

- 93 -

trees supplying hollow organs. Med.Eng.Phys. 28:416-429, 2006 Karch R, Neumann M, Neumann F, Ullrich R, Neumüller J, Schreiner W: A Gibbs point field model for the spatial pattern of coronary capillaries. Physica A. 369:599-611, 2006 Karch R, Neumann F, Ullrich R, Neumüller J, Podesser BK, Neumann M, Schreiner W: The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy. Cardiovasc Pathol. 14(3):135-144, 2005 Nadler BA, Karch R, Neumann M, Neumann F, Aharinejad S, Schreiner W: Error estimation of geometrical data obtained by histomorphometry of oblique vessel sections: a computer model study. Comput.Biol.Med. 35:829-844, 2005 Karch R, Neumann F, Podesser BK, Neumann M, Szawlowski P, Schreiner W: Fractal properties of perfusion heterogeneity in optimized arterial trees: A model study. J.Gen.Physiol. 122:307-321, 2003. Karch R, Neumann F, Neumann M, Szawlowski P, Schreiner W: Voronoi polyhedra analysis of optimized arterial tree models. Ann.Biomed.Eng. 31:548-563, 2003. Schreiner W, Karch R, Neumann M, Neumann F, Roedler SM, Heinze G: Heterogeneous perfusion is a consequence of uniform Shear stress in optimized arterial tree models. J.Theor.Biol. 220:285-301, 2003.

- 94 -

Curriculum Vitae

Univ.-Prof. Dipl.-Ing. Dr. Hannes Stockinger Department of Molecular Immunology, Center for Physiology, Pathophys io logy and Immunology, Medical University of Vienna, A-1090 Vienna, Lazarettgasse 19, Austria Tel.: +43-1-40160 33001; Fax: +43-1-40160 933001; E-mail: [email protected]; Internet: http://www.meduniwien.ac.at/immunology

Personal Data

Date of Birth: May 8, 1955

Place of Birth: Ried i. I., Upper-Austria

Nationality Austrian

Education

1985 Ph.D. (Dr. rer. nat. tech.) University of Natural Resources and Applied Life Sciences Vienna, Austria

1982-1985 Postgraduate training and Ph.D. thesis at the Institute of Immunology, University of Vienna, and the Institute of Applied Microbiology, University of Natural Resources and Applied Life Sciences Vienna, Austria

1982 Biotechnology diploma University of Natural Resources and Applied Life Sciences Vienna, Austria

1975-1982f University of Natural Resources and Applied Life Sciences Vienna, Field of study: Biotechnology

Career History

2004-present Chairman of the Department of Molecular Immunology, Medical University of Vienna, Austria

2004-present Appointment as Full University Professor for Molecular Immunology, Medical University of Vienna, Austria

2004-present Director of the Doctoral Programs of the Medical University Vienna 2002-present CEO Competence Center for Biomolecular Therapeutics Research Vienna 1997-2004 Ao. University Professor, University of Vienna, Austria 1991-1997 Associate Professor, University of Vienna, Austria 1991 Appointment as university lecturer (Univ.-Doz.), University of Vienna,

Austria 1989-2004 Head of independent research unit, Inst. Immunology, Univ. Vienna, Austria 1989-1991 Assistant Professor, University of Vienna, Austria 1987 Visitor scientist. Laboratory Dr. Sanna Goyert, New York University,

Hospital for Joint Diseases, New York, USA;

- 95 -

1985-1989 Research Associate, Inst. Immunology, Univ. Vienna, Austria

Career-related Activities 2007-present Treasurer of the Federation of Austrian Scientific Societies (VWGÖ) 2006-present Treasurer of the European Federation of Immunological Societies (EFIS) 2005-present Board member of the Austrian Science Fund 2004-present Member of the International Human Cell Differentiation Molecules Council 2004-2006 Past-president of the Austrian Society for Allergology and Immunology 2003-present Executive editor of Immunology Letters 2002-2004 President of the Austrian Society for Allergology and Immunology 2000-2002 President-elect of the Austrian Society for Allergology and Immunology 2000-2006 Advisory Board member of Signal Transduction – Receptors, Mediators,

Genes. 2000-2004 Member of the International Advisory Board of Russian Journal of

Immunology 1999-2004 Deputy-chairman of the Institute of Immunology, University of Vienna 1997-present Member of the Editorial Board of International Archives of Allergy and

Immunology 1997-2002 Member of the Managing Board of the European Confederation of

Laboratory Medicine 1995-present Member of the Clinical Immunology Group of the European Federation of

Immunological Societies (EFIS-CIG) 1996-1997 Council member of the Austrian Society for Allergology and Immunology 1994-2004 Deputy speaker of the program project grant Microvascular Injury and

Repair 1994-1996 Secretary General of the Austrian Society for Allergology and Immunology 1992-1994 Vice Secretary of the Austrian Society for Allergology and Immunology 1986-1988 Treasurer of the Collegium Immunologicum Vindobonense

Awards

2007 UPPER-AUSTRIAN CULTURE PRIZE FOR SCIENCE 1991 KARL LANDSTEINER-PRIZE of the Austrian Society for Allergology and

Immunology

1990 CLEMENS VON PIRQUET-PRIZE of the Austrian Society for Allergology and Immunology

1988 WILHELM-TÜRK-PRIZE of the Austrian Society for Hematology and Oncology

1987 INTERNATIONAL CANCER RESEARCH TECHNOLOGY TRANSFER Award supported by the National Cancer Institute of the USA and International Union Against Cancer members

1987 HOECHST-Foundation Prize

- 96 -

1986 WOLFGANG-DENK-PRIZE of the Austrian Society for Hematology and Oncology

1985 UPPER-AUSTRIAN AWARD for Young Scientists

1985 THESIS-PRIZE of the Austrian Society for Allergology and Immunology

Memberships

Austrian Society for Allergology and Immunology American Association of Immunologists German Society for Immunology Austrian Biochemical Society American Society for Biochemistry and Molecular Biology Austrian Society for Hematology and Oncology Austrian Society for Biotechnology Austrian Society for Food- and Biotechnologists International Union Against Cancer

Sources of funding in last 5 years (2003-2008)

Period Organization Short Title K€/year

2000-2004 FWF Receptor microdomains of cells of the microvascular unit and their role in signal transduction and cell function

486,326.61

2000-2005 BMT

Identification of novel pathways for immune-intervention by characterization and molecular cloning of genes encoding immunoregulatory proteins of accessory cells and T-cells“

700,000.00

2001-2004

Austrian Student Exchange Service

North South Dialog Program 40,320.00

2001-2004 FWF

Defined stimulation of T cells by combined force and optical single molecule microscopy: The design and development of the cellular part“

218,190.74

2002-2006 GEN-AU

Ultra-sensitive Proteomics and Genomics: Development of protein microarray chips for investigation of T cell regulation and diagnosis of T cell-mediated immunological diseases and disorders

539,431.00

2004-2007

Austrian Student Exchange Service, Pakistan Higher Education Commission

North South Dialog Program 40,320.00

- 97 -

2005-2006 BMT Characterization and generation of killer T cells for treatment of malignant diseases 266,714.00

2006-2009 GEN-AU Ultrasensitive Proteomics and Genomics II 311,412.00

2006-2009 FWF, MUV Doctoral program Cell Communication in Health and Disease 293,853.50

2006-2007 Austrian and Slovak Republic

Slovak –Austrian Science and Technology Co-operation 3,500.00

PhD supervision in last 5 years (2003-2008)

Period Name of student Topic

1999-2003 Andreas SZEKERES Identification of monoclonal antibody recognized immuno-modulatory leukocyte surface molecules by retroviral expression cloning

2001-2005 Birgit RICHTER The role of the CD147 molecule in negative regulation of T cells

2001-2005 Panida KHUNKAEWLA Identification and characterization of functional partners of the CD147 molecule

2002-2007 Elke FUERTBAUER Identification and characterization of differentaition factors for natural regulatory T cells

2002-2006 Wolfgang PASTER Genetically encoded conformation-sensitive fluorescence reporters of the Src-family kinase Lck

2002-2006 Christa HOLZHAUSER T cell membrane compartmentalization: Molecular analysis of the T cell receptor signaling

2004-2007 Arshad MUHAMMAD Role of CD2 and CD48 in recruitment of signaling molecules to the TCR/CD3 complex in T cells

2004- Herbert SCHILLER Characterization of plasma membrane reorganization and transmembrane signaling underlying migration of immune cells

2006- Barbara GRAUWALD, Spatio-temporal analysis of early signaling events of T cell activation by live-FRET and single molecule analysis

2007- Pavan KUMAR Influence of adhesion receptors to the T cell antigen receptor signaling pathway

2008- Paul ECKERSTORFER Role of homodimers and -multimers of signaling molecules for function and signal transduction

Publications

80 original publications in scientific journals, 47 book chapters, 37 invited lectures 2003-2008, 4 patents

Peer reviewed manuscripts 2003-2008 (original research and reviews)

- 98 -

First, last or corresponding author manuscripts:

1. Staffler, G., A. Szekeres, G.J. Schütz, M.D. Säemann, E. Prager, M. Zeyda, K. Drbal, G.J. Zlabinger, T. Stulnig, and H. Stockinger. 2003. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J. Immunol. 171:1707. Impact Factor: 6,834

2. Leksa, V., S. Godar, H. B. Schiller, E. Fuertbauer, A. Muhammad, K. Slezakova, V. Horejsi, P. Steinlein, U. H. Weidle, B. R. Binder, and H. Stockinger. 2005. TGF-beta induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J. Cell Sci. 11:4577. Impact Factor: 6.910

3. Drbal, K., M. Moertelmaier, C. Holzhauser, A. Muhammad, E. Fürtbauer, S. Howorka, M. Hinterberger, H. Stockinger*, and G. J. Schütz. 2007. Single molecule microscopy reveals heterogeneous dynamics of lipid raft components upon T cell receptor engagement. Int. Immunol. 9: 675. *Corresponding author. Impact Factor: 3,317

4. Khunkaewla, P., H. Schiller, V. Leksa, L. Andera, V. Horejsi, and H. Stockinger. 2008. LFA-1-mediated leukocyte adhesion regulated by interaction of CD43 with LFA-1 and CD147. Mol. Immunol: 45: 1703. Impact Factor: 4,768

Co-author manuscripts:

1. Säemann, M. D., M. Zeyda, C. Diakos, A. Szekeres, G. A. Böhmig, P. Kelemen, O. Parolini, H. Stockinger and G.J. Zlabinger. 2003. Suppression of early T-cell receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 75:1864. Impact Factor: 4,035

2. Schütz, G., M. Mörtelmaier, K. Drbal, and H. Stockinger. 2003. Einzelmolekülmikroskopie an lebenden Zellen. Bio-TecReport 27:6.

3. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Höfler, E. Guthann, U. Korthäuer, G.J. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stöckl. 2003. B7-h1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T-cell anergy. J Immunol. 170:3637. Impact Factor: 6,834

4. Zeyda, M., A. Szekeres, M. D. Saemann, R. Geyeregger, H. Stockinger, G. J. Zlabinger, W. Waldhäusl, and T. M. Stulnig. 2003. Suppression of T cell signaling by polyunsaturated fatty acids: Selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J .Immunol. 170:6033. Impact Factor: 6,834

5. Prager, G. W., J. M. Breuss, S. Steurer, D. Olcaydu, J. Mihaly, P. M. Brunner, H. Stockinger, and B. R. Binder. 2004. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ. Res. 94:1562. Impact Factor: 8,65

6. Moertelmaier, M., M. Brameshuber, M. Linimeier, H. Stockinger, and G. J. Schütz. 2005. TOCCSL: Thinning Out Clusters while Conserving Stoichiometry of Labeling. Appl. Phys. Lett. 87: 263903/1-263903/3. Selected for: Virtual Journal of Biological Physics Research. 11: Jan 1, 2006. Impact Factor: 4,308

7. Chiampanichayakul, S., P. Peng-In, P. Khunkaewla, H. Stockinger, and W. Kasinrerk. 2006. CD147 contains different bioactive epitopes involving the regulation of cell adhesion and lymphocyte activation. Immunobiology 211:167. Impact Factor: 2,274

8. Madl, J., S. Rhode, H. Stangl, H. Stockinger, P. Hinterdorfer, G. J. Schütz, and G. Kada. 2006. A combined optical and atomic force microscope for live cell investigations. Ultramicroscopy 106:645. Impact Factor: 2,215

9. Kirchberger, S., H. Vetr, O. Majdic, H. Stockinger, and J. Stöckl. 2006. Engagement of ICAM-1 by major group rhinoviruses activates the LFA-1/ICAM-3 cell adhesion pathway in mononuclear phagocytes. Immunobiology 211: 537. Impact Factor: 2,274

- 99 -

10. Groyer, E., A. Nicoletti, H. Ait-Oufella, J. Khallou-Laschet, A. Varthaman, A. T. Gaston, O. Thaunat, S. V. Kaveri, R. Blatny, H. Stockinger, Z. Mallad, and G. Caligiuri. 2007. Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T cells. J. Am. Coll. Cardiol. 50: 344. Impact Factor: 9,20

11. Wieser, S., M. Moertelmaier, E. Fürtbauer, H. Stockinger, and G. J. Schütz. 2007. (Un)confined diffusion of CD59 in the plasma membrane determined by high-resolution single molecule microscopy. Biophys. J. 92: 3719. Impact Factor: 4,507

12. Wieser, S., M. Cooper, H. Stockinger, and G. J. Schütz. 2007. Single molecule diffusion analysis on cellular nanotubules – implications on plasma membrane structure below the diffraction-limit. Appl. Phys. Lett.: 91:233901/1-3. Impact Factor: 3,977

13. Zola, H., B. Swart, A. Banham, S. Barry, A. Beare, A. Bensussan, B. L, C. D. Buckley, H. J. Bühring, G. Clark, P. Engel, D. Fox, B. Q. Jin, P. J. Macardle, F. Malavasi, D. Mason, H. Stockinger, and X. Yang. 2007. CD molecules 2006 — Human cell differentiation molecules. J.Immunol. Meth. 319:1. Impact Factor: 2,572

14. Beare, A., H. Stockinger, H. Zola, and J. Nicholson. 2007. The CD system of leukocyte surface molecules. Monoclonal antibodies to human cell-surface antigens. In Current Protocols in Immunol. J. E. Coligan, B. Bierer, D. H. Margulies, E. M. Shevach, W. Strober, and R. Coico, eds. Wiley-Interscience, New York. In press.

15. Paar, C., W. Paster, H. Stockinger, G.J. Schütz, M. Sonnleitner, and A. Sonnleitner. 2008. Live Cell High Throughput FRET Screening of the Plasma Membrane Based on TIRFM. Cytometry Part A. In press. Impact Factor: 3.293

Invited Talks:

2003 5th Congress of the Federation of African Immunological Societies, Victoria Falls, Zimbabwe

2003 15th European Immunology Congress of the European Federation of Immunological Societies, Rhodes, Greece

2003 4th European Biophysics Congress, Alicante, Spain

2003 12th Symposium on Signals and Signal Processing in the Immune System, Sopron, Hungary

2003 1st GEN-AU Summer School Ultrasensitive Proteomics and Genomics, Litschau, Austria

2004 21. Ernährungskongress des Verbandes der Dipl. DiätassistentInnen & Ernährungsmed. BeraterInnen Österreichs, Vienna, Austria

2004 Faculté de Médecine Necker-Enfants Malades, Paris, France

2004 Minisymposium Advances in Immunology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

2004 Medizinische Hochschule Hannover, Hannover, Germany

2004 Wörthersee-Symposium “What´s New in Allergy, Velden am Wörthersee, Austria

2004 6th EFIS Tatra Immunology Conference, Tatranske Zruby, Slovakia

2004 2nd Slovenian Immunology Congress with International Participation - Tumor Immunology and Immunointerventions. Portoroz, Slovenia

2004 8th International Conference on Human Leukocyte Differentiation Antigens, Adelaide, Australia

- 100 -

2005 Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovak Republic

2005 11th Immunology Seminar, Eötvös Lorand University, Budapest, Hungary

2005 2nd GEN-AU Summer School Ultrasensitive Proteomics and Genomics, Litschau, Austria

2005 13th Symposium on Signals and Signal Processing in the Immune System, Balatonöszöd, Hungary

2006 XXIII International Congress of the International Society of Analytical Cytology (ISAC), Quebec, Canada

2006 4th GEN-AU Summer School Ultrasensitive Proteomics and Genomics, Litschau, Austria

2006 1st Joint Meeting of European National Societies of Immunology and 16th European Congress of Immunology, Paris, France

2006 Workshop Clinical Proteomics of the Max Planck Institute of Biochemistry, Martinsried/Munich, Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratorioumsmedizin (DGKL), Deutsche Gesellschaft für Proteomforschung (DGPF) and Deutsche Gesellschaft für Zytometrie (DGfZ), Munich, Germany

2006 University of Salzburg and Austrian Society for Genetic and Gentechnic, Salzburg, Austria

2006 PhD Program of the Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

2006 Institute for Molecular and Cell Biology, Porto, Portugal

2006 1st Mediterranean Workshop on Clinical Immunology, Evora, Portugal

2006 XXIIIrd Congress of Czech and Slovak Allergologists and Clinical Immunologists, and XIth Congress of Czech and Slovak Immunologists, Hradec Kralove, Czech Republic

2007 Internationales Pädiatrisches Symposium, Obergurgl, Austria

2007 Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic

2007 EFIS-EJI Course on Autoimmunity, Tartu, Estonia

2007 Deutsch-Österreichischer AIDS Kongress, Frankfurt, Germany

2007 Otto-von-Guericke-University, Magdeburg, Germany

2007 13th International Congress of Immunology, Rio de Janeiro, Brazil

2007 ORPHEUS 2007, European PhD Programmes in Clinical Medicine, Helsinki, Finland

2007 14th Symposium on Signals and Signaling Processing in the Immune System, Balatonöszöd, Hungary

2007 Centre de Recherche des Cordeliers, University Pierre et Marie Curie Paris 6, Paris, France

2007 Division of Molecular and Experimental Surgery, Department of Surgery, University of Erlangen, Erlangen, Germany

2008 From Molecules to Clinic, Medical University of Vienna, Vienna, Austria

- 101 -

Curriculum Vitae

Herbert Strobl Divison: Molecular Biology of Hematopoietic Stem Cells and Dendritic Cells. Institute of

Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of

Vienna, Lazarettgasse 19, 1090 Wien, Austria; Phone: +43-1-40160-65001, Fax: +43-1-

40160-965006;

Email: [email protected];

Homepage: www.meduniwien.ac.at/immunologie Personal Data

Date of Birth: 15.11.1964

Place of Birth: Vienna

Nationality Austria

Education

2001 MD degree: Facharzt für Immunology

1998 2001 Post-doctoral fellow with Garry P. Nolan, Stanford

University, Department of Molecular Pharmacology

1996-1998 Clinical training, Vienna General Hospital and Lainz

Hospital (Turnusarzt)

1994-1996 Laboratory head, hematopoiesis research laboratory,

Institute of Immunology VIRCC at Novartis Research

Institute Vienna

1991-1996 Training in immunology laboratory diagnosis and research

fellow, Institute of Immunology, University of Vienna

1991 MD University of Vienna

1989-1991 Pre-doctoral research, superivisor: Walter Knapp, Institute

of Immunology, University Vienna

Career History

07/2004-present Group leader and divison head, Institute of Immunology at

VCC A-1090 Vienna, Medical University Vienna

03/2001-07/2004 Group leader, Institute of Immunology at VIRCC at

Novartis Research Institute Vienna

Since 2002 Associate Professor (a.o.Univ.Prof)

Career-related Activities

Since 2008 Head Innovation and process optimazation, Clinical

immunologic laboratory diagnosis at Institute of

- 102 -

Immunology, Medical University Vienna

2006 Listenplatz Professur „Pathophysiologie“ Medical University Vienna

2006-present Lecturer at FH Biotechnology, Vienna Biocenter

2006 - present Deputy director„ PhD program “Inflamation and Imunity“ at

Medical University Vienna.

2004-present Member of EGIL, European group of immunologic

leukemia diagnosis

2001-present Clinical consultant in immunologic laboratory diagnosis,

Institute of Immunology, Medical University Vienna

Awards

2000 START Prize, BMBWK und FWF

Memberships

Austrian Society for Allergology and Immunology, European Society of Hematology

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2007 - 2010 FWF Transcriptional Networks in human dendritic

cell subset differentiation

117

2007 - 2010 FWF + MUW DK W1212: Inflammation and Immunity,

Subproject

44

2005 - 2009 FWF SFB F23 Immunological Tolerance:

Subproject 4

110

2006 - 2008 Federal Bank of

Austria

Signal integration by epithelial Langerhans

cells

23

2003 - 2006 Federal Bank of

Austria

Identification of signaling processes that

downregulate antigen-specific immune

responses

23

2001 - 2007 FWF and BM:WF

START

Functional genomic analysis of human

dendritic cell development

200

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2001 - 2005 Barbara Platzer Molecular analysis of human dendritic cell

development

2001 - 2006 Sabine Taschner Functional analysis of nuclear receptor signaling

- 103 -

in myeloid development

2001 - 2006 Almut Jörgl Molecular analysis of human dendritic cell

maturation

2003 - 2007 Florian Göbel Molecular analysis of the differentiation and life

cycle of dendritic cells

2005-2006 Peter Reisner

2005-

present

Susanne Richter The role of AhR in Langerhans cell differentiation

2006-

present

Jennifer Jurkin Identification of regulators of Langerhans cell

differentiation

2007-

present

Thomas Bauer The role of RelB in dendritic cells

Since 2008 Yasmin Nighat Induction of epithelial genes in Langerhans cells

Publications 44 peer reviewed publications in scientific journals, 4 book chapters, 6 review articles, 1

patent

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: A. Original research articles: Scholz W, Platzer B, Schumich A, Höcher B, Fritsch G, Knapp W, Strobl H. Initial human myeloid/dendritic cell progenitors identified by absence of myeloperoxidase protein expression. Exp Hematol. 2004 Mar;32(3):270-6. Platzer B, Jörgl A, Taschner S, Höcher B, Strobl H. (2004) RelB regulates human dendritic cellsubset development by promoting monocyte intermediates. Blood, 104(12):3655-63 Heinz LX, Platzer B, Reisner P, Jörgl A, Taschner S, Göbel F and Strobl H. Differential involvement of PU.1 and Id2 downstream of TGF-b1 during Langerhans cell commitment. Blood, 2006 Feb 15;107(4):1445-53. Jörgl, A., B. Platzer, S. Taschner, L. X. Heinz, B. Höcher, P. M. Reisner, F. Göbel, and H. Strobl. Human Langerhans cell activation triggered in vitro by conditionally expressed MKK6 is counter regulated by the downstream effector RelB. Blood 2007; 1;109(1):185-93, Taschner S, Koesters C, Platzer B, Jorgl A, Ellmeier W, Benesch, T, Strobl H. Downregulation of RXRa expression is essential for neutrophil development from granulocyte/monocyte progenitors. Blood, 2007 109: 971-979 Platzer B, Richter S, Waltenberger D, Wisetschläger M, Strobl H. Aryl hydrocarbon receptor (AhR) activation perturbs myeloid sublineage differentiation by inhibiting PU.1 upregulation,

- 104 -

submitted Taschner S, Göbel F, Kumerz M, Jurkin J, Richter S, Mühlbacher C, Jörgl A, Strobl H. Interplay between the nuclear receptors VDR, RXRα and the master regulators PU.1, GATA-1/GATA-1s in normal and leukemic hematopoiesis, submitted Göbel F, Taschner S, Jurkin J, Vaculik C, Richter S, Bieglmayer C, Elbe-Bürger A, Strobl H. GATA-1-mediated repression of vitamin D3 receptor is decisive for inflammatory dendritic cell development, but not for Langerhans cells, submitted B. Review articles Strobl H. Molecular mechanisms in dendritic cell sub-lineage development from human hematopoietic progenitor/stem cells. Int. Archives of Allergy and Immunology. 2003; 131(2): 73-79 (review article) Strobl, H. and W.Knapp. Myeloid cell-associated lysosomal proteins as flow cytometry markers for leukocyte lineage classification. Review J. Biol. Regul. Homeost. Agents 18:335-9 (2004) (review article) Strobl, H., B.Platzer, A.Jörgl, S.Taschner, L.Heinz, and P.Reisner. Growth Factors. Handbook of Dendritic Cells – Biology, Diseases and Therapies. Steinkasserer, Lutz (Eds). WILEY-VCH, Vol 1, page 27-52 (2006) (book chapter) Co-author manuscripts: Hertel L, Lacaille VG, Strobl H, Mellins ED, Mocarski ES. Susceptibility of Immature and Mature Langerhans Cell-type Dendritic Cells to Infection and Immunomodulation by Human Cytomegalovirus. J Virol. 2003;77(13): 7563-74 Mann G, Attarbaschi A, Steiner M, Simonitsch I, Strobl H, Urban C, Meister B, Haas O, Dworzak M, Gadner H; Austrian Berlin-Frankfurt-Munster (BFM) Group.Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping. Pediatr Hematol Oncol. 2006 Apr-May;23(3):167-76.

Strehl, S.,. K.Nebral, M.König, J.Harbott, H.Strobl, R.Ratei, S.Struski, B.Bielorai, M.Lessard, M.Zimmermann, O.A.Haas, S.Izraeli ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. Clinical Cancer Research 14:977-983 (2008)

Selected Invited Talks 2002-2008 2004 • Invited talk at session Stem cell biology ; DgfZ meeting Heidelberg • Invitation to talk at the 12th International Congress of Immunology, Montreal, 2005 • Invited talk at Langerhans cell workshop, Madeira 2006 • Invited seminar talk at ENII 2006 meeting Carbo Caccio, Italy • Invited talk at the stem cell workshop, EHA 2006 meeting Amsterdam

- 105 -

2007 • Invited Talk at Institute of Microbiology and Immunology, Technical University Munich • Invited talk at EHA 2007 meeting Vienna

- 106 -

Curriculum Vitae

Julia Walochnik Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology

Medical University of Vienna, Kinderspitalgasse 15, 1095 Wien, Austria;

Phone: +43-1-40490-79446, Fax: +43-1-40490-79435

e-mail: [email protected]

Homepage: www.meduniwien.ac.at/hygiene/?s=parasitologie

Personal Data

Date of Birth: 12.12.1973

Place of Birth: Berlin

Nationality Germany

Education

1997-2000 PhD studies (Medical Parasitology, Microbiology, Electron

Microscopy), University of Vienna, with distinction

2000 Training course on free-living amoebae and

endocytobiosis at the Ernst-Rodenwaldt-Institute in

Koblenz

1996-1997 Diploma thesis, University of Vienna

1991-1997 Studies in Biology (Zoology, Microbiology), University of

Vienna

1982-1983 American school of Algiers/ Algeria

Career History

2004 Habilitation in Medical Parasitology, Medical University of

Vienna

since 2001 Full-time scientific collaborator at the Department of

Medical Parasitology

since 2000 Group Leader, Molecular Parasitology, University of

Vienna

since 1998 Supervision of students (MS and PhD) in the field of

molecular biology and immunobiology of parasites

1997-2001 Parttime Scientific collaborator at the Department of

Medical Parasitology, University of Vienna

Career-related Activities Since 2006 Collaboration as teacher in a training course for “Médecins

Sans Frontières”

- 107 -

Since 2005 Chief editor of the Austrian Society for Tropical Medicine and Parasitology

Since 2003 Editor of the Supplement of the Wiener Klinische Wochenschrift for the Austrian Society for Tropical Medicine and Parasitology

2003 Election into the board of the Austrian Society for Tropical Medicine and Parasitology

Awards 2002 Austrian Award of Hygiene 2002 Gerhard Piekarski Award

Memberships Member of the Austrian Proteomics Association Member of the Society for Biological Systematics Member of the Austrian Society for Hygiene and Prevention Medicine Member of the German Society for Protozoology Member of the German Society for Parasitology Member of the Austrian Society for Tropical Medicine and Parasitology Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2008-2011 FWF Glycosilation in Acanthamoeba (FWF20565);

collaborator

2007-2010 FFG Bioactive substances against protozoa and

fungi (FFG814280/13094); collaborator

2007-2010 FWF En- and excystation in Acanthamoeba

castellanii (FWF19044); project leader

2005-2006 EU Detection of pathogens in thermal waters

(EU-PHARE); collaborator

2004-2007 EU Tick-borne pathogens and Borrelia vaccine

development (EU-BOVAC); collaborator

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2007-2010 Florian Astelbauer Bioactive substances against protozoa and fungi

2007-2010 Wilawan Pumidonming Identification of pathogenicity related proteins in

Acanthamoeba spp.

2004-2008 Ursula Fürnkranz Effectivity of N-chlorotaurine against protozoa

2004 -2008 Marion Blaschitz Molecular detection of pathogens in ticks from

Austria

2003-2007 Martina Köhsler Discrimination, encystment behaviour,

pathogenicity and drug susceptibility of

- 108 -

Acanthamoeba

Publications 49 peer reviewed publications in scientific journals, 20 book chapters, >20 invited lectures

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts:

Walochnik J, Duchene M, Seifert K, Eibl HJ, Obwaller A, Aspöck H. 2002. Cytotoxic Activities of Various Alkylphosphocholines (APCs) against Clinical Isolates of Acanthamoeba. Antimicrob Agents Chemother 46:695-701.

Walochnik J, Michel R, Aspöck H. 2002. Discrepancy between morphological and molecularbiological characters in a strain of Hartmannella vermiformis Page, 1967 (Lobosea, Gymnamoebia). Protistology 2 (3):185-188.

Walochnik J, Sommer K, Haller-Schober EM, Obwaller A, Aspöck H. 2004. Characterisation and differentiation of pathogenic and non-pathogenic Acanthamoeba strains by their protein and antigen profiles. Parasitol Res 92(4):289-98.

Walochnik J, Michel R, Aspöck H. 2004. A molecularbiological approach to the phylogenetic position of the genus Hyperamoeba (Protozoa). J Euk Microbiol 51:433-440.

Walochnik J, Müller KD, Aspöck H, Michel R. 2005. An endocytobiont harbouring Naegleria strain identified as N. clarki De Jonckheere, 1994. Acta Protozoologica 44:301-310.

Köhsler M, Leitner B, Blaschitz M, Michel R, Aspöck H, Walochnik J. 2006. ITS1 sequence variabilities correlate with 18S rDNA sequence types in the genus Acanthamoeba. Parasitol Res 98(2):86-93.

Blaha C, Duchene M, Aspöck H, Walochnik J. 2006. Comparative studies on the effect of hexadecylphosphocholine on different strains of Trichomonas vaginalis. J Antimicrob Chemother 57(2):273-8.

Blaschitz M, Kohsler M, Aspock H, Walochnik J. 2006. Detection of a serine proteinase gene in Acanthamoeba genotype T6 (Amoebozoa: Lobosea). Exp Parasitol. 114(1):26-33.

Ertabaklar H, Türk M, Dayanir V, Ertuğ S, Walochnik J. 2007. Acanthamoeba keratitis due to Acanthamoeba genotype T4 in a non-contact lens wearer in Turkey. Parasitol Res 100(2):241-6.

Köhsler M, Michel R, Lugauer, Aspöck, Walochnik J. 2007. Molecular identification and classification of Cochlonema euryblastum, a zoopagalean parasite of Thecamoeba quadrilineata. Mycologia 99: 215-221.

Köhsler M, Soleiman A, Auer H, Aspöck H, Walochnik J. 2007. First molecular identification of Onchocerca jakutensis as a causative agent of a human filariosis. Emerg Inf Dis. 13: 1749-1752.

Walochnik J, Aichelburg A, Assadian O, Steuer A, Visvesvara G, Vetter N, Aspöck H. 2008. Acanthamoeba genotype T2 as causative agent of GAE in an HIV negative patient. J Clin Microbiol 46:338-340.

Fürnkranz U, Nagl M, Gottardi W, Köhsler M, Aspöck H, Walochnik J. 2008. Cytotoxic activity

- 109 -

of N-chlorotaurine (NCT) on Acanthamoeba spp. Antimicrobial Agents Chemother 52:470-476.

Ozkoc S, Tuncay S, Bayram Delıbas S, Akisu C, Ozbek Z, Durak I, Walochnik J. Identification of Acanthamoeba genotype T4 and Paravahlkampfia sp. from two clinical isolates. J Med Microbiol (in press).

Blaschitz M, Gföller M, Kanzler M, Walochnik J, Stanek G. Borrelia burgdorferi sensu lato genospecies in questing Ixodes ricinus ticks in Austria. Int J Med Microbiol 297 (Supp 1) (in press).

Blaschitz M, Gföller M, Kanzler M, Walochnik J, Stanek G. First detection of Rickettsia helvetica in Austria. Vector-Borne Zoonot (in press).

Müller MG, Kinne J, Schuster RK, Walochnik J. Outbreak of Microsporidiosis caused by Enterocytozoon bieneusi in falcons. Vet Parasitol (in press).

Köhsler M, Leitsch D, Fürnkranz U, Duchêne M, Aspöck H, Walochnik J. 2008. Acanthamoeba strains lose their abilities to encyst synchronously upon prolonged axenic culture. Parasitol Res. (in press). Co-author manuscripts:

Hiti K, Walochnik J, Haller-Schober E M, Faschinger C, Aspöck H. 2002. Viability of Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two hydrogen peroxide systems. Brit J Ophthalmol 86:144-146.

Hiti K, Walochnik J, Faschinger C, Haller-Schober EM, Hiti B, Aspöck H. 2003. Wirkung von Mikrowellenbestrahlung auf Akanthamöben: eine geeignete Möglichkeit zur Kontaktlinsenbehältersterilisation? Spektrum Augenheilkd 17 (3).

Michel R, Walochnik J, Aspöck H. 2003. "Pseudodidymium cryptomastigophorum nov. g., nov. sp.", a Hyperamoeba or a slime mould?" A combined study on morphology and 18S rDNA sequence data. Acta Protozool 42 (4): 331-343.

Tsvetkova N, Schild M, Panaiotov S, Kurdova-Mintcheva R, Gottstein B, Walochnik J, Aspöck H, Lucas M, Müller N. 2004. Isolation and taxonomic identification of free-living amoebae in the environment of in Bulgaria. Parasitol Res 92(5):405-13.

Obwaller A, Schneider R, Walochnik J, Gollackner, Deutz, Janitschke, Aspöck H, Auer H. 2004. Sequence heterogeneities among cytochrome c oxidase-1 and NADH-dehydrogenase-1 genes of Echinococcus granulosus isolates and their significance on strain differentiation. Parasitology 128:569-575.

Collingro A, Walochnik J, Michel R, Horn M, Wagner M, Obwaller A, Aspöck H. 2004. Chlamydia-related endocytobionts of free-living amoebae alter the growth rate of their hosts. Eur Journal Protistol 40:57-60.

Strimitzer S, Obwaller A, Schmoll F, Joachim A, Walochnik J, Juncker M. 2004. Entwicklung und Evaluierung einer Polymerasekettenreaktion (PCR) zum Nachweis von Eperythrozoon (syn. Mycoplasma) suis. Wien Tierarztl Monat 91:120-126.

Fürnkranz U, Walochnik J, Grimm F, Deplazes P, Aspöck H. 2004. Vergleichende Versuche zur Etablierung und Optimierung einer Leishmanien-PCR für diagnostische Zwecke. Wien Klin Wochenschr. 116 (Suppl 4): 30-35.

- 110 -

Obwaller A, Duchene M, Walochnik J, Wiedermann G, Auer H, Aspöck H. 2004. Association of autoantibodies against small nuclear ribonucleoproteins (snRNPs) with symptomatic Toxocara canis infestation. Parasite Immunol 26(8-9):327-33.

De Jonckheeere JF, Brown S, Walochnik J, Aspöck H, Michel R. 2005. Morphological investigation of three Tetramitus spp. which are phylogenetically very closely related: T. horticolus, T. russelli n. comb. and T. pararusselli n. sp. Europ J Protistol 41:139-150.

Michel R, Müller KD, Zöller L, Walochnik J, Hartmann M, Schmid EN. 2005. Free-living amoebae serve as a host for the Chlamydia-like bacterium Simkania negevensis. Acta Protozool 44:113-121.

Hiti K, Walochnik J, Faschinger C, Haller-Schober EM, Aspöck H. 2005. One and Two Step Hydrogen Peroxide Contact Lens Disinfecting Solutions against Acanthamoeba: How effective are they? Eye 19: 1301-1305.

Petry F, Torzewski M, Bohl J, Wilhelm-Schwenkmezger T, Scheid P, Walochnik J, Michel R, Zöller L, Werhahn K J, Bhakdi S, Lackner K J. 2006. Early Diagnosis of Acanthamoeba in Routine Cerebrospinal Fluid Cytology. J Clin Microbiol 44(5):1903-4.

Hiti K, Walochnik J, Haller-Schober EM, Faschinger C, Aspöck H. 2006. A new Multipurpose Contact Lens Disinfection System in Comparison with eight other Solutions – Effectiveness against Acanthamoeba. Cornea 25(4):423-7.

Mitteregger D, Aberle SW, Makristathis A, Walochnik J, Schwarz SM, Kramer G, Marberger M. 2007. Screening for pathogenic microorganisms in advanced benign prostatic hyperplasia (BPH). J Urology 177 (4): 448-449.

Murphy TM, Walochnik J, Hassl A, Moriarty J, Mooney J, Toolan D, Sanchez-Miguel C, O'loughlin A, McAuliffe A. 2007. Study on the prevalence of Toxoplasma gondii and Neospora caninum and molecular evidence of Encephalitozoon cuniculi and Encephalitozoon (Septata) intestinalis infections in red foxes (Vulpes vulpes) in rural Ireland. Vet Parasitol 146(3-4):227-34.

Meersseman W, Lagrou K, Sciot R, De Jonckheere JF, Claes K, Spriet I, Haberler C, Walochnik J, Wollants E Peetermans WE, Van Wijngaerden E. 2007. Rapidly fatal Acanthamoeba encephalitis and treatment of cryoglobulinemia. Emerg Inf Dis 13 (3):469-471.

Lorenzo-Morales J, Kliescikova J, Gómez-Pérez D, Batista N, Álvarez-Marín J, Bahaya Y, Walochnik J, Valladares B. 2007. Early diagnosis of amoebic keratitis due to a mixed infection with Acanthamoeba and Hartmannella. Parasitol Res 102(1):167-9.

Wöhrl S, Schnedl J, Auer H, Walochnik J, Stingl G, Geusau A. 2008. Successful treatment of a married couple for American leishmaniasis with miltefosine. J Eur Acad Dermatol Venereol 22(2):258-9.

Schneider R, Gollackner B, Edel B, Schmid K, Wrba F, Tucek G, Walochnik J, Auer H. Development of a new PCR protocol for the detection of species and genotypes (strains) of Echinococcus in formalin-fixed, paraffin-embedded tissues. Int J Parasitol (in press).

Haider S, Collingro A, Walochnik J, Wagner M, Horn M. 2008. Chlamydia-like bacteria in respiratory samples of community-acquired pneumonia patients. FEMS Letters. (in press)

- 111 -

Invited Talks 2002-2008 2002 • Institute of Parasitology, VetUniversity of Zurich, Switzerland • University Hospital of Zurich, Switzerland • Museum for Natural History, Linz, Austria 2003 • Museum for Natural History, Vienna, Austria 2004 • ÖGTP-advanced training, AKH, Vienna, Austria • Giftiger Dienstag, AKH, Vienna, Austria • Department of Microbial Ecology, University of Vienna, Austria 2005 • Institute of Parasitology, University of Bern, Switzerland • ÖGTP-advanced training, AKH, Vienna, Austria • University of Budapest, Hungary 2006 • Institute of Parasitology, VetUniversity of Zurich, Switzerland • Meeting of the Austrian Society for Biotopes, Wels, Austria • Billrothhaus, Vienna, Austria 2007 • Robert-Koch-Institute Berlin, Germany • ÖGTP-advanced training, AKH, Vienna, Austria • Meeting of the German Society of Biological Systematics, Vienna, Austria • Giftiger Dienstag, Ärztekammer Vienna, Austria • St. Anna Kinderspital Vienna, Austria • Meeting of the German Society for Entomology, Berlin, Germany 2008 • Billrothhaus, Vienna, Austria

- 112 -

Curriculum Vitae

Thomas Wekerle Division of Transplantation, Department of Surgery

Vienna General Hospital, Medical University of Vienna

Waehringer Guertel 18, 1090 Wien, Austria

Phone: +43-1-40400-5621, Fax: +43-1-40400-6872;

Email: [email protected];

Homepage: www.muw.ac.at/transplant-lab Personal Data

Date of Birth: 26.12.1968

Place of Birth: Vienna

Nationality: Austria

Education

2003 – 2006

1998 – 1999

Residency in Immunology, Vienna General Hospital

Residency in Surgery, Department of Surgery, Vienna

General Hospital

1996 – 1998 Post-doctoral research fellow at the BMT-Section (Head:

Megan Sykes, M.D.) of the Transplantation Biology

Research Center (Director: David H. Sachs, M.D.),

Massachusetts General Hospital, Harvard Medical School,

Boston, USA

1994 – 1996 Residency in Surgery, Department of Surgery, Vienna

General Hospital

January 1994 Graduation (M.D.)

1987 – 1994 University of Vienna Medical School

Career History

April 2006 Licensure as Specialist in Immunology, Austrian Medical

Chamber

February 2001 Appointment as Associate Professor of Experimental

Surgery at the University of Vienna (now Medical

University of Vienna)

October 1999 to date Group leader at the Research Laboratories of the

Department of Surgery, Vienna General Hospital

- 113 -

Career-related Activities

2002 to date Co-Editor-in-Chief of Transplant International

since 2007 Member of the Basic Science Committee of the European

Society of Organ Transplantation (ESOT)

2007 Participation in the 1st Scientific Advisory Council Meeting

of „Transplantation Research Integration in Europe”

(TRIE), a Specific Support Action supported by the 6th EU-

RTD Framework Programme; Brussels

since 2007 Member of the Basic Science Committee of the European

Society of Organ Transplantation (ESOT)

2006 Member of the Scientific Program Committee for the 20th

Annual Meeting of the Austrian Society of Transplantation,

Fuschl, Austria

2004

Co-Organizer of the Early Morning Course on Applied

Immunology, XX International Congress of The

Transplantation Society, Vienna, Austria

2004 Member of the Program Committee for the XX

International Congress of The Transplantation Society,

Vienna, Austria

2003 Member of the Scientific Program Committee for the 23rd

Annual Meeting and Scientific Session of the International

Society for Heart and Lung Transplantation, Vienna,

Austria

2002 and 2003 Reviewer for the Awards Committee of the International

Society for Heart and Lung Transplantation

2001 Faculty-Member of the Basic Sciences Symposium of The

Transplantation Society, Bern, Switzerland

Awards and Fellowships

November 2005 Researcher of the Month: Medical University of Vienna

2002 Habilitation Award of the Association for the promotion of

science and research at the Vienna General Hospital

2000 Erste Bank Research Award: 1st place, Medical Chamber

of Vienna

2000 Austrotransplant-Award of the Austrian Society of

Transplantation

2000 Young Investigator Award: American Society of Transplant

Surgeons and the American Society of Transplantation,

- 114 -

2000

1999 Young Investigator Award: American Society of

Transplantation

1997 – 1998 Erwin Schrödinger Fellowship of the Austrian Science

Fund (FWF)

1996 – 1997 Research fellowship of the Max Kade Foundation

Memberships

since 2007 European Society of Organ Transplantation (ESOT)

since 2002 Austrian Society of Surgical Research

since 1999 Austrian Society of Transplantation

since 1999 The Transplantation Society and International

Xenotransplantation Association

since 1998 American Society of Transplantation

since 1996 International Society for Heart and Lung Transplantation

Publications Original articles: 43

Review articles: 19

Book chapters: 3

Editorials: 6

Patent application: 1 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) A. Finished theses:

Dr.med.univ. Maximilian Schmid: "The influence of calcineurin-inhibitors on the deletion of donor-reactive T-cells after bone marrow transplantation with costimulation blockade", 2002 (M.D. thesis)

Dr.med.univ. Franz Romeder: "Mycophenolate mofetil in renal transplantation – A retrospective single centre analysis", 2005 (M.D. thesis)

Dr.rer.nat. Zvonimir Koporc: "Use of mobilized peripheral blood stem cells (mPBSC) for the induction of mixed chimerism and tolerance", 2006 (Ph.D. thesis)

Mag.rer.nat. Ines Pree: "The role of IDO (indoleamine 2, 3-dioxygenase) in tolerance induction through mixed chimerism in a murine transplantation model using bone marrow transplantation and costimulation blockade", 2005 (diploma thesis)

Mag.rer.nat. Martina Gattringer: "Induction of tolerance through transplantation of Bet v 1-transduced hematopoietic stem cells", since 2007 (diploma thesis)

B. Ongoing theses:

Mag.rer.nat. Nina Pilat: "The therapeutic use of T regulatory cells in models of mixed

- 115 -

chimerism", since 2005 (Ph.D. thesis)

Mag.rer.nat. Christoph Klaus: since 2006 (Ph.D. thesis)

Mag.rer.nat. Martina Gattringer: since 2007 (Ph.D. thesis)

Dr.med.univ. Elisabeth Schwaiger: since 2006 (Dr.sci.med. N090)

Haley Ramsey, MSc: since 2007 (Ph.D. thesis, N094, PhD program (DK) “inflammation and immunity”)

Sources of funding in last 6 years (2002-2008) "Tolerance through hematopoietic cell transplantation with costimulation blockade", international research grant from the independent Roche Organ Transplantation Research Foundation (ROTRF), Meggen, Switzerland, awarded in 2001, 130.000€ (period 2002-2004)

"Tolerance through the transplantation of mobilized peripheral blood stem cells: Identifying the factors responsible for their lower tolerogenic potential under costimulation blockade", research grant from the Jubilee Fund of the Austrian National Bank, awarded in 2004, 32.000€

"Research for the development of immunological tolerance strategies for the prevention and treatment of IgE-mediated allergies", research agreement with Biomay Inc., Vienna, ongoing since 2003, 300.000€ (period 2003-2008)

"Hematopoietic chimerism for the induction of tolerance"; project is part of the Special Research Program SFB23 on "Mechanisms of the establishment and maintenance of immunological tolerance" of the Austrian Science Fund (FWF), awarded in 2004, 451.000€ (period 2005-2008)

“Tolerance induction in organ transplantation and allergy”, Doctoral Program (Doktoratskolleg – DK) “Inflammation and Immunity”; awarded in 2006, 269.000€ (period 2007-2010) Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts

Wekerle, T., Kurtz, J., Bigenzahn, S., Takeuchi, Y., and Sykes, M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 14:592-600 (2002). Wekerle, T., Blaha, P., Langer, F., Schmid, M., and Muehlbacher, F. Tolerance through bone marrow transplantation with costimulation blockade. Transpl Immunol 9:125-33 (2002). Wekerle, T., Blaha, P., Asari, R., Schmid, M., Kiss, C., Roth, E., and Mühlbacher, F. Tolerance induction through mixed chimerism. Europ Surgery 34:131-5 (2002). Wekerle, T., Nikolic, B., Pearson, D. A., Swenson, K. G., and Sykes, M. Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transpl Int 15:248-53 (2002).

- 116 -

Wekerle, T., Blaha, P., Koporc, Z., Bigenzahn, S., Pusch, M., and Muehlbacher, F. Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem cells: central versus peripheral. Transplantation 75:21S-5S (2003). Blaha, P., Bigenzahn, S., Koporc, Z., Schmid, M., Langer, F., Selzer, E., Bergmeister, H., Wrba, F., Kurtz, J., Kiss, C., Roth, E., Muehlbacher, F., Sykes, M., and Wekerle, T. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 101:2886-93 (2003). Saemann, M., Muehlbacher, F., Zlabinger, G., and Wekerle, T. Selected commentary to: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Europ Surgery 36:205-6 (2004). Wekerle, T. and Sykes, M. Induction of tolerance. Surgery 135:359-64 (2004). Heitger, A., Blaha, P., Bigenzahn, S., Muehlbacher, F., and Wekerle, T. The influence of immunosuppressive drugs on cell-induced graft tolerance. Curr Opin Organ Transplant 9:307-13 (2004). Bigenzahn, S., Blaha, P., Koporc, Z., Pree, I., Selzer, E., Bergmeister, H., Wrba, F., Heusser, C., Wagner, K., Muehlbacher, F., and Wekerle, T. The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant 5:1237-47 (2005). Blaha, P., Bigenzahn, S., Koporc, Z., Sykes, M., Muehlbacher, F., and Wekerle, T. Short-term immunosuppression facilitates induction of mixed chimerism and tolerance after BMT without cytoreductive conditioning. Transplantation 80:237-43 (2005). Pree, I. and Wekerle, T. Inducing mixed chimerism and transplantation tolerance through allogeneic bone marrow transplantation with costimulation blockade. In: Immunological Tolerance: Methods and Protocols, P. J. Fairchild, Ed. (Humana Press, 2006)(in press). Pree, I. and Wekerle, T. New approaches to prevent transplant rejection: Costimulation blockers anti-CD40L and CTLA4Ig. Drug Discovery Today: Therapeutic Strategies 3:41-7 (2006). Koporc, Z., Bigenzahn, S., Blaha, P., Fariborz, E., Selzer, E., Sykes, M., Muehlbacher, F., and Wekerle, T. Induction of mixed chimerism through transplantation of CD45-congenic mobilized peripheral blood stem cells after nonmyeloablative irradiation. Biol Blood Marrow Transplant 12:284-92 (2006). Linhart, B., Bigenzahn, S., Hartl, A., Lupinek, C., Thalhamer, J., Valenta, R., and Wekerle, T. Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J Immunol 178:3924-31 (2007). Pree, I., Bigenzahn, S., Fuchs, D., Koporc, Z., Nierlich, P., Winkler, C., Brandacher, G., Sykes, M., Muehlbacher, F., Langer, F., and Wekerle, T. CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of indoleamine-2,3-dioxygenase. Transplantation 83:663-7 (2007).

- 117 -

Co-author manuscripts: Takeuchi, Y., Ito, H., Kurtz, J., Wekerle, T., Ho, L., and Sykes, M. Earlier low-dose TBI or DST overcomes CD8+ T-cell-mediated alloresistance to allogeneic marrow in recipients of anti-CD40L. Am. J Transplant 4:31-40 (2004). Birsan, T., Loinig, C., Bodingbauer, M., Wekerle, T., Rockenschaub, S., Berlakovich, G., Soliman, T., Muehlbacher, F., and Steininger, R. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: Retrospective analysis of a single center experience. Transplantation 78:1787-91 (2004). Saemann, M. D., Zeyda, M., Stulnig, T., Böhmig, G. A., Wekerle, T., Hörl, W. H., and Zlabinger, G. Janus kinase-3 (JAK3) inhibition: a new immunosuppressive modality for allogeneic transplantation. Transpl Int 17:481-9 (2004). Kurtz, J., Wekerle, T., and Sykes, M. Tolerance in mixed chimerism - a role for regulatory cells? Trends Immunol 25:518-23 (2004). Andres, A., Toso, C., Morel, P., Bosco, D., Bucher, P., Oberholzer, J., Mathe, Z., Mai, G., Wekerle, T., Berney, T., and Buhler, L. Macrophage depletion prolongs discordant but not concordant islet xenograft survival. Transplantation 79:543-9 (2005). Andres, A., Toso, C., Morel, P., Bosco, D., Bucher, P., Oberholzer, J., Mathe, Z., Mai, G., Wekerle, T., Berney, T., and Buhler, L. H. Phylogenetic disparity influences the predominance of direct over indirect pathway of antigen presentation in islet xenotransplantation. Transplant Proc 37:463-5 (2005). Mai, G., Bucher, P., Morel, P., Mei, J., Bosco, D., Andres, A., Mathe, Z., Wekerle, T., Berney, T., and Buhler, L. H. Role of CD40-CD154 pathway in the rejection of concordant and discordant xenogeneic islets. Transplant Proc 37:460-2 (2005). Mai, G., Bucher, P., Morel, P., Mei, J., Bosco, D., Andres, A., Mathe, Z., Wekerle, T., Berney, T., and Buhler, L. H. Anti-CD154 mAb treatment but not recipient CD154 deficiency leads to long-term survival of xenogeneic islet grafts. Am J Transplant 5:1021-31 (2005). Bucher, P., Mai, G., Morel, P., Mathe, Z., Bosco, D., Pernin, N., Wekerle, T., Berney, T., and Buhler, L. H. Transplantation of discordant xenogeneic islets using repeated therapy with anti-CD154. Transplantation 79:1545-52 (2005). Vincenti, F. , Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., Hagerty, D., Levy, E., Zhou, W., Natarajan, K., and Charpentier, B. for the belatacept study group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770-81 (2005). Fehr, T., Takeuchi, Y., Kurtz, J., Wekerle, T., and Sykes, M. Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation. Eur J Immunol 35:2679-90 (2005). Perco, P., Blaha, P., Kainz, A., Mayer, B., Hauser, P., Wekerle, T., and Oberbauer, R.

- 118 -

Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transpl Int 19:146-57 (2006). Bodingbauer, M., Pakrah, B., Steininger, R., Berlakovich, G., Rockenschaub, S., Wekerle, T., and Muehlbacher, F. The advantage of allocating kidneys from old cadaveric donors to old recipients: a single-center experience. Clin Transplant 20:471-5 (2006). Silberhumer, G., Pokorny, H., Hetz, H., Herkner, H., Rasoul-Rockenschaub, S., Soliman, T., Wekerle, T. , Berlakovich, G., Steininger, R., and Muehlbacher, F. Combination of extended donor criteria and changes in the model for end-stage liver disease score predict patient survival and primary dysfunction in liver transplantation: A retrospective analysis. Transplantation 83:588-92 (2007). Bodingbauer, M., Wekerle, T., Pakrah, B., Roschger, P., Peck-Radosavljevic, M., Silberhumer, G., Grampp, S., Rockenschaub, S., Berlakovich, G., Steininger, R., Klaushofer, K., Oberbauer, R., and Muehlbacher, F. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 7:1763-9 (2007). Hainz, U., Jurgens, B., Seidel, M. G., Wekerle, T., and Heitger, A. Indoleamine 2,3-dioxygenase in hematopoietic stem cell transplantation. Curr Drug Metab 8:267-72 (2007) Invited Talks 2002-2008 2002

• The 16th European Histocompatibility Conference, Strasbourg, Frankreich, März 2002; "Mixed chimerism and transplantation tolerance" • 22nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, Washington DC, USA, April 2002; "Review of experimental tolerance protocols" • Ninth N.A.T. (Nantes/Actualités/Transplantation), Nantes, Frankreich, Juni 2002; "Tolerance through the induction of macrochimerism" • Austrotransplant 2002, Loipersdorf; "Immunglobuline als Therapie in der Transplantation"

2003

• "Effects of immunosuppressive drugs on tolerance induction through BMT with costimulation blockade", Novartis Research Day, Frankfurt, Germany, 2003 • "Xenotransplantation", Austrotransplant 2003, Gosau, Austria • "Experimental aspects of tolerance induction", Wyeth Symposium on 'Islet transplantation and immune tolerance', Geneva, Switzerland, 2003 • "Immune tolerance - strategies, clinical application", Symposium of the Working Association • 'Transplantation of thoracic organs' of the German Society of Cardiology, Heidelberg, Germany, 2003

2004

• TBRC May 2004: “Studies on the role of regulation and the use of mobilized peripheral blood stem cells in murine mixed chimerism models involving costimulation blockade”, Boston, USA • ROTRF symposium, XX International Congress of The Transplantation Society, "Tolerance through hematopoietic cell transplantation with costimulation blockade", Vienna, Austria • Seminar "From basic science to clinical application", organized by Rudolf Valenta, “Transplantation tolerance through hematopoietic chimerism”, Vienna, Austria

- 119 -

• Ges. der Chirurgen in Wien: "Organtransplantation: Visionen und Utopien", Vienna, Austria

2005 • Gastroenterologiefortbildung, AKH Wien, "Induktion immunologischer Toleranz in der Organtransplantation" • Ethik-Symposium des Österreichischen Grünen Kreuz, Goldegg, "Xenotransplantation – Eine Alternative?" • 5th Wyeth International Transplantation Symposium on Sirolimus, Athen, "Advances in experimental tolerance induction through hematopoietic cell transplantation" • Akademie für Transplantationsimmunologie - 1. Seminar " Statistik und Medical Writing", München, "Wie kommt ein Journal zustande – Sicht eines Editors" • Symposium "Advances in solid organ and stem cell transplantation", Berlin, Charité, "Non-myeloablative protocols for stem cell transfer to induce tolerance to organ transplants" • 12th Congress of the European Society for Organ Transplantation (ESOT), Genf, opening plenary session, “Peripheral or central tolerance, what is best?” • Austrotransplant, 19. Jahrestagung, Alpbach, “Toleranzinduktion: Gegenwart, Zukunft oder Wunschtraum?” • Hesperis Course, ESOT, Wien, "Experimental tolerance protocols"

2006 • XXV Congress of the European Academy of Allergology and Clinical Immunology, EAACI 2006, Wien, "Progress towards clinical tolerance induction" • Seminar Statistik und Medical Writing, Akademie für Transplantationsimmunologie, Astellas, München, "Wie kommt ein Journal zustande - Sicht eines Editors" • Wissenschaftliches Symposium: "30 Jahre Kinder-Dialyse Wien", Wien, "Derzeitiger Stand der Toleranzinduktion" • Astellas Transplant360 Wien "Tolerance" • 37. Kongress der (Dt.) Ges. f. Nephrologie, Essen, "Möglichkeiten der Toleranzinduktion bei Organtransplantation" • Österr. Ges. für Nephrologie Jahrestagung 2006, Semmering, "Die Rolle von Costimulations-Blockern – einer neuen Klasse an Biologicals – in der Zukunft der Nierentransplantation" • 30. Seminar der Österr. Ges. für Experimentelle Chirurgie, Gosau, "Transplantationsimmunologie" • Universitäres Transplantationszentrum Hamburg, Fortbilungsveranstaltung der Transplantations-Akademie, Hamburg, Deutschland, "Toleranzinduktion in der Organtransplantation: Standortbestimmung" 2007 • “Toleranz: Eine Standortbestimmung”, invited seminar at the Medical Univ. of Innsbruck, March 2007 •“Toleranzinduktion: Realistisch oder Utopie?”, 2. Interdisziplinäres Tübinger Transplantationsgespräch, Tübingen, Germany, April 2007 • “Tolerance: Basic principles and experimental models”, Hesperis Course of ESOT, St. Gallen, Switzerland, November 2007

- 120 -

Curriculum Vitae

Ursula Wiedermann-Schmidt Institute of Specific Prophylaxis and Tropical Medicine, Center for Physiology,

Pathophysiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090

Wien, Austria; Phone: +43-1-404 90/64890, Fax: +43-1-404 90/64899;

Email: [email protected];

Homepage: www.meduniwien.ac.at/tropenmedizin Personal Data

Date of Birth: 06.08.1965

Place of Birth: Vienna

Nationality Austria

Education

01/2004 Special degree (Facharzt) in “Specific Prophylaxis and

Tropical Hygiene”

01/2002 Special degree (Facharzt) in “Immunology”

2001 - 2002 Physician in training at the Department of Internal

Medicine and Department of Clinical Pharmacology of the

University of Vienna, General Hospital Vienna, Austria

1999 - 2003 Physician in training in „Specific Prophylaxis and Tropical

Hygiene“ at the University of Vienna, Austria

1996 – 1998 Physician in training in „Immunology“ at the University of

Vienna, Austria, and at the Allergy Outpatient Clinic 1100

Vienna

05/1993 – 12/1995 PhD-Thesis at the Department of Clinical Immunology,

University Göteborg, Sweden

11/1990 – 05/1993 Master-Thesis at the Department of Clinical Immunology,

University Göteborg, Sweden

10/1990 Graduation from the Faculty of Medicine, University

Vienna, with “Medical doctor” (MD)

1975 – 1983 High School (Gymnasium) and Graduation (Matura),

Vienna, Austria

1971 – 1975 Primary School, Vienna, Austria

Career History

since 10/2006 University Professor for Vaccinology

10/2004 Head of the Department of Specific Prophylaxis and

- 121 -

Tropical Medicine at the Center for Physiology,

Pathophysiology and Immunology, Medical University,

Vienna

03/2000 Associate Professor and leader of the researche group

“Mucosal Immunity and Vaccination”

11/1999 Venia docendi at the University of Vienna, Medical School

1999 - 2000 University Assistant at the Department of General and

Experimental Pathology, University of Vienna

1996 - 1999 Research Assistant at the Department of General and

Experimental Pathology, University of Vienna

12/1995 Doctor of Philosophy (PhD9, University of Göteborg,

Sweden

05/1993 Master of Science (M. Med. Sci.)

Career-related Activities

Since 05/2007 Board Member of the “International Archives of Allergy and

Clinical Immunology”

since 12/2005 Member of the Austrian Advisory Committee of

Immunization Practice (AACIP) of the Austrian Supreme

Board of Health of the Federal Ministry of Health, Women

& Adolescence

since 09/2005 Board Member of the Austria Society of Tropcial Medicine

and Parasitology

Since 11/2003 Chair of the committee “Vaccinology” (“Standeskommittee

für Impfwesen”)

Awards and Fellowships

2006 Poster prize at the 26th Collegium Internationale Allergologicum, Malta, 5th-10th May 2006 K. Hufnagl, C. Wild, H. Breiteneder, O. Scheiner, M. Wallner, F. Ferreira, U. Wiedermann. Development of a mucosal polyvalent allergy vaccine for primary prevention of multi-sensitization (poster)

2005 Sanofi Aventis award to Stefan Wagner

“Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro”. Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H,

- 122 -

Breiteneder H. J Immunol. 2005 15;174(2):976-82 2004 Awards from the Forschungsentwicklungspreis des Fonds

der Stadt Wien für Innovative Interdisziplinäre Krebsforschung to

Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C, Breiteneder H, Pehamberger H, Scheiner O, Wiedermann U*, Zielinski CC. 2003. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int. J. Cancer. 107: 976-983. Hafner C., H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, WM. Schmidt, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2004. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int. J. Cancer Dec 1;

2003 Poster Award of the Austrian Society of Allergy and Immunology for the presentation, Salzburg Dec 2003:

“Studies on regulatory mechanisms of intranasal tolerance using recombinant Ves v 5, a major wasp venom allergen”, by Winkler B, Bolwig C, Sepälä U, Spangfort M, Ebner C and Wiedermann U.

1990 - 1995 Fellowship from the University of Göteborg, Sweden for a

PhD-program

Sources of funding in last 6 years (2002-2008) Peer-reviewed projects (FWF, EU and equivalent projects)

Period Organization Short Title K€/year

03/2008 –

02/2009

Intercell Infektionsepidemiologie von streptococcus

pneumoniae

35

2007 - 2009 ÖNB Genet. Typisierung d. Keuchhustenerregers

Bordetella Pertussis bei österr. Patienten

45

2007 - 2009 Nestlé Prenatal and perinatal intervention against

allergic diseases

182

2006 - 2008 BioLife Science Multiepitope vaccine against breast cancer 158

2005 –

2012

FWF SFB – Mucosal tolerance induction: a

strategy for prevention and therapy of type I

allergy

732

2004 - 2006 Nestlé Allergene prevention with probiotic

preparations/recombinant probiotics

182

2004 - 2006 Amadeus travel-grant Lactic acid bacteria as expression systems 5

- 123 -

for vaccine antigens

2006 Fonds des

Bürgermeisters Wien

Entwicklung einer eßbaren Vakzine gegen

Allergien

28

2002 –

2004

EU grant LABDEL Oral Va. Lactic acid bacteria 52

2000 –

2002

EU Project TRAFSA Therapeutic recombinant allergens from

structual allergology

317

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Only students in your lab, no external

Period Name of student Topic

1999-2000 Birgit Wagner (MD thesis) Mucoal tolerance as therapy of type I allergy

2003 - 2005 Carmen Wild (PhD theis) Production, characterization and in vivo testing of

novel allergen chimers

2004 –

2005

Martin Sturm (Diploma

thesis)

Mucosal vaccination against Type I allergy: a new

treatment approach using lactic acid bacteria as

delivery system for hypoallergenic molecules

2004 –

2005

Maria Korinek

(Diploma thesis)

Edible vaccines

2005 - Elisabeth Hoflehner (PhD-

thesis)

“Production and Characterization of allergen chimers for mucosal treatment of allergic diseases”

2007 - Angelika Wagner (MD-PhD

thesis)

Immunomodulation by Toxoplasma gondii

2008- Markus Mandl (PhD thesis) Pre-peri-and postnatal intervention by probtiotics

Publications Grönlund, H., S. Vrtala, U. Wiedermann, G. Dekan, D. Kraft, R. Valenta, M. Van Hage-Hamsten. 2002. Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 107(4): 523-9. Winkler, B., C. Bolwig, U. Seppala, M. D. Spangfort, C. Ebner, and U. Wiedermann*. 2003.Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 110:376. Repa, A., C. Grangette, C. Daniel, R. Hochreiter, K. Hoffmann-Sommergruber, J. Thalhamer, D. Kraft, H. Breiteneder, A. Mercenier, and U. Wiedermann*. 2003. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 22:87. Jasinska, J., S. Wagner, C. Radauer, R. Sedivy, T. Brodowicz, C. Wiltschke, H. Breiteneder,

- 124 -

H. Pehamberger, O. Scheiner, U. Wiedermann*, and C. C. Zielinski. 2003. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 107:976. Wiedermann, U*. 2003. Mucosal immunity--mucosal tolerance. A strategy for treatment of allergic diseases. Chem Immunol Allergy 82:11. Hufnagl, K., B. Wagner, B. Winkler, K. Baier, R. Hochreiter, J. Thalhamer, D. Kraft, O. Scheiner, H. Breiteneder, and U. Wiedermann*. 2003. Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice. Clin Exp Immunol 133:170. Melzer, H., K. Baier, F. Felici, B. U. von Specht, G. Wiedermann, H. Kollaritsch, U. Wiedermann, and M. Duchene. 2003. Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. FEMS Immunol Med Microbiol 37:179. Kozakova, H., L. A. Hanson, R. Stepankova, H. Kahu, U. I. Dahlgren, and U. Wiedermann*. 2003. Vitamin A deficiency leads to severe functional disturbance of the intestinal epithelium enzymes associated with diarrhoea and increased bacterial translocation in gnotobiotic rats. Microbes Infect 5:405. Hanniffy, S., U. Wiedermann, A. Repa, A. Mercenier, C. Daniel, J. Fioramonti, H. Tlaskolova, H. Kozakova, H. Israelsen, S. Madsen, A. Vrang, P. Hols, J. Delcour, P. Bron, M. Kleerebezem, and J. Wells. 2004. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 56:1. Focke, M., B. Linhart, A. Hartl, U. Wiedermann, W. R. Sperr, P. Valent, J. Thalhamer, D. Kraft, and R. Valenta. 2004. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 34:1525. Repa, A., C. Wild, K. Hufnagl, B. Winkler, B. Bohle, A. Pollak, and U. Wiedermann*. 2004. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy. Clin Exp Immunol 137:12. Westritschnig, K., M. Focke, P. Verdino, W. Goessler, W. Keller, A. Twardosz, A. Mari, F. Horak, U. Wiedermann, A. Hartl, J. Thalhamer, W. R. Sperr, P. Valent, and R. Valenta. 2004. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol 172:5684. Wagner, B., K. Hufnagl, C. Radauer, S. Wagner, K. Baier, O. Scheiner, U. Wiedermann, and H. Breiteneder. 2004. Expression of the B subunit of the heat-labile enterotoxin of Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its characterization as mucosal immunogen and adjuvant. J Immunol Methods 287:203. Herz, U., H. Renz, and U. Wiedermann*. 2004. Animal models of type I allergy using recombinant allergens. Methods 32:271. Wiedermann, U*. 2005. Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs. Curr Drug Targets Inflamm Allergy 4:577. Hufnagl, K., B. Winkler, M. Focke, R. Valenta, O. Scheiner, H. Renz, and U. Wiedermann*. 2005. Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. J Allergy Clin Immunol 116:370.

- 125 -

Linhart, B., A. Hartl, B. Jahn-Schmid, P. Verdino, W. Keller, M. T. Krauth, P. Valent, F. Horak, U. Wiedermann, J. Thalhamer, C. Ebner, D. Kraft, and R. Valenta. 2005. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 115:1010. Hafner, C., S. Wagner, J. Jasinska, D. Allwardt, O. Scheiner, K. Wolff, H. Pehamberger, U. Wiedermann, and H. Breiteneder. 2005. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J Invest Dermatol 124:125. Wagner, S., C. Hafner, D. Allwardt, J. Jasinska, S. Ferrone, C. C. Zielinski, O. Scheiner, U. Wiedermann, H. Pehamberger, and H. Breiteneder. 2005. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 174:976. Hafner, C., H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, W. M. Schmidt, J. Jasinska, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2005. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 114:426. Wiedermann-Schmidt*, U., and W. Maurer. 2005. Adjuvants and additives in vaccines--medical relevance. Wien Klin Wochenschr 117:510. Wiedermann, U., and H. Kollaritsch. 2006. Vaccines against traveler's diarrhoea and rotavirus disease - a review. Wien Klin Wochenschr 118:2. Rendi-Wagner, P., M. Kundi, A. Mikolasek, I. Mutz, K. Zwiauer, U. Wiedermann, A. Vecsei, and H. Kollaritsch. 2006. Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wien Klin Wochenschr 118:280. Daniel, C., A. Repa, C. Wild, A. Pollak, B. Pot, H. Breiteneder, U. Wiedermann*, and A. Mercenier. 2006. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61:812. Winkler, B., K. Hufnagl, A. Spittler, M. Ploder, E. Kallay, S. Vrtala, R. Valenta, M. Kundi, H. Renz, and U. Wiedermann*. 2006. The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 61:173. Tasanor, O., D. Engelmeier, B. Brem, U. Wiedermann-Schmidt, H. Greger, and W. H. Wernsdorfer. 2006. Development of a pharmacodynamic screening model with Crithidia fasciculata. Wien Klin Wochenschr 118:42. Rendi-Wagner, P., M. Korinek, B. Winkler, M. Kundi, H. Kollaritsch, and U. Wiedermann*. 2007. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 25:927. Rendi-Wagner, P., M. Paulke-Korinek, M. Kundi, U. Wiedermann, B. Laaber, and H. Kollaritsch. 2007. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine 25:5097. Wiedermann, U.*, and A. Mercenier. 2007. New allergy intervention strategies: hitting the mucosal road. Clin Exp Allergy 37:473.

- 126 -

Kollaritsch, H., and U. Wiedermann. 2007. Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea. Wien Med Wochenschr 157:102. Wagner, S., J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C. Zielinski, and U. Wiedermann*. 2007. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat. Wild, C., M. Wallner, K. Hufnagl, H. Fuchs, K. Hoffmann-Sommergruber, H. Breiteneder, O. Scheiner, F. Ferreira, and U. Wiedermann*. 2007. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 62:33. Daniel, C., Repa, A., Mercenier, A., U. Wiedermann, J. Wells. 2007. The European LABDEL project and its relevance to the prevention and treatment of allergies. Allerg. 62/11: 1237-1242 Bublin, M., E. Hoflehner, B. Wagner, C. Radauer, S. Wagner, K. Hufnagl, D. Allwarth, Scheiner, U. Wiedermann*, H. Breiteneder.2007. Use of a genetic cholera toxin B subunit/allergen-fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine 25(50):8395-404 Repa, A., H. Kozakova, T. Hudcovic, R. Stepankova, T. Hrncir, H. Tlaskalova-Hogenova, A. Pollak, U. Wiedermann. 2008. Susceptibility to nasal and oral tolerance induction of the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora. Immunol. Letters 117(1):50-56 Rendi-Wagner, P., M. Paulke-Korinek, M. Kundi, U. Wiedermann, B. Laaber, H. Kollaritsch. 2008. Seroprotection 4 years following booster vaccination against tick-born encephalitis. Int. J. Med Microbiology, Epub ahead of print. Karin Hufnagl, PhD, Margit Focke, PhD, Florian Gruber, PhD, Peter Hufnagl, PhD, Gerhard Loupal, DVM Otto Scheiner, PhD, Ursula Wiedermann, MD, PhD. 2008. Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides. Clin. Exp. Allergy, In press. Neimert-Andersson, T., S.Thunberg, L. Swedin, U. Wiedermann, G. Jacobsson-Ekman, S. Dahlén, A. Scheynius, H. Grönlund, M. van Hage , G. Gafvelin G. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy, in press. Invited Talks 2002-2008 (Ärztefortbildungen) 2002 Internationales Pädiatrisches Symposium Obergurgl, Jan 2002 „Allergie und Impfungen“ Immunologischer Fortbildungstag, Weitra, June 2002 „Impferfolgsuntersuchungen“ Reisemedizinische Konsensustagung, Wien, Oct. 2002 „Sinn und Unsinn serologischer Untersuchungen“ 2003 1. Wiener Pädiatr. Infektionssymposium, Kinderklinik Wien, Nov. 2003 „Pneumokokkenerkrankung und Impfung“

- 127 -

2004 Immunological Symposium (BMGF), Steyr, Austria, March 2004

“Immunologische Grundlagen des Impfwesens” 4. Reisemedizinische Konsensustagung, Leongang, Styria, September 2004 “Hilfs- und Zusatzstoffe von Impfstoffen – medizinische Relevanz“ Impfsymposium des Grünen Kreuzes, Gmunden, October 2004 „Impfreaktionen und Nebenwirkungen durch Inhaltsstoffe“ 19. Pädiatrischer Impftag, Linz, November 2004 „Mukosale Immunität – Zukunft der Impfstrategien“ 2005 2. Wiener Pädiatr. Infektionssymposium, Kinderklinik Wien, Febr. 2005 „Neue Impfstoffe und neue Impfentwicklungen“ Impfsymposium des österr. Bundesheeres, Grünes Kreuz, Salzburg, April 2005 „Neue Impfstrategien“ 14. Österr. Impftag, Salzburg, April 2005 „Neue Impfstrategien: die Zukunft von nasalen und oralen Vakzinen“ Impfsymposium des Grünen Kreuzes, Gmunden Oct. 200 „Impfungen gegen Reisedurchfallserreger: Dukoral, Einsatz und Wirkung“ 39th Annual meeting of the Austrian Society of Tropical Medicine and Parasitology, Vienna, 17-19 Nov. „Impfstoffe gegen Reisedurchfall: ETEC and Rotavirusinfektionen“ Symposium on Pneumococcal Diseases, 14th Dec 2005, Vienna “Epidemiology of pneumococcal diseases – benefits of vaccination” 2006 15. Österr. Impftag, 25th March 2006 “Wieviele Impfdosen sind genug?” (Hib, Meningokokken, Hep. B) Impffortbildung der Ärztekammer Niederösterreich, 19th April 2006 „Impfen aktuell“ Symposium on Vaccination in Prematures, GNPI Vienna, 20th May 2006 (chair) “Österreichischer Impfplan 2006” 3. Wiener Pädiatr. Infektionssymposium 2006, GNPI Vienna, 20th May 2006 “Welche neuen Impfstoffe für Kinder und Jugendliche sind zu erwarten” 2007 Pädiatr. Immunolog. Symposium u. Pädiatr. Kongreß, Jänner 2007 “Invasive Pneumokokkenerkrankungen” Pädiatr. Immunolog. Symposium u. Pädiatr. Kongreß, Jänner 2007 „Empirie od. evidenzbasierende Medizin?“ ISW-Expert Meeting on FSME, Jänner 2007

- 128 -

“Travel Expert Advisery Board on TBE-First Outcome Bundesheer Symposium Salzburg, März 2007 “Choleraimpfung – Dukoral Bundesheer Symposium Salzburg, März 2007 „Wie gefährlich ist impfen wirklich?“ Österr. Impftag Salzburg, März 2007 „Ist impfen wirklich gefährlich?“ Österr. Impftag Salzburg, März 2007 „Hep. A Immunität 10 Jahre nach Grundimmunisierung“ Impftagung Bregenz, Juni 2007 “Impfdosen Empirie oder evidenzbasierende Medizin” 4. Wiener Infektionssymposium, September 2007 „Neue Impfungen – Neue Impfentwicklungen“ Impfsymposium in Gmunden, September 2007 „Brustkrebsvakzine – von der Entwicklung zur klinischen Testung“ 41. Jahrestagung der Österr. Gesellschaft für Tropenmedizin und Parasitologie, Nov. 2007 „Neue Impfungen – Neue Adjuvantien“ Pressefrühstück “Kick off Meeting des Sprechergremiums von Forum Impfschutz”, Nov. 2007 „Schutz vor Epidemien durch ausreichende Durchimpfungsrate“ Expertenmeetin „Ambulant erworbene Pneumonie“, Dezember 2007 „Pneumokokkenimpfung“ Wiener Impftag, Jan 2008 „neue Impfungen, neue Adjuvantien“ Reise- und Tropenmedizinische Tagung, Innsbruck, Jan. 2008 „Wie gefährlich ist Impfen wirklich?“ Fortbildungsveranstaltung der Univ. Ärzte AKH, Febr. 2008 „Impfen aktuell – wann soll was geimpft werden?“ ESIDOG, März 2008 „Immunologische Grundlagen des Impfwesens“ Invited lectures at Scientific Meetings 2002-2008 American Academy of Allergy, Asthma and Immunology, San Diego, USA, March 2000 “Oral tolerance and its relation to allergic disease”

Gastvortrag beim Immunologischen Seminar an der Medizinischen Fakultät der Universität, Marburg, Dec. 2000. “Mukosale Vakzination, Mukosale Toleranz” Annual meeting of the Society of Immunology and Allergy, Deutsche Gesellschaft für HNO, Ulm, Deutschland. Nov. 2000

- 129 -

“Mukosale Adjuvantien” European Commission - Joint Research Center, Workshop on GMOs, Ispra, Italy, Febr. 2001 “Use of animal models in allergy research” Deutsche Gesellschaft für Allergologie und Immunologie; Universität Bochum, Bochum, Deutschland , May 2002 „Mukosale Toleranzinduktion“ 24th Symposium of the Collegium International Allergologicum, Bermuda, Nov. 2002 “From mucosal tolerance induction to edible vaccines – possible treatment strategies against allergy?” Berna Biotech, Bern, Switzerland, Februar 2004 „Hepatitis A vaccination – characterization and modulation of immune responses in mice and men“ ALK Abello, Kopenhagen, Demark, April 2004 „Mucosal tolerance induction: a treatment strategy against allergy with multiple sensitivities“ FRM Workshop “Frontier in Allergology Research” Paris May 2004 “Animal Models using recombinant allergens” EU-workshop Brussels “Food allergy in Europe, Future Prospectives” Brussels, June 2004 “Future prospectives for immunotherapy and oral vaccination” Symposium, Institute Pasteur de Lille, May 2005 „Mucosal tolerance induction: a strategy for prevention and therapy of type I allergy“ CESP/EAP European Academy of Pediatrics, Dec 2005, Brussels “Mucosal immunity – impact on nasopharyngeal carriage and on viral shedding at mucosal respiratory surfaces” EMEA (European Medicines Agency), London, Jan 2006 Workshop on “Regulatory and scientific issues related to concomitant administration of vaccine” Mucosal tolerance induction: a strategy for prevention and therapy of type I allergy. Symposium on Immunoregulation, Institute Pasteur de Lille, May 2005 Mucosal immunity – impact on nasopharyngeal carriage and on viral shedding at mucosal respiratory surfaces. CESP/EAP European Academy of Pediatrics, Brussels, 19-20 Dec 2005 Mechanisms of Mucosal Tolerance Induction. XXV EAACI, Vienna, Austria, 10.-14.6.2006 Mucosal Tolerance as treatment strategy against allergic diseases. 5th Meeting of the Mucosal Immunology Group (EMIG), Praque, Czech Republic, 5-7 Oct. 2006 Humoral and Cellular Immune responses 10 years after hepatitis A primary vaccination. 16th Annual Austrian Symposium of Vaccination, Salzburg, 23-24 March 2007. Mucosal tolerance. XXVI EAACI, Göteborg, Sweden, 9.- 13.6.2007.

Mucosal tolerance – a treatment strategy against allergies. Seminarreihe "Immunologie, Allergologie, Pneumologie" an der Uni-Klinik Giessen und Marburg, Prof. H. Renz; Marburg,

- 130 -

Deutschland; 25.-26. Juni 2007. 10th Conference of the Internat. Society of Travel Medicine, Mai 2007 “Travellers Diarrhoea Vaccines – past, present, future 26. EAACI Congress in Göteburg, Juni 2007 “Mucosal Tolerance Induction” Invited Lecture at Univ. Marburg, Deutschland, Juni 2007 “Mucosal Tolerance as a Treatment strategy against allergies” Invited Lecture Institute of Immunology and Infect. Diseases, R. Maizels, Oktober 2007 “Mucosal Tolerance for Treatment of Allergies” Invited Lecture Institute Cell Biology, Univ. Amsterdam, M. Kapsenberg Dezember 2007 “Treatment of allergies on the bases of Mucosal Tolerance Induction” World Immunregulation Meeting, Davos, March 2008 “Mucosal tolerance and Intestinal homeostasis” (chair)

- 131 -

Curriculum Vitae

Gerhard J. Zlabinger Division of Clinical and Experimental Immunology, Institute of Immunology, Center for

Physiology, Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse

8a, 1090 Wien, Austria;

Phone: +43-1-4277-64971, Fax: +43-1-4277-64972;

Email: [email protected];

Homepage: www.meduniwien.ac.at/immunologie/content/research/zlabinger.htm Personal Data

Date of Birth: 30.09.1955

Place of Birth: Traun

Nationality Austria

Education

1981 - 1988 Medical Specialization in Immunology

1975 - 1981 Study of Medicine, University of Vienna

1974 Matura at Realistisches Gymnasium, Linz

Career History

07/2007 Full Professor of Clinical and Experimental Immunology

09/2004 Head of Institute of Immunology

1992 Habilitation in Immunology, University of Vienna Medical

School

1987 – 1988 Visiting Fellow at the Department of Internal Medicine II,

University of Vienna Austria

1986 Group Leader, Institute of Immunology, University of

Vienna

Career-related Activities

since 09/2007 Curriculumdirektor Humanmedizin

2000 - present Scientific Director of the Academy for Biomedical

Scientists at the general Hospital of Vienna

Awards

2005 Landeskulturpreis Öberösterreich for Natural Sciences

1993 Förderungspreis der Stadt Wien

- 132 -

1993 Dr. Kardinal Innitzer Förderungspreis

1993 Austrotransplantpreis

1991 Förderungspreis der Ersten österr. Sparkasse

1991 Förderungspreis der Österr. Ges. für Nephrologie.

1990 Shaper & Brummer Award for Coumarin Investigators,

1990 Kolassapreis

1989 Talentförderungsprämie des Landes OÖ 1987 Staatspreis für Rheumatologie

1985 Staatspreis für Rheumatologie

Memberships

Austrian Society for Allergology and Immunology

Austrotransplant

Austrian Society for Rheumatology

Austrian Society for Nephrology

Austrian Society for Laboratory Medicine

The Transplantation Society

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2008 - 2010 Else Kröner Stiftung Immunological Hallmarks of humoral

rejection

59

2007 - 2010 FWF Identification of functional receptor for Tamm

Horsfall Protein

48

2001 - 2004 FWF Molecular characterization of the anti-

inflammatory and immunosuppressive

effects of butyrate

113

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2006 –

present

Johannes Hofer Immunomodulatory effects of C4d

2007 –

present

Johannes Kovarik Molecular mechanisms of butyrate

2008 –

present

Markus Hölzl Identification THP receptors

- 133 -

Publications 85 peer reviewed publications in scientific journals, 42 reviwes, book chapters and other

publications, > 30 invited lectures

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Säemann MD, Parolini O., Böhmig GA, Kelemen P., Krieger PM, Neumüller J, Knarr K, Kammlander W, Hörl WH, Diakos C, Stuhlmeier K, Zlabinger GJ. (2002) Bacterial metabolite interference with maturation of human monocyte-derived dendritic cells. J Leukocyte Biol 71: 238-246. Diakos C, Prieschl EE, Säemann MD, Novotny V, Böhmig GA, Csonga R, Baumruker T, Zlabinger GJ (2002) Novel mode of interference with nuclear factor of activated T-cells regulation in T-cells by the bacterial metabolite n-butyrate. J. Biol Chem 27: 24243-51. Säemann MD, Böhmig GA, Zlabinger GJ (2002) Short-chain fatty acids:bacterial mediators of a balanced host-microbial relationship in the human gut. Wien Klin Wochenschr 114: 289-300. Säemann MD, Zeyda M, Diakos C, Szekeres A, Böhmig GA, Kelemen P, Parolini O, Stockinger H, Prieschl EE, Stuhlnig T, Baumruker T, Zlabinger GJ. (2003) Suppression of early T-cell receptor-triggered cellular activation by the Janus kinase inhibitor WHI-P154. Transplantation 75: 1864 – 72. Saemann MD, Diakos C, Kelemen P, Kriehuber E, Zeyda M, Böhmig GA, Hörl WH, Baumruker T, Zlabinger GJ. Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. Am J Transplant. 3: 1341-9 2003. Säemann MD, Zlabinger GJ. How to make clinical use of bacterial evasion strategies. Eur J Clin Invest 33: 189-90, 2003. Säemann MD, Kelemen P, Böhmig GA, Hörl WH, Zlabinger GJ. Hyporesponsiveness in Alloreactive T-cells by NF-kappaB Inhibitor-Treated Dendritic Cells: Resistance to Calcineurin Inhibition. Am J Transplant 4:1448-58, 2004. Säemann MD, Zeyda M, Stulnig TM, Böhmig GA, Wekerle T, Hörl WH, Zlabinger GJ. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transplant Int. 17:481-9, 2004. Säemann, MD., Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y, Stulnig TM, Akira S, von Gabain A, von Ahsen U, Hörl W, and Zlabinger GJ. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a TLR4-dependent mechanism. J Clin Invest 115:468-75, 2005. Säemann MD, Weichhart T, Hörl WH, Zlabinger GJ. Tamm-Horsfall Glycoprotein: A multilayered defense molecule against urinary tract infection. Eur J Clin Invest, 35:227-35, 2005. Diakos C, Prieschl EE, Saemann MD, Bohmig GA, Csonga R, Sobanov Y, Baumruker T, Zlabinger GJ. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine

- 134 -

transcription in mast cells. Biochem Biophys Res Commun. 349:863-8, 2006 Stefanova T, Nikolova N, Michailova A, Mitov I, Iancov I, Zlabinger GJ, Neychev H Enhanced resistance to Salmonella enterica serovar Typhimurium infection in mice after coumarin treatment. Microbes Infect 9:7-14, 2007 Co-author manuscripts: Chiampanichayakul S, Szekeres A, Khunkaewla P, Moosom S, Leksa V, Drbal K, Zlabinger GJ, Hofer-Warbinek, R, Stockinger H, Kasinrerk W Engagement of Na, K-ATPase beta3 subunit by a specific mAb suppresses T and B lymphocyte activation. Int Immunol 14: 1407-14, 2002 Selenko-Gebauer N, Majdic O, Szekeres A, Höfler G, Guthann E, Korthäuer U, Zlabinger GJ, Pickl WF, Stockinger H, Knapp W, Stöckl J. B7-H1 (PD-L1) on dendritic cells is involved in the induction and maintenance of T-cell anergy. J Immunol 170:3637-44, 2003. Stollberger C, Finsterer J, Zlabinger GJ, Weihsengruber F, Redtenbacher S, Bonner G, Herkner K, Deutsch M. Antineutrophil cytoplasmic autoantibody-negative antiproteinase 3 syndrome presenting as vasculitis, endocarditis, polyneuropathy and Dupuytren's contracture. J Heart Valve Dis. 12: 530-4, 2003. Staffler G, Szekeres A, Schutz GJ, Saemann MD, Prager E, Zeyda M, Drbal K, Zlabinger GJ, Stulnig TM, Stockinger H. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J Immunol 171: 1707-14, 2003. Zeyda M, Szekeres AB, Saemann MD, Geyeregger R, Stockinger H, Zlabinger GJ, Waldhausl W, Stulnig TM. Suppression of T cell signaling by polyunsaturated fatty acids: selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J Immunol 170: 6033-9, 2003. Wahrmann M, Exner M, Regele H, Derfler K, Körmöczi GF, Lhotta K, Zlabinger GJ, Böhmig GA. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 275: 149-60, 2003 Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF, Stöckl J, Knapp W. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol. 172:2352-9, 2004. Koller H, Hochegger K, Zlabinger GJ, Lhotta K, Mayer G, Rosenkranz AR. Apoptosis of human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation of the complement system. Nephrol Dial Transplant. 19:3104-11, 2004. Pfistershammer K, Majdic O, Stöckl J, Zlabinger G, Kirchberger S, Steinberger P, Knapp W. CD63 as an activation-linked T cell costimulatory element. J Immunol. 173:6000-8, 2004. Zeyda M, Säemann MD, Geyeregger R, Zlabinger GJ, Waldhäusl W, Stulnig TM. Polyunsaturated fatty acids inhibit dendritic cells function without impairment of NF-kB. J Biol Chem, 280:14293-301,2005. Geyeregger R, Zeyda M, Zlabinger GJ, Waldhäusl W, Stulnig TM. Polyunsaturated fatty acids interfere with formation of the immunological synapse. J Leukoc Biol. 77: 680-8, 2005. Weichhart T, Zlabinger GJ, Säemann MD. The multiple functions of Tamm-Horsfall Protein in

- 135 -

health and disease: a mystery clears up. Wien Klin Wochenschr 117:316-22, 2005. Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Hörl WH, Zlabinger GJ, Säemann MD The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Research & Therapy, 7:R694-R703, 2005. Bluml S, Kirchberger S, Bochkov VN, Kronke G, Stuhlmeier K, Majdic O, Zlabinger GJ, Knapp W, Binder BR, Stockl J, Leitinger N. Oxidized Phospholipids Negatively Regulate Dendritic Cell Maturation Induced by TLRs and CD40. J Immunol. 175:501-8, 2005. Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Horl WH, Waldhausl W, Stulnig TM, Saemann MD. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 52:2730-9, 2005. Kirchberger S, Majdic O, Steinberger P, Bluml S, Pfistershammer K, Zlabinger G, Deszcz L, Kuechler E, Knapp W, Stockl J. Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. J Immunol. 175:1145-52. 2005 Zeyda M, Kirsch BM, Geyeregger R, Stuhlmeier KM, Zlabinger GJ, Horl WH, Saemann MD, Stulnig TM. Inhibition of human dendritic cell maturation and function by the novel immunosuppressant FK778. Transplantation 80:1105-11. 2005 Pfistershammer K, Klauser C, Pickl WF, Stockl J, Leitner J, Zlabinger G, Majdic O, Steinberger P. No evidence for dualism in function and receptors. PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 36:1104-13, 2006 Zeyda M, Geyeregger R, Poglitsch M, Weichhart T, Zlabinger GJ, Koyasu S, Horl WH, Stulnig TM, Watschinger B, Saemann MD. Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-{kappa}B in immunological synapse formation. J Leukoc Biol. 81:319-27, 2007. Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, Bornancin F, Cai R, Zemann B, Urtz N, Stingl G, Zlabinger G, Woisetschlager M, Baumruker T, Billich A. Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal. 19:748-60, 2007 Mechtcheriakova D, Wlachos A, Sobanov J, Bornancin F, Zlabinger G, Baumruker T, Billich A FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett. 7581:3063-8, 2007 Geyeregger R, Zeyda M, Bauer W, Kriehuber E, Saemann MD, Zlabinger GJ, Maurer D, Stulnig TM. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin. Blood 109:4288-95, 2007 Hochegger K, Eller P, Huber JM, Bernhard D, Mayer G, Zlabinger GJ, Rosenkranz AR Expression of granzyme A in human polymorphonuclear neutrophils. Immunology. 121:166-73, 2007 Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ, Stulnig TM Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond). 31: 1420-8, 2007 Pfistershammer K, Klauser C, Leitner J, Stöckl J, Majdic O, Weichhart T, Sobanov Y,

- 136 -

Bochkov V, Säemann M, Zlabinger G, Steinberger P. Identification of the scavenger receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein. J Leukoc Biol. 83:131-8, 2008

- 137 -

6.2 Teachers

Herbert Auer 133

Adelheid Elbe-Bürger 139

Thomas Felzmann 143

Gottfried Fischer 147

Elisabeth Förster-Waldl 151

Renate Fuchs 155

Ulrich Jäger 160

Peter Pietschmann 169

Clemens Scheinecker 177

Veronika Sexl 180

Maria Sibilia 184

Peter Steinberger 188

Günter Steiner 191

Johannes Stöckl 197

Martin Willheim 201

- 138 -

Curriculum Vitae

Herbert Auer

Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology,

Medical University of Vienna, Kinderspitalgasse 15, 1095 Vienna, Austria

Phone: +43 1 40490-79443, Fax: +43 1 40490-79435

Email: [email protected]

Homepage: http://www.meduniwien.ac.at/hygiene/

Personal Data

Date of Birth: 21.02.1953

Place of Birth: Zams/Tyrol

Nationality Austria

Education

1971-1977 PhD studies (Zoology, Botany, Limnology), University of

Innsbruck

1971 University entrance qualification, Gymnasium

Landeck/Tyrol

Career History

10/2004 Leader of the Dept. Med. Parasitology

10/1997 Associate Professor

01/1991 Habilitation in Med. Parasitology, University of Vienna

Medical School

Awards

1987 Filmpreis (wissenschaftlicher Film) Budweis und Barcelona

„Echinococcus multilocularis: Protoscolices in vivo und in

vitro.“

2003 Hovorka Medal, Slovak Academy of Science,

Helminthological Institute Kosice/Slovak Republic

- 139 -

Memberships

Austrian Society of Tropical Medicine and Parasitology (Member of the Executive Board:

since 11/1983; as Treasurer, Secretary, President and Vice-President)

German Society of Parasitology

Sources of funding in last 6 years (2002-2008)

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

1995-1998 Barbara Bauder Experimentelle Untersuchungen zur B- und T-

Zell-Immunantwort bei primärer alveolärer

Echinokokkose

1995-1999 Andreas Obwaller Toxocarosis in humans: Antibodies and antigens

involved in the humoral immune response

Publications

Peer reviewed manuscripts 2002-2008 (original research and reviews)

Deutz A, Fuchs K, Auer H, Schuller W, Nowotny N, Kerbl U, Aspöck H, Köfer J. (2002):

Seroepidemiologische Untersuchungen disponierter Personen auf ausgewählte

Kontaktzoonosen. Fleischwirtschaft 82 (1), 101 – 104.

Kinceková J, Auer H, eiterová K, Dubinský P, Szilagyiová M, Lauko L, Aspöck H. (2002): The

- 140 -

first case of autochthonous human alveolar echinococcosis in the Slovak Republic (Case

report). Mitt. Österr. Ges. Tropenmed. Parasitol. 23, 33-38.

Westritschnig K, Sibanda E, Thomas W, Auer H, Aspöck H, Pittner S, Vrtala S, Spitzauer S,

Kraft D, Valenta R. (2003): Analysis of the sensitization profile towards allergens in central

Africa. Clin. Exp. Allergy 33: 22-27.

Kern P, Bardonnet K, Renner E, Auer H, Pawlowski Z, Ammann RW, Vuitton DA, Kern P.

(2003): European echinococcosis registry: human alveolar echinococcosis, Europe, 1982-

2000. Emerg Infect Dis 2003 Mar;9(3), 343-9.

Deutz A, Fuchs K, Schuller W, Nowotny N, Auer H, Aspöck H, Stünzner D, Kerbl U, Klement

Ch, Köfer J. (2003): Seroepidemiologische Untersuchung von Jägern auf Zoonosen in

Südostösterreich – Prävalenzen, Risikopotentiale und Vorbeugemaßnahmen. Berl. Münch.

Tierärztl. Wschr. 116: 306-311.

Auer H. (2003): Toxocara-Infestationen und Toxokarose in Mitteleuropa: Eine Übersicht. In:

Infektiologie – Aktuelle Aspekte (O. Janata, E. Reisinger, Hrsg.). Jahrbuch 2003/2004, pm-

Verlag: 77-92.

Deutz A, Fuchs K, Nowotny N, Auer H, Schuller W, Stünzner D, Aspöck H, Kerbl U, Köfer J

(2003): Seroepidemiologische Untersuchungen von Jägern auf Zoonosen – Vergleich mit

Untersuchungen bei Tierärzten, Landwirten und Schlachthofarbeitern. Wien. Klin. Wschr.

115 Suppl 3):61-67.

Auer H, Vander-Möse A, Aspöck H (2003): Die verwirrende Vielfalt der IgM-Tests in der

Diagnostik von Toxopalsma-Infektionen: Versuch einer optimalen Strategie. Wien. Klin.

Wschr. 115 (Suppl 3): 18-22.

Rauhofer U, Prager G, Hörmann M, Auer H, Kaserer K, Niederle B (2003): Cystic

echinococcosis of the thyroid gland in children and adults. Thyroid 13, 497-502 (Impact

2000: 2,047)

Westritschnig, Sibanda A, Thomas W, Auer H, Aspöck H, Pittner G, Vrtala S, Spitzauer S,

- 141 -

Kraft D, Valenta R (2003): Analysis of the sensitization profile towards allergens in central

Africa. Clin. Exp. Allergy. 33: 22-27.

Obwaller A, Schneider R, Walochnik J, Gollackner B, Deutz A, Janitschke K, Aspöck H, Auer

H. (2004): Echinococcus granulosus strain differentiation based on sequence heterogeneity

in mitochondrial genes of cytochrome c oxidase-1 and NADH dehydrogenase-1. Parasitology

128: 569-575.

Auer H, Aspöck H (2004): Nosologie und Epidemiologie der Toxokarose des Menschen – die

aktuelle Situation in Österreich. Wien Klin Wochenschr 116 (Suppl. 4): 7-18.

Obwaller A, Duchêne M, Walochnik J, Wiedermann G, Auer H, Aspöck H. (2005):

Association of autoantibodies against small nuclear ribonucleoproteins (snRNPs) with

symptomatic Toxocara canis infestation. Parasite Immunol 26 (8-9): 327-333.

Auer H, Aspöck H. (2005): Vertikale Transmission von Helminthen beim Menschen. Nova

Acta Leopoldina 89 (334): 351-363.

Aspöck H, Auer H, Walochnik J. (2005): Die Prävention der pränatalen Toxoplasmose:

Strategien, Stand der Kenntnis, aktuelle Probleme. Nova Acta Leopoldina 89 (334): 229-268.

Juncker-Voss M, Prosl H, Lussy H, Enzenberg U, Auer H, Lassnig H, Müller M, Nowotny N.

(2005): Untersuchungen auf Antikörper gegen Zoonoseerreger bei Angestellten des Wiener

Tiergartens Schönbrunn. Berl. Münch. Tierärtztl. Wschr. Heft 09/10: 404-409.

Deutz A, Fuchs K, Auer H, Kerbl U, Aspöck H, Köfer J. (2005): Toxocara-infestations in

Austria: a study on the risk of infection of farmers, slaughterhouse staff, huntes and

veterinarians. Parasitol Res. 97: 390-394.

Auer H, Vander-Möse A, Picher O, Aspöck H. (2005): Toxoplasmose-Ringversuche in

Österreich: Ergebnisse und Grenzen des serologischen Schwangeren-Screenings. Wiener

Klinische Wochenschrift 117: 20-28.

Auer H. (2005): Die Trichinellose des Menschen in Österreich. Vet. Med. Austria/Wien.

Tierärztl. Mschr 92: 288-294.

- 142 -

Auer H, Aspöck H. (2006): Die Diagnostik der Toxocara-Infestationen und der Toxokarose

des Menschen. Journal of Laboratory Medicine 30: 1-12.

Finsterer J, Mei Li , Rasmkogeler K, Auer H. (2006): Chronic Long-Standing Headache due

to Neurocysticercosis. – Headache, 46: 523-524.

Auer H. (2006): Die Bedeutung laboratoriumsdiagnostischer Untersuchungen für die Klinik,

Epidemiologie und Prävention der alveolären Echinokokkose – Erfahrungen zweier

Jahrzehnte in Österreich. - Wien. Klin. Wochenschr 118: 18-26.

Hörweg CH., Sattmann H., Auer H. (2006): Cercarial dermatitis in Austria: Questionnaires as

useful tools to estimate risk factors. - Wien. Klin. Wochenschr 118: 77-80.

Cetin E, Sotoudeh M, Auer H, Stanek G. (2006): Paradigm Burgenland: Risk of Borrelia

burgdorferi sensu lato infection indicated by variable seroprevalence rates in hunters. – Wien

Klin Wochenschr 118/21-22: 677-681.

Kinčeková J, Hrčková G, Auer H, Szilágyiová M, Hudačková J, Stanislayová M, Poláček H,

Šimeková K. (2006): Clinical and serological study of human alveolar echinococcosis in

Slovakia in relation to the outcome of chemotherapy. – Helminthologia 43, 4: 213-219.

Koehsler M, Soleiman A, Aspöck H, Auer H, Walochnik J. (2007): Onchocerca jakutensis

Filariasis in Humans. – Emerg Infect Dis. 13: 1749-1752.

Hrčkova G, Velebný S, Obwaller A, Auer H, Kogan G. (2007): Evaluation of follow-up of

therapy with fenbendazole incorportated into stabilized liposomes and immunomodulator

glucan in mice infected with Toxocara canis larvae. – Acta Tropica 104: 122-132.

Schnedl J, Auer H, Fischer M, Tomaso H, Pustelnik T, Mooseder G. (2007): Kutane

Leishmaniose – Import aus Belize. – Wien KlinWochenschr 119: 102-105.

Auer H, Leskowschek H, Engler J, Leitner G, Wentzel Ch, Wolkerstorfer W, Schneider R.

- 143 -

(2007): Epidemiologie und Nosologie der Anisakiose, einer in Mitteleuropa selten

diagnostizierten Helminthozoonose – zwei Fallberichte. – Wien Klin Wochenschr 119: 106-

109.

Finsterer J, Auer H. (2007): Neurotoxocarosis. – Rev. Inst. Med. trop. S. Paulo 49: 279-287.

Wöhrl S, Schnedl J, Auer H, Walochnik J, Stingl G, Geusau A. (2007): Successful treatment

of a married couple for American leishmaniasis with miltefosine. – Jorunal of the European

Academy of Dermatology and Venerology 22: 258-259.

Schneider R, Gollackner B, Edel B, Schmid K, Wrba F, Tucek G, Walochnik J, Auer H.

Development of a new PCR protocol for the detection of species and genotypes (strains) of

Echinococcus in formalin-fixed, paraffin-embedded tissues Int J Parasitol. 2007 Dec 4 [Epub

ahead of print]

- 144 -

Curriculum Vitae

Adelheid Elbe-Bürger Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology,

Vienna Competence Center, Medical University of Vienna, Lazarettgasse 19, 1090 Vienna,

Austria;

Phone: +43-1-40160-63001, Fax: +43-1-40160-963005;

Email: [email protected]

Homepage: www.meduniwien.ac.at/immundermatologie/?main

Personal Data

Date of Birth: 11.12.1961

Place of Birth: Globasnitz

Nationality Austria

Education

1984 – 1987 PhD studies (Cellular Immunology, Immunodermatology),

Department of Dermatology, University of Vienna Medical

School, and University of Vienna, Faculty of Natural

Sciences

1980 – 1984 Studies in Biology, University of Vienna

1980 University entrance qualification,

Bundesoberstufenrealgymnasium Klagenfurt

Career History

Since 1997 Associate Professor (a.o.Univ.Prof.)

01/1996 Habilitation in Immunology and Immunodermatology,

University of Vienna Medical School

1992 - 1995 Faculty position (Univ. Ass.) Group Leader, Department of Dermatology I, University of

Vienna Medical School

1988 - 1992 Postdoctoral fellow at the Department of Dermatology I,

and at the Laboratory of Molecular Biology of Retroviruses,

Memorial Sloan-Kettering Cancer Center, New York, USA

1984 - 1988 PhD thesis performed at the Department of Dermatology I,

Division of Immunobiology, University of Vienna Medical

School

- 145 -

Career-related Activities

1996 - 1997 Board Member of the Austrian Society of Allergology and Immunology

Awards

1993 Karl Landsteiner Award, Austrian Society of Allergology

and Immunology

1988 Thesis Award, Austrian Society of Allergology and

Immunology

Memberships Arbeitsgemeinschaft Dermatologische Forschung (ADF; German Society for Investigative

Dermatology)

Deutsche Gesellschaft für Stammzellforschung

European Society for Dermatological Research (ESDR)

ITERA – Life-Sciences Forum

Österreichische Gesellschaft für Transplantation, Transfusion und Genetik

(AUSTROTRANSPLANT)

Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI; Austrian Society for

Allergology and Immunology)

Österreichische Gesellschaft für Dermatologie und Venerologie (ÖGDV; Austrian Society of

Dermatology and Venerology)

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2006 - 2009 FWF Ontogeny of human cutaneous dendritic cells

81

2008 - 2008 HJST Effects of glucocorticosteroids on neonatal

and infant skin

5

2005 - 2007 HJST Isolation, purification and ex vivo expansion of human dermal stem/progenitor cells

3

2004 - 2008 FWF Dermal hematopoietic stem cells 68

2003 - 2004 HJST Characterization of human dermal hematopoietic stem cells

10

2000 - 2003 FWF Search for Langerhans stem/progenitor cells

62

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

- 146 -

Period Name of student Topic

2000 - 2004 Souyet Chang-Rodriguez Phenotypical, maturational and functional

characterization of dendritic epidermal leukocytes

in fetal and neonatal mice

2001 - 2004 Wolfram Hötzenecker Effects of topical immunomodulators on the

immune system of the skin

2001 - 2005 Simone Meindl Characterization, purification and differentiation

potential of cells expressing hematopoietic stem

cell markers in newborn and adult mouse skin

2004 -

present

Christine Vaculik Characterization of human dermal cells

exypressing stem cell markers

2008 –

present

Nousheen Iram Molecular analysis of Toll like receptors in

differentiating human skin cells

Publications 41 peer reviewed publications in scientific journals, 4 reviews, 10 book chapters, 4 varia,

>250 presentations at national and international meetings

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Elbe-Bürger A., Egyed A., Olt S., Klubal R., Mann U., Rappersberger K., Rot A., Stingl G. (2002). Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol, 118:767-778. Hoetzenecker W., Meingassner J.G., Ecker R., Stingl G., Stuetz A., Elbe-Bürger A. (2004). Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol, 122:673-684. Chang-Rodriguez S., Ecker R., Stingl G., Elbe-Bürger A. (2004). Autocrine IL-10 partially prevents differentiation of neonatal dendritic epidermal leukocytes into Langerhans cells. J Leukoc Biol, 76:657-666. Elbe-Bürger A., and Stingl G. (2004). Dendritic cells: role in skin immunity and potential clinical uses. Ann Dermatol Venereol. 131:93-103. Meindl S., Rot A., Hoetzenecker W., Kato S., Cross H., Elbe-Bürger A. (2005). Vitamin D receptor ablation alters skin architecture and homeostasis of dendritic epidermal T cells. Br J Dermatol, 152: 231-241. Chang-Rodriguez S., Hoetzenecker W., Schwärzler C., Biedermann T., Saeland S., Elbe-Bürger A. (2005). Fetal and neonatal murine skin harbors Langerhans cell precursors. J Leukoc Biol, 77:352-360. Hoetzenecker W., Ecker R., Kopp T., Stuetz A., Stingl G., Elbe-Bürger A. (2005). Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol, 115:1276-1283.

- 147 -

Hoetzenecker W., Meindl S., Stuetz A., Stingl G., Elbe-Bürger A. (2006). Both pimecrolimus and corticosteroids deplete plasmacytoid dendritic cells in patients with atopic dermatitis. J Invest Dermatol, 126:2141-2144. Meindl S., Schmidt U., Vaculik C., Elbe-Bürger A. (2006). Characterization, isolation and differentiation of murine skin cells expressing hematopoietic stem cell markers. J Leukoc Biol, 80:816-826. Co-author manuscripts: Meingassner J.G., Kowalsky E., Schwendinger H., Elbe-Bürger A., Stütz A. (2003). Pimecrolimus does not affect Langerhans cells in murine epidermis, in contrast to corticosteroids. Br J Dermatol, 149:853-857. Ortiz-Urda S., Elbe-Bürger A., Smolle J., Marquart Y., Chudnovsky Y., Ridky T.W., Bernstein P., Wolff K., Rappersberger K. (2003). The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo. J Immunol, 171:6244-6250. Tripp C., Chang-Rodriguez S., Stoitzner P., Holzmann S., Stössel H., Saeland S., Koch F., Elbe-Bürger A., Romani N. (2004). Ontogeny of Langerin / CD207 expression in the epidermis of mice. J Invest Dermatol, 122:670-672. Abrahamsberg C., Fuchs P., Osmanagic-Myers S., Fischer I., Propst F., Elbe-Bürger A., Wiche G. (2005). Targeted ablation of plectin isoform 1 uncovers role of cytolinker proteins in leukocyte recruitment. PNAS, 102:18449-18454. Invited Talks 2002-2008 2002 • Klinik für Pathophysiologie, Wien, Österreich

2003 • Novartis Forschungsinstitut, Wien 2004 • ISAC XXII International Congress. Montpellier, Frankreich 2005 • 6. GD Jahrestagung, Wien • 35th ESDR Annual Meeting. Tübingen, Deutschland 2006 • Universitätshautklinik Innsbruck

- 148 -

Curriculum Vitae

Thomas Felzmann Laboratory of Tumour Immunology, St. Anna Children’s Cancer Research Institute,

Kinderspitalgasse 6, 1090 Vienna, Austria;

Phone: +43-1-40170-4060, Fax: +43-1-40170-7150;

Email: [email protected];

Homepage: www.ccri.at Personal Data

Date of Birth: 15.11.1960

Place of Birth: Vienna

Nationality Austria

Education

2007 Habilitation in Immunology, Medical University Vienna

2003-2005 Executive MBA program of the Danube University Krems,

graduation as Master of Business Administration,

November 25, 2005

1999 Board certification as Clinical Immunologist

1986-1989 Training in group dynamics

1980-1987 Medical University, Vienna, A, graduation as Medical

Doctor, December 11, 1987

1975-1980 Secondary College for Chemical Technology,

specialization in Biochemistry and Biochemical

Technology, Vienna, A, graduation, June 3, 1980

Career History

2003- Founder and CEO, I-Med Cancer Immune Therapy GmbH

1995- Group leader, Laboratory of Tumor Immunology, St. Anna

Children’s Cancer Research Institute, Vienna, A

1995-1998 Clinical training in pediatric oncology at the St. Anna

Children’s Hospital, Vienna, A

1992-1995 Research Fellow at the Clinical Gene Therapy Branch,

National Human Genome Research Institute, National

Institute of Health, Bethesda, MD, USA

1991-1992 Clinical training in oncology at the I. Medical Department,

Wilhelminenspital, Vienna, A

- 149 -

1988-1992 Postdoctoral fellow at the Institute of Immunology, Medical

University, Vienna, A

1987-1989 Physician at the blood bank of the Austria Red Cross,

Vienna, A.

1987 Social worker as ambulance physician for the Austria Red

Cross, Vienna, A.

1975-1987 Various full and part time jobs as a working student

Awards

2003 Fellowship for the Executive MBA program of the Danube

University Krems, A

1994 Fogarty Fellowship, National Institute of Health, Bethesda,

MD, USA

1992 Max Kade Fellowship, Austrian Academy of Science

Memberships

Austrian Society for Allergology and Immunology

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2005 - 2006 Austrian Research

Promotion Fund

Gemodec 450

2003 - 2006 EU FP6 Dendritophages 500

2002 - 2008 Vienna Busniess

Agency

Clinical Development of a DC Cancer

Vaccine

1000

2001 - 2006 Austrian Research

Promotion Fund

Biology of DC Cancer Vaccination 500

2000 - 2002 Mayor of Vienna Xenogenisation of Tumour Cells 200

1999 - 2001 Austrian National

Bank

Genetic Engineering of Tumour Cells 200

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2000 - 2004 Katharina Hüttner Development of a mouse tumour model for

dendritic cell cancer vaccination

2004 - 2008 Mareike Lindbauer Knock down of IDO in a mouse tumour model to

improve dendritic cell cancer vaccination

- 150 -

2006 - 2007 Petra Paul Two-step maturation of dendritic cells

2007-2008 Romana Luger Lentiviral engineering of dendritic cells

2007-2008 Michael Traxlmayr Immun eregulation by γδ T-cells.

Publications 20 peer reviewed publications in scientific journals, 3 international patent families

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Dohnal A, Witt V, Hugel H, Holter W, Gadner H, Felzmann T.Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy. 2007 Oct;9(8):755-70 Hüttner KG, Breuer SK, Paul P, Majdic O, Heitger A, Felzmann T. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother. 2005 Jan;54(1):67-77. Felzmann T, Hüttner KG, Breuer SK, Wimmer D, Ressmann G, Wagner D, Paul P, Lehner M, Heitger A, Holter W. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol Immunother. 2005 Aug;54(8):769-80. Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, Paul P, Huttner K, Fritsch G. Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy. 2003;5(5):391-8. Felzmann T, Gadner H, Holter W. Dendritic cells as adjuvants in antitumor immune therapy. Onkologie. 2002 Oct;25(5):456-64. Felzmann T, Buchberger M, Lehner M, Printz D, Kircheis R, Wagner E, Gadner H, Holter W. Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. Cancer Lett. 2001 Jul 26;168(2):145-54. Felzmann T, Buchberger M, Jechlinger M, Kircheis R, Wagner E, Gadner H. Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells mediated by polycations and liposomes. Cancer Lett. 2000 Dec 20;161(2):241-50. Felzmann T, Ramsey WJ, Blaese RM. Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer. Cancer Lett. 1999 Jan 8;135(1):1-10. Felzmann T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther. 1997 Dec;4(12):1322-9. Felzmann T, Gisslinger H, Ludwig H. Immunological findings in patients with myelodysplastic syndrome. Leuk Lymphoma. 1994 Oct;15(3-4):201-8. Review. Felzmann T, Gisslinger H, Krieger O, Majdic O, Ludwig H, Koller U. Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome. Br J Haematol. 1993 Jul;84(3):428-35.

- 151 -

Felzmann T, Gadd S, Majdic O, Maurer D, Petera P, Smolen J, Knapp W. Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol. 1991 Jul;11(4):205-12. Co-author manuscripts: Lehner M, Stockl J, Majdic O, Knapp W, Huttner K, Felzmann T, Holter W. MHC class II antigen signaling induces homotypic and heterotypic cluster formation of human mature monocyte derived dendritic cells in the absence of cell death. Hum Immunol. 2003 Aug;64(8):762-70. Lehner M, Felzmann T, Clodi K, Holter W. Type I interferons in combination with bacterial stimuli induce apoptosis of monocyte-derived dendritic cells. Blood. 2001 Aug 1;98(3):736-42. Kircheis R, Kichler A, Wallner G, Kursa M, Ogris M, Felzmann T, Buchberger M, Wagner E. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 1997 May;4(5):409-18. Maurer D, Felzmann T, Holter W, Petera P, Smolen J, Knapp W. Evidence for the presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients with rheumatoid arthritis. Clin Exp Immunol. 1992 Mar;87(3):429-34. Gadd SJ, Felzmann T, Majdic O, Maurer D, Petera P, Chen WJ, Smolen J, Knapp W. Phenotypic analysis of functionally associated molecules on peripheral blood and synovial fluid monocytes from arthritis patients. Rheumatol Int. 1992;12(4):153-7. Szekeres T, Fritzer M, Pillwein K, Felzmann T, Chiba P. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin. Life Sci. 1992;51(16):1309-15. Maurer D, Fischer GF, Felzmann T, Majdic O, Gschwantler E, Hinterberger W, Wagner A, Knapp W. Ratio of complement receptor over Fc-receptor III expression: a sensitive parameter to monitor granulocyte-macrophage colony-stimulating factor effects on neutrophils. Ann Hematol. 1991 Apr;62(4):135-40. Maurer D, Felzmann T, Knapp W. A single laser flow cytometry method to evaluate the binding of three antibodies. J Immunol Methods. 1990 Dec 31;135(1-2):43-7.

- 152 -

Curriculum Vitae

Gottfried Fischer Division of Blood Group Serology, Department for Blood Group Serology and Transfusion

Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria;

Phone: +43-1-40400 5320, Fax: +43-1-40400 5321;

Email: [email protected];

Homepage: n.e. Personal Data

Date of Birth: 16.09.1960

Place of Birth: Vienna

Nationality Austria

Education

1985 Promotion Dr. med. Univ

1978 – 1985 Studies in Medicine, University of Vienna

1978 University entrance qualification, BG Bruck/Leitha

Career History

1993 Habilitation in Blood Group Serology, University of Vienna

Medical School

Since 1987 Assistant Doctor at the Institute for Blood Group Serology

1985 – 1987 Post Doctoral Stay at the Institute for Immunology,

University of Vienna Medical School, Group Prof. Knapp

Career-related Activities

2002-2007 Commissioner for Region 05, Accreditation Committee of

the European Federation for Immunogenetics

Since 2007 – present Chairman of the Accreditation Committee of the European

Federation for Immunogenetics

Awards

1991-1993 Erwin-Schrödinger Postdoctoral Fellowship, FWF

Memberships

Austrian Society for Allergology and Immunology, Deutsche Gesellschaft für Immungenetik

- 153 -

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2005 - 2008 EU EU Marie Curie Research & Training

Network (TRANSNET)

40

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

None

Publications >25 peer reviewed publications in scientific journals, >2 book chapters, >5 invited lectures, 0

patents Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Ludajic, K., Balavarca , Y., Bickeböller H., Pohlreich D., Kouba M., Dobrovolna M, Vrana M.,

Rosenmayr A., Fae, I., Fischer, G.F, Kalhs P. & Greinix H.T. (2008) Impact of HLA-DPB1 Allelic and Single Amino Acid Mismatches on HSCT. Br. J Haematology, in press

Ludajic, K., Fae, I. & Fischer, G.F. (2006) Characterization of a new HLA-DPB1 allele, DPB1*010103. Tissue Antigens, 67, 255-256.

Greinix, H.T., Fae, I., Schneider, B., Rosenmayr, A., Mitterschiffthaler, A., Pelzmann, B., Kalhs, P., Lechner, K., Mayr, W.R. & Fischer, G.F. (2005) Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant, 35, 57-62.

Fischer, G. (2002) Immunogenetic selection of donors for haematopoietic stem cell transplantation: an approach. Transpl Immunol, 10, 223-225.

Co-author manuscripts: Leb, V.M., Jahn-Schmid, B., Schmetterer, K.G., Kueng, H.J., Haiderer, D., Neunkirchner, A.,

Fischer, G.F., Nissler, K., Hartl, A., Thalhamer, J., Bohle, B., Seed, B. & Pickl, W.F. (2008) Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol, 121, 64-71.

Mrazek, F., Fae, I., Ambruzova, Z., Raida, L., Kriegova, E., Indrak, K., Fischer, G.F. & Petrek, M. (2006) A single amino acid exchange shifts the serological reactivity of the novel HLA-B*4442 allele product from HLA-B44 to HLA-B21. Int J Immunogenet, 33, 197-200.

Penn, D.J., Oberzaucher, E., Grammer, K., Fischer, G., Soini, H.A., Wiesler, D., Novotny, M.V., Dixon, S.J., Xu, Y. & Brereton, R.G. (2007) Individual and gender fingerprints in human body odour. J R Soc Interface, 4, 331-340.

Tiercy, J.M., Fischer, G. & Setterholm, M. (2007) Quality control for registry HLA data. Tissue Antigens, 69 Suppl 1, 13-14.

Vidan-Jeras, B., Ambroz, N., Fae, I., Kemperle, I. & Fischer, G. (2007) HLA-B*350802, a novel allele, which has arisen by silent mutation at codon 67. Tissue Antigens, 69, 363.

Worel, N., Greinix, H.T., Supper, V., Leitner, G., Mitterbauer, M., Rabitsch, W., Fischer, G., Rosenmayr, A., Hocker, P. & Kalhs, P. (2007) Prophylactic red blood cell exchange for

- 154 -

prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion, 47, 1494-1502.

Danzer, M., Polin, H., Proll, J., Hofer, K., Fae, I., Fischer, G.F. & Gabriel, C. (2007) High-throughput sequence-based typing strategy for HLA-DRB1 based on real-time polymerase chain reaction. Hum Immunol, 68, 915-917.

Karvunidis, T., Jindra, P., Fischer, G., Venigova, P., Dorner, A. & Koza, V. (2007) Identification of a novel HLA-DRB1*14 allele, HLA-DRB1*1458, by sequence-based typing. Tissue Antigens, 70, 348-349.

Meraner, P., Horejsi, V., Wolpl, A., Fischer, G.F., Stingl, G. & Maurer, D. (2007) Dendritic cells sensitize TCRs through self-MHC-mediated Src family kinase activation. J Immunol, 178, 2262-2271.

Vidan-Jeras, B., Kunilo, S., Fae, I., Kandus, A. & Fischer, G.F. (2006) A novel HLA-B*2730 allele found in a Slovene patient affected with IgA nephropathy. Int J Immunogenet, 33, 371-373.

Danzer, M., Polin, H., Fae, I., Fischer, G.F. & Gabriel, C. (2006) Exon 1-4 sequence analysis of a novel HLA-A allele, HLA-A*2458. Tissue Antigens, 68, 177-178.

Bohle, B., Zwolfer, B., Fischer, G.F., Seppala, U., Kinaciyan, T., Bolwig, C., Spangfort, M.D. & Ebner, C. (2005) Characterization of the human T cell response to antigen 5 from Vespula vulgaris (Ves v 5). Clin Exp Allergy, 35, 367-373.

Jahn-Schmid, B., Fischer, G.F., Bohle, B., Fae, I., Gadermaier, G., Dedic, A., Ferreira, F. & Ebner, C. (2005) Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1 *01. J Allergy Clin Immunol, 115, 399-404.

Mrazek, F., Fae, I., Ambruzova, Z., Raida, L., Indrak, K., Petrek, M. & Fischer, G.F. (2005) A novel HLA-B*420502 allele identified by PCR-SSO/SSP routine typing and confirmed by Sequencing-based typing. Tissue Antigens, 65, 275-277.

Danzer, M., Leitner, D., Gangl, E., Fae, I., Fischer, G.F. & Gabriel, C. (2004) A novel HLA-DRB1*13 allele (DRB1*1357) identified by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens, 64, 213-214.

Fae, I., Lau, M., Voorter, C., Mayr, W.R. & Fischer, G.F. (2004) HLA-B*8102*, a new allele found in an external proficiency testing scheme. Tissue Antigens, 64, 608-610.

Voorter, C.E., Fischer, G.F. & van den Berg-Loonen, E.M. (2004) Identification of a new HLA-C allele, Cw*0316, by sequence-based typing. Tissue Antigens, 63, 484-486.

Weiwad, M., Werner, A., Rucknagel, P., Schierhorn, A., Kullertz, G. & Fischer, G. (2004) Catalysis of proline-directed protein phosphorylation by peptidyl-prolyl cis/trans isomerases. J Mol Biol, 339, 635-646.

Bohle, B., Radakovics, A., Jahn-Schmid, B., Hoffmann-Sommergruber, K., Fischer, G.F. & Ebner, C. (2003) Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level. Eur J Immunol, 33, 3303-3310.

Spatz, M., Eibl, N., Hink, S., Wolf, H.M., Fischer, G.F., Mayr, W.R., Schernthaner, G. & Eibl, M.M. (2003) Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol, 221, 15-26.

Vogelsang, H., Panzer, S., Mayr, W.R., Granditsch, G. & Fischer, G.F. (2003) Distribution of HLA class I alleles differs in celiac disease patients according to age of onset. Dig Dis Sci, 48, 611-614.

Winter, D., Fiebiger, E., Meraner, P., Auer, H., Brna, C., Strohal, R., Trautinger, F., Knobler, R., Fischer, G.F., Stingl, G. & Maurer, D. (2003) Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma. J Immunol, 171, 2714-2724.

Jahn-Schmid, B., Kelemen, P., Himly, M., Bohle, B., Fischer, G., Ferreira, F. & Ebner, C. (2002) The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by

- 155 -

one epitope. J Immunol, 169, 6005-6011. Worel, N., Biener, D., Kalhs, P., Mitterbauer, M., Keil, F., Schulenburg, A., Hocker, P.,

Dieckmann, K., Fischer, G., Rosenmayr, A., Linkesch, W., Hinterberger, W., Lechner, K. & Greinix, H.T. (2002) Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant, 30, 619-626.

Worel, N., Greinix, H.T., Keil, F., Mitterbauer, M., Lechner, K., Fischer, G., Mayr, W., Hocker, P. & Kalhs, P. (2002) Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion, 42, 1293-1301.

Invited Talks 2002-2008 2005 • Invited talk at the DGI Tagung, Dresden 2006 • Invited talk at the DGI Tagung, Innsbruck 2007 • Invited talk at the Balcanic Immunogentics Conference, Bukarest 2008 • Invited Talk at the East West Conference, Prague

- 156 -

Curriculum Vitae

Elisabeth Förster-Waldl Department of Pediatrics & Adolescent Medicine, Division of General Pediatrics &

Neonatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria;

Phone: +43-1-40400-3232, Fax: +43-1-40400-3238;

Email: [email protected];

Homepage: www.meduniwien.ac.at/kikli Personal Data

Date of Birth: 07.12.1960

Place of Birth: Pittsburgh, Pa., U.S.A.

Nationality Austria

Education 1988 Graduation as Doctor Medicinae (M.D.)

1979-1988 Graduate studies at the University of Vienna Medical

School

1971-1979 High school in Vienna, Austria

1966-1971 French elementary school (Lycée français de Vienne) in

Vienna, Austria

Career History

since 2007 Consultant for Pediatric Immunology at the St. Anna

Children’s Hospital, Vienna, Austria

since 2005 Head of the Pediatric Immunology Outpatient Ward at the

Department of Pediatrics, Medical University of Vienna

since 2005 Group leader of the Working Group Pediatric & Neonatal

Immunology at the Department of Pediatrics, Medical

University of Vienna, Austria

since 11/2004 Associate Professor of Pediatrics (a.o.Univ.Prof)

11/2004 Habilitation in Pediatrics, Medical University of Vienna

since 2002 Medical specialist for Immunology

2001 Guest Scientist at the Institute of Immunology, Medical

University of Vienna

since 2000 Medical specialist for Pediatrics & Adolescent Medicine

1992 – 1999 Resident in pediatrics at the Dept. of Pediatrics, Univ. of

- 157 -

Vienna. Special training in clinical immunology and

allergology/pulmology

1996 – 1998 Research Fellow (Erwin Schrödinger Grant of the Austrian

Science Fund) at the Dept. of Pediatric Immunology

(Head: Prof. Dr. G.A. Holländer), Basel, CH. Topic: The

role of CD40-mediated costimulation in T-cell activation

and tolerance (in a mouse allogeneic transplantation

model)

1991 – 1992 Research Fellow (Otto Loewi-Grant of the Austrian

Science Fund) at the Dept. of Pediatrics, Univ. of Vienna,

working on T-cell regulation of allergic diseases (model:

bee venom allergy) and on the allergenic profile of

recombinant bee venom Phospholipase A2, the major bee-

venom allergen

1988 – 1991 Research fellow at the Dept. of Dermatology, Univ. of

Vienna, Ludwig Boltzmann-Institute for cell biology in

immunodermatological reactions (Head: Prof. Dr. T.A.

Luger), working on the cytokine regulation of inflammatory

immune reponses in the skin

Career-related Activities 2003

4th Advanced Vaccinology Course at the Fondation

Mérieux

1999 Guest Scientist at the Scripps Research Institute, La Jolla, USA, working on immunomodulatory therapies by DNA vaccines and antibody-cytokine fusion proteins

1996 – 1998 Research Fellow (Erwin Schrödinger Grant of the Austrian

Science Fund) at the Dept. of Pediatric Immunology

(Head: Prof.Dr.G.A. Holländer), Basel, CH

Awards

2006 Scientific award of the GNPI (Gesellschaft für

Neonatologie und Pädiatrische Intensivmedizin) for the

original publication (first author) ‚Monocyte Toll-like

receptor 4 expression and LPS-induced cytokine

- 158 -

production increase during gestational aging’

2005 Poster-Award (last author) at the Annual Meeting of the

Austrian Society of Pediatrics Sept.2005; „ Impaired

Immune Responses to Bacterial Cell Wall Components in

Preterm Newborns“

1999 Hofrat von Domanig Award of the Van Swieten

Gesellschaft to work as guest-scientist at the Scripps

Research Institute, La Jolla, USA, with immunomodulating

therapies through DNA-vaccines and antibody-cytokine

fusion proteins

Memberships Austrian Society for Allergology and Immunology

Working Group for Pediatric Immunology (API)

Austrian Society of Pediatrics

European Society for Pediatric Infectious Diseases (ESPID)

Van Swieten Gesellschaft

Research Topics Neonatal and Pediatric Immunology, Immunological Immaturity and Immunodeficiencies, Preventive and therapeutic strategies against infectious diseases, vaccine failures due to immunodefiency and strategies to prevent such failures, vaccine adjuvant strategies and vaccine delivery systems (experimentally: DNA-vaccines)

Publications 22 peer reviewed publications in scientific journals, 4 reviews & book chapters Peer reviewed manuscripts 2002-2008 (original research) Sadeghi K., Berger A., Langgartner M., Prusa A.R., Hayde M., Herkner K., Pollak A., Spittler A., Förster-Waldl E. Immaturity of infection control in preterm and term newborns is associated with impaired TLR signaling. J Infect Dis. 195: 296–302 (2007)

Fest S., Huebener N., Weixler S., Zeng Y., Strandsby A., Bleeke M., Volkmer-Engert R.,

Landgraf C., Gaedicke G., Riemer A., Jensen-Jarolim E., Michalsky E., Jaeger I.S.,

Preissner R., Förster-Waldl E., Lode H.N.. Characterisation of GD2 Peptide Mimotope DNA Vaccines effective against spontaneous neuroblastoma metastasis. Cancer Res.

66 (21): 10567-75 (2006) Riemer A.B., Förster-Waldl E., Brämswig K., Pollak A., Zielinski C.C., Pehamberger H., Lode H.N., Scheiner O., Jensen-Jarolim E. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur J Immunol.

- 159 -

36(5):1267-74 (2006) Förster-Waldl E., K. Sadeghi, D. Tamandl, B. Gerhold, U. Hallwirth, K. Rohrmeister, M. Hayde, K. Herkner, G. Boltz-Nitulescu, A. Pollak, and A. Spittler. Monocyte Toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res. 58 (1):121-24. (2005) Förster-Waldl, E., A.B. Riemer, A.K. Dehof, D. Neumann, K. Brämswig, G. Boltz- Nitulescu, H. Pehamberger, C.C. Zielinski, O. Scheiner, A. Pollak, H. Lode, E. Jensen-Jarolim. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol. 42(3):319-25 (2005) Szalai K., Schöll I., Förster-Waldl E., Riemer AB, Boltz-Nitulescu G, Polito L, Bolognesi A., Stirpe F., Jensen-Jarolim E. Occupational sensitization to ribosome-inactivating proteins (RIPs) in Researchers. Clin Exp Allergy 35 (10):1354-60 (2005) Schöll I, Weissenböck A, Förster-Waldl E, Untersmayr E, Walter F, Willheim M, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E: Allergen-loaded biodegradable PLGA nanoparticles downregulate an ongoing Th2-response in the Balb/c mouse model. Clin.Exp.Allergy 34(2):315-21 (2004)

Schuller E, Förster-Waldl E, Slavc I, Maurer W: Immunity against vaccine-preventable potentially neurotropic diseases in children treated for malignant brain tumours with HIT-91 chemo- and radiotherapy. Eur J Cancer 40(2):236-44 (2004) Förster-Waldl E, Marchetti M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I, Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E: Type I Allergy to Elderberry is elicited by a 33.2 kDa Allergen with significant Homology to Ribosomal Inactivating Proteins (RIPs). Clin.Exp.Allergy, 33: 1703-10 (2003)

Untersmayr E, Schöll I, Swoboda I, Beil W, Förster-Waldl E, Walter F, Riemer A, Kraml G, Kinaciyan T, Spitzauer S, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E: Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in Balb/c mice. J Allergy Clin Immunol. 112:616-23 (2003) Förster-Waldl E, Cokoja L, Förster O, Maurer W: Mannose binding lectin: comparison of two assays for the quantification of MBL in serum of pediatric patients. J Immunol Methods. 276(1-2):143-46 (2003) Schöll I, Wiedermann U, Förster-Waldl E, Ganglberger E, Baier K, Boltz-Nitulescu G, Scheiner O, Ebner C, Jensen-Jarolim E: Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B-cell responses to the natural antigen using bystander T-cell help. Clin.Exp.Allergy 32:1583-88 (2002)

- 160 -

Curriculum Vitae

Renate Fuchs Research Group for Cell Biology, Division of Cellular and Molecular Pathophysiology,

Department of Pathophysiology, Center for Physiology, Pathophysiology and Immunology,

Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria;

Phone: +43 1 40400-5127, Fax: +43 1 40400-5130

Email: [email protected];

Homepage: www.meduniwien.ac.at/ipp Personal Data

Date of Birth: 24.12.1950

Place of Birth: Vienna

Nationality Austria

Education

2.5.1984 Ph.D. (Dr.rer.nat.techn.) University of Agriculture, Vienna,

Austria

1977-1983 Thesis:”Influence of vitamin D on chick small intestinal

transport systems (interrupted by 2 maternal leaves)

7.7.1977 Master of Science in Food- and Biotechnology (Dipl.Ing.)

1976-1977 Diploma Thesis: „Glucosidehydrolases“

1969-1977 Food- and Biotechnology, University of Agriculture,

Vienna, Austria

1961-1969 High School; graduation with distinction

Career History

2004 - present Associate Professor, Department of Pathophysiology,

Medical University of Vienna, Austria

1994 Title: “tit. Ao.Prof.”

1991 Head of Research Group for Cell Biology

1990-2004 Associate Professor, Department of General and

Experimental Pathology – 2000 renamed Department of

Pathophysiology

1.3.1990 Habilitation (Venia docendi) in Experimental Pathology,

Univ. Vienna, Austria

1989-1990 Assistant Professor, Department of General and

Experimental Pathology, Univ. Vienna

- 161 -

1986-1989 Research Associate, Department of General and

Experimental Pathology, Univ. Vienna, Austria

1985-1986 Post-doctoral Associate, Dept. Cell Biology, Yale Univ.,

New Haven, USA

1984-1985 Post-doctoral Fellow: Dept. Cell Biology, Yale Univ., New

Haven, USA

1983 Visiting Scientist at the Max Planck-Institute of Biophysics,

Frankfurt, Germany

1979 Visiting Scientist at the Max Planck-Institute of Biophysics,

Frankfurt, Germany

1977-1984 Department of General and Experimental Pathology, Univ.

Vienna, Austria

Career-related Activities 1990 - present Supervision of 14 Ph.D and 8 diploma students

1990 - present Reviewer for the following journals: MBC, JBC, EMBO J,

Traffic, J Virol, Virology, Mol Ther, Clin Exp Allergy, Exp.

Gerontol, Int. Hepatol.

1990 - present Grant reviewer for: Academy of Finland (chairman), ESF,

ETH Swiss, CNRS France, German-Israel Foundation for

Scientific Research, British Research Council (BBSRC),

OeNB

Awards 1996 Hoechst Research Award

1990 Kardinal-Innitzer-Förderungspreis

1988 Hans Popper Award of the American Liver Association

1986 Hoechst Research Award

1984 - 1986 Max-Kade Fellowship

1980 Hoechst Research Award

Memberships

American Society for Cell Biology

American Society for Microbiology, Section Virology

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

- 162 -

2004-2007 FWF 17590 Rhinovirus RNA uncoating and membrane

translocation

152

2004 AP00032OFF

Aktion Österreich-

Tschechien

Visualization of placental membrane

transporters

6

2000-2004 Virologie-Fonds

Kooperation Dr. Blaas

Viral receptors in human rhinovirus infection 44

1999-2002 OeNB 7511 Elektrophysiology of virus infection 6

2000-2004 FWF 14079-MED hFcRn expression in the placenta 58

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

1999-2003 Leitner Karl hFcRn/Beta-2-Mikroglobulin (β2m) expression in

human placental sycytiotrophoblasts

2000-2004 Baravalle Günther Characterization of the intracellular pathways

and requirements for infection of the minor group

human rhinovirus serotype 2

2000-2004 Exner Bettina Functional expression of the human neonatal Fc-

receptor, hFcRn, in Ewing´s sarcoma

1999-2007 Brabec Marianne Mechanism of entry and RNA release of human

rhinovirus serotype 2 (HRV2)

2003 Busch Bernhard FcRn mediated IgG-transport

2005-

present

Berka Ursula

Human rhinovirus RNA translokation

Publications 52 peer reviewed publications in scientific journals; 16 publications: book chapters,

handbooks and proceedings; 28 invited lectures. Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Ellinger, I., Klapper, H., Courtoy, P.J., Vaerman, J.P.and Fuchs, R. (2002). Different temperature-sensitivity of endosomes involved in transport to lysosomes and transcytosis in rat hepatocytes: Analysis by free-flow electrophoresis. Electrophoresis, 23, 2117-2129.

Leitner, K., Ellinger, A., Zimmer, K.P., Ellinger, I. and Fuchs, R. (2002). Localization of ß2-microglobulin in term villous syncytiotrophoblasts. Histochem. Cell Biol, 117, 187-193.

Brabec, M., Baravalle, G., Blaas, D. and Fuchs, R (2003). Conformational changes, plasma membrane penetration and infection of human rhinovirus 2: role of receptors and low pH. J Virol, 77, 5370-5377. Baravalle, G., Snyers, L., Brabec, M., Blaas, D. and Fuchs, R. (2004). Human rhinovirus type

- 163 -

2-antibody complexes enter and infect cells via Fc-gamma receptor IIB1. J. Virol., 78, 2729-2735. Fuchs, R., Ellinger, I. (2004). Endocytic and transcytotic processes in villous syncytiotrophoblast: role in nutrient transport to the human fetus. Traffic, 5, 725-738. Brabec, M., Schober, D., Wagner, E., Bayer, N., Murphy, R.F. and Blaas, D. (2005). Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis. J Virol, 79, 1008-1016. Baravalle, G., Schober, D., Huber, M., Bayer, N., Murphy, R.F. and Fuchs, R. (2005). Transferrin recycling and dextran transport to lysosomes is differentially affected by bafilomycin, nocodazole, and low temperature. Cell Tissue Res, 320, 99-113. Ellinger, I., Reischer, H., Lehner, C., Leitner, K., Hunziker, W. and Fuchs, R. (2005). Overexpression of the human neonatal Fc-receptor alpha-chain in trophoblast-derived BeWo cells increases cellular retention of beta2-microglobulin. Placenta ,26,171-182. Brabec, M., Blaas, D. and Fuchs, R. (2006) Wortmannin delays transfer of human rhinovirus serotype 2 to late endocytic compartments. Biochem Biophys Res Commun, 348,741-749. Brabec-Zaruba, M., Blaas, D. and Fuchs, R (2007). Induction of autophagy does not affect human rhinovirus type 2 production. J Virol, 81,10815-10817. Co-author manuscripts: Goncalves, C., Mennesson, E., Fuchs, R., Gorvel, J.P., Midoux, P., Pichon, C. (2004) Macropinocytosis of polyplexes and recycling of plasmid via the clathrin-dependent pathway impair the transfection efficiency of human hepatocarcinoma cells. Mol Ther, 10, 373-385. Roth-Walter, F., Scholl, I., Untersmayr, E., Fuchs, R., Boltz-Nitulescu, G., Weissenbock A., et al. (2004). M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J Allergy Clin Immunol, 114, 1362-1368. Invited Talks 2002-2008 2002

• 23.8.-25.8.2002:Virus-cell interactions, Tvarminne, Finnland "Receptor independent uncoating of the minor group human rhinovirus HRV2”

2003

• 24.2.2003: Institut für Molekulare Pathologie, Universität Louvain, Brüssel „Influence of bafilomycin and nocodazole on HRV2 entry pathways“

• 26.2.2003: Institut für Med. Biochemie, Univ. Wien „HRV2 entry and uncoating“ 2004

• 26.11.2004: Frauenklinik Graz; „IgG Transport in der Plazenta“

2005 • 9.2.2005: Kongreß “The brush border membrane”, Fulda, Deutschland; “IgG transport

across epithelia mediated by the human neonatal Fc-Receptor, hFcRn” • 1.8.2005: Kongreß “Virus Cell Interactions”, Seli, Finnland; “Entry and replication of

human rhinoviruses” • 24.8.2005: Microscopy Conference – Dreiländertagung, Davos, Schweiz; “Dynamics

of human rhinovirus infections”

- 164 -

• 2.10. 2005: GRC Summer School, Hannover, Deutschland; “Entry and replication of human rhinoviruses”

• 3.10. 2005: Dept. Biochemie, Universität Hannover, Deutschland; “IgG transport in the human placenta”

2006

• 17.6.-22.6.2006: FASEB Research Conference on Virus Assembly; Vermont Academy, VT, USA; “Entry and uncoating of human rhinoviruses.

• 6.-9.9.2006: IFPA Meeting 2006, Kobe, Japan; “IgG transport in placental trophoblasts”

• 26.11.-1.12.2006: EUROPIC 2006, Inari, Finnland; “Entry and uncoating of human rhinoviruses

• 19.8.2005: Kongreß “Virus Cell Interactions”, Seli, Finnland; “Entry and replication of human rhinoviruses”

2007 • 19.8.-21.8.2007: Kongreß Virus Cell Interactions, Archipelago Research Institute,

Seli, Finland: Entry and RNA release of the minor group virus HRV2. 2008

• 8. 2.2008: Univ. Cambridge, GB : Mechanism of human rhinovirus infections

- 165 -

Curriculum Vitae

Ulrich Jäger Department of Internal Medicine I, Division of Hematology, Medical University of Vienna,

Waehringer Guertel 18-20, 1090 Wien, Austria;

Phone: +43-1-40400-4409, Fax: +43-1-40400-4030

Email: [email protected]; Personal Data

Date of Birth: 04.06.1956

Place of Birth: Lienz

Nationality Austria

Education

1996 Specialist of Hematology and Oncology

1990 Internist

1974 - 1982 University of Vienna, Medical School

Career History

Since 2004 Professor of Hematology

2001 - 2004 Director of Hematology Outpatient Service 1994 Habilitation in Internal Medicine, University of Vienna

Medical School

1989 - 2001 Clinical studies: Minimal residual disease in lymphoma and

leukaemia

1989 - present Group Leader - Div. of. Hematology, University of Vienna:

Oncogene Laboratory. Scientific projects: Molecular

biology of lymphoma and leukemia, mechanism of

chromosomal translocations

1986 - 1989 Howard Hughes Medical Institute, Washington University,

St. Louis, MO, USA (Prof. S.J.Korsmeyer) – Scientific

projects: Molecular biology of lymphoma

1984-1986 Scientific projects in Hematology/Immunology

1984-1990 Specialized training in Hematology/Hemostaseology

(Board certification:28-05-1996)

1982-1990 Training in General Internal Medicine, University of Vienna

Medical School (Board certification: 07-08-90

- 166 -

Career-related Activities 2005 - Member of the Habilitations Commission (conservative) of

the Medical University of Vienna

2005 - Editor of the Educational series of the Wiener Klinische

Wochenschrift

2001 – 2006 Organizer: Young Investigators Meeting of the Austrian

Society of Hematology and Oncology

2000 Secretary of the Annual Meeting of the Austrian Society of

Hematology and Oncology

1998 - 1999 Postgradual Course in Medical Management

Awards

2003, 2004 Aventis-Award

2002 Award of the „Erste Bank“

1996 Award of the Austrian Cancer Society

1993, 1998, 2002, 2003 Wilhelm Tuerk Award of the Austrian Society of

Hematology and Oncology

Memberships Austrian Society of Hematology and Oncology Austrian Society of Medicine

American Society of Hematology

European Society of Hematology

Society on Progress in Medicine

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2003-2005 ÖAW CeMM 20010 “Genetic instability of the

immune system”

104

2006-2008 bm:bwk Oncogenomics – GEN-AU CHILD 55

2006-2010 AGMT NHL-13 114

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2006-2009 Dr. Edit Porpaczy Biological function and signaling cascade of lipoprotein

lipase in B-cell chronic lymphocytic leukemia (N094)

- 167 -

Publications 192 peer reviewed publications in scientific journals, 10 book chapters, > 70 invited lectures Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: • Skrabs C, Müller C, Agis H, Mannhalter C, Jaeger U. Treatment of HBV carrying

lymphoma patients with Rituximab and CHOP: A diagnostic and therapeutic challenge. Leukemia 2002; 16: 1884-1886.

• Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T, Fonatsch C, Haas OA, Mannhalter C, Lechner K, Jaeger U. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21), or inv(16). Hematol J/Haematologica 2002; 3: 283-289.

• Heintel D, Streubel B, Welzel N, Le T, Schwarzinger I, Haas OA, Simonitsch I, Lechner K, Jaeger U. Burkitt Lymphoma following splenic marginal zone lymphoma: Evidence for two independent B-cell clones. Cancer Genet Cytogen 2003; 141: 86-88.

• Jaeger U, Kainz B. Monitoring Minimal Residual Disease in AML: The right time for Real Time. Ann Hematol 2003; 82: 139-147.

• Jaeger U. Innovative strategies in lymphoma therapy. Wien Klin Wochenschr 2003; 115: 13-14.

• Simonitsch-Klupp I, Skrabs C, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, Weltermann A, Greinix HT, Skrabs C, Dittrich C, Lutz D, Pötter R, Mannhalter C, Lechner K, Chott A, Jaeger U. Diffuse Large B-Cell Lymphomas with Plasmablastic/Plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia 2004; 18: 146-155.

• Heintel D, Kroemer E, Kienle D , Schwarzinger I, Gleiß A , Schwarzmeier J, Marculescu R, Le T, Mannhalter C , Gaiger A, Stilgenbauer S, Fonatsch C, Jaeger U. Expression of activation-induced cytidine deaminase (AID) mRNA is a marker for IGVH gene mutational status and cytogenetic aberrations in patients with chronic lymphocytic leukemia. Leukemia 2004; 18: 756-762.

• Mitterbauer G, Mannhalter C, Skrabs C, Mitterbauer M, Simonitsch I, Winkler K, Lechner K, Chott A, Jaeger U. Prognostic value of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). Leukemia 2004; 18: 1102-1107.

• Gaiger A, Heintel D, Jäger U. Novel Molecular Diagnostic and Therapeutic Targets in Chronic Lymphocytic Leukemia. Eur J Clin Invest 2004; 34 Suppl 2: 25-30.

• Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, Mitteregger D, Gleiß

A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Döhner H, Stilgenbauer

S, Jäger U. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1216-1223.

• Schützinger C, Gaiger A, Thalhammer R, Vesely M, Fritsche-Polanz R, Schwarzinger I, Öhler L, Simonitsch-Klupp I, Reinhard F, Jäger U. Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 2005; 19: 2005-2008.

• Bilban M, Heintel D, Scharl T, Wölfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey VJ, Shehata M, Zielinski C, Pickl W, Stilgenbauer S, Gaiger A, Wagner O, Jäger U. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 2006; 20:1080-8.

• Hauswirth AW, Skrabs C, Schützinger C, Gaiger A, Lechner K, Jäger U. Autoimmune haemolytic anaemias (AIHA), Evans’ syndrome and pure red cell aplasia (PRCA) in Non-Hodgkin lymphomas. Leuk Lymph 2007; 48: 1139-1149

• Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Krömer-Holzinger E, Le T, Kröber A, Heller G, Schwarzinger I, Demirtas D, Chott A, Döhner H, Zöchbauer-Müller S, Fonatsch C, Zielinski C, Stilgenbauer S, Gaiger A, Wagner O, Jäger U. Overexpression of the

- 168 -

paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukaemia. Int J Cancer 2007; 121: 1984-1993

• Coiffier B, Tabacof J, Shen ZX, Jäger U. Aggressive non-Hodgkin’s lymphoma – long-term survival for all patients? Hematology Meeting Reports 2007; 1: 27-41

• Hauswirth A, Skrabs C, Schützinger C, Raderer M, Lechner K, Jäger U. Autoimmune thrombocytopenia in Non-Hodgkin lymphomas. Haematol/ Hematol J 2007; 93: 447-450.

• Schützinger C, Esterbauer H, Hron G, Skrabs C, Uffmann M, Raderer M, Hauswirth A, Mannhalter C, Dieckmann K, Wagner O, Formanek M, Stift A, Friedl J, Gaiger A, Chott A, Jäger U. Prognostic value of T-cell receptor γ rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas. Leuk Lymphoma 2008; 49: 237-246

• Hauswirth AW, Jäger U. Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukaemia. Haematol/Hematol J 2008; 93: 14-19.

Co-author manuscripts: • Marculescu R, Le T, Simon P, Jaeger U, Nadel B. V(D)J-mediated translocations in

lymphoid neoplasms: A functional assessment of genomic instability by cryptic sites. J Exp Med 2002; 195: 85-98.

• Marculescu R, Le T, Böcskör S, Mitterbauer G, Chott A, Mannhalter C, Jaeger U, Nadel B. Alternative end-joining in follicular lymphomas’ t(14;18) translocation. Leukemia 2002; 16: 120-126.

• Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HAT, Karanikas G, Pötzi C, Raderer M, Dudzak R, Kletter K. Positron emission tomography with [18F]2-Fluoro-D-2-Deoxyglucose (FDG-PET) for relapse prediction of malignant lymphoma after high-dose therapy with stem cell support. Leukemia 2002; 16: 260-267.

• Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C, Pirker R. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002; 8: 729-733.

• Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, Jaeger U, Lechner K, Schneider B, Fonatsch C, Schwarzinger I. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol 2002; 117: 380-389.

• Agis H, Weltermann A, Fonatsch C, Haas O, Mitterbauer G, Müllauer L, Schreiber S, Schwarzinger I, Juretzka W, Valent P, Jaeger U, Lechner K, Geissler K. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol 2002; 81: 90-95.

• Österborg A, Brandberg Y, Molostova V, Iosawa G, Abdulkadyrov K, Hedenus M, Messinger D for the Epoetin Beta Hematology Study Group (including Jaeger U). Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies. J Clin Oncol 2002; 20: 2486-2494.

• Selenko N, Majdic O, Jaeger U, Sillaber C, Stöckl J, Knapp W. Cross priming of cytotoxic T-cells promoted by apoptosis inducing tumor cell reactive antibodies? J Clin Immunol 2002; 22: 124-130.

• Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, Semper H, Jordan JH, Chott A, Drach J, Jaeger U, Geissler K, Greschniok A, Horny HP, Lechner K, Valent P. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002; 43: 1097-1105.

• Raderer M, Chott A, Drach J, Montalban C, Dragosics B, Jaeger U, Puspok A, Osterreicher C, Zielinski CC. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann Oncol 2002; 13: 1094-1098.

• Parolini O, Kagerbauer B, Simonitsch-Klupp I, Ambros P, Jaeger U, Mann G, Haas OA,

- 169 -

Morra M, Gadner H, Terhorst C, Knapp W, Holter W. Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's lymphoma. Ann Hematol 2002; 81: 441-447.

• Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, Benci A, Sparano JA. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results in Cancer Res 2002; 159: 149-153.

• Hallek M, Bergmann M, Brittinger G, Dohner H, Dreger P, Herold M, Hopfinger G, Jäger U, Knauf W, Nerl C, Rummel M, Schmitt B, Wendtner CM, Emmerich B. Chronisch lymphatische Leukämie und verwandte Leukämien: Aktuelle Therapiekonzepte. Internist 2002; 43: 1245-1254.

• Spina M, Sparano JA, Jaeger U, Rossi G, Tirelli U. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS 2003; 17: 137-138.

• Marculescu R, Vanura K, Le T, Simon P, Jäger U, Nadel B. Distinct t(7;9)(q34;q32) breakpoints in healthy individuals and T-ALL patients: Signal joint reactivity as a novel pathway of V(D)J-mediated oncogene activation. Nat Genet 2003; 33: 342-344.

• Feierl E, Dejaco C, Heintel D, Wagner A, Chatwani S, Stelzhammer R, Hammer J, Jaeger U, Thurnher S, End A. Arterial bleeding of the esophagus associated with diffuse large B-cell lymphoma. Gastrointest Endosc 2003; 57: 387-388.

• Hauser AC, Brichta A, Pabinger-Fasching I, Jaeger U, Lechner K. Fibrinolytic therapy with r-tPA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome. Ann Hematol 2003; 82: 299-302.

• Hoffmann M, Kletter K, Becherer A, Jäger U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003; 64: 336-340.

• Berer A, Kainz B, Jäger U, Jäger E, Stengg S, Streubel B, Fonatsch C, Mitterbauer G, Lechner K, Geissler K, Ohler L. Relation of in vitro growth characteristics to cytogenetics and treatment outcome in acute myeloid leukemia: prognostic significance in patients with a normal karyotype. Int J Hematol 2003; 78: 241-247.

• Becherer A, Jaeger U, Kletter K. Prognostic value of FDG-PET in malignant lymphoma. Q J Nucl Med 2003; 47: 14-21.

• Becherer A, Jaeger U, Kletter K. Prognostic value of FDG-PET in malignant lymphoma. Q J Nucl Med 2003; 47: 14-21.

• Vanura K, Marculescu R, Le T, Jaeger U, Nadel B. Physiological and Physiopathological Roles of Signal Joint Reactivity. Recent Research Developments in Immunology 2003; 5: 167-178.

• Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kalhs P, Mitterbauer G, Jaeger U, Geissler K, Valent P, Sperr W, Knoebl P, Schwarzinger I, Gleiss A, Kainz B, Lechner K. The Impact of Cytogenetics on the Prognosis of Adults with de novo AML in First Relapse. Leukemia 2004; 18: 293-302.

• Hoffmann M, Chott A, Püspök A, Jäger U, Kletter U, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol 2004; 83: 276-278.

• Mitterbauer M, Mitterbauer-Hohendanner G, Sperr WR, Kalhs P, Greinix HT, Fonatsch C, Haas OA, Jäger U, Mannhalter C, Lechner K. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: A single center study. Leuk Lymphoma 2004; 45: 971-977.

• Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Knobl P, Jäger U, Lechner K, Valent P. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Clin Cancer Res 2004; 10: 3965-3971.

• Schmidt HH, Strehl S, Thaler D, Strunk D, Sill H, Linkesch W, Jäger U, Sperr W, Greinix HT, König M, Emberger W, Haas OA. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: Breakpoint cluster

- 170 -

region and clinical implications. Leukemia 2004; 18: 1115-1121. • Streubel B, Chott A, Huber D, Exner M, Jäger U, Wagner O, Schwarzinger I. Lymphoma-

specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250-259.

• Langerak A, Nadel B, de Torbal A, Wolvers-Tettero ILM, van Gastel-Mol EJ, Verhaaf B, Jäger U, Van Dongen JJ. Unraveling the consecutive recombination events in the human IGκ locus. J Immunol 2004; 173: 3878-3888.

• Füreder W, Filipits M, Sperr WR, Kainz B, Jäger U, Fonatsch C, Schwarzinger I, Haas OA, Pirker R, Lechner K. Highly refractory acute myeloid leukemia. Wien Klin Wochenschr 2004; 116: 561-564.

• Kaufmann H, Ackermann J, Baldia C, Nösslinger T, Wieser R, Seidl S, Sagaster V, Gisslinger H, Jäger U, Pfeilstöcker M, Zielinski C, Drach J. Both IgH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18: 1879-1882.

• Hallek M, Bergmann M, Emmerich B for the German CLL Study Group (Incl. Jäger U). Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment. Onkologie 2004; 27: 97-104.

• Ziegler S, Sperr W, Knöbl P, Lehr S, Weltermann A, Jäger U, Valent P, Lechner K. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors and impact on prognosis. Thromb Res 2005; 115: 59-64.

• Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, Rossi G, Nigra E, Berretta M, Cattaneo C, Rieger AC, Vaccher E, Tirelli U. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase II trials. Blood 2005; 105: 1891-1897.

• Kainz B, Fonatsch C, Schwarzinger I, Sperr WR, Jäger U, Gaiger A. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukaemia. Hematol J / Haematologica 2005; 90: 695-696.

• Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, Seymour JF. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom’s macroglobulinemia and related disorders. Clin Lymphoma 2005; 5: 294-297.

• Raderer M, Streubel B, Wöhrer S, Püspök A, Jäger U, Formanek M, Chott A. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005; 11: 3349-3352.

• Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, Kröber A, Jäger U, Lichter P, Döhner H, Stilgenbauer S. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005; 23: 3780-3792.

• Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, Jäger U, Fonatsch C, Kyrle PA, Valent P, Lechner K, Sperr WR. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res 2005; 29: 609-615.

• Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, Jäger U, Lechner K, Valent P. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res 2005; 11: 6536-6543.

• Woehrer S, Hejna M, Skrabs C, Drach J, Zielinski CC, Jaeger U, Raderer M. Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. Oncology 2005; 69: 499-502.

• Raderer M, Wöhrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B, Zielinski CC. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 8442-8446.

• Schwarzmeier JD, Hubmann R, Düchler M, Jäger U, Shehata M. Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia. Leukemia Lymphoma 2005;

- 171 -

46: 157-165. • Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger

U, Bergmann M, Schweighofer C, Wendtner CM, Brittinger G, Emmerich B, Hallek M. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.

• Kienle D, Benner A, Kröber A, Winkler D, Mertens D, Bühler A, Seiler T, Jäger U, Lichter P, Döhner H, Stilgenbauer S. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006; 107: 2090-2093.

• Grünberger B, Wöhrer S, Streubel B, Formanek M, Petkov V, Püspök A, Häfner M, Hejna M, Jäger U, Chott A, Raderer M. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006; 24: 1370-1375.

• Wöhrer S, Jäger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, Raderer M, Hoffmann M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17: 780-784.

• Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jäger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Löffler M, for the MabThera International Trial (MInT) Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International (MInT) Study Group. Lancet Oncology 2006; 7: 379-391.

• Raderer M, Wöhrer S, Streubel B, Troch M, Turetschek K, Jäger U, Skrabs C, Gaiger A, Drach J, Püspök A, Formanek M, Hoffmann M, Hauff W, Chott A. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24: 3136-3141

• Strehl S, König M, Meyer C, Schneider B, Harbott J, Jäger U, von Bergh AR, Loncarevic IF, Jarosova M, Schmidt HH, Moore SD, Marschalek R, Haas OA. Molecular dissection of t(11;17) in acute myeloid leukemia reveals a variety of gene fusions with heterogeneous fusion transcripts and multiple splice variants. Genes Chromosomes Cancer 2006; 45: 1041-1049

• Raderer M, Wöhrer S, Streubel B, Drach J, Jäger U, Turetschek K, Troch M, Püspök A, Zielinski CC, Chott A. Activity of rituximab lus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006; 70: 411-417

• Marculescu R, Vanura K, Montpellier B, Roulland S, Le T, Navarro JM, Jäger U, McBlane F, Nadel B. Recombinase, chromosomal translocations and lymphoid neoplasia: targeting mistakes and repair failures. DNA Repair 2006; 5: 1246-1258.

• Smolen JS, Keystone EC, Emry P, Breedveld FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger U, Klareskog L, Kvien TK, Martin-Mola E, Pavelka K; Working Group on the Rituximab Consensus Statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-150

• Wöhrer S, Troch M, Zwerina J, Schett G, Skrabs C, Gaiger A, Jäger U, Zielinski C, Raderer M. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol 2007; 18: 647-651

• Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-274

• Vanura K, Montpellier B, Le T, Spicuglia S, Navarro JM, Cabaud O, Roulland S, Vachez E, Prinz I, Ferrier P, Marculescu R, Jäger U, Nadel B. In vivo reinsertion of excised episomes by the V(D)J recombinase: a potential threat to genomic stability. PLoS Biol 2007 Feb 13;5(3):e43

• Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, Gisslinger H,

- 172 -

Drach J, Gaiger A, Jäger U, Ludwig H. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2007 Aug 9; (Epub ahead of print)

• Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knöbl P, Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jäger U, Valent P. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 2007; 37: 808-813

• Agis H, Sperr WR, Herndlhofer S, Semper H, Pirc-Danoewinata H, Haas OA, Mannhalter C, Esterbauer H, Geissler K, Sillaber C, Jäger U, Valent P. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol 2007; 18: 1834-1841

• Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, Sperr WR, Sillaber C, Jäger U, Valent P. Myeloid leukemias express a broad spectrum of FEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma 2007; 48: 1997-2007

Invited Talks 2002-2008 2002 • „MRD bei Lymphomen“. Symposion: Minimale residuelle Erkrankung bei soliden Tumoren

und Hämoblastosen. Retz, 28. 2. - 1. 3. 2002. • „Antikörpertherapie bei Lymphomen“. Wissenschaftliche Sitzung der Gesellschaft für

Innere Medizin für Wien und Niederösterreich, Wien, 21. 3. 2002. • „Mechanismen der Entstehung von Translokationen bei lymphatischen Neoplasien“;

Frühjahrstagung der ÖGHO, Linz 25. 4. – 27. 4. 2002. • „Antikörpertherapie bei hämatologischen Erkrankungen“. 33.Jahrestagung der

Österreichischen Gesellschaft für Innere Medizin. Salzburg, 19. - 21. 9. 2002. • „Lymphome im Rahmen von AIDS“. 13.Österreichischer AIDS Kongress. Wien, 8. - 9. 11.

2002. • “Treatment modalities for Morbus Waldenström“. IV.International Workshop of the

German CLL study group. Kloster Irsee, 13. - 15. 2. 2002. 2003 • ”EBV und AIDS-assoziierte Lymphome”. Deutsch - Österreichischer AIDS Kongress.

Hamburg, 16. 5. 2003. 2004 • „EBV/Infektion und PTLD nach Organtransplantation2. ÖGN Wintermeeting. Flachau, 31.

3. – 3. 4. 2004. • „Lymphome“. State of the Art, Diagnostik und Therapie. Österreichische Gesellschaft für

Innere Medizin. 25. 3. 2004. • „VDJ-mediated translocations in leukemia and lymphoma“. “From Basic Science to

Clinical Application”. Wien, 3. 9. 2004. • „Molekulare Pathogenese von Lymphomen“. 2. Jahrestagung der Österreichischen

Gesellschaften für Klinische Chemie und Laboratoriumsmedizin. Salzburg, 29. 9. – 2. 10. 2004.

• „NHL inkl. CLL, M. Hodgkin: Staging, Therapie (inkl. Kosten), Prognose“. Seminar. 20. 9. und 27. 9. 2004.

• „Monoklonale Antikörper“. 35. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. Wien, 16. – 18. 9. 2004.

• „Prognosefaktoren bei NHL“. Herbsttagung der Österreichischen Gesellschaft für Pathologie. Retz, 15. – 16. 10. 2004.

• „IgVH mutational status and LGL in CLL“. V. International Workshop of the German CLL Study Group. Irsee, 24. – 26. 9. 2004.

• „Molekulare Diagnostik bei NHL“. Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie.

- 173 -

Innsbruck, 2. – 6. 10. 2004. • „Stehen wir vor einem Paradigmenwechsel in der Therapie der CLL und der indolenten

Lymphome?“. Satelliten-Symposium „Überleben verlängern bei CLL und indolenten Lymphomen – Ferne Vision oder baldige Realität?“. Innsbruck, 3. 10. 2004.

• „Hematological malignancies“. 29. ESMO Kongress. Wien, 29. 10. – 2. 11. 2004. 2006 • Vorsitze und zusammenfassende Vorträge. 4. MabThera Winterworkshop. Schladming,

13. – 15. 1. 2006. • „Klinische Aspekte der Erhaltungstherapie“. Symposium „Überlebensverlängerung beim

follikulären NHL“ im Rahmen der Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Onkologie. Wels, 27. – 29. April 2006.

• „Follikuläres Lymphom: Was ist jetzt State-of-the-Art?“. MabThera Meeting. Wien, 15. – 16. 9. 2006.

• “Lymphome”. Wissenschaftliche Sitzung “Hämatologie im Alter”. Gesellschaft der Ärzte. Wien, 16. 11. 2006

• „PI3K“. Studientreffen. Basel, 24. April 2006. • Educational “Aggressive Non-Hodgkin Lymphome”. Annual Joint Meeting of the German,

Austrian and Swiss Societies of Hematology and Oncology 2005. Hannover, 1.-.5.October 2005.

• Vorsitz und Vortrag beim Meeting “Challenging Cases in Hematologic Malignancy” des Oncology Network Europe (ONE). Wien, 23. 9. 2006.

• Vorsitz und Vortrag “Current treatment strategies for B-CLL”. Satellitensymposium “Clinical Aspects of B-CLL and Related Entities”. Wien, 9. 10. 2006.

2007 • Vortrag “Update NHL-13” sowie Zusammenfassung der Sitzung “MCL + Autoimmun”. 5.

MabThera Winterworkshop. Schladming, 12. – 14. 1. 2007. • Vortrag “What is the role of maintenance therapy in aggressive lymphoma?” beim Expert

Investigator Forum “Maintaining life: optimal strategies to improve survival”. Lissabon, 20. – 22. 4. 2007.

• Educational “Genetics in CLL: Impact for prognosis and treatment decisions”. EHA-Kongress. Wien, 7. – 10. 6. 2007.

• Vortrag “Novel molecular risk factors and targets in CLL”. 3rd Joint Meeting on Experimental and Clinical Cancer Research Translational Research. Wien, 11. – 12. 10. 2007.

• Organisation und abschließender Vortrag sowie Vortrag “Was ist die CLL? Risiko- und Prognosefaktoren, Krankheitsverlauf der CLL” beim Patienteninformationstag. 20. Arbeitstreffen der Deutschen CLL Studiengruppe. Wien, 9. – 10. 11. 2007.

• Diskutant zum Thema “Clinical trial sponsorship”. Vienna Initiative to Save European Academic Research II (VISEAR II). Wien, 12. 11. 2007.

• Vortrag “Mabthera in maintenance therapy”. NHL-13 Study Meeting. Sarajevo, 15. 11. 2007.

• Vortrag “Overview of prognostic factors”. Annual Education Day des UK CLL Forum. 19. 11. 2007.

- 174 -

Curriculum Vitae Peter Pietschmann Department of Pathopyhsiology, Medical University of Vienna, Währinger Gürtel 18-20, A –

1090 Vienna, Austria,

Phone +43-1-40400-51-26; Fax: +43-1-40-400-51-30;

E-mail [email protected]

Personal Data

Date of Birth: May 13, 1960 Place of Birth: Vienna

Nationality Austria

Education

2002 Appointment as Associate Professor of Pathophysiology,

Medical School,University of Vienna

2001 Certification as Specialist of Pathophysiology

1994 Certification as Specialist of Rheumatology

1992 Appointment as Associate Professor of Internal Medicine,

Medical School,University of Vienna

1990 Certification as Specialist of Internal Medicine

1984 Graduation as Medical Doctor

1979 – 1984 Medical School, University of Vienna

1978 – 1979 Military Service

1970-1978 Secondary School (Vienna)

1966-1970 Elementary School (Vienna)

Career History

2007- present Head of the Division of Cellular and Molecular

Pathophysiology

2006 – present Deputy Head of the Department of Pathophysiology

2006 - 2007 Head of the Division of Molecular and Biochemical

Pathology

2002 – present Associate Professor of Pathophysiology at the Department

of Pathophysiology,Medical University of Vienna

1999-present Head of the “Bone, Cartilage and Connective Tissue

Research Group”

1998-present Department of Pathophysiology (former Department of

- 175 -

General and Experimental Pathology), University of

Vienna (since 2004: Medical University of Vienna)

1997-1998 Institute of Immunology, University of Vienna

1992-1997 Division of Rheumatology/Department of Internal Medicine

3, University of Vienna

1992-present Associate Professor of Internal Medicine,(Medical)

University of Vienna

1991-1992 Rheumatic Diseases Division, Department of Internal

Medicine, Southwestern Medical Center at Dallas,

University of Texas, Dallas, TX, USA

1990-1991 Department of General and Experimental Pathology,

University of Vienna

1984-1990 Department of Medicine 2, University of Vienna

Career-related Activities

2007-present President of the Austrian Society for Geriatrics and

Gerontology

2000-present Treasurer of the Austrian Society for Bone and Mineral

Research

1998-present Board member of the Austrian Society for Geriatrics and

Gerontology

1993-present Scientific colaborationwith the Luwdig Boltzmann Institute

of Aging Research, Vienna

Awards

1986 Paracelsus Award Austrian Society for Internal Medicine

1996 Young Investigator Award World congress on

Osteoporosis

Memberships

American Society for Bone and Mineral Research

Austrian Society for Bone and Mineral Research (Member of the Board)

Austrian Society for Geriatrics and Gerontology (Member of the Board)

Society for Internal Medicine of Vienna and Lower Austria

Austrian Society for Rheumatology

Austrian Society for Endocrinology and Metabolism

Austrian Society for Cytometry

Austrian Diabetes Society

Medical Society of Vienna

- 176 -

Affiliation with the Ludwig Boltzmann Institute for Aging Research, Vienna

Sources of funding in last 5 years (2000-2005) Only FWF and equivalent projects

Period Organization Short Title K€

2007-2009 Jubiläumsfonds-

projekt der

Österreichischen

Nationalbank,

ProjektNr. 12544

Vergleichsstudie von Hüftknochen 47

2007-2009 FWF

Forschungsprojekt

P20239-B13

Cathepsin S: ein Modulator in der

Osteoimmunologie

82

2002-2004 Medizinisch-

wissenschaftlicher

Fonds des

Bürgermeisters der

Bundeshauptstadt

Wien, Projekt # 2240

Die Wirkung von Bone morphogenetic

protein-5 auf die Generation von

Osteoklasten in Knochenmarkskulturen.

26

2002-2004 Hochschuljubiläumsst

iftung der Stadt Wien,

Projekt # H-

1166/2003

The role of lymphocyte subpopulations in

osteoclast generation in murine bone

marrow cultures.

4

2001 –

2005

FWF

Forschungsprojekt

P16060-B05 (Co-

aplicant)

Extended studies on the modulation of the

ageing processes in the rat by physical

exercise and food restriction

-

2001 Medizinisch-wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien

Die Bedeutung des Vitamin D-Rezeptors für die Zytokinproduktion von T-Lymphozyten

6

2000-2001 Jubiläumsfonds der

Österreichischen

Nationalbank

The relationship of cytokines, sex steroids and bone turnover in aging men and women.

36

Dr. rer.nat., Dr. sci.med.Dr. techn. or PhD supervisions in the last 6 years (2002-2008)

Period Name of student Topic

- 177 -

2005-2008 Daniela Stupphann Bone metabolism in HLA-B27 transgenic rats,

an animal model for spondyloathropathies

2005-present Brigitte Behal Meta-Analysis of the spontaneous course of

osteoporosis

2006-present Janina Patsch Microarchitecture of bone in osteoporotic men:

relation with osteoblastic gene expression

patterns and treatment effects

2006-present Martina Rauner Molecular mechanism of osteoblast

differentiation: relevance to senile osteoporosis

Publications 104 original publications and 20 reviews in peer reviewed scientific journals, 10 book chapters, over 200 invited lectures,

Peer reviewed manuscripts 2000-2008 (original research and reviews) First, last or corresponding author manuscripts: Pietschmann P, Hahn P, Kudlacek S, Thomas R, Peterlik M (2000) Surface markers and transendothelial migration of dendritic cells from elderly subjects. Exp Gerontol 35: 213 - 224 Redlich K, Ziegler S, Kiener HP, Spitzauer S, Stohlawetz P, Bernecker P, Kainberger F, Grampp S, Kudlacek S, Woloszczuk W, Smolen JS, Pietschmann P (2000) Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 59: 308 – 310

Pietschmann P, Stöckl J, Draxler S, Majdic O, Knapp W (2000) Functional and phenotypic characterization of dendritic cells generated in human plasma supplemented medium. Scand J Immunol 51: 377 – 383

Grisar J, Hahn P, Brosch S, Peterlik M, Smolen JS, Pietschmann P (2001) Phenotypic characteristics of human monocytes undergoing transendothelial migration. Arthritis Res 3: 127 - 132 Pietschmann P, Kudlacek S, Grisar J, Spitzauer S, Woloszczuk W, Willvonseder R, Peterlik M (2001) Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 31: 444 – 451

Pietschmann P, Grisar J, Thien R, Willheim M, Kerschan-Schindl K, Preisinger E, Peterlik M (2001) Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol 36: 1749-1759 Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P (2002). Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 29: 1430 – 1436

- 178 -

Lernbass I, Wutzl A, Grisar J, Schett G, Redlich K, Spitzauer S, Grampp S, Imhof H, Peterlik M, Pietschmann P (2002) Quantitative ultrasound in the assessment of bone status of patients suffering from rheumatic diseases. Skeletal Radiol 31: 270 – 276

Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Biegelmayer C, Pacher R, Maurer G, Fialka-Moser V, Pietschmann P (2003) Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transpl 22: 843 – 850

Pietschmann P, Gollob E, Brosch S, Hahn P, Kudlacek S, Willheim M, Woloszczuk W, Peterlik M, Tragl KH (2003) The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol 38: 1119 – 1127 Kerschan-Schindl K, Mitterbauer M, Füreder W, Kudlacek S, Grampp S, Biegelmayer C, Fialka-Moser V, Pietschmann P, Kahls P (2004) Post- transplant complications – Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplantation 34:491-496 Sipos W, Willheim M, Hofbauer G, Pietschmann P (2005) Evaluation of the suitability of monoclonal antibodies for flow cytometric intracellular cytokine detection in peripheral blood lymphocytes. J Vet Med A 52: 55-60

Kerschan-Schindl K, Hawa G, Kudlacek S, Woloszczuk W, Pietschmann P (2005) Serum levels of cathepsin K decrease with age in both women and men. Exp Gerontol 40: 532 – 535

Sipos W, Duvigneau JC, Hofbauer G, Schmoll F, Baravalle G, Hartl R, Exel B, Dobretsberger M, Pietschmann P (2005) Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1α,25(OH)2D3. J Vet Med A52: 382-387

Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C, Watzinger F, Peterlik M, Pietschmann P (2006) Bone morphogenetic proteins 5 and g stimulate osteoclast generation. J Biomed Mater Res A 77 (1): 75-83 Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P (2006) Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer. Eur J Clin Invest 36: 566-573 Brosch S, Shehata M, Hofbauer G, Peterlik M, Pietschmann P (2006) Alendronate stimulates expression of functional surface molecules ICAM-1, HLA-DR and B7-2 on human monocytes. Osteol 15: 188-196 Rauner M, Winzer M, Stupphann D, Krenbek D, Pietschmann P (2007) RANKL and OPG gene expression in bone marrow stromal cells and calvarial osteoblasts in mouse and rat. Osteol 16: 19-28 Pietschmann P, Skalicky M, Kneissel M, Rauner M, Hofbauer G, Stupphann D, Viidik A (2007) Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol 42: 1099-1108 Mikosch P, Kerschan-Schindl K, Woloszczuk W, Stettner H, Kudlacek S, Kresnik E, Gallowitsch HJ, Lind P, Pietschmann P (2008)High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy. Thyroid 18:27-33. Kerschan-Schindl K, Ruzicka M, Mahr S, Paireder M, Krestan C, Gleiss A, Bieglmayer C,

- 179 -

Fialka-Moser V, Pacher R, Grimm M, Pietschmann P (2008) Unexpected low incidence of vertebral fractures in heart transplant recipients: analysis of bone turnover. Transpl Int 21:255-262. Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P (2008) Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes, Epub ahead of print Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C, Resch H, Pietschmann P (2008) Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatology Int: in press

Co-author manuscripts: Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Silverman S, Felsenberg D, Vandormael K, Daifotis A, Lombardi A (2000) Alendronate treatment of osteoporosis in men. N Engl J Med 343: 604 – 610 Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G (2001) A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 37: 1247 – 1252 Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C, Kato S, Cross HS (2001) Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22: 1429-1435 Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Türk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G (2002) Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46: 785 – 792 Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R (2003) Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32: 681 –686 Sipos W, Duvigneau CJ, Pietschmann P, Willheim M, Höller K, Hartl RT, Wahl K, Steinborn R, Gemeiner M, Schmoll F (2003) Parameters of humoral and cellular immunity following vaccination of pigs with a European modified-live strain of porcine reproductive and respiratory syndrome virus (PRRSV), Viral Immunol 16: 335 – 346 Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004) Soluble RANKL and risk of non-traumatic fracture. JAMA 291: 1108 – 1113 Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Hörl WH, Mayer G, Luger A (2004) Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis. J Nephrol 17: 87 – 94 Sipos W, Duvigneau JC, Willheim M, Schilcher F, Hartl RT, Hofbauer G, Exel B, Pietschmann P, Schmoll F (2004) Systemic cytokine profile in feeder pigs suffering from natural postweaning multisystemic wasting syndrome (PMWS) as determined by semiquantitative RT-PCR and flow cytometric intracellular cytokine detection. Vet Immunol Immunopathol 99: 63 – 71

- 180 -

Grisar J, Aringer M, Köller MD, Stummvoll GH, Eselböck D, Zwölfer B, Steiner CW, Zierhut B, Wagner L, Pietschmann P, Smolen JS (2004) Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 63: 1632-1637 Cavanagh LL, Boyce A, Smith L, Padmanabha J, Filgueira L, Pietschmann P, Thomas R (2005) Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther 7: R230-40 Karanikas G, Schütz M, Wahl K, Paul M, Kontur S, Pietschmann P, Kletter K, Dudczak R, Willheim M (2005) Relation of anti-TPO antibody titre and T-lymphocyte cytokine production patterns in Hashimoto’s thyroiditis. Clin Endocrinol 63: 191 – 196 Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M (2005) Interactions of 1α,25-dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes. J Allergy Clin Immunol 116: 683 – 689 Sipos W, Duvigneau JC, Pietschmann P, Schilcher F, Hofbauer G, Hartl RT, Schmoll F (2005) Porcine dermatitis and nephropathy syndrome (PDNS) is associated with a systemic cytokine expression profile indicative of proinflammation and a Th1 bias. Vet Immunol Immunopathol, A52: 382-387 Gugatschka M, Dobnig H, Fahrleitner-Pammer A, Pietschmann P, Kudlacek S, Strele A, Obermayer-Pietsch B (2005) Molecularly-defined malabsorption, milk consumption and anthropometric differences in adult males. Q J Med 98: 857-863 Fischer P, Gruenblatt E, Pietschmann P, Tragl KH (2006) Serotonin Transporter Polymorphism and LDL-Cholesterol. Mol Psychiatry 11 (8): 707-709 Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A. (2006) Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 118 (15-16): 473-478 Gugatschka M, Hoeller A, Fahrleitner-Pammer A, Dobnig H, Pietschmann P, Kudlacek S, Obermayer-Pietsch B (2007) Calcium supply, bone mineral density and genetically defined lactose maldigestion in a cohort of elderly men. J Endocrinol Invest 30 (1): 46-51 Reviews: Kudlacek S, Willvonseder R, Stohlawetz P, Hahn P, Pietschmann P (2000) Immunology and aging. The aging male 3: 137 – 142 Resch H, Gollob E, Kudlacek S, Pietschmann P (2001) Die Osteoporose beim Mann. Wien Med Wschr 151: 457-463 Pietschmann P (2001) Geschlechtsunterschiede bei Gelenkserkrankungen: pathophysiologische Grundlagen. Wien Med Wschr 151: 573-575 Mitringer A, Pietschmann P (2002) Osteoporose bei prämenopausalen Frauen. Wien Med Wschr 152: 586 - 590 Dimai HP, Pietschmann P, Resch H, Klaushofer K (2002) Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose. Wien Med Wschr 152: 596 - 612 Brosch S, Redlich K, Pietschmann P. (2003) Pathogenese der Osteoporose bei chronischer

- 181 -

Polyarthritis. Acta Med Austriaca 30: 1 – 5

Pietschmann P, Kerschan-Schindl K (2004) Osteoporosis: Gender specific aspects. Wien Med Wschr 154/17-18: 411- 415

Rauner M, Sipos W, Pietschmann P (2007) Osteoimmunology. Int Arch Allergy Immunol 143: 31-48

Patsch J, Muschitz C, Resch H, Pietschmann P (2007) Of mice and men: pathophysiology of male osteoporosis. JMHG 4(1): 87-93

Bröll H, Resch H, Pietschmann P, Sieghart S, Dobnig H, Erlacher L, Finkenstedt G, Holzer G, Pecherstorfer M, Pirich C (2007) Konsensus-Statement: Therapie der postmenopausalen Osteoporose -Anwendungsbereiche von parenteralen Bisphosphonaten. J Miner Stoffwechs 1: 45-48

Patsch J, Pietschmann P (2007) Controversial question- does histomorphometry still have a role to play?. Medicographia 29(2): 151

Burckhardt P, Concin H, Dimai H, Dobnig H, Erlacher L, Finkensedt G, Gasser R, Holzer G, Klaushofer K, Kotz R, Kraenzlin M, Minne HW, Obermayer-Pietsch B, Peichl P, Pietschmann P, Roschger P, Schütz W, Sieghart S, Windhager R (2007) Med ahead consensus-Osteoporose- Stellenwert der PTH-Therapie. Österreichische Ärztezeitung (Suppl März): 3-10

Sipos W, Pietschmann P. Rauner M (2008) Strategies for novel therapeutic approaches targeting ytokines and signaling pathways of osteoclasto-and osteoblastgenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem 15(2); 127-136

- 182 -

Curriculum Vitae

Clemens Scheinecker

Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Währinger

Gürtel 18-20, A-1090 Vienna, Austria

Phone: +43 1 40400 4300, Fax: +43 1 40400 4306

E-mail: [email protected]

Homepage: http://www.meduniwien.ac.at/rheuma/

Personal Data

Date of Birth: 12.03.1966

Place of Birth: Eisenstadt

Nationality Austria

Education

1984 – 1991 Academic studies of medicine at the University of Vienna,

Austria

Graduation to Doctor medicinae: 19.12.1991

1984 University entrance qualification, BG – BRG Oberschützen

Career History

Since 2004 Associate (a.o. Univ. Prof.) Professor of Internal Medicine

9/2004 Habilitation in Internal Medicine

2004 Specialist in Internal Medicine

2000 - 2003 Postdoctoral fellowship at the Laboratory of Immunology,

Lymphocyte Biology Section, National Institute of Allergy

and Infectious Diseases (NIAID), National Institutes of

Health (NIH), Bethesda, MD, USA

1999 - 2000 Training in Internal Medicine at the University of Vienna,

General Hospital of Vienna, Div. of Rheumatology, Clinic

for Internal Medicine III 1996 - 1999 Training in Internal Medicine at the Lainz Hospital, II. Dept.

of Medicine with Rheumatology, Vienna

1995 - 1996 Training in General Medicine at the Wilhelminenspital, I.

Dept. of Medicine with Oncology, Vienna

- 183 -

1992 - 1995 Postdoctoral fellowship at the Institute of Immunology,

University of Vienna

Awards 2005 “Habilitationspreis 2005 des Vereins zur Förderung von

Wissenschaft und Forschung in den neuen

Unversitätskliniken am Allgemeinen Krankenhaus der

Stadt Wien (vfwf)

2005 Fellows Award for Research Excellence, National Institutes

of Health, Fellows Committee, Bethesda, MD, USA

2001 Erwin Schrödinger Postdoctoral Fellowship, FWF,

“Analysis of the regulatory mechanism involved in support

of peripheral tolerance for tissue specific self-antigens”, #

J2059

2000 Erwin Schrödinger Postdoctoral Fellowship, FWF,

“Analysis of the regulatory role of dendritic cells in support

of peripheral self tolerance”, # J1863

Memberships

Austrian Society for Allergology and Immunology

Austrian Society of Rheumatology

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2008-2010 ÖNB - Jubiläumsfond

„Die Wirkung von Abatacept und Rituximab auf regulatorische T Zellen in der Rheumatoiden Arthritis“ # AP12754ONB

35

2005 - 2008 FWF “Analysis of T cell –antigen presenting cell interaction in collagen induced arthritis (CIA) and effect of cell based immunomodulatory therapies“, # P18374-B13.

81

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2004 - 2005 Michael Bonelli Analysis of regulatory T cells under steady state and autoimmune conditions

- 184 -

2004 - 2006 Sonia Herman Untersuchung der Interaktion von regulatorischen T-Zellen und Dendritischen Zellen, in Hinblick auf Phänotyp und Funktion.

Publications 26 peer reviewed publications in scientific journals, 3 book chapters, Peer reviewed manuscripts 2002-2008 (original research and reviews)

1. Fritsch R, Eselbock D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, Tohidast-Akrad M, Hayer S, Neumuller J, Pinol-Roma S, Smolen JS, Steiner G: Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol. Jul 15;169(2):1068-76, 2002.

2. Scheinecker C, McHugh R, Shevach EM, Germain RN: Constitutive presentation of a

natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med. 2002 Oct 21;196(8):1079-90. Comment in: J Exp Med. 2002 Oct 21;196(8):1013-6.

3. Köller M, Zwölfer B, Steiner G, Smolen J and Scheinecker C: Phenotypic and functional

deficiencies of monocyte derived dendritic cells in systemic lupus erythematodes (SLE) patients. Int Immunol. Nov;16(11):1595-604, 2004.

4. Scheinecker C: Application of in vivo microscopy: evaluating the immune response in

living animals Arthritis Res Ther; 7(6):246-52, 2005 Review. 5. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN:

Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. Apr 13;440(7086):890-5, 2006.

6. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J,

Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G: Dickkopf-1 is a master regulator of joint remodeling. Nature Med, Mar;13(2):156-163, 2007.

7. Zwerina J, Redlich K, Polzer K, Joosten L, Kroenke G, Distler J, Hess A, Pundt N, Pap

T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G.: TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci., 104:11742-7, 2007.

8. Bonelli M, von Dalwigk K, Savitskaya A, Smolen JS, and Scheinecker C: Foxp3

expression in CD4+ T cells of patients with systemic lupus erythematosus (SLE): A comparative phenotypic analysis. Ann Rheum Dis. 2007 Aug 29; [Epub ahead of print]

9. Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, Kenner L,

Tschachler E, Wagner EF: Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther. 2008 Jan 18;10(1):201 [Epub ahead of print]

- 185 -

Curriculum Vitae Veronika Sexl Institute of Pharmacology, Centre for Biomolecular Medicine and Pharmacology, Medical

University of Vienna, Währinger Strasse 13a, A-1090 Vienna, Austria;

Phone +43 1 4277 64137; Fax +43 1 4277 9641

Personal Data

Date of Birth: 27.2.1966

Place of Birth: Vienna

Nationality Austria

Education

1992 - 2002 training as medical specialist in Pharmacology and

Toxicology

1984-1992 studies of Human Medicine

1976-1984 secondary school: Bundesgymnasium XIX, Vienna

Career History

12/07 Full Professor for Signaltransduction and Development of

Molecular Targeted Therapies, Medical University of

Vienna

2001 – present associate Professor at the Department of Pharmacology,

Medical University of Vienna, Head of the Working Group

Experimental Hemato-Oncology

2000 Materenity leave

1998-1999 Postdocteral fellow ship, St. Judes Childrens Research

Hospital, Memphis, TN, USA, with Prof. James N Ihle, Dpt

of Biochemistry

1996-1997 Erwin Schroedinger postdoctoral fellowship, St. Judes

Childrens Research Hospital, Memphis, TN, USA, with

Charles Sherr, Dpt Tumor Cell Biology

1996 short-term visiting fellow, Hutchinson Cancer Research

Center, Seattle, WA, USA, with Prof. James Roberts

1992-1996 university assistent, Institute of Pharmacology, University

of Vienna

1990-1992 Voluntary thesis and laboratory work in the laboratory of

Prof. W Base, Dpt of Internal Medicine Vienna University

- 186 -

Clinics

Career-related Activities

2002-present Lecturer for Pharmacology and Toxicology at the

Fachhochschule für Biotechnologie, Krems

2005-2007 Lecturer for Pharmacology at the Paracelsus Medical

University (PMU) in Salzburg, Austria

Awards

1989-1992 Award for outstanding performance “Leistungsstipendium”,

Medical Dpt, University of Vienna

2003 Award for innovative interdisciplinary cancer research of

the city of Vienna

2004 Award for innovative interdisciplinary cancer research of

the city of Vienna

2004 Billroth Award of the Medical Society

2005 Sanofi-Aventis-Award

2006 Novartis Arward for Medicine

2006 Alos Sonnleitner Award of the Austrian Academy of

Science

Memberships

Austrian Pharmacological Society (APHAR)

Elected member of the European Academy of Science

Sources of funding in last 5 years (2000-2005)

Period Organization Short Title K€/year

2001-2003 FWF IFN gamma dependent tumor surveillance 40

2002-2005 FWF AP-1 and leukemia 60

2004-05 OENB PI3K and leukemia 50

2005-09 SFB 28-10 Jaks and Stats 90

2005-09 GenAU Functional Pharmaco-Genomics and -

proteomics

70

2007-10 FWF Cdk6-a therapeutic target in leukemia 90

PhD supervision in last 5 years (2000-2005)

Period Name of student Topic

2002-2006 Rene G Ott JunB and B lymphoid leukemia

- 187 -

2004- Andrea Hölbl Stat5 in Abelson induced leukemia

2004- Olivia Simma Role of Tyk2 in immune functions

2004- Christian Schuster Tyk2 and Emu-myc induced tumors

2006- Karoline Kollmann Cdk6 and leukemia formation

2006- Eva Eckelhart Jak2 and Abelson induced malignancies

2007- Eva-Maria Putz Stat1 – tumor suppressor or promoter?

2007- Nina Neugebauer Stat1 in mammary tumor formation

Publications 35 peer reviewed publications in scientific journals, about 20 invited lectures

Peer reviewed manuscripts 2002-2007 (original research and reviews) First, last or corresponding author manuscripts: Klinger M, Kudlacek O, Seidel MG, Freissmuth M, Sexl V (2002). MAP Kinase Stimulation by

cAMP Does Not Require RAP1 but SRC Family Kinases. J Biol Chem 277:32490-7

Sexl V, Kovacic B, Piekorz R, Moriggl R, Stoiber D, Hoffmeyer A, Liebminger R, Kudlacek O, Weisz E, Rothammer K, Ihle JN (2003). Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood 101: 4937-43.

Szremska A, Kenner L, Weisz E, Passegué E, Artwohl M , Freissmuth M, Stoxreiter R, Theussl HC, Baumgartner Parzer S , Moriggl R, Wagner EF, Sexl V (2003). JunB inhibits proliferation and transformation in B lymphoid cells. Blood, 102:4159-4165.

Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors (2004).Cancer Res;64(3):1087-93.

Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz E, Artwohl M, Kleine O, Müller M, Baumgartner-Parzer S, Ghysdael J, Freissmuth M, Sexl V. Tyk2 is a key regulator of the surveillance of B-lymphoid tumors (2004). J Clin Invest. 114:1650-1658.

Hölbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, Beug H, Hennighausen L,

Moriggl R, Sexl V. Clarifying the role of Stat5 in lymphoid development and Abelson induced transformation (2006). Blood 107:4898-906.

Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth

M, Sexl V. STAT1 acts as a tumor promoter for leukaemia development (2006). Cancer Cell 10:77-87.

Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M, Heller G,

Zochbauer S, Wagner EF, Freissmuth M, Sexl V. Jun Bis a gatekeeper for B-lymphoid leukemia (2007). Oncogene 26: 4863-71.

Schuster C, Fernbach N, Rix U, Superti-Furga G, Holy M, Freissmuth M, Sitte HH, Sexl V.

Selective serotonin reuptake.-inhibitors – a new modality for the treatment of lymphoma/leukemia? (2007). Biochem.Pharmacol. 74: 424-35.

- 188 -

Co-author manuscripts: Piekorz RP, Hoffmeyer A, Duntsch CD, McKay C, Nakajima H, Sexl V, Snyder L,

Rehg J, Ihle JN (2002). The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J 21:653-664.

Shelburne C, McCoy M, Piekorz R, Sexl V, Gillespie S, Bailey D, Gharse A, Mirmonsef P, N

Mann M, Kashyap M, Wright H, Chong H, Bouton L, Ramirez C, Lantz C, Ryan J (2002). Stat5: an essential regulator of mast cell biology. Mol Immunol 38:1187-1191.

Shelburne CP, McCoy ME, Piekorz R, Sexl V, Roh KH, Jacobs-Helber SM, Gillespie SR, Bailey DP, Mirmonsef P, Mann MN, Kashyap M, Wright H, Chong H, Bouton L, Ramirez C, Lantz C, Ryan J (2003). Stat5 expression is critical for mast cell development and survival. Blood 102:1290-1297.

Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, Gingras S, Hoffmeyer A, Bauer A, Piekorz

R, Wang D, Bunting KD, Wagner EF, Sonneck K, Valent P, Ihle JN, Beug H. Stat5 Tetramers formation is associated with leukemogenesis (2005). Cancer Cell. 7:87-99.

Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wachek V, Gleave

ME, Pehamberger H, Jansen B. Clusterin confers drug-resistance in melanoma cells (2005). J Invest Dermat. 124:1300-7.

Höller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R, Heere-Ress E, Roka F,

Sexl V, Pehamberger H. The non receptor associated tyrosine kinase p72Syk is a regulator of metastatic behaviour in human melanoma cells (2005). J Invest Dermat. 124: 1293-9.

Staber PB, Veley P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W,

Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L, Hoefler G. The oncoprotein NPM-ALK of anaplastic large cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signalling (2007). Blood, 110:3374-83.

Mayerhofer M, Gleixner KV, Mayerhofer J, Hoermann G, Jaeger E, Aichberger K, Ott RG,

Greish K, Nakamura H, Derdak S, Samorapoompichit P, Pickl WF, Sexl V, Esterbauer H, Schwarzinger I, Sillaber C, MaedaH, Valent P. Targeting of heat shock protein 32 (HsP32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myleoid leukemia: a novel approach to overcome resistance against imatinib. (2007). Blood; epub ahead of print.

- 189 -

Curriculum Vitae Maria Sibilia Institute for Cancer Research, Department of Medicine I, Medical University of Vienna,

Borschkegasse 8a, A-1090 Vienna, Austria

Phone: 43 1 40160-63011, Fax: +43 1 40160-963005

Email: [email protected]

http://www.meduniwien.ac.at/innere-med-1/krebsforschung

http://www.meduniwien.ac.at/phd-iai/

http://www.meduniwien.ac.at/sfb23/

Personal Data

Date of Birth: 26.11.1963

Place of Birth: Chur

Nationality Switzerland

Education 1970 – 1984 Schools in Thusis and Chur (GR), Switzerland. 1984 – 1989 Study of Biological Sciences, University of Pavia, Italy, with

honours. 1986 – 1989 Experimental thesis (Laurea), Department of Genetics and

Microbiology, University of Pavia, Italy. 1990 – 1992 Ph.D. Studies in Genetics and Molecular Biology,

University of Pavia and Department of Biotechnology and Virology, Brescia, Italy.

Career-related Activities 1993 – 1996 Postdoctoral fellow at the Institute of Molecular Pathology

(IMP), Vienna, Austria. 1996 – 1998 Staff Scientist at the Institute of Molecular Pathology (IMP),

Vienna, Austria. 01/1999 Assistant Professor / Group Leader (Univ. Ass.) at the

Department of Dermatology, DIAID, University of Vienna Medical School, Vienna, Austria.

07/2002 Habilitation in Molecular Biology and Genetics, University of Vienna Medical School. Associate Professor (a.o. Univ. Prof.) at the Department of Dermatology, DIAID, University of Vienna Medical School, Vienna, Austria.

04/2007 Professor for Cellular and Molecular Tumorbiology, Institute for Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Awards 1990 - 1992 Graduate Student Fellowship from the “Fondazione Istituto

Zooprofilattico Sperimentale Brescia”.

- 190 -

1992 - 1994 Postdoctoral fellowship from the “Associazione Italiana per la Ricerca sul Cancro (AIRC)”.

12/2000 ÖGDV-Unilever Dermatology Prize 2000 11/2002 Habilitation prize “Verein zur Förderung von Wissenschaft

und Forschung in den Neuen Universitätskliniken am AKH der Stadt Wien” (VFWF).

05/2003 Otto-Kraupp-Prize: 1st Prize for the best Habilitation in Austria for the year 2002.

10/2005 Alois-Sonnleitner Prize, Austrian Academy of Sciences (ÖAW) for outstanding achievements in Cancer Research.

Publications Research papers: M. B. Boniotti, C. Wirblich, M. Sibilia, G. Mayers, H.-J. Thiel and C. Rossi. “Identification and characterisation of a 3C-like protease from Rabbit Hemorrhagic Disease Virus, a Calicivirus”, J. Virology 68, 6487-6495 (1994). M. Sibilia, M.B. Boniotti, P. Angoscini, L. Capucci and C. Rossi. “Two independent pathways of expression lead to self-assembly of the Rabbit Hemorrhagic Disease Virus capsid protein”, J. Virology 69, 5812-5815 (1995). C. Wirblich, M. Sibilia, M.B. Boniotti, C. Rossi, H.-J. Thiel and G. Mayers. “3C-like protease of Rabbit Hemorrhagic Disease Virus: Identification of cleavage sites in the ORF1 polyprotein and analysis of cleavage specificity”, J. Virology 69, 7159-7168 (1995). M. Sibilia and E. F. Wagner. “Strain-dependent epithelial defects in mice lacking the EGF receptor”, Science 269, 234-238 (1995). M. Sibilia, J. P. Steinbach, L. Stingl, A. Aguzzi and E. F. Wagner. “A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor”, EMBO J. 17, 719-731, (1998). V. Tropepe, M. Sibilia, B. G. Ciruna, J. Rossant, E. F. Wagner and D. van der Kooy. “Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon”, Dev. Biology 208, 166-188 (1999). A. Behrens, M. Sibilia and E. F. Wagner. “Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation” Nature Genetics 21, 326-329 (1999). R. Eferl, M. Sibilia, F. Hilberg, A. Fuchsbichler, I. Kufferath, B. Guertl, R. Zenz, E. F. Wagner and K. Zatloukal. “Functions of c-Jun in liver and heart development”, J. Cell Biol. 145, 1049-1061 (1999). M. Sibilia*, A. Fleischmann, A. Behrens, L. Stingl, J. Carroll, F. M. Watt, J. Schlessinger and E. F. Wagner*. “The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development”, Cell 102, 211-220 (2000). (*corresponding authors) A. Behrens, W. Jochum, M. Sibilia and E. F. Wagner. “Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation“, Oncogene 19, 2657-2663 (2000). S. W. Stoll, S. Kansra, S. Peshick, D. W. Fry, W. R. Leopold, J. F. Wiesen, M. Sibilia, T. Zhang, Z. Werb, R. Derynck, E. F. Wagner and J. T. Elder. "Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant

- 191 -

keratinocytes", Neoplasia 3,339-350, 2001. A. H. F. M. Peters, D. O'Carroll, H. Scherthan, K. Mechtler, S. Sauer, C. Schöfer, K. Weipoltshammer, M. Pagani, M. Lachner, A. Kohlmaier, S. Opravil, M. Doyle, M. Sibilia and T. Jenuwein. "Loss of the Suv39h Histone Methyltransferases impairs mammalian heterochromatin and genome stability", Cell 107, 323-337 (2001). A. Behrens*, M. Sibilia*, J. P. David, U. Möhle-Steinlein, F. Tronche, G. Schütz and E. F. Wagner. “Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver”, EMBO J. 21, 1782-1790, (2002). (*equally contributing authors) M. Sibilia, B. Wagner, A. Hoebertz, C. Elliott, S. Marino, W. Jochum and E. F. Wagner. “Mice humanized for the EGF receptor display hypomorphic phenotypes in skin, bone and heart”, Development 130, 4515-4525, (2003). R. Zenz, H. Scheuch, P. Martin, C. Frank, R. Eferl, L. Kenner, M. Sibilia and E. F. Wagner. “c-Jun regulates eyelid closure and skin tumor development through EGFR signaling”, Dev. Cell 4, 879-889, (2003). F. Palamara, S. Meindl, M. Holcmann, P. Lührs, G. Stingl and M. Sibilia. “Identification and characterization of ‘pDC-like cells’ in normal mouse skin and melanomas treated with Imiquimod”, J. Immunology 173, 3051-3061, (2004). B. Wagner, A. Natarajan, S. Grünaug, R. Kroismayr, E.F. Wagner and M. Sibilia. “Neuronal survival depends on EGF receptor signaling in cortical but not midbrain astrocytes”, EMBO J. 25, 752-762, (2006). K. Fortschegger, B. Wagner, R. Voglauer, H. Katinger, M. Sibilia and J. Grillari. “Early Embryonic Lethality of Mice Lacking the Essential Protein SNEV”, Mol. Cell Biol. 27, 3123-3130 (2007). A. Natarajan, B. Wagner and M. Sibilia. “The EGF receptor is required for efficient liver regeneration”, PNAS, 104:17081-17086 (2007). E. Schraml, R. Voglauer, K. Fortschegger, M. Sibilia, I. Stelzer, J. Grillari and K. Schauenstein. “Haploinsufficiency of SNEV causes defects of hematopoietic stem cells functions“, Stem Cells Dev., in press (2008) U. Schmidt, N. Boucheron, E. Eckelhart, I. Bilic, M. Kneidinger, B. Unger, M. Hammer, M. Sibilia, P. Valent and W. Ellmeier. “The protein tyrosine kinase Tec regulates mast cell function“, J. Immunology, accepted pending revision (2008). M. Holcmann, B. Drobits, P. Lührs, G. Stingl, D. Maurer and M. Sibilia. “Tolerance induction in the skin under homeostatic conditions“, J. Immunology, accepted pending revision (2008). Book chapters and reviews C. Rossi, M. B. Boniotti, M. Sibilia, L. Capucci. “Expression by a recombinant Baculovirus of the capsid protein VP60 from the Rabbit Hemorrhagic Disease Virus results in assembly of empty capsids and production of an effective Vaccine”, in ‘State of the Art of the Italian Research in Biotechnology applied to Veterinary Sciences‘, Vol 35, 45-55 (1993). M. Sibilia and E. F. Wagner. “Transgenic animals”, European Review, Vol 4, No. 4, 371-391 (1996).

- 192 -

E. F. Wagner and M. Sibilia. “Transgenics revisited”, Trends in Genetics, 13, 501-502 Book Comment to ‘Transgenic Animals: Generation and Use’ ed. L.M. Houdebine, Harwood Academic Publishers (1997). M. Sibilia, R. Kroismayr, A. Natarajan, B. M. Lichtenberger, M. Hecking, M. Holcmann. “The Epidermal Growth Factor Receptor: from development to tumorigenesis“. Differentiation, 75, 770-787 (2007)

- 193 -

Curriculum Vitae

Peter Steinberger Division of Immune Receptors and T cell Activation, Institute of Immunology, Center for

Physiology, Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse

8a, 1090 Wien, Austria;

Phone: +43 1 4277-64941, Fax: +43 1 4277-9649;

Email: [email protected];

Homepage: www.meduniwien.ac.at/immunologie/ellmeier Personal Data

Date of Birth: 28.11.1965

Place of Birth: Leoben, Austria

Nationality Austria

Education

1992 – 1995 Ph.D. in Biochemistry at the University of Vienna,

1988 – 1992 Diploma degree in Zoology and Biochemistry; University of

Vienna

1986 – 1988 Prediploma in Biology; University of Graz

1985 University entrance qualification, HBLA Raumberg

Career History

06/2007 Habilitation at the Medical University of Vienna

Since 03/2007 Independent group leader at the Institute of Immunology

Since 06/2006 Permanent research position at the Institute of

Immunology

Since 02/2000 Institute of Immunology in the group of Prof. Walter Knapp

and since 08/2004 in the group of Prof. Johannes Stöckl

06/1996-12/1999 Postdoctoral Studies at The Scripps Research Institute in

the group of Professor Dr. Carlos F. Barbas III.

1992-1995 PhD Thesis at the Dept. of Pathophysiology in the group of

Professor Rudolf Valenta

Awards and Fellowships

06/1998 Austrian National Award for Alternatives to Animal

Experimentation

1997-1998 Erwin Schroedinger Fellowship from the Austrian Science

- 194 -

Foundation

12/1995 Award for Ph. D. thesis of the Austrian Society of Allergy

and Clinical Immunology

09/1995 Travel award from the Austrian Society for Allergology and Immunology

Memberships

Austrian Society for Allergology and Immunology

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2008 - 2010 ONB Alternative costimulators in CD28-negative T

cells

37

2006 - 2008 FWF Role of B7-H3 during T cell activation 70

2005 - 2008 CCRI DC-reactive antibodies 55

2004 - 2006 ONB Search for HSP-Receptors 40

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

01/2006-

present

Judith Leitner Identification of tumour antigens using antibodies

induced by DC-based vaccines

Publications Scientific papers: 34 Reviews: 4 Book Chapters: 5

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: 1 Pfistershammer, K, Klauser, C., Leitner, J., Stöckl, J, Majdic, O., Weichhart, T.,

Sobanov, J., Bochkov, V., Säemann, M., Zlabinger, G., Steinberger, P* Identification of the Scavenger Receptors SREC-I, SR-B1/Cla-1 and SR-A-1 as cellular receptors for Tamm-Horsfall Protein. J Leukoc Biol. 2008. 83: 131-8.

2 Pfistershammer, K., Klauser, C., Pickl, W. F., Stockl, J., Leitner, J., Zlabinger, G., Majdic, O. and Steinberger, P*., No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 2006. 36: 1104-1113.

3. Steinberger, P*., O. Majdic, S. V. Derdak, K. Pfistershammer, S. Kirchberger, C. Klauser, G. Zlabinger, W. F. Pickl, J. Stockl, and W. Knapp. 2004. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172:2352.

4. Steinberger, P.*, A. Szekeres, S. Wille, J. Stockl, N. Selenko, E. Prager, G. Staffler, O. Madic, H. Stockinger, and W. Knapp. 2002. Identification of human CD93 as the

- 195 -

phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol 71:133. * corresponding author Co-author manuscripts: 1. Flicker, S., Steinberger, P., Eibensteiner, P. B., Lebecque, S., Kraft., D., and

Valenta, R. Molecular characterization of a human IgG4 antibody specific for the major birch pollen allergen, Bet v 1. Clin. Exp. Allergy. in press

2. Swan, C. H., Buhler, B., Steinberger, P., Tschan, M. P., Barbas, C. F., 3rd and Torbett, B. E., T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 2007. 14: 626.

3. Flicker, S., Steinberger, P., Ball, T., Krauth, M. T., Verdino, P., Valent, P., Almo, S. and Valenta, R., Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. J Allergy Clin Immunol 2006. 117: 1336-1343.

4. Kirchberger, S., O. Majdic, P. Steinberger, S. Bluml, K. Pfistershammer, G. Zlabinger, L. Deszcz, E. Kuechler, W. Knapp, and J. Stockl. 2005. Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. J Immunol 175:1145.

5. Pfistershammer, K., O. Majdic, J. Stockl, G. Zlabinger, S. Kirchberger, P. Steinberger, and W. Knapp. 2004. CD63 as an activation-linked T cell costimulatory element. J Immunol 173:6000.

6. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Hofler, E. Guthann, U. Korthauer, G. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stockl. 2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170:3637.

7. Flicker, S., P. Steinberger, L. Norderhaug, W. R. Sperr, Y. Majlesi, P. Valent, D. Kraft, and R. Valenta. 2002. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 32:2156.

- 196 -

Curriculum Vitae

Günter Steiner Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18, A 1090 Vienna; E-mail: [email protected]

Personal Data

Date of Birth: 29.10.1953

Place of Birth: Vienna

Nationality Austrian

Education

1981-1986 PhD studies (Biochemistry) at the Institute of Biochemstry,

University of Vienna Medical School

1979-1981 Diploma thesis at the Institute of Biochemstry, University of

Vienna Medical School

1973-1979 Studies in Biochemistry, University of Vienna

1964-1972 High school, Bundesgymnasium 21, Vienna

Career History

2000- Associate Professor (a.o.Univ.Prof), Head of Laboratory,

Division of Rheumatology, Univ. of Vienna Medical School

2000 Habilitation in Biochemistry, Univ. of Vienna Medical School

1995-2000 Group leader, Division of Rheumatology, Internal Medicine III,

Univ. of Vienna Medical School

1989-1995 Group leader, Ludwig Boltzmann-Institute for Rheumatology,

Vienna

1986-1989 Postdoctoral Fellow, Ludwig Boltzmann-Institute for Clinical

Endocrinology, Vienna

Career-related Activities

2005-present Member of the International Organizing Committee of the

International Congress on Autoimmunity

2002-2006 Board member, Austrian Society for Biochemistry and

Molecular Biology

2002-2005 Scientific programme committee member, European League

against Arthritis and Rheumatism (EULAR)

2001 Coorganizer, European Workshop for Rheumatoloy Research

- 197 -

2000 - present International Advisory Board, Dresden Symposium on

Autoantibodies

1999 Coorganizer, 4th European Conference on SLE

1997 Advisory board, 10th EULAR Workshop

1992 Coorganizer, Int. Symposium on Ribonucleoproteins

1991 Coorganizer, Int. Workshop on Cytokines in Rheumatology

Awards

1997, 2000 Austrian State Award for Rheumatology

1992 Young Investigator´s Award of the European Workshop for

Rheumatology Research (EWRR)

1990 Forschungsförderungspreis der 1. Österr. Sparkasse

1987 Theodor Körner Award

Memberships Austrian Society for Biochemistry and Molecular Biology

Austrian Society for Allergology and Immunology

Austrian Society for Rheumatology

Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year

2008 - 2012 EU MASTERSWITCH (Integrated Project) 160

2006 - 2011 EU AUTOCURE (Integrated Project) 90

2005 - 2007 ÖAW CeMM 20060 121

2003 - 2004 ÖAW CeMM 20060 152

2002 ÖAW CeMM 20060 43

2001 - 2007 FWF SFB 017/F1705: RNA Fate and Function 49

PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

1999 - 2003 Silvia Hayer Molecular and cellular mechanisms leading to

autoimmune responses and tissue destruction in

rheumatoid arthritis

2002 - 2004 Atijeh Valai Interactions of hnRNP I and hnRNP K with

autoantibodies and human Y1 RNA

2004-2008 Markus Hoffmann The role of the autoantigen hnRNP-A2/B1 (RA33)

in the pathogenesis of rheumatoid arthritis

- 198 -

Publications 86 peer reviewed publications in scientific journals, 20 book chapters, > 30 invited lectures Peer reviewed manuscripts 2002-2008 (original research and reviews)

First, last or corresponding author manuscripts

Fritsch R, Eselböck D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, Tohidast-Akrad M, Hayer S, Neumüller J, Pinol-Roma S, Smolen J, Steiner G. Characterization of autoreactive T cells to the autoantigens RA33 (hnRNP A2) and filaggrin in patients with rheumatoid arthritis. J Immunol 169:1068-1076; 2002.

Steiner G, Shovman O, Skriner K, Gilburd B, Langevitz P, Miholits M, Hoet R, Levy Y, Hoefler E, Smolen JS, Shoenfeld Y. Idiotypic manipulation with anti-RA33 antibody preparation in mice induces the production of anti-RA33 hnRNP autoantibodies and transient spread to snRNP complex of spliceosome. Clin Exp Rheumatol 20:517-524; 2002.

Schett G, Smolen J, Hiessberger H, Hoefler E, Fournel S, Muller S, Rubin RL, Steiner G. The autoimmune response to chromatin antigens in systemic lupus erythematosus (SLE): autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 11:704-715; 2002.

Schett G, Steiner CW, Xu Q, Smolen JS, Steiner G. TNFα mediates susceptibility to heat-induced apoptosis by protein phosphatase-mediated downregulation of the HSF-1/hsp70 stress response. Cell Death Diff 10:1126-1136; 2003.

Smolen JS, Steiner G. Current and future therapeutic strategies for rheumatoid arthritis. Nature Rev Drug Disc 2:473-488; 2003.

Belisova A, Semrad K, Kocian G, Mayer O, Waigmann E, Schroeder R, Steiner G. RNA chaperone activity of protein components of human Ro RNPs. RNA 11, 1084-1094; 2005. Nell VPK, Machold KM, Stamm TA, Eberl G, Heinzl H, Uffmann M, Smolen JS, Steiner G. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731-6; 2005.

Hayer S, Tohidast-Akrad M, Haralambous S, Jahn-Schmid B, Skriner K, Trembleau S, Dumortier H, Pinol-Roma S; Redlich K, Schett G, Muller S, Kollias G, Smolen J, Steiner G. Aberrant expression of the autoantigen hnRNP-A2/B1 (RA33) and spontaneous formation of rheumatoid arthritis associated anti-RA33 autoantibodies in TNFα transgenic mice. J Immunol 175:8327-36; 2005. Fritsch-Stork R, Mullegger D, Skriner K, Jahn-Schmid B, Smolen JS, Steiner G. The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus. Arthritis Res Ther. 8:R118; 2006.

Steiner G. Autoantibodies and autoreactive T cells in rheumatoid arthritis: pathogenetic players and diagnostic tools. Clin Rev Allergy Immunol. 32:23-36; 2007.

Hoffmann MH, Tuncel J, Skriner K, Tohidast-Akrad M, Türk B, Pinol-Roma S|, Serre G, Schett G, Smolen JS, Holmdahl R, Steiner G. The human autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol. 179:7568-7576; 2007.

Skriner K, Hueber W, Süleymanoglu E, Höfler E, Kren V, Smolen J, Steiner G.The regulator of TNFα mRNA decay AU-rich element binding factor 1 (AUF1) is targeted by autoantibodies of patients with systemic rheumatic diseases. Arthritis Rheum 58:511-520; 2008.

- 199 -

Stummvoll GH, Fritsch RD, Meyer B, Hoefler E, Aringer M, Smolen JS, Steiner G. Characterization of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythematosus. Ann Rheum Dis; Epub ahead of print; March 2008.

Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen J, Steiner G. Autoantibodies to the translational suppressors TIA-1 and TIAR in patients with rheumatic diseases. Increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. Arthritis Rheum, in press.

Co-author manuscripts

Redlich K, Hayer S, Maier A, Dunstan CR, Lang S, Tohidast-Akrad M, Türk B, Pietschmann P, Woloszczuk W, Haralambos S, Kollias G, Steiner G, Smolen JS, Schett G. TNF-α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46:785-792; 2002.

Aringer M, Feierl E, Steiner G, Stummvoll GH, Hoefler E, Steiner CW, Radda I, Smolen JS, Graninger WB. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 11:102-108; 2002. Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, Pottel H, Serre G, de Keyser F. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for anti-filaggrin autoantibody detection by Line Immunoassay. Arthritis Rheum. 46:1185-1195; 2002. Redlich K, Hayer S, Ricci R, David J-P, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF� -mediated joint destruction. J Clin Invest 110:1419-1427; 2002.

Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS. Osteoprotegerin protects from generalized bone loss in TNF-transgenic mice. Arthritis Rheum 48:2042-2051; 2003.

Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 48: 3308-3319; 2003.

Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G. Single and combined inhibition of TNF, IL-1 and RANKL pathways in TNF-induced arthritis: effects on synovial inflammation, bone erosion and cartilage destruction. Arthritis Rheum 50: 277-290; 2004.

Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, Bergmeister H, Kollias G, Steiner G, Smolen JS, Schett G. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 164: 543-555; 2004.

Redlich K, Görtz B, Hayer S, Zwerina J, Kollias G, Steiner G, Smolen JS, Schett G. Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum 50: 1001-1005; 2004.

Görtz B, Hayer S, Redlich K, Zwerina J, Tohidast-Akrad M, Türk B, Hartmann C, Kollias G, Steiner G, Smolen JS, Schett G. Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J Bone Miner Res 19: 980-988; 2004.

- 200 -

Koller M, Zwolfer B, Steiner G, Smolen JS, Scheinecker C. Phenotypic and functional deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE) patients. Int Immunol 16:1595-604; 2004.

Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 50: 3161-3169; 2004.

Köller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, Smolen JS, Wagner EF, Schett G. JNK1 is not essential for TNF-mediated joint disease. Arthritis Res. Ther.:R166-73, 2005.

Hayer S, Steiner G, Görtz B, Reiter E, Tohidast-Akrad M, Amling M, Hoffmann O, Redlich K, Zwerina J, Skriner K, Hilberg F, Wagner EF, Smolen JS, Schett G. CD44 as a regulator of inflammatory bone loss. J Exp Med 201:903-914, 2005.

Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzinger I, Wolozcszuk W, Steiner G, Smolen JS. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111:204-11, 2005.

Smolen JS, Redlich K, Zwerina J, Aletaha D, Steiner G, Schett G. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol 28:239-48; 2005.

Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 46:342-349; 2007.

Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 56:274-279; 2007.

Grisar JC, Aletaha D, Steiner CW, Kapral T, Steiner S, Saemann M, Schwarzinger I, Buranyi B, Steiner G, Smolen JS. Endothelial progenitor cells in active rheumatoid arthritis: Effects of TNF and of glucocorticoid therapy. Ann Rheum Dis. 66:1284-8;2007.

Rozman B, Euènik S, Sodin-Semrl S, Czirják L, Varjú C, Distler O, Huscher D, Aringer M, Steiner G, Matucci-Cerinic M, Guiducci S, Stamenkoviæ B, Stankoviæ A, Kveder T. Prevalence and clinical associations of anti-KU antibodies in patients with systemic sclerosis: a European EUSTAR - initiated multicentre case-control study. Ann Rheum Dis, Epub ahead of print, Dec. 2007.

Book chapters

Steiner G, Skriner K, Fabini G, Jimenez-Boj E, Kedersha N, Zimmermann C, Tohidast-Akrad M, Schett G, Fritsch R, Höfler E, Anderson P, Smolen J. Translational regulators as autoantigens in systemic autoimmune diseases. In: Autoantigens, Autoantibodies, Autoimmunity; Volume 3. Conrad K, Fritzler M, Meurer M, Sack U, Shoenfeld Y, eds. Pabst Science Publishers, Lengerich, pp 116-121; 2002.

Steiner G, Conrad K. Autoantigene. In: Molekularmedizinische Grundlagen von rheumatischen Erkrankungen. Ganten D, Ruckpaul K eds. Springer Verlag Berlin Heidelberg New York, pp123-164; 2003.

Steiner G. Autoantibodies in rheumatoid arthritis. In: Rheumatology, 3rd edition. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH eds. Harcourt Sciences Ltd, pp833-842; 2003.

Steiner G, Belisova A, Valai A, Hayer S, Höfler E, Smolen J. Reflections about structure, function and pathogenetic significance of Ro ribonucleoproteins. In: Autoantigens, Autoantibodies, Autoimmunity; Volume 4. Conrad K, Bachmann MP, Chan EKL, Fritzler MJ,

- 201 -

Humbel RL, Sack U, Shoenfeld Y. eds. Pabst Science Publishers, Lengerich, pp 236-242; 2004.

Steiner G, Smolen J. Anti-RA33 autoantibodies (antibodies to the hetereogeneous nuclear ribonucleoprotein A2). In: Autoantibodies 2nd edition. Shoenfeld Y, Gershwin E, Meroni P-L eds. Elsevier BV, pp 211-216; 2007.

Steiner G, Hoffmann M, Hayer S, Fritsch R, Smolen J. Autoimmune responses in experimental models of rheumatoid arthritis. In: Autoantigens, Autoantibodies, Autoimmunity; Volume 5. Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Sack U, Shoenfeld Y., Wiik AS eds. Pabst Science Publishers, Lengerich, pp 45-53; 2007.

Voll R, Steiner G. Autoantikörper - Diagnostik und Pathogenese. In: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Aringer M ed. Uni-Med Verlag, pp16-24; 2007. Steiner G, Serre G. Autoantibodies in rheumatoid arthritis. In: Rheumatology, 4tth edition. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH eds. Mosby Elsevier, pp 819-827; 2008.

Invited Talks 2002-2008 Diagnostic criteria for early rheumatoid arthritis, Vienna, 25.-27. 1.2002. International Congress on Autoimmunity, Geneva, 20.-24.2. 002. First Meeting of the Global Arthritis Research Network, Luzern, 4.-6.4.2002. Dresden Symposium on Autoantibodies, Dresden, 4.-7.9.2002. European Workshop for Rheumatology Research, Marseille, 1.3.2003. International Symposium on Autoimmunity; Vienna, 4.4.2003. International Workshop on Autoantibodies and Autoimmunity; Berlin, 12.9.2003. Workshop for Use of New Technologies in Rheumatology Research; Stockholm, 3.10.2003. Yale University School of Medicine; New Haven, 7.5.2004. Dresden Symposium on Autoantibodies; Dresden, 1.-4.9.2004. Austrian Proteome Form; Wien, 14.-15.10.2004. Kennedy Institute of Rheumatology; London, 7.3.2005. Annual European Congress of Rheumatology, Vienna, 8.-11.6.2005. International Workshop on Autoantibodies and Autoimmunity, Gainesville, 29.9.-2.10.2005. Workshop New Trends in Rheumatology, Kühtai, 30.3.-1.4. 2006. First International Aesku.Kipp Institute Symposium Autoimmunity, Wendelsheim, 6.5.2006. 34. Kongress der Deutschen Gesellschaft für Rheumatologie, Wiesbaden, 18.-21.10.2006. Menarini Diagnostics International Symposium on Autoimmunity, Sorrento, 27.-28.11.2006. Third Cellaid Symposium, Florence, 20-22.2. 2007. Eighth Dresden Symposium on Autoantibodies, Dresden, 12.-15.9.2007. Jahrestagung der ÖGLKC und der DGKL, Vienna, 19.-21.9.2007. European Workshop for Rheumatology Research, Toulouse, 28.2.-1.3.2008.

- 202 -

Curriculum Vitae

Johannes Stöckl Division of Immune-Regulation, Institute of Immunology, Center for Physiology,

Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse 8a, 1090

Vienna, Austria;

Phone: +43 1 4277-64951, Fax: +43 1 4277-9649;

Email: [email protected];

Homepage: www.meduniwien.ac.at/immunologie Personal Data

Date of Birth: 15.12.1965

Place of Birth: Vienna

Nationality Austria

Education

1992 – 1994 PhD studies (Immunology), University of Vienna

1992 Diploma thesis at the Institute of Immunology, in Vienna

1985 – 1991 Studies in Microbiology, University of Vienna

1984 University entrance qualification, BGR Hollabrunn

Career History

Since 10/2003 Habilitation in Immunology, University of Vienna Medical

School, Associate Professor (a.o.Univ.Prof)

Since 2000 University Assistant (Group leader)

1994 - 2000 Postdoctoral Fellow, University of Vienna Medical School

Career-related Activities

2003 – present Member of the Editorial Board, JCMM

2004 - present Board Member of the Austrian Society of Allegology and

Immunology

Awards

2006 Wissenschaftspreis 2006 des Landes Niederösterreich

2004 Otto-Kraup Preis (Habilitation), sponsored by Aventis

2002 Aventis Prize

2001 START Prize, BMBWK und FWF

1997 Karl Landsteiner Prize (Austrian Society of Allergology and

- 203 -

Immunology)

1993 Thesis Prize (Austrian Society of Allergology and

Immunology)

Memberships

Austrian Society for Allergology and Immunology

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2007 - 2009 FWF Regulatory T cells and SREC-I 95

2007 - 2009 FWF SFB F23 Immunological Tolerance:

Vision fund (together with Maria Sibilia)

68

2005 - 2007 FWF SFB F23 Immunological Tolerance:

Subproject 7

110

2004 - 2007 WWTF Oxidized phospholipids and DC 175

1995 - 2004 FWF SFB-05-02: Polarized phagocyte

differentiation

105

2000 - 2004 K-Plus BMT Molecular Analysis of Dendritic Cell Function 100

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

2002 - 2006 Stefanie Kirchberger Modulation of immune cell function by human

rhinoviruses

2004 - 2007 Nina Gundacker Effects of oxidized phospholipids on dendritic cell

protein expression

2007 -

present

Maria Seyerl Novel pathways of anergy induction in human T

cells

2008 -

present

Catharina Schrauf Recognition of viral RNA by DC

Publications 43 peer reviewed publications in scientific journals, 3 book chapters, 18 invited lectures, 2

patents

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts:

1. Selenko, N., O. Majdic, U. Jager, C. Sillaber, J. Stockl, and W. Knapp. 2002. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive

- 204 -

antibodies? J Clin Immunol 22:124.

2. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Hofler, E. Guthann, U. Korthauer, G. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stockl. 2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170:3637.

3. Bluml, S., S. Kirchberger, V. N. Bochkov, G. Kronke, K. Stuhlmeier, O. Majdic, G. J. Zlabinger, W. Knapp, B. R. Binder, J. Stockl, and N. Leitinger. 2005. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol 175:501.

4. Kirchberger, S., O. Majdic, P. Steinberger, S. Bluml, K. Pfistershammer, G. Zlabinger, L. Deszcz, E. Kuechler, W. Knapp, and J. Stockl. 2005. Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. J Immunol 175:1145.

5. Kirchberger, S., H. Vetr, O. Majdic, H. Stockinger, and J. Stockl. 2006. Engagement of ICAM-1 by major group rhinoviruses activates the LFA-1/ICAM-3 cell adhesion pathway in mononuclear phagocytes. Immunobiology 211:537.

6. Kirchberger, S., O. Majdic, and J. Stockl. 2007. Modulation of the immune system by human rhinoviruses. Int Arch Allergy Immunol 142:1.

7. Seyerl, M., S. Bluml, S. Kirchberger, V. N. Bochkov, O. Oskolkova, O. Majdic, and J. Stockl. 2008. Oxidized phospholipids induce anergy in human peripheral blood T cells. Eur J Immunol 38:778.

Co-author manuscripts:

1. Schoppmann, S. F., P. Birner, J. Stockl, R. Kalt, R. Ullrich, C. Caucig, E. Kriehuber, K. Nagy, K. Alitalo, and D. Kerjaschki. 2002. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161:947.

2. Steinberger, P., A. Szekeres, S. Wille, J. Stockl, N. Selenko, E. Prager, G. Staffler, O. Madic, H. Stockinger, and W. Knapp. 2002. Identification of human CD93 as the phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol 71:133.

3. Lehner, M., J. Stockl, O. Majdic, W. Knapp, K. Huttner, T. Felzmann, and W. Holter. 2003. MHC class II antigen signaling induces homotypic and heterotypic cluster formation of human mature monocyte derived dendritic cells in the absence of cell death. Hum Immunol 64:762.

4. Pfistershammer, K., O. Majdic, J. Stockl, G. Zlabinger, S. Kirchberger, P. Steinberger, and W. Knapp. 2004. CD63 as an activation-linked T cell costimulatory element. J Immunol 173:6000.

5. Steinberger, P., O. Majdic, S. V. Derdak, K. Pfistershammer, S. Kirchberger, C. Klauser, G. Zlabinger, W. F. Pickl, J. Stockl, and W. Knapp. 2004. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172:2352.

6. Traxler, E., E. Bayer, J. Stockl, T. Mohr, C. Lenz, and C. Gerner. 2004. Towards a standardized human proteome database: quantitative proteome profiling of living cells. Proteomics 4:1314.

7. Gundacker, N., E. Bayer, E. Traxler, H. Zwickl, M. Kubicek, J. Stockl, and C. Gerner. 2006. Knowledge-based proteome profiling: considering identified proteins to evaluate separation efficiency by 2-D PAGE. Electrophoresis 27:2712.

- 205 -

8. Pfistershammer, K., C. Klauser, W. F. Pickl, J. Stockl, J. Leitner, G. Zlabinger, O. Majdic, and P. Steinberger. 2006. No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 36:1104.

9. Pfistershammer, K., J. Stockl, J. Siekmann, P. L. Turecek, H. P. Schwarz, and B. M. Reipert. 2006. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 96:309.

10. Koesters, C., B. Unger, I. Bilic, U. Schmidt, S. Bluml, B. Lichtenberger, M. Schreiber, J. Stockl, and W. Ellmeier. 2007. Regulation of dendritic cell differentiation and subset distribution by the zinc finger protein CTCF. Immunol Lett 109:165.

Invited Talks 2002-2008 2002 • ENT-meeting, AKH, Vienna, Austria 2003 • EMDS meeting, Leicester, UK 2004 • University of Innsbruck, Austria 2005 • Vienna Biocenter, Austria 2006 • Semmelweis University, Budapest, Hungary 2007 • Medical University of Innsbruck, Austria 2008 • Novo Nordisk, Kopenhagen, Denmark

- 206 -

Curriculum Vitae

Martin Willheim Division of Cellular and Molecular Pathophysiology, Institute of Pathophysiology, Center for

Physiology, Pathophysiology and Immunology, Medical University of Vienna, Währinger

Gürtel 18-20, 1090 Wien, Austria;

Phone: +43 1 40400-5133, Fax: +43 1 40400-5130;

Email: [email protected]; Personal Data

Date of Birth: 31.08.1962

Place of Birth: Linz

Nationality Austria

Education

2006 Certification as Specialist of Pathophysiology

2005 Certification as Specialist of Laboratory Medicine

1980 – 1994 Studies in Medicine, Medical Faculty, University of Vienna

Career History

Since 2001 Associate Professor (a.o.Univ.Prof)

2001 Venia docendi in „Pathophysiology“

since 2001 Head of the research group „Cytokine research“, Institute

of Pathophysiology, Medical University of Vienna

since 04/2005 Institute of Pathophysiology, Medical University of Vienna

10/2001 – 03/2005 Clinical Institute of Medical and Chemical Laboratory

Diagnostics, Medical University of Vienna (Resident)

10/2000 – 09/2001 Division of Rheumatology, Department of Internal

Medicine III, Medical University of Vienna (Resident)

03 – 09/2000 Error! Not a valid link. (Resident)

12/1995 – 02/2000 Institute of Pathophysiology, Medical University of Vienna

(Resident)

Career-related Activities

2006 - present Head of the Core Unit Cytometry, Medical University of

Vienna

02/2001 – present President of the Austrian Society for Cytometry

- 207 -

Awards

2005 B.R.A.H.M.S Forschungspreis für

Schilddrüsenerkrankungen 2005

Memberships

Austrian Society for Cytometry Austrian Society for Allergology and Immunology

International Society for Analytical Cytology

Austrian Society for Bone and Mineral Research

Sources of funding in last 6 years (2002-2008)

Period Organization Short Title K€/year

2007 Medizinisch

Wissenschaftlicher

Fonds des

Bürgermeisters der

Bundeshauptstadt

Wien

Tumorstammzellen im malignen Melanom 15

2006 Medizinisch

Wissenschaftlicher

Fonds des

Bürgermeisters der

Bundeshauptstadt

Wien

Anti-TPO Autoantikörper Spiegel und

Zytokin-Produktionsmuster von

Lymphozyten als mögliche Indikatoren der

Aktivität einer Hashimoto Thyreoiditis unter

dem Einfluss einer L-Thyroxin

Substitutionstherapie

15

Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)

Period Name of student Topic

Thien Ralf

2004-2007 Ernstbrunner Lino Änderung der Wirkung von 1α,25(OH)2 Vitamin

D3 auf das Zytokin-Produktionsmuster von T

Lymphozyten im Laufe der kindlichen Entwicklung

03/2007 -

present

Maldonado Eduardo Effect of the short–term thyrotropin increase after

administration of Recombinant Human

Thyrotropin (Thyrogen) on T lymphocyte cytokine

production pattern and bone metabolism in

healthy subjects

11/2007 -

present

Semrad Ursula Extended cytokine profiling of functional human

peripheral blood CD4+ T lymphocytes (Th1, Th2

- 208 -

and Th17) and the effect of different micro-

environments on their differentiation

Publications 76 peer reviewed publications in scientific journals

Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: 1α,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Josefa Pichler, Marianne Gerstmayr, Zsolt Szépfalusi, Radvan Urbanek, Meinrad Peterlik and Martin Willheim Pediatr Res, 52:12-8, 2002 Donor dependent, interferon-gamma induced HLA-DR expression on human neutrophils in vivo. Reinisch W, Lichtenberger C, Steger G, Tillinger W, Scheiner O, Gangl A, Maurer D, Willheim M. Clin Exp Immunol. 2003 Sep;133(3):476-84. T-lymphocyte cytokine production patterns in nonimmune severe hypothyroid state and after thyroid hormone replacement therapy. Karanikas G, John P, Wahl K, Schuetz M, Dudczak R, Willheim M. Thyroid. 2004 Jul;14(7):488-92. Relation of anti-TPO Autoantibody Titer and T Lymphocyte Cytokine Production Patterns in Hashimoto’s Thyroiditis. Karanikas G, Schütz M, Wahl K, Paul M, Kontur S, Pietschmann P, Kletter K, Dudczak R, Willheim M. Clin Endocrinol (Oxf). 2005 Aug;63(2):191-6. Interactions of 1α,25-dihydroxyvitamin D3 with interleukin-12 and interleukin-4 on cytokine expression of human T lymphocytes. Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M. J Allergy Clin Immunol 2005, 116/3, pp 683-689. T lymphocyte cytokine production patterns in hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Matthias Schütz, Heying Duan, Katharina Wahl, Christian Pirich, Anna Antoni, Spyridoula Kommata, Kurt Kletter, Robert Dudczak, Georgios Karanikas, Martin Willheim Anticancer Res., 2006 Nov-Dec;26(6B):4591-6. No immunological benefit of Selenium in consecutive patients with autoimmune thyroiditis Georgios Karanikas, Matthias Schuetz, Sylvester Kontur, Heying Duan, Spyridoula Kommata, Robert Schoen, Anna Antoni, Kurt Kletter, Robert Dudczak, and Martin Willheim Thyroid, accepted July 2007